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In most cases, spontaneous intracerebral haemorrhage (ICH) is thought to 
result from cerebral small vessel diseases (SVDs). Cerebral amyloid 
angiopathy (CAA) and arteriolosclerosis (non-CAA SVD) are the two main 
types of SVD associated with ICH. The risk of recurrent ICH and post-stroke 
dementia may be higher with CAA-associated ICH compared with non-CAA 
SVD-associated ICH. It is, therefore, important to identify the type of SVD 
associated with ICH. Commonly, ICH in the cerebral lobes (lobar ICH) is 
thought to be associated with CAA, whereas non-lobar ICH is associated with 
non-CAA SVD. However, this generalisation is not accurate. 
The aims of my thesis were to (a) histopathologically assess the types and 
severity of SVDs associated with lobar and non-lobar ICH using brain 
autopsy tissue, (b) explore whether brain imaging (magnetic resonance 
imaging (MRI), positron emission tomography (PET) and computed 
tomography (CT)) biomarkers can be used in living patients to identify the 
type of SVDs associated with ICH and (c) determine whether CT biomarkers 
can predict outcome after ICH. 
Throughout my thesis, I use data from two overlapping studies of ICH. The 
Lothian Audit of the Treatment of Cerebral Haemorrhage (LATCH) is a 
prospective community-based audit of all residents in the Lothian Health 
board region of Scotland who were aged 16 years or above and had an 
incident ICH between 1st June 2010 and 31st May 2013 inclusive. During 
LATCH and until 31st May 2016, consecutive adults with SVD-associated 
ICH were able to consent to have apolipoprotein E genotyping, brain MRI 
and brain autopsy as part of the prospective Lothian INtraCerebral 
Haemorrhage Pathology, Imaging and Neurological outcome (LINCHPIN) 
study. 
In an autopsy study of 126 LINCHPIN participants with first-ever SVD-
associated ICH, I found that 98% of participants with a non-lobar ICH had 
moderate or severe non-CAA SVD. In contrast, 60% of participants with a 
 xvi 
lobar ICH had moderate or severe CAA, while many had moderate or severe 
non-CAA SVD, either with or without CAA. 
The most common approach used in clinical practice to identify CAA-
associated ICH is the MRI-based modified Boston criteria for CAA. However, 
I found that only about one-third of ICH patients during LATCH were able to 
undergo MRI. Also, in 16 LINCHPIN participants with research MRI, the 
modified Boston criteria showed limited accuracy against the 
histopathological assessment of CAA on subsequent research autopsy. 
Molecular imaging using tracers designed to detect parenchymal -amyloid in 
Alzheimer’s disease, such as flutemetamol, may also identify the perivascular 
-amyloid found in CAA. I found that in LINCHPIN brain tissue samples, the 
amyloid tracer flutemetamol labelled both parenchymal and perivascular -
amyloid. Among 20 participants with first-ever ICH, flutemetamol PET scans 
were 86% sensitive and 77% specific for CAA-associated ICH based on the 
modified Boston criteria. 
Brain CT is the test that usually diagnoses ICH. I found in 62 LINCHPIN 
participants with first-ever lobar ICH that subarachnoid haemorrhage and 
finger-like projections on CT, and APOE 4 allele possession were 
independently associated with CAA-associated lobar ICH defined on 
subsequent autopsy. I developed diagnostic models and criteria (“Edinburgh 
criteria”) based on these predictors that could accurately rule in or exclude 
CAA-associated lobar ICH. I performed a multicentre external validation 
study of the Edinburgh criteria. In a preliminary analysis, the CT-only 
diagnostic criteria (subarachnoid haemorrhage and finger-like projections) 
had high sensitivity (88%) and good specificity (84%) for CAA-associated 
lobar ICH. 
The risk of recurrent ICH is a key outcome for ICH survivors. I found that the 
risk of recurrent ICH was significantly higher in participants with first-ever 
lobar compared with non-lobar ICH. Among lobar ICH participants, the risk of 
recurrent ICH was significantly higher in those classified as high risk on the 
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CT-only Edinburgh criteria for CAA-associated lobar ICH compared with 
those classified as low risk. 
Predicting death or disability is also important in ICH. I found that the severity 
of SVD on the diagnostic brain CT was an independent predictor of death or 
disability at one year after the ICH, after adjusting for known prognostic 
factors. 
Brain imaging biomarkers, particularly on brain CT, are potentially useful for 
identifying the type of SVD associated with ICH. Having developed the CT-
based Edinburgh criteria for CAA-associated lobar ICH, I performed 
preliminary multicentre studies assessing their diagnostic accuracy and 
prognostic value. In the future, I aim to perform the full analyses of these 
diagnostic test accuracy and prognostic studies to determine the clinical 
utility of the Edinburgh criteria. Other research should assess the clinical and 
economic effect of the Edinburgh criteria on the prognosis of ICH. More work 
is needed to investigate the prognostic relevance of coexistence of CAA and 
non-CAA SVDs in lobar ICH, and whether these groups can be differentiated 




Stroke due to bleeding within the brain is called intracerebral haemorrhage 
(ICH). In most cases, ICH is thought to caused by bleeding from previously 
damaged small blood vessels in the brain (small vessel diseases – SVD). 
SVD can result from an abnormal protein accumulating in the small blood 
vessel walls, known as cerebral amyloid angiopathy (CAA), or high blood 
pressure (non-CAA SVD). Identifying ICHs associated with CAA is important 
because the risk of recurrent ICH appears higher in these patients. 
The aims of my thesis were to (a) assess the types and severity of SVD 
associated with ICH using brain autopsy tissue, (b) explore whether brain 
imaging (magnetic resonance imaging (MRI), molecular imaging and 
computed tomography (CT)) features can be used in living patients to identify 
CAA-associated ICH and (c) determine whether brain CT features can 
predict outcome after ICH. 
In an autopsy study of 126 ICH participants, I found that almost all with an 
ICH deep within the brain (non-lobar ICH) had advanced non-CAA SVD. In 
contrast, 60% of those with a bleed located superficially in the brain (lobar 
ICH) had advanced CAA, while many had advanced non-CAA SVD, either 
with or without CAA. 
Identifying lobar ICH patients who have CAA is useful for predicting outcome. 
The most common approach used in clinical practice is brain imaging with 
MRI. However, I found that only about one-third of ICH patients are able to 
undergo MRI. Also, the widely used MRI criteria for CAA showed limited 
accuracy for CAA identified at subsequent autopsy, which is the best 
approach for identifying CAA. 
Molecular brain imaging using tracers designed to detect the amyloid protein 
in Alzheimer’s disease may also detect the amyloid protein found in CAA. I 
found that in brain tissue samples, the amyloid tracer labelled both 
Alzheimer’s and CAA amyloid. Molecular amyloid scans showed good 
accuracy for CAA in ICH patients based on the MRI criteria. 
 xx 
Brain CT is the test that usually diagnoses ICH. I found that two features on 
the diagnostic brain CT (blood in the fluid around the brain and a lobulated 
contour of the ICH) were highly accurate for identifying CAA-associated lobar 
ICH at subsequent autopsy. CT is widely available, so these diagnostic 
criteria for CAA-associated lobar ICH are potentially useful worldwide. 
One of the main concerns in ICH survivors is their risk of a recurrent ICH. I 
found that the CT criteria for CAA-associated ICH were able to identify lobar 
ICH patients at high or low risk of recurrent ICH. 
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Chapter 1 Introduction 
 
1.1 Cerebral small vessel diseases 
Cerebral small vessel diseases (SVDs) are pathological processes affecting 
the small blood vessels in the brain.[1] Small blood vessels are defined as 
vascular structures in the brain parenchyma or subarachnoid space 
(leptomeningeal) ranging from 2 mm to 5 m in diameter and include small 
arteries, arterioles, capillaries and venules.[1] The term SVDs is often used to 
relate to the small arteries and arterioles. However, it also encompasses 
diseases of the venules and capillaries.[2, 3] 
Anatomically, there are two origins of the cerebral small arteries and 
arterioles. They can arise directly from large arteries at the base of the brain 
as deep arterial perforators and supply the basal ganglia (lenticulostriate and 
anterior choroidal arteries), thalami (predominantly posterior choroidal and 
thalamogeniculate arteries) and brainstem (predominantly small perforating 
branches of the basilar and superior cerebellar arteries). Alternatively, they 
can originate from medium-sized arteries in the subarachnoid space on the 
brain surface and penetrate the cortex superficially to supply the grey-matter 
and subcortical white matter. These two systems converge in the deep 
subcortical white matter, although they do not anastomose.[1, 4-7] 
1.1.1 Types of SVDs 
There are several categories of underlying pathology in SVDs, of which 
arteriolosclerosis and cerebral amyloid angiopathy (CAA) are the most 
common. Genetic SVDs, such as cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy (CADASIL) and Fabry’s 
disease, are a less frequent type of SVD.[8-11] Inflammatory and 
immunologically mediated SVDs, such as granulomatosis related to 
polyangiitis, Churg-Strauss syndrome and systemic vasculitis associated with 
connective tissue disorders,[12] venous collagenosis and post-radiation 
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angiopathy can affect cerebral small blood vessels but are not typically 
considered under the term SVDs. 
In my thesis, I will concentrate on SVDs thought to result from 
arteriolosclerosis and sporadic CAA, and I will use the term SVDs to refer to 
these two types of SVD. 
1.1.1.1 Arteriolosclerosis 
Arteriosclerosis is common, affecting up to 70% of the elderly.[14] It is 
associated with hypertension, ageing and diabetes,[2, 15, 16] although many 
people with arteriolosclerosis are not hypertensive.[2, 17] It has variably been 
called arteriolosclerosis, age-related or vascular risk-factor-related SVD, 
hypertensive arteriopathy or sporadic non-amyloid microangiopathy in the 
literature.[1, 4] 
Arteriolosclerosis is characterised by the initial hypertrophy then subsequent 
loss of smooth muscle cells in the media of small vessels (cerebral, retinal, 
renal), collagenous thickening of the vessel wall and deposition of fibro-
hyaline material. It typically affects the deep arterial perforators supplying the 
basal ganglia, thalami and brainstem.[1]  
The pathophysiology of arteriolosclerosis is not fully understood. At a simple 
level, the pathological changes can be thought to result in luminal narrowing 
and dilatation, microatheroma and microaneurysms, which in turn can cause 
ischaemic or haemorrhagic (micro and macrohaemorrhages) consequences. 
However, the vascular changes involved are much more complicated, with 
ischaemia and haemorrhages being end-stage events of a long-standing 
complex cascade of vascular dysfunction. 
1.1.1.2 Sporadic CAA 
CAA can occur as a sporadic form or as rare inherited versions.[18] Sporadic 
CAA frequently occurs in the general elderly population, affecting 20-40% of 
non-demented elderly and 50-60% of demented elderly,[14, 19] and in 
Alzheimer’s disease.[14, 19-21] Increasing age is the strongest clinical risk 
factor for CAA.[22, 23] The apolipoprotein E (APOE) 4 allele has a dose-
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dependent association with pathologically proven sporadic CAA,[24, 25] 
whereas a recent meta-analysis did not show a statistically significant 
association between APOE 2 allele and sporadic CAA.[24] 
CAA is characterised by progressive accumulation of perivascular -amyloid 
peptide in the media and adventitia of cortical and leptomeningeal arteries 
and arterioles.[26] The cerebral cortex is most commonly affected. However, 
the cerebellum can also be involved to a lesser extent.[23, 27, 28] -amyloid 
in CAA is predominantly composed of the 40 amino acid fragment, whereas 
the 42 amino acid fragment is the major type in Alzheimer’s disease.[29-31] 
The pathophysiology of vascular -amyloid deposition is incompletely 
understood. Current theories suggest it results from impaired clearance 
rather than overproduction of the -amyloid protein,[32, 33] via disrupted 
perivascular drainage pathways.[34, 35]  
When severe, CAA can result in the complete replacement of vascular 
smooth muscle with -amyloid, and the vessels become irregular, dilated and 
demonstrate secondary vasculopathic changes, such as fibrinoid necrosis 
and microaneurysm formation.[33, 36] Vessel disruption and fragmentation is 
thought to result in extravasation of blood (micro and 
macrohaemorrhages),[1] while luminal occlusion can result in ischaemia and 
infarction.[37] 
1.1.2 Clinical consequences of SVDs 
SVDs can result in both ischaemic and haemorrhagic consequences. SVDs 
cause 20-25% of ischaemic strokes[38, 39] and 85% of spontaneous 
intracerebral haemorrhage,[40] yet the pathophysiology is incompletely 
understood.[1] 
As described above, the pathophysiology underlying arteriolosclerosis and 
CAA is not fully understood. Several mechanisms have been suggested for 
ischaemic consequences of SVDs. SVD-related vessel wall thickening can 
cause a narrowing of the vessel lumen. This is postulated to result in chronic 
white matter hypoperfusion, leading to oligodendrocyte death and ultimately 
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demyelination.[41-43] Endothelial dysfunction, disruption of the blood-brain 
barrier and oligodendrocyte apoptosis may also contribute to diffuse chronic 
white matter interstitial fluid increase with or without hypoperfusion, resulting 
in white matter lesions on neuroimaging (1.1.3).[2, 3, 44-46] Endothelial 
dysfunction and inflammation may precipitate acute occlusion of the vessel 
lumen and is considered to be the cause of most small subcortical infarcts, 
while a minority of acute small subcortical infarcts are thought to result from 
large vessel atheroma and embolism.[2, 44, 47-50] 
The haemorrhagic consequences are hypothesised to relate to SVD-related 
vessel wall damage, which can lead to fragile, brittle walls and 
microaneurysm formation, especially in CAA. Subsequent vessel rupture is 
thought to account for microscopic (cerebral microbleed (CMB) – see 1.1.3.5) 
and macroscopic haemorrhages. 
SVDs are a major contributor to cognitive impairment in the elderly,[51] 
accounting for nearly half of dementias.[52] Strategically located lacunes,[53] 
particularly in the thalamus,[54] as well as multiple lacunes[55] are 
associated with worse cognition. White matter lesions thought to be related to 
SVDs are associated with cognitive decline in longitudinal studies,[56] and 
act as a predictor for cognitive decline[57] and dementia.[58] CAA is an 
important contributor to cognitive decline independent of Alzheimer’s disease 
and other dementia-related neuropathologies.[14, 21, 59, 60] The 
mechanisms through which CAA causes cognitive impairment are not 
understood but may relate to CMBs, microinfarcts and white matter 
lesions.[61-63] 
The presence and severity of SVDs are associated with the development of 
physical disabilities in the elderly.[64, 65] Patients with severe white matter 
lesions have a twofold higher risk of developing a disability or dying 
compared to patients with mild white matter lesions.[65] 
CAA can also result in transient focal neurological episodes (“amyloid 
spells”).[66] These episodes commonly involve spreading sensory 
symptoms, such as paraesthesia or numbness, although motor seizure-like 
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episodes and visual disturbance can also occur. They usually progress over 
seconds to minutes, last less than 30 minutes and are often recurrent and 
stereotyped.[23, 66] Their cause is unclear; they may relate to a direct effect 
of -amyloid on local cortical function, or reflect seizure-like activity from local 
haemorrhage,[67, 68] spreading cortical depression[69, 70] or local 
vasospasm.[23, 66, 69] CAA-associated transient focal neurological episodes 
may be associated with an increased risk of early symptomatic lobar ICH.[71] 
1.1.3 Neuroimaging features of SVDs 
Studying SVDs is challenging. There is often limited tissue available for 
histopathological assessment as brain biopsies are invasive and seldom 
performed, while post-mortem material is scant as many SVDs are rarely 
fatal in the acute setting.[72, 73] Animal models are currently used with 
caution because of lack of a clear mechanism to mimic.[74, 75] 
The small cerebral vessels affected by SVDs are generally too small to 
directly identify on clinical neuroimaging.[76] However, neuroimaging can 
identify brain changes and vascular dysfunction thought to represent some of 
the consequences of SVDs, making it a useful technique for studying SVDs. 
Magnetic resonance imaging (MRI) is the neuroimaging reference standard 
for SVDs because it has better sensitivity and specificity for SVD imaging 
biomarkers compared with computed tomography (CT).[77] However, CT is 
more widely available and better tolerated than MRI, making it a useful 
imaging modality in routine clinical practice. 
The nomenclature and definitions of SVD neuroimaging biomarkers has 
varied considerably in the past.[77-79] In 2013, an international working 
group published a position paper proposing a unified approach to defining 
and reporting SVD neuroimaging biomarkers (Standards for ReportIng 






Figure 1.1 STRIVE definitions of MRI SVD biomarkers 
Example axial MRI images (upper) and schematic representations (middle) of SVD MRI biomarkers, with a summary of 
imaging characteristics (lower) for individual lesions. Reproduced with permission from [77] 
 
DWI = diffusion-weighted imaging. FLAIR = fluid-attenuated inversion recovery. GRE = gradient-recalled echo. MRI = 
magnetic resonance imaging. STRIVE = standards for reporting vascular changes on neuroimaging. SWI = susceptibility-
weighted imaging.
  Chapter 1 
 9 
1.1.3.1 Recent small subcortical infarcts 
A recent small subcortical infarct is an area of infarction in the territory of a 
perforating arteriole (i.e. subcortical white matter, basal ganglia, thalami or 
brainstem) with neuroimaging features or clinical symptoms consistent with a 
lesion occurring in the preceding few weeks.[77] It should be less than 20 
mm in axial diameter. There is no minimum diameter. 
Recent small subcortical infarcts usually correspond with a clinically evident 
lacunar stroke syndrome, although occasionally they can be 
asymptomatic.[80, 81] MRI, however, is not completely sensitive for acute 
lacunar stroke syndrome as there is no corresponding recent small 
subcortical infarct in up to 30% of patients.[82] Evolution of small subcortical 
infarcts is variable; they may become a lacune or white matter hyperintensity, 
or disappear.[77] 
1.1.3.2 Lacune of presumed vascular origin 
A lacune of presumed vascular origin (lacune) is a small round or ovoid 
subcortical cavity consistent with a previous acute brain infarct or 
haemorrhage in the territory of a perforating arteriole.[77] Lacunes range in 
size from 3 to 15 mm. The contents of the cavity usually follow the signal of 
cerebrospinal fluid (CSF), however, sometimes the central cavity can have 
high signal on FLAIR.[83] There is often a rim of hyperintense FLAIR signal. 
On CT, lacunes are small focal areas of subcortical hypoattenuation. Most 
lacunes are thought to be the sequelae of symptomatic or asymptomatic 
small subcortical infarcts, although some may evolve from small subcortical 
haemorrhages.[77, 84] Post-mortem MRI studies show that MRI-defined 
lacunes correlate with irregular cavities, around which there may be reactive 
gliosis with myelin and axonal loss.[73] Some lacunes do not show cavitation 
but are associated with selective neuronal loss.[73] 
Lacunes are common in asymptomatic elderly patients, but they are also 
associated with an increased risk of stroke, dementia and gait 
impairment.[85-88] 
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1.1.3.3 White matter hyperintensity of presumed vascular origin 
White matter hyperintensities of presumed vascular origin (WMH) are areas 
of increased T2-weighted signal.[77] T2-weighted hyperintensities in the 
deep grey matter and brainstem are not usually included in this definition. 
WMH are usually bilateral and often symmetrical. Periventricular WMH are 
often differentiated from subcortical or deep WMH.[89] The terms white 
matter hypoattenuation and white matter lucencies are used for describing 
these abnormalities on CT. 
WMH are correlated with a heterogeneous variety of histopathological 
findings, including myelin, axonal and oligodendrocyte loss, dilated 
perivascular spaces, white matter infarcts and arteriolosclerosis.[73] The 
severity of histopathological changes mirrors the severity of WMH on 
neuroimaging; smooth periventricular or punctate deep WMH are associated 
with mild changes on histopathology, whereas irregular periventricular and 
confluent deep WMH correlate with more severe histopathological 
features.[73]  
WMH are associated with cerebrovascular disease and traditional vascular 
risk factors, as well as an increased risk of stroke, dementia and death.[90] 
Their pathogenesis is not fully understood but may relate to chronic 
hypoperfusion, endothelial dysfunction, disruption of the blood-brain barrier 
and oligodendrocyte apoptosis (1.1.2). 
1.1.3.4 Perivascular spaces 
Perivascular spaces are fluid-filled spaces following the expected course of a 
perforating vessel in grey or white matter and have the same signal intensity 
as CSF.[77] They are linear when imaged parallel to the vessel and round or 
ovoid and less than 3 mm in diameter when imaged perpendicular to the 
vessel. Perivascular spaces are seen in the basal ganglia, cerebral white 
matter and midbrain. They usually do not have a hyperintense T2-weighted 
rim, unlike lacunes, unless they occur in a WMH.[73, 91] 
Normal perivascular spaces are microscopic and not visible on MRI. Only 
when they enlarge do they become visible. They are associated with other 
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SVD neuroimaging biomarkers, such as WMH[92] and lacunes.[93] They are 
also postulated to be involved in the pathogenesis of CAA (1.1.1.2).[94, 95] 
1.1.3.5 Cerebral microbleeds 
A CMB is a small area of signal loss between 2 mm and 10 mm in diameter 
with associated blooming on T2*-weighted or susceptibility-weighted 
sequences.[77] They are usually round or oval with homogeneously low 
signal on T2*-weighted or susceptibility-weighted imaging, and not visible on 
T1-weighted, T2-weighted or FLAIR sequences. CMBs are most frequently 
seen at the cortico-subcortical junction, deep cerebral or cerebellar grey and 
white matter, and in the brainstem. 
CMBs have been shown to correlate with tiny foci of hemosiderin on 
histopathology. However, some CMBs relate to small lacunes, vessel wall 
dissection and microaneurysms.[73, 96, 97] CMBs are associated with 
SVDs.[98-100] The adjacent small blood vessels are often abnormal, being 
affected by arteriolosclerosis or CAA.[101, 102] CAA-associated CMBs tend 
to be located at the cerebral grey-white matter junction,[103] whereas CMBs 
associated with arteriolosclerosis tend to be found in the non-lobar 
regions.[104] CMBs restricted to the lobar regions is a key imaging feature of 
CAA-associated lobar ICH and are associated with an increased risk of 
recurrent ICH in such patients.[105] They are also associated with cognitive 
decline.[106] However, the strengths of associations and specificity of CMB 
distribution remain unclear. 
1.1.3.6 Cortical superficial siderosis 
Cortical superficial siderosis is defined as curvilinear hypointensities over the 
cortex with blooming artefact on T2*-weighted or susceptibility-weighted 
imaging.[77, 107, 108] The hypointense signal should run parallel to the 
cerebral sulci and superficial cortical layers. The sensitivity of MRI for cortical 
superficial siderosis depends on the sequence type and field strength.[107, 
109] 
Cortical superficial siderosis relates to haemosiderin deposits within the 
subarachnoid space, the leptomeninges and the superficial (subpial) layers of 
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the cerebral cortex.[107] It is thought to result from the breakdown of acute 
cerebral convexity subarachnoid haemorrhage.[108, 110-112] 
Cortical superficial siderosis can result from traumatic subarachnoid 
haemorrhage, vascular malformations, reversible cerebral vasoconstriction 
syndrome, or it can be idiopathic.[107, 113, 114] It is now recognised as an 
important imaging biomarker of CAA.[107, 110, 115] In CAA, cortical 
superficial siderosis is thought to be a marker of cortical or leptomeningeal 
vessel rupture or expansion of a lobar ICH into the subarachnoid space. It is 
associated with transient focal neurological episodes [71] and an increased 
risk of recurrent spontaneous ICH.[116-118] 
1.1.3.7 Brain atrophy 
Brain atrophy is defined as a reduced volume of brain parenchyma that is not 
related to a specific focal macroscopic injury, such as previous trauma or an 
infarct.[77] Its presence is inferred by enlargement of the CSF containing 
spaces; cortical sulci for cortical atrophy and the ventricular system for 
central atrophy. 
Brain atrophy can be generalised or focal, symmetrical or asymmetric. It 
occurs in many neurological disorders as well as normal ageing. Brain 
atrophy related to SVDs is a heterogeneous process and corresponds to 
neuronal loss, white matter rarefaction and secondary neurodegenerative 
changes.[119-121] 
SVD severity is associated with brain atrophy.[122, 123] There is also 
evidence that CAA is associated with brain atrophy even in the absence of 
Alzheimer’s disease.[124, 125] Brain atrophy is thought to account for at 
least some of the cognitive impairment associated with SVDs.[126, 127] 
 
1.2 Symptomatic spontaneous ICH 
1.2.1 Terminology 
Spontaneous ICH refers to bleeding within the brain parenchyma, which is 
not caused by trauma.[128] Spontaneous ICH can extend into the extra-axial 
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spaces (intraventricular, subarachnoid or subdural). However, it is important 
to distinguish spontaneous ICH from pure intraventricular, subarachnoid, 
subdural or extradural haemorrhage (Figure 1.2) given the differences in risk 
factors, aetiology and treatments.[129] Spontaneous ICH and subarachnoid 
haemorrhage are sometimes considered together under the term 
“haemorrhagic stroke”. 
Spontaneous ICH can be further classified based on the underlying aetiology 
(Section 1.2.6). “Primary ICH” is often used in the literature and clinical 
practice to refer to an ICH where no macroscopic cause is evident and the 
ICH is presumed due to SVDs. However, this term is confusing, as it implies 
there is no cause underlying the ICH. “Secondary ICH” is used when a 
macroscopic cause, such as an aneurysm, arteriovenous malformation or 
tumour, is present. 
Throughout my thesis, I use the abbreviation ICH to represent spontaneous 
ICH, the term haemorrhagic stroke to represent ICH and subarachnoid 
haemorrhage, and SVD-associated ICH to represent spontaneous ICH 
presumed secondary to SVDs (i.e. when no macroscopic cause of ICH is 
evident). 
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Figure 1.2 Axial illustration of the brain showing the subtypes of intracranial 
haemorrhage. 
Reproduced with permission from [129] 
 
 
In research and clinical practice, SVD-associated ICH is frequently 
categorised by anatomical location because this partly influences the likely 
underlying SVDs (1.1.1) and prognosis (1.2.7). In my thesis I use the term 
lobar ICH to refer to haematomas where the main bulk and presumed 
epicentre is in the cerebral lobes (frontal, parietal, temporal or occipital lobes, 
or the insular cortex). I use the term non-lobar ICH when the main bulk and 
presumed epicentre of the haematoma is in the basal ganglia, thalamus, 
brainstem or cerebellum (Figure 1.3).  
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Figure 1.3 Axial T1-weighted images of the brain showing the lobar (red 
shaded) and non-lobar (blue shaded) regions 
 
 
1.2.2 The burden of ICH 
Stroke is the second most common cause of death worldwide and the 
second most common cause of disability.[130] Haemorrhagic stroke 
accounts for approximately one-third of incident strokes worldwide, but 49% 
of stroke deaths and 58% of disability-adjusted life years due to stroke.[131] 
Haemorrhagic stroke is a global disease. However, its main burden is in low 
and middle-income countries; 80% of incident haemorrhagic strokes, 84% of 
deaths from haemorrhagic strokes and 86% of disability-adjusted life years 
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due to haemorrhagic stroke occurred in low and middle-income 
countries.[132] 
ICH is the major cause of haemorrhagic stroke and the second most 
common cause of stroke after ischaemic stroke. Between 2000 and 2008, 
ICH accounted for 9% to 13% of strokes in high-income countries, and 14% 
to 27% in low to middle-income countries.[133] 
1.2.3 Epidemiology of ICH 
The overall incidence of ICH in 29 population-based studies without age 
limits was 23.5 per 100,000 person-years (95%CI 20.1-27.6).[134] The 
incidence of ICH in low to middle-income countries was nearly double the 
incidence in high-income countries. The difference in ICH incidence between 
high-income and low to middle-income countries is thought to relate to 
differences in the frequency of risk factors, such as hypertension and 
smoking.[133] 
The incidence of ICH increases with age and is highest amongst east and 
southeast Asian people compared with other ethnicities (incidence ratio 2.1, 
95%CI 1.6-2.9 compared with white people).[134] The incidence in women is 
lower than men, although this difference is not statistically significant 
(incidence ratio 0.85, 95%CI 0.61-1.18).[134] 
Overall there has been no substantial decrease in the incidence of ICH since 
1980 in 26 high-quality population-based studies (annual decrease of 0.3% 
per year, 95%CI -2.7-3.3).[134] In one population-based study from Oxford, 
the change in ICH incidence over time varied according to the presumed 
aetiology of ICH. The incidence of ICH associated with premorbid 
hypertension fell between 1981 and 2006 (rate ratio 0.37, 95%CI 0.20-0.69), 
whereas the incidence of antithrombotic-associated ICH (rate ratio 7.4, 
95%CI 1.7-32) and ICH associated with presumed CAA (rate ratio 4.0, 
95%CI 1.1-17) increased.[135] Similar findings were identified between 1985 
and 2008 in a population-based registry of ICH in Dijon, France.[136] There 
is no accurate data on the change in stroke incidence according to stroke 
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subtype in low and middle-income countries before 2000, preventing the 
assessment of temporal changes in ICH incidence in these countries.[133] 
1.2.4 Risk factors for spontaneous ICH 
Hypertension is the most commonly identified risk factor for ICH. The risk of 
ICH in those with hypertension is two times that of non-hypertensive 
people.[137-140] The risk also appears to increase with increasing average 
blood pressure,[137] and is higher for non-lobar compared with lobar 
ICH.[138, 141] Increasing age is another strong risk factor for ICH, with the 
relative risk of ICH doubling with every decade increase.[137, 139] High 
alcohol intake is also associated with an increased risk of ICH.[137, 140, 142] 
Genetic polymorphisms account for up to 44% of ICH risk.[143] APOE is the 
best-studied gene. The presence of APOE 2 and 4 alleles are associated 
with ICH, especially lobar ICH.[138, 144, 145] However, APOE only accounts 
for a proportion of the genetic risk for ICH, and other genes are also likely to 
influence the risk of ICH. 
1.2.5 Clinical presentation of spontaneous ICH 
The clinical features caused by ICH depend on its size and location. They 
can relate to damage in the area affected by the ICH, remote effects of 
displaced brain, as well as raised intracranial pressure. ICH usually results in 
an abrupt onset of clinical features. Patients usually have an acute stroke 
syndrome with focal neurological deficit. They may have a severe headache, 
nausea, vomiting and altered consciousness. Patients may also present with 
confusion, personality change or seizures. Some ICH can be 
asymptomatic.[146] 
Currently, it is not possible to reliably differentiate ICH from ischaemic stroke 
clinically.[147] Neuroimaging is required to confirm ICH.[148, 149]  
1.2.6 Cause of spontaneous ICH 
Spontaneous ICH is caused by a specific macroscopic structural cause, such 
as an arterial aneurysm, arteriovenous malformation, cerebral cavernous 
malformation, venous sinus thrombosis, tumour or abscess, in approximately 
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15% of cases.[40] It is important to identify such patients as there may be 
specific management options depending on the underlying cause.[150]  
The majority of patients with spontaneous ICH, however, have no 
macroscopic structural cause. In these patients, the ICH is thought to be due 
to SVDs, either arteriolosclerosis or CAA (SVD-associated ICH).[40] As 
discussed in 1.1.2, SVD-related vessel wall damage is thought to lead to 
vessel rupture and ICH. 
1.2.7 Prognosis of SVD-associated ICH 
The most clinically relevant outcomes in SVD-associated ICH are death, 
disability and recurrent ICH. 
1.2.7.1 Death 
Median one-month case fatality for ICH is approximately 40%.[133, 134] 
Median one-year case fatality is approximately 55%.[134] Overall, case 
fatality increases with age and is similar for men and women. There has been 
no substantial change in one-month case fatality of ICH since 1980 (annual 
decrease 0.2% per year, 95%CI -1.1 to 0.7).[134] 
The most well-established risk factors for death after ICH are increasing age, 
increasing ICH volume, decreasing Glasgow Coma Scale (GCS) score on 
hospital admission and infratentorial ICH location.[151]  
1.2.7.2 Disability  
Survivors of SVD-associated ICH are often left disabled. A systematic review 
of four population-based studies of functional outcome after ICH 
demonstrated that 16-46% of survivors were functionally dependent at six 
months (modified Rankin scale 3-5), while 43-46% were dependent at one 
year.[151] Predictors of functional outcome after ICH are similar to the risk 
factors for death. Pre-ICH cognitive impairment is also independently 
associated with functional outcome.[152] 
The severity of SVDs may be a risk factor for death and disability after SVD-
associated ICH given its association with physical disabilities and death in 
elderly patients without ICH.[64, 65] 
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1.2.7.3 Recurrent ICH 
The risk of a recurrent ICH is important for survivors of SVD-associated ICH. 
The annualised rate of recurrent ICH is 2.0-2.4%, with 1.8% to 7.4% of 
patients having a recurrent ICH within the first year.[151] Patients with a lobar 
ICH appear to be at higher risk than non-lobar ICH.[151] This is thought to 
reflect the likely types of SVDs underlying these ICHs. CAA is associated 
with some lobar ICH,[153] whereas non-lobar ICH is usually associated with 
arteriolosclerosis. MRI-based studies suggest the risk of recurrent ICH is 
higher with CAA-associated ICH rather than arteriolosclerosis-associated 
ICH.[105, 154-157] 
The risk of antithrombotic-related recurrent ICH may also be higher in 
survivors of CAA-associated lobar ICH. Biffi et al. assessed the association 
between clinical characteristics, APOE genotype, neuroimaging features and 
antithrombotic drug use and the risk of recurrent ICH in CAA-associated 
lobar ICH in a single centre prospective cohort study of 104 SVD-associated 
lobar ICH survivors.[158] A previous lobar ICH, two or more lobar CMBs, 
posterior white matter lucencies on CT and aspirin use after the index ICH 
were independently associated with the risk of recurrent ICH. However, the 
study had several limitations. Only survivors of lobar ICH who underwent a 
MRI were included, which is likely to introduce a selection bias. The sample 
size was modest, with only 29 recurrent ICHs during follow-up. The 
regression models were overfitted, especially given the stepwise selection 
methods used. The authors did not account for death as a competing risk, 
which will overestimate the strength of the reported associations. Finally, the 
findings may be the result of confounding as this was not a randomised 
study. In particular, the authors did not account for blood pressure control 
during follow-up, which is known to affect the risk of recurrent ICH.[159] 
A recent randomised controlled trial assessed the risk of antiplatelet drugs on 
recurrent ICH in SVD-associated ICH survivors who were taking an 
antiplatelet drug for the prevention of occlusive vascular disease at the time 
of ICH. In contrast to the findings described by Biffi et al, in this study the 
group restarted on an antiplatelet agent after the ICH had a borderline 
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statistically significant lower risk of recurrent ICH than the group not restarted 
on an antiplatelet drug (adjusted hazard ratio 0.51, 95% CI 0.25–1.03; 
p=0.060).[160] There were no statistically significant hazards of antiplatelet 
drug use on recurrent ICH according to CT or MRI markers of CAA. 
However, the power of these imaging subgroup analyses was limited, and 
there is likely to be selection bias in the study.[161] 
It is therefore unclear whether aspirin does increase the risk of recurrent ICH 
in those with a CAA-associated lobar ICH. Nonetheless, clinicians often avoid 
antithrombotic drugs in patients with a presumed CAA-associated ICH. 
 
1.3 Diagnosing SVD-associated ICH 
Differentiating CAA-associated ICH from arteriolosclerosis-associated ICH is 
clinically important to inform prognosis and potentially guide some treatment 
decisions. However, diagnosing the types of SVDs underlying SVD-
associated ICH is currently difficult. 
1.3.1 Histopathology 
Histopathology is the reference standard for diagnosing SVD-associated ICH. 
Arteriolosclerosis and CAA have characteristic features on histology (1.1.1) 
and CAA can be accurately identified using immunohistochemistry. 
Furthermore, other causes of ICH, such as aneurysms, arteriovenous 
malformations and tumours, may be excluded. However, brain tissue is rarely 
available during life. A cortical biopsy is an invasive procedure, and 
haematoma evacuation samples are not commonly available given the lack 
of clear benefit from early surgical haematoma evacuation.[162, 163] Even 
when tissue is available for histopathology, the quantity is often small, and 
inaccuracies can occur due to sampling error.[164] Therefore, differentiation 
of CAA-associated and arteriolosclerosis-associated ICH is usually based on 
ICH location and neuroimaging features. 
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1.3.2 ICH location 
Given the distribution of vessels affected,[1, 26, 28] clinicians frequently 
attribute non-lobar ICH to arteriosclerosis and lobar ICH, particularly in the 
elderly, to CAA.[165] However, these generalisations are not completely 
accurate. The link between CAA and lobar ICH is relatively weak, being based 
on a few clinicopathological case-control studies with methodological 
problems, such as poorly matched control groups and differences in CAA 
histopathological diagnosis.[153] A meta-analysis of these studies showed a 
statistically significant but imprecise association between CAA and lobar ICH 
(OR 2.2 95% CI 1.1 to 4.5). No association between deep ICH and CAA was 
identified (OR 0.8 95% CI 0.3 to 2.2).[153] CAA is therefore likely to account 
for only some lobar ICH, indicating that ICH location alone is insufficient for 
reliably identifying the underlying SVDs. 
1.3.3 Genetics 
As discussed in 1.1.1.2, APOE 4 allele has a dose-dependent association 
with pathologically proven sporadic CAA.[24, 25] Possession of an APOE 4 
allele may, therefore, be useful for differentiating CAA-associated from 
arteriolosclerosis-associated ICH. However, the diagnostic value of APOE 
genotype on its own or in combination with other clinical and neuroimaging 
features for CAA-associated ICH is unknown. 
1.3.4 Neuroimaging 
Brain imaging is commonly performed in ICH. CT, MRI and positron emission 
tomography (PET) are neuroimaging techniques that can potentially help 
differentiate CAA-associated from arteriolosclerosis-associated ICH. 
1.3.4.1 CT 
CT is widely available, has few contraindications and is often the first test to 
diagnose ICH, yet no CT-based diagnostic criteria for CAA-associated or 
arteriolosclerosis-associated ICH currently exist. 
A recent systematic review identified 23 studies (21 case series without 
controls and two cross-sectional studies with controls) that assessed CT 
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features in lobar or cerebellar ICH in 319 adults with pathologically proven 
CAA.[166] In the case series, subarachnoid haemorrhage was the most 
frequent CT feature in pathologically proven CAA (pooled proportion 82%, 
95%CI 69-93%), followed by an irregular ICH border (64%, 95%CI 32-91%). 
Multiple acute ICHs were present in 37% (95%CI 18-58%). The frontal and 
parietal lobes were the most frequently affected by ICH, followed by the 
occipital lobe and then the temporal lobe. In one of the retrospective hospital-
based cross-sectional studies of 41 cases and 42 controls, CAA-associated 
lobar ICHs were more likely to be multiple, have subarachnoid haemorrhage 
and a lobulated border. There was no association between subarachnoid 
haemorrhage and CAA-associated lobar ICH in the other cross-sectional 
study of 22 cases and nine controls. 
Given its widespread availability, CT-based diagnostic criteria to differentiate 
CAA-associated from arteriolosclerosis-associated ICH would be very useful. 
CT features, such as subarachnoid haemorrhage and a lobulated ICH border 
may be useful for identifying CAA-associated lobar ICH. However, rigorous 
diagnostic test accuracy studies are required to assess this. 
1.3.4.2 MRI 
MRI is the in vivo reference standard for assessing SVDs.[77] A range of 
SVD biomarkers can be identified on MRI (1.1.3). The presence and 
distribution of these SVD biomarkers may be useful for identifying the types 
of SVDs underlying ICH. 
The Boston criteria are MRI-based diagnostic criteria for CAA, which are 
frequently used in clinical practice and in research to guide further, often 
invasive, investigations, treatment decisions and recruitment into 
studies.[103, 110, 167, 168] These criteria use the number and distribution of 
haemorrhagic foci to determine the likelihood of underlying CAA. 
The original Boston criteria were first published in 1995 and consider CMBs 
and macrohaemorrhages as haemorrhagic foci (Table 1.1).[169] Three 
external validation studies of the original Boston criteria in ICH participants 
showed good to excellent specificity (81%-100%) and moderate to good 
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sensitivity (73-90%) against a histopathological reference standard.[103, 110] 
However, all these studies were small with significant methodological 
limitations. In 2010, cortical superficial siderosis was added to the criteria as 
a further potential haemorrhagic focus to create the modified Boston criteria 
(Table 1.1), which are now the clinical reference standard for diagnosing 
CAA. While the modified Boston criteria showed excellent sensitivity and 
good specificity for CAA-associated ICH during their development,[103, 110] 
they have never been rigorously externally validated. Their true diagnostic 
accuracy is, therefore, unknown. 
1.3.4.3 Positron emission tomography 
CT and MRI can detect structural brain changes secondary to SVDs, such as 
CMBs and macrohaemorrhages, subarachnoid haemorrhage and cortical 
superficial siderosis, WMH and perivascular spaces. The presence and 
distribution of these imaging biomarkers may be useful to infer the underlying 
SVD type. However, the imaging biomarkers associated with 
arteriolosclerosis and CAA are likely to overlap given their overlapping brain 
distribution and shared pathophysiology, thus limiting their specificity. Also, 
these structural changes are likely to represent relatively late consequences 
of SVDs. In particular, haemorrhages are thought to be a late consequence 
of advanced CAA.[170] Therefore, structural imaging biomarkers may not be 
sensitive for identifying those patients in the earliest stages of these 
diseases. 
Positron emission tomography (PET) is a form of in vivo molecular imaging 
that may improve the identification of SVDs during life through the direct 
detection of specific molecular changes. For example, β-amyloid PET 
radioligands designed for Alzheimer’s disease may be able to detect the 
perivascular β-amyloid in CAA,[171, 172] and may have better sensitivity and 
specificity for CAA-associated ICH than structural imaging biomarkers. 
However, the diagnostic accuracy of -amyloid PET in SVD-associated ICH 
is not known. Well-designed diagnostic test accuracy studies are required. 
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Table 1.1 Comparison of the original and modified Boston criteria for CAA-
associated haemorrhage 
 Original Boston criteria Modified Boston criteria 
Probable 
CAA 

















 Absence of other cause 
of haemorrhage 
 Single lobar, cortical or 
cortical-subcortical 
macrohaemorrhage or 




 Absence of other cause 





 Aged 55 years or over   Aged 55 years or over  
 









 Absence of other cause 
of haemorrhage  




 Absence of other cause 




 Cases not meeting the 
criteria for probable or 
possible CAA 
 Cases not meeting the 
criteria for probable or 
possible CAA 
CAA = cerebral amyloid angiopathy. CMB = cerebral microbleed 
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1.4 Ideal design of diagnostic test accuracy studies 
Rigorous diagnostic test accuracy studies of CT, MRI and -amyloid PET 
imaging biomarkers in SVD-associated ICH are required to determine their 
diagnostic value.[173] The ideal diagnostic test accuracy study design 
includes: 
 Prospective study design. 
 Using a representative sample of cases and controls drawn from the 
same population to minimise selection bias. 
 Performing the index test and reference standard at standardised time 
points after the index ICH. 
 Performing the same index test and reference standard to avoid 
differential verification bias.[174] 
 Using systematic approaches for analysing the index test (assessing 
CT, MRI or -amyloid PET imaging biomarkers) and reference 
standard with pre-specified definitions for imaging biomarkers and 
reference standard cut-offs to minimise information bias. 
 Assessment of the index test and reference standard by several raters 
to determine inter-rater agreement. 
 Masking of the raters to other relevant data.  
 Pre-specifying the statistical analyses. 
 Appropriately powered with sufficient numbers of participants with 
each target pathology to allow statistical analysis of the diagnostic test 
performance characteristics. 
 Describing the flow of participants through the studies and the 
differences between those who did and did not undergo the reference 
standard to illustrate partial verification bias.[174, 175] 
 Reporting the baseline clinical and radiographic features and the 
distribution of CAA and non-CAA SVD severity in the study groups to 
describe the spectrum of participants.[175, 176] 
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1.5 Aims 
There are no effective acute or specific treatments for ICH. Better prevention 
of ICH (first-ever and recurrent) is likely to be a more promising strategy to 
decrease its burden. Identifying the types of SVDs underlying SVD-
associated ICH is a fundamental step to increase our understanding of the 
disease processes. It may allow us to better recognise those at highest risk 
of death, disability and subsequent ICH, and help guide some treatment 
decisions. 
The main aims of my thesis were to:  
 Assess the incidence and distribution of clinical and non-contrast brain 
CT features in first-ever SVD-associated ICH according to ICH 
location in a community-based cohort of ICH (Chapter 3). 
 Assess APOE genotype and the distribution of MRI SVD biomarkers in 
first-ever SVD-associated ICH according to ICH location in a research 
cohort study of ICH (Chapter 3). 
 Evaluate the prevalence, severity and associations of 
histopathologically assessed SVDs in first-ever SVD-associated lobar 
ICH according to ICH location in a research cohort study of ICH 
(Chapter 4). 
 Assess the diagnostic accuracy of the MRI-based Boston criteria for 
CAA-associated ICH against a histopathological reference standard in 
a research cohort study of ICH (Chapter 5). 
 Investigate the feasibility and utility of -amyloid MRI-PET in first-ever 
SVD-associated ICH (Chapter 6). 
 Assess the diagnostic accuracy of CT biomarkers and APOE 
genotype for diagnosing first-ever CAA-associated lobar ICH and 
derive multivariable diagnostic models and criteria (The Edinburgh 
Diagnostic Criteria) for first-ever CAA-associated lobar ICH (Chapter 
7). 
 Perform multicentre external validation studies of the Edinburgh 
diagnostic models for CAA-associated with lobar ICH, and assess the 
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diagnostic accuracy of the Edinburgh Diagnostic Criteria against a 
histopathological reference standard (Chapter 8). 
 Assess the diagnostic accuracy of the Edinburgh Diagnostic Criteria 
for CAA-associated lobar ICH against the modified Boston criteria 
(Chapter 9). 
 Investigate the association between the Edinburgh Diagnostic Criteria 
for CAA-associated lobar ICH and the risk of recurrent ICH in 
survivors of lobar ICH (Chapter 10). 
 Develop multivariable logistic regression prognostic models to predict 
the risk of death and death or disability after first-ever SVD-associated 
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Chapter 2 Methods 
 
To investigate the diagnostic and prognostic value of SVD imaging 
biomarkers in SVD-associated ICH, I used data from two overlapping cohort 
studies; The Lothian Audit of the Treatment of Cerebral Haemorrhage 
(LATCH) and The Lothian INtraCerebral Haemorrhage Pathology, Imaging 
and Neurological outcome (LINCHPIN) study. The studies were conducted 
by the Research to Understand Stroke due to Haemorrhage (RUSH) team at 
the University of Edinburgh. This chapter describes the design of these 
studies, including methods of case ascertainment, baseline data collection 
and follow-up. I will also describe the methods used for brain CT and MRI 
acquisition and analysis, DNA extraction and APOE genotyping and research 
brain autopsy. 
 
2.1 Cohort studies 
2.1.1 Overview of studies 
LATCH is a community-based cohort study of all residents in the NHS 
Lothian Health Board region of Scotland who were aged 16 years or above 
and had an incident ICH between 1st June 2010 and 31st May 2013 inclusive. 
The purpose of LATCH was to monitor the quality of care, treatment and 
outcomes for adults with ICH. Its primary aim was to audit neurosurgical 
referrals and prescription of antihypertensive drugs at hospital discharge 
against European[177] and NICE guidelines.[178] Observational 
epidemiology can be performed using an anonymised extract of the audit 
dataset to examine the clinical and imaging characteristics of ICH as well as 
the factors that are associated with prognosis after ICH in a community-
based study. LATCH aimed to identify all ICH regardless of cause, including 
those due to a macrovascular or neoplastic cause as well as those without 
any detectable macroscopic cause (SVD-associated ICH) (Table 2.1). 
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During LATCH and until 31st May 2016, consecutive adults with SVD-
associated ICH were given the opportunity to consent to the LINCHPIN study 
(Figure 2.1). LINCHPIN is an ethically-approved, prospective, community-
based cohort study of SVD-associated ICH designed to pathologically assess 
the SVDs associated with SVD-associated ICH, determine the diagnostic 
utility of genetic and SVD biomarkers on brain CT and MRI for diagnosing 
pathologically-proven CAA, and assess the prognostic value of genetic and 
imaging SVD biomarkers in ICH. Eligible participants were invited to consent 
to any of the components of LINCHPIN (Figure 2.2): 
 
 A clinical assessment. 
 Permission for the research team to access their medical records. 
 Apolipoprotein E genotyping. 
 Research brain MRI scan. 
 Research autopsy limited to the brain. 
 
Table 2.1 Structural causes of intracerebral haemorrhage in LATCH. 
Cause of intracerebral haemorrhage Frequency (%) 
SVD-associated 
ICH 




Malignancy 31 5.8 
Arterial aneurysm 21 4.0 
Arteriovenous malformation 16 3.0 
Cavernous malformation 8 1.5 
Intracranial venous thrombosis 3 0.6 
Dural arteriovenous fistula 2 0.4 
Abscess 1 0.2 
ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of 
cerebral haemorrhage. SVD = small vessel disease. 
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Figure 2.1 The overlap between LATCH and the LINCHPIN study 
 
ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of 
cerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. SVD = small vessel disease. 
 
Figure 2.2 The numbers of participants consenting to the different 
components of the LINCHPIN study 
 
APOE = apolipoprotein E. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. MRI = magnetic resonance 
imaging.  
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2.1.2 Study settings 
Both LATCH and LINCHPIN were set in the NHS Lothian Health Board 
region of Scotland. According to Scotland’s Census 2011, the total population 
within this region was 834,350, with 51.4% females. 692,542 were aged 16 
or above.[179] 
NHS Lothian has three hospitals with emergency departments or acute 
medical receiving units (Royal Infirmary of Edinburgh, Western General 
Hospital, Edinburgh and St John’s Hospital, Livingston). All three hospitals 
have in-patient and out-patient stroke services, including acute stroke units. 
2.1.3 Study inclusion and exclusion criteria 
2.1.3.1 LATCH 
Patients were included in LATCH if they met all of the following: 
 Incident first-ever or recurrent spontaneous ICH. 
 ICH was confirmed by brain imaging or autopsy. 
 ICH symptom onset between 1st June 2010 and 31st May 2013 
inclusive. 
 Aged 16 years or over at ICH onset. 
 Resident within NHS Lothian Health Board region. 
Patients with any of the following were excluded from LATCH: 
 ICH was definitely secondary to trauma. 
 ICH was definitely secondary to haemorrhagic transformation of an 
ischaemic stroke (HTI). 
 Exclusively extra-axial intracranial haemorrhage (i.e. extradural, 
subdural, subarachnoid or intraventricular haemorrhage). 
2.1.3.2 LINCHPIN 
Patients were invited to consent to the LINCHPIN study if they met all of the 
following: 
 Incident first-ever or recurrent spontaneous ICH. 
 ICH was confirmed by brain imaging or autopsy. 
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 No evidence of underlying cause other than SVDs. 
 ICH symptom onset between 1st June 2010 until and 31st May 2016 
inclusive. 
 Aged 16 years or over at ICH onset. 
 Resident within NHS Lothian Health Board region. 
Patients with any of the following were excluded from LINCHPIN: 
 ICH was definitely secondary to trauma. 
 ICH was definitely secondary to a neoplastic, abscess or 
macrovascular cause. 
 ICH was definitely secondary to HTI. 
 Exclusively extra-axial intracranial haemorrhage (i.e. extradural, 
subdural, subarachnoid or intraventricular haemorrhage). 
2.1.4 Sources of ascertainment 
The RUSH team used multiple overlapping sources of case ascertainment to 
identify all incident ICH cases during the study periods. 
Prospective methods involved: 
 A collaborative network of acute and emergency medicine physicians, 
neurologists, stroke physicians and stroke nurse specialists, 
neurosurgeons, radiologists, rehabilitation physicians and pathologists 
who prospectively identified adults with incident ICH who attended 
hospital or neurovascular clinic. 
 Weekday review of all brain CT scans and their reports in the NHS 
Lothian Health Board region by trained members of the RUSH team to 
identify adults with ICH. 
Retrospective methods used by the RUSH team involved: 
 Six monthly review of the Scottish Stroke Care Audit, a national audit 
of stroke management and outcome in Scotland.[180] 
 Annual review of ICD-10-coded records of hospital discharges held by 
the Information Services Division. 
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 Annual review of records of sudden deaths held by the Office of the 
Procurator Fiscal. 
2.1.5 Diagnosis of ICH 
ICH was defined as the abrupt symptomatic onset of severe headache, 
altered level of consciousness, or focal neurological deficit, anatomically 
referable to a focal collection of blood within the brain parenchyma as 
observed on brain imaging (CT or MRI) or at autopsy, with characteristics 
consistent with the time of symptom onset, which was not attributable to prior 
trauma or HTI.[40] 
2.1.5.1 Traumatic ICH vs spontaneous ICH 
Patients with ICH can present with a history of trauma. Determining whether 
the ICH is the cause or a consequence of trauma can be difficult. Several 
approaches were used to differentiate spontaneous ICH from traumatic ICH: 
 Clinical history – A history of stroke symptoms before trauma suggests 
a spontaneous ICH, while a history of major trauma without preceding 
stroke symptoms suggests a traumatic ICH. 
 Physical examination – Signs of significant head trauma, such as clear 
fluid (CSF) running from the ears or nose, bleeding from the ears, 
bruising around the orbits or ears and scalp haematoma, suggest a 
traumatic ICH. 
 Radiographic – Features on non-contrast CT imaging suggestive of 
trauma include haemorrhagic cerebral contusions. These are 
hyperattenuating areas within the parenchyma which represent acute 
haemorrhage. They are typically located in the inferior frontal lobes 
and temporal pole, areas which are adjacent to the skull.[181, 182] A 
coup-contrecoup pattern of subarachnoid haemorrhage and 
parenchymal contusions may be present, where there is haemorrhage 
at both the site of impact and the opposite side. 
Spontaneous ICH can result in a fall and traumatic brain injury. Therefore, 
patients may have features of both spontaneous and traumatic ICH. These 
types of cases were included as the initial haemorrhage was spontaneous. 
  Chapter 2 
37 
2.1.5.2 HTI vs spontaneous ICH 
Ischaemic stroke can subsequently undergo petechial or parenchymal 
haemorrhagic transformation and be confused with spontaneous ICH. 
Differentiating HTI from spontaneous ICH was straightforward when there 
was baseline imaging showing an acute or subacute ischaemic stroke and 
subsequent imaging showing haemorrhage within the infarcted tissue. It was 
more difficult when the patient presented subacutely, and haemorrhage was 
present on the baseline imaging. In this situation, HTI was suspected when 
petechial or parenchymal haemorrhage occurred in a region with features of 
a subacute infarct on brain imaging, such as a hyperattenuating artery and/or 
a region of low attenuation which involved both cortex and white matter, with 
positive mass effect and was confined to an expected arterial territory. 
2.1.5.3 Stroke imaging meeting review 
A combination of clinical and imaging features was used to determine 
whether an ICH was HTI, traumatic, spontaneous or a combination of 
spontaneous and traumatic. Neurologists, stroke physicians and 
neuroradiologists discussed the cases in a weekly multidisciplinary stroke 
imaging meeting, and a consensus decision was reached based on all 
available evidence. Cases where further investigations were recommended 
were re-discussed at the stroke imaging meeting once all investigations were 
complete. 
2.1.6 ICH onset date 
The ICH onset date was defined as the date when symptoms attributable to 
the ICH began or when the patient was last seen well, if symptom onset was 
unknown. It was determined by the RUSH team through interviewing the 
patient or their relatives and reviewing hospital records. The ICH onset date 
was not necessarily the same as the date of hospital admission or diagnostic 
scanning. The ICH onset date was the inception point for the study and the 
point from which prospective follow-up began. 
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In rare cases where ICH was identified incidentally, the ICH onset date was 
the date of the hospital admission or outpatient clinic which resulted in the 
imaging. 
2.1.7 Baseline data collection 
The RUSH team recorded demographics, comorbidities, baseline clinical 
data and medication use at the time of index ICH (Table 2.2) by interviewing 
patients and their families at the time of presentation, and through review of 
primary and secondary care records. Where possible, multiple sources were 
used to corroborate information. 
2.1.7.1 Co-morbidities 
The condition and the date of diagnosis were recorded. When the date of 
diagnosis was not known, the following approaches were used 
 If the day of diagnosis was unknown but the month and year were 
known, then the midpoint of the month was entered (i.e. 15/mm/yyyy). 
 If the day and month were unknown but the year was known then the 
midpoint of the year was entered (i.e. 01/07/yyyy). 
 If the day, month and year were unknown, then no date was entered.  
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Table 2.2 Completeness of selected baseline clinical characteristics collected 









Age (years) 100.0  100.0  
Sex 100.0  100.0  
Co-morbidities     
Hypertension 99.8  100.0  
Hyperlipidaemia 99.8  100.0  
Atrial fibrillation 99.8  100.0  
Myocardial infarction 99.8  100.0  
Ischaemic stroke 99.8  100.0  
Transient Ischaemic Attack 99.8  100.0  
Dementia 100.0  100.0  
Diabetes 99.8  100.0  
Smoking status 99.1  100.0  
Alcohol intake 94.6  84.9  
Pre-ICH modified Rankin scale 98.9  99.4  
Medications on admission     
Antiplatelet drug(s) 100.0  100.0  
Anticoagulant drug(s) 100.0  100.0  
Antihypertensive drug(s) 100.0  100.0  
Admission Glasgow coma scale 99.1  99.4  
Admission systolic blood 
pressure 
94.6  95.4  
Admission diastolic blood 
pressure 
94.2  97.2  
ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of 
cerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. SVD = small vessel disease. 
 
A history of hypertension was defined as either a documented diagnosis of 
hypertension in the medical records or if the patient was taking 
antihypertensive medications at the time of their ICH. 
A patient was classified as having a history of hyperlipidaemia when there 
was a documented diagnosis of hyperlipidaemia in their medical records. The 
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use of a statin medication at the time of their ICH on its own was not 
sufficient for a history of hyperlipidaemia, as these medications are also used 
in patients without hyperlipidaemia. 
A history of dementia was defined as either a diagnosis of dementia in their 
medical records or if a relative or close friend completed the short form 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) and 
the score was ≥64.[183] 
A history of diabetes mellitus was defined as either a diagnosis of diabetes 
mellitus, or prescription of a sulphonylurea or insulin in their medical records, 
or evidence in the medical records that the World Health Organization 2011 
criteria for diabetes mellitus had been fulfilled.[184] 
Patients with a history of diabetes mellitus were further classified as: 
 Type 1 diabetes. If this was not specified, it was assumed if the 
diagnosis was made before the age of 30 years and treated with 
insulin therapy alone. 
 Type 2 diabetes. If this was not specified, it was assumed if the patient 
was on diet control or oral hypoglycaemic drugs alone, or diabetes 
diagnosed after the age of 30 years. 
 Diabetes, type unknown was recorded if there was insufficient 
information to determine the type. 
2.1.7.2 Pre-ICH level of functioning 
The pre-ICH level of functioning was assessed by a trained rater (Dr N 
Samarasekera, C Lerpinere or Professor R Al-Shahi Salman) by interviewing 
patients and their families at the time of presentation and was quantified 
using the modified Rankin scale[185]. 
2.1.7.3 Clinical data on admission 
The first systolic and diastolic blood pressure and Glasgow Coma Scale 
(GCS) score on hospital admission were recorded from the medical records 
or clinic assessment (Table 2.2). 
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2.1.7.4 Investigations 
Results from the first blood samples (full blood count, renal profile, 
coagulation screen) taken on the day of admission or clinic assessment were 
recorded. 
The date, time and type of all diagnostic brain imaging, such as non-contrast 
CT, CT angiography, CT venography and MRI, were recorded. The 
underlying structural cause of the ICH after diagnostic workup was also 
documented. 
2.1.8 Follow-up data collection 
2.1.8.1 Ascertainment of follow-up data 
The RUSH team used multiple sources of information to follow-up 
participants in LATCH and LINCHPIN. 
 Annual GP postal questionnaire: This asked the GP about the 
occurrence of any major vascular outcomes listed below, development 
of dementia or hypertension and the level of functioning, based on the 
modified Rankin scale. The GP was also asked to send the most 
recent GP electronic summary of co-morbidities and current 
prescriptions, as well as the most recent blood pressure recording. 
 NHS Lothian’s secondary care electronic records system (TRAK): This 
was reviewed annually by members of the RUSH group for vital status 
and occurrence of the relevant outcomes listed below. 
 Scottish National Picture Archive and Communication System (PACS): 
This was reviewed annually for the occurrence of the relevant vascular 
outcomes listed below. 
 GP primary care records: The RUSH team requested and reviewed 
these in all participants who died. 
Follow-up is still ongoing for all surviving LATCH and LINCHPIN participants. 
2.1.8.2 Outcomes of interest 
The outcomes recorded were death, functional outcome according to the 
modified Rankin scale,[185]  major vascular outcomes, such as ischaemic 
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stroke, transient ischaemic attack, deep vein thrombosis/pulmonary 
embolism, acute coronary syndrome, ICH or other intracranial and 
extracranial bleeding, and development of dementia. 
2.1.8.3 Outcome adjudication 
All outcomes for death and major vascular events were adjudicated by 
Professor R Al-Shahi Salman, a consultant neurologist with an interest in 
stroke medicine. 
 For deaths, the death certificate, GP and hospital records, and 
autopsy report, if performed, were reviewed to confirm the date and 
cause of death. 
 For major vascular outcomes, any GP or hospital records and any 
relevant imaging on the Scottish National PACS relating to the 
outcome were reviewed to confirm the type and date of the outcome. 
2.1.9 Regulatory approvals 
The NHS Lothian Caldicott Guardian approved LATCH. Patients in NHS 
Lothian were informed about the use of their data for audit, and information 
leaflets about LATCH were distributed to inform patients and their carers 
about their right to opt out.[40] Analysis of an anonymised data set did not 
require research ethics committee approval. 
LINCHPIN was approved by the Scotland A Research Ethics Committee 
(10/MRE00/23). The RUSH team obtained written informed consent from all 
participants or their nearest relative or welfare guardian when participants did 
not have mental capacity. 
 
2.2 Image acquisition and analysis 
2.2.1 Diagnostic non-contrast brain CT scan 
2.2.1.1 Scan acquisition 
The diagnostic non-contrast brain CT scans in LATCH and LINCHPIN were 
performed in NHS Lothian as part of routine clinical practice. CT scan 
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parameters (tube current and voltage, default windowing levels) varied 
between the radiology departments at the three hospitals within NHS Lothian. 
All diagnostic non-contrast brain CT scans were acquired as volumetric 
scans, allowing reconstruction in any plane. 
2.2.1.2 Scan reformatting 
It was not always possible to use standard patient positioning in the CT 
scanner, particularly for acutely unwell patients who for example, may only 
be able to lie on their side rather than on their back. I therefore, reformatted 
the first diagnostic non-contrast brain CT scan performed after ICH onset 
using standard planes for consistency (Figure 2.3 and Figure 2.4): 
 Axial: Parallel to a line linking the floor of the sella turcica to the 
fastigium of the fourth ventricle in the sagittal plane and parallel to the 
inferior aspect of the temporal poles in the coronal plane. 
 Coronal: parallel to the posterior surface of the brainstem in the 
sagittal plane and perpendicular to the interhemispheric fissure in the 
axial plane. 
 Sagittal: parallel to the interhemispheric fissure in both the coronal and 
axial planes. 
I standardised the slice thickness (5mm), spacing (3mm) and windowing 
(centre 35, width 80). I chose the slice thickness and spacing to make the CT 
images comparable to the 2D MRI sequences acquired as part of the 
research MRI scans. The slice thickness also increases signal to noise ratio. 
I performed the reformatting of the diagnostic non-contrast brain CT scans 
using Carestream Vue PACS version 11.3.2, Carestream Health, Inc, USA. 
2.2.1.3 Image analysis 
I rated the reformatted first diagnostic non-contrast brain CT scan performed 
after ICH onset using a standardised pro forma (Appendix 1) modified from 
previous large-scale stroke studies[186-189] to include the assessment of 
recommended CT imaging features of SVDs[77] and CT imaging features 
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associated with pathologically proven CAA.[166] If necessary, I also reviewed 
the source volumetric CT data if required to complete the ratings. 
ICH features 
I recorded the location of all acute ICHs using the Cerebral Haemorrhage 
Anatomical RaTing Scale (CHARTS),[190] a published tool for determining 
ICH location. I assessed the volume of each ICH using the ABC/2 method, 
where A is the largest ICH diameter in the axial plane in centimetres, B is the 
largest diameter perpendicular to A on the same slice in centimetres, and C 
is the maximal cranio-caudal diameter in centimetres.[191] I recorded the 
presence or absence of haemorrhage within the ventricular, subarachnoid or 
subdural spaces. I assessed the presence or absence of three separate 
features of ICH shape; finger-like projections, defined as elongated 
extensions arising from the haematoma that are longer than they are wide, 
an irregular contour, and a round/oval shape (Supplementary Appendix in 
Chapter 7 and Appendix 1).[166]  
I recorded whether there was a fluid level within the haematomas and 
whether they had a dilute or “seeping” appearance, as well as whether the 
ICH reached the cortex.[166, 192] I defined dilute/“seeping” as adjacent 
areas of relative hypoattenuation and hyperattenuation within a haematoma 
with a well-defined margin between these regions. I used representative 
images to define the features associated with ICH shape and appearance, 
such as irregular contour, finger-like projection and dilute/”seeping” 
(Appendix 1). 
Brain SVDs features 
I recorded the presence, type and location of old infarcts, the severity of 
anterior and posterior white matter lucencies using the van Swieten 
scale,[193] and deep (enlargement of the ventricles) and superficial 
(enlargement of the sulci) cerebral atrophy using a template based three-
point scale (0 = absent/mild, 1 = moderate and 2 = severe).[186, 194, 195]  
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I calculated a CT SVD burden score based on the presence and severity of 
white matter lucencies, lacunes and atrophy.[196] 1 point was awarded for 
each of the following if present:  
 Severe lucencies (van Swieten Scale = 2) in anterior or posterior 
periventricular white matter 
  ≥2 lacunes 
 Severe (=2) central or cortical atrophy 
The combined 4-point ordinal score, therefore, assessed the global burden of 
SVD from 0 (no imaging features of severe SVDs) to 3 (imaging features of 
SVDs scored as severe for each imaging variable). The biological plausibility 
and prognostic value of SVDs burden scores have been demonstrated on 
MRI.[186, 197, 198] 
CT rating 
I performed the visual ratings of the diagnostic non-contrast brain CT scans 
using Carestream Vue PACS version 11.3.2, Carestream Health, Inc, USA. I 
performed all assessments masked to clinical, genetic, MRI, 
histopathological and outcome data.  
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Figure 2.3 Standard planes used to reformat the first diagnostic non-contrast 
brain CT scan 
A. Axial plane. The white dot-dashed line indicates the plane parallel to the 
interhemispheric fissure used to align the coronal and sagittal planes. 
B. Coronal plane. The white dot-dashed line indicates the plane parallel to 
the interhemispheric fissure used to align the sagittal plane. The red dotted 
line indicates the plane parallel to the inferior aspect of the temporal poles 
used to align the axial plane. 
C. Sagittal plane. The white dotted line indicates the plane parallel to the 
posterior surface of the brainstem used to align the coronal plane. The yellow 
dashed line indicates the plane parallel to a line linking the floor of the sella 
turcica to the fastigium of the fourth ventricle used to align the axial plane. 
 
CT = computed tomography. 
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Figure 2.4 Reformatting of first diagnostic non-contrast brain CT scan 
A. Unformatted diagnostic non-contrast brain CT. 
B. Reformatted axial plane 
C. Reformatted coronal plane 
D. Reformatted sagittal plane 
 
CT = computed tomography. 
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2.2.2 Diagnostic (clinical) brain MRI scan 
In a small number of patients, the first diagnostic scan performed after ICH 
was a brain MRI, typically because of a delayed presentation or mild or 
atypical symptoms. The diagnostic brain MRI scans were performed in NHS 
Lothian as part of routine clinical practice. MRI scan parameters varied 
between the radiology departments within the three hospitals in NHS Lothian, 
although all scans were performed on 1.5T scanners. 
For these patients, I assessed the number, location[190] and volume[191] of 
acute ICHs as described above. I also recorded the presence of 
haemorrhage within the ventricular, subarachnoid or subdural spaces. 
2.2.3 Research LINCHPIN brain MRI scan 
2.2.3.1 Eligibility 
All participants within the LINCHPIN study were given the opportunity to 
consent to a research brain MRI. LINCHPIN participants were excluded from 
research brain MRI if they had any of the following: 
 A contraindication to MRI, such as a non-MRI compatible implantable 
device or metallic foreign bodies in the eye. 
 They were unable to tolerate MRI scanning because they were 
claustrophobic, unable to lie flat or were too unwell. 
 They were unable to fit into the scanner. 
 They had died before ascertainment. 
2.2.3.2  Scan acquisition 
LINCHPIN research brain MRIs were performed around six months from the 
index ICH on one of two 1.5T MRI scanners (GE Signal LX EchoSpeed 
scanner, Milwaukee, WI, USA at the Brain Research Imaging Centre, 
Western General Hospital, Edinburgh, and Philips Gyroscan Intera scanner, 
Philips Ltd, Best, The Netherlands at the Royal Infirmary of Edinburgh). The 
MRI protocol comprised of sagittal T1-weighted, and axial T2-weighted, 
FLAIR and T2*-weighted gradient recalled echo (GRE) sequences for all 
participants. Axial susceptibility weighted imaging (SWI), susceptibility 
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weighted angiography (SWAN) and diffusion-weighted imaging (DWI) 
sequences were later added to the MRI protocol. Therefore, some 
participants also had these sequences as well as the basic protocol 
described above. Standardised sequence parameters were used for all 
participants (Table 2.3 and Table 2.4). 
2.2.3.3 Image analysis 
I rated LINCHPIN brain MRI scans using a standardised pro forma (Appendix 
2). I defined neuroimaging features of SVDs (lacunes, WMH, perivascular 
spaces, CMB, cortical superficial siderosis and brain atrophy) according to 
STRIVE (section 1.1.3).[77]  
Acute ICH 
I defined the age of an ICH according to the recognised MRI characteristics 
of the breakdown of haemoglobin with time.[199] I recorded the location and 
volume of all acute ICHs using CHARTS[190] and the ABC/2 method,[191] 
respectively, described in Section 2.2.1.3. 
Acute ischaemic infarct 
I recorded the number and location of acute infarcts, defined as regions of 
DWI hyperintensity with hypointensity on the corresponding apparent 
diffusion coefficient map, and normal or hyperintense signal on T2-weighted 
and FLAIR sequences.[186-188, 200-202] 
Chronic infarcts and haemorrhages 
I recorded the number and location of chronic infarcts and haemorrhages. I 
defined chronic infarcts as lesions with T2-weighted and FLAIR 
hyperintensity and T1-weighted hypointensity in an expected arterial territory. 
I defined lacunes as a round or ovoid, subcortical lesions between 3 and 15 
mm in diameter in the territory of one perforating arteriole.[77] I defined 
chronic haemorrhages as slit-like cavities or areas of gliosis with peripheral 







Table 2.3 LINCHPIN study research brain MRI sequence parameters at the Brain Research Imaging Centre, Western General 
Hospital, Edinburgh 




FLAIR SWAN SWI DWI 
Orientation SAG AC-PC AC-PC AC-PC AC-PC AC-PC AC-PC 
TE MIN 40 86.2 140 50 25 MIN 
TR 380 300 5000 9000 78.9 5000 10000 
TI    2000    
Flip angle  20   15 90  
Field of view 24 24 24 24 24 24 24 
Slice thickness 
(mm) 
5 5 5 5 3.8 3 5 
Slice gap (mm) 1.5 1.5 1 1 0 0 1 
Matrix 384x256 384x224 384x384 384x224 288x224 224x352 128x128 
AC-PC = anterior commissure-posterior commissure. DWI = diffusion-weighted imaging. FLAIR = fluid-attenuated inversion 
recovery. FSE = fast spin echo. GRE = gradient recalled echo. LINCHPIN = Lothian intracerebral haemorrhage pathology, 
imaging and neurological outcome. MIN = minimum. MRI = magnetic resonance imaging. SAG = sagittal. SWAN = 
susceptibility weighted angiography. SWI = susceptibility weighted imaging. TE = echo time. TI = inversion time. TR = 
repetition time. 
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Table 2.4 LINCHPIN study research brain MRI sequence parameters at the 
Royal Infirmary of Edinburgh 





Orientation SAG AC-PC AC-PC AC-PC 
TE 15 40 100 100 
TR 623.0 300 4841.6 6000 
TI    2000 
Flip angle  20   
Field of view 23 24 23 23 
Slice thickness 
(mm) 
5 5 5 5 
Slice gap (mm) 1 1.5 1 1 
Matrix 256x205 268x166 384x242 256x161 
AC-PC = anterior commissure-posterior commissure. DWI = diffusion-
weighted imaging. FLAIR = fluid-attenuated inversion recovery. FSE = fast 
spin echo. GRE = gradient recalled echo. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. MIN = minimum. 
SAG = sagittal. MRI = magnetic resonance imaging. SWAN = susceptibility 
weighted angiography. SWI = susceptibility weighted imaging. TE = echo 
time. TI = inversion time. TR = repetition time. 
 
WMH 
I rated WMH using the Fazekas scale.[89] The Fazekas scale differentiates 
periventricular and subcortical WMH, which is potentially relevant for 
characterising the types of SVDs associated with ICH. Also, it has been 
widely used in previous stroke trials. 
Enlarged perivascular spaces 
I assessed enlarged perivascular spaces using a validated qualitative rating 
scale.[204] I used a scale of zero to four to rate the number of enlarged 
perivascular spaces in four different brain regions - the hippocampus, basal 
ganglia, centrum semiovale and midbrain - where zero = no enlarged 
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perivascular spaces, one = ≤10, two = 11-20, three = 21-40 and four = >40. 
For each region, I rated the number of perivascular spaces on each side 
before using the mean to produce an overall score for each region. 
CMB 
I assessed CMBs by modifying two validated qualitative rating scales. The 
Brain Observer MicroBleed Scale (BOMBS) was developed on T2*-weighted 
GRE MRI sequences at 1.5T from 264 adults with stroke or transient 
ischaemic attack and tested on a separate cohort of 156 adult stroke 
patients.[205] BOMBS rates the total number of CMBs in the following areas: 
supratentorial cortex/grey-white matter junction, supratentorial subcortical 
white matter, basal ganglia, internal and external capsule, thalamus, 
brainstem and cerebellum. It distinguishes definite and possible CMBs as 
well as those <5 mm in diameter versus 5-10 mm. The Microbleed 
Anatomical Rating Scale (MARS) was developed on 301 consecutive stroke 
patients with T2*-weighted GRE MRI sequences at 1.5T.[206] Like BOMBS, 
MARS distinguishes definite from possible CMBs in the basal ganglia, 
thalamus, brainstem and cerebellum. MARS differentiates the different 
cerebral lobes (frontal, parietal, temporal, occipital and insula), but does not 
distinguish cortical and subcortical lobar CMBs. It also has separate 
categories for the corpus callosum and deep and periventricular white matter 
and includes a total number of CMBs in lobar, deep and infratentorial 
regions. 
I added individual cerebral lobe categories (frontal, parietal, temporal and 
occipital lobes) to BOMBS, as this may be informative given the perceived 
posterior predominance of CMBs in CAA.[27, 207, 208] Also, I included totals 
for lobar, deep and infratentorial locations, which may be relevant to 
differentiate different types of SVDs given the typical distribution of CAA and 
non-CAA SVDs.[1, 153] I included deep and periventricular white matter 
(defined as adjacent to or within approximately 10 mm of the lateral 
ventricular margins) in the deep region given that small penetrating arteries 
supply all these regions. I only recorded definite CMBs given this improved 
inter-rater agreement in both BOMBS and MARS.[205, 206] I also recorded 
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the number of CMBs visible on SWI given its higher sensitivity and reliability 
for CMBs compared with T2*-weighted GRE.[209] I did not record CMB size 
given the current definition of CMBs in consensus guidelines for 
neuroimaging features of SVDs.[77] I considered potential CMB mimics when 
rating CMBs, such as flow voids in small cortical vessels, mineralization in 
the globi pallidi or dentate nuclei and partial volume effects adjacent to the 
petrous apex and orbit, particularly when I identified only one CMB.[205, 206] 
Cortical superficial siderosis 
I rated the location, extent (number of sulci involved) and proximity to index 
ICH (adjacent, distant, mixed) of cortical superficial siderosis using T2*-
weighted GRE, and SWI when available. 
Brain atrophy 
I recorded deep (enlargement of the ventricles) and superficial (enlargement 
of the sulci) cerebral atrophy using a validated template-based approach 
(based on T2-weighted images of 105 subjects aged 75-80).[194] I used a 
scale of one to six, where one = ≤5th centile on atrophy template, two = 25th – 
50th centile, three = 50th – 75th centile, four = 75th – 95th centile, five = >95th 
centile and six = >>95th centile. 
Boston criteria for CAA 
I used the original and modified Boston criteria to classify each brain MRI 
scan as showing probable CAA, possible CAA or no CAA based on the 
presence and distribution of macrohaemorrhages, CMBs and cortical 
superficial siderosis as described in Table 1.1.[110] 
There is ambiguity over the implementation of the original and modified 
Boston criteria. Firstly, it is not clear whether cerebellar haemorrhages should 
be considered as a compatible haemorrhagic focus for probable CAA or 
possible CAA. The published original and modified Boston criteria specifically 
state that cerebellar haemorrhage is permitted in the multiple haemorrhage 
criterion of probable CAA. However, there is no mention of cerebellar 
haemorrhage, either positively or negatively, in the rest of the criteria. In my 
thesis I considered macrohaemorrhages and CMBs within the cerebellum as 
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compatible haemorrhagic foci for both probable CAA and possible CAA when 
using the original and modified Boston criteria. 
Secondly, the modified Boston criteria include focal or disseminated cortical 
superficial siderosis as a compatible haemorrhagic focus for probable CAA or 
possible CAA, without specifying any restriction over its proximity to 
macrohaemorrhages or CMBs. Therefore, I considered any focus of cortical 
superficial siderosis as an independent haemorrhagic focus when applying 
the modified Boston criteria, regardless of its relationship with other 
haemorrhagic foci. 
MRI brain SVD burden score 
The MRI brain SVD burden score is an ordinal score of four MRI SVD 
biomarkers: lacunes, WMH, CMBs and enlarged perivascular spaces. It 
provides a “total SVD burden” score. It was developed in a prospective 
cohort of 122 participants with first-ever lacunar stroke who underwent 
standardised 1.5T or 3T MRI.[210] The scans were assessed independently 
by two vascular neurologists for asymptomatic lacunes, CMBs, enlarged 
perivascular spaces and WMH. One point is scored for each of the following 
if present: 
 ≥1 lacune 
 ≥1 CMBs 
 Moderate to severe perivascular spaces in the basal ganglia (grade 3 
or 4 – see Section 2.2.3.3) 
 Periventricular WMH Fazekas 3 and/or deep WMG Fazekas 2-3 (see 
Section 2.2.3.3) 
The combined 5-point ordinal score, therefore, assesses the global burden of 
SVDs from a minimum score of 0 to a maximum score of 4. 
The validity of the MRI brain SVD burden score was initially assessed in 222 
participants with acute lacunar stroke and 239 with mild cortical ischaemic 
stroke.[197] The MRI brain SVD burden score is associated with an 
increased risk of recurrent ischaemic stroke and ICH in patients with previous 
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TIA or ischaemic stroke,[211] mortality after acute ischaemic stroke[212] and 
predicts cognitive impairment.[198, 213] 
MRI CAA burden score 
The MRI CAA SVD burden score is an ordinal score of four MRI CAA 
biomarkers: lobar CMBs, cortical superficial siderosis, enlarged perivascular 
spaces in the centrum semiovale and WMH.[214] It provides a “total SVD 
burden” score in CAA. It was developed in a retrospective single-centre 
cross-sectional study 105 participants with pathologic evidence of CAA and 
1.5T or 3T brain MRI, 54 of whom had a symptomatic lobar ICH. The MRI 
scans were assessed by trained observers using the definitions for SVD 
biomarkers set out in STRIVE,[77] and masked to the clinical and 
histopathological information. The scoring system was pre-specified, based 
on evidence from cross-sectional and longitudinal studies in CAA. Points 
were awarded as follows: 
 Lobar CMBs 
o 2-4 lobar CMBs = 1 point 
o ≥5 lobar CMBs = 2 points 
 Cortical superficial siderosis 
o Focal cortical superficial siderosis = 1 point 
o Disseminated cortical superficial siderosis = 2 points 
 Moderate to severe enlarged perivascular spaces in the centrum 
semiovale (grade 3 or 4 – Section 0) = 1 point 
 Periventricular WMH Fazekas 3 and/or deep WMG Fazekas 2-3 
(Section 0) = 1 point. 
The combined 7-point ordinal score, therefore, assesses the global burden of 
SVDs from a minimum score of 0 to a maximum score of 6. 
The severity of CAA-associated vasculopathic changes and CAA 
presentation with symptomatic ICH were independently associated with the 
total MRI CAA SVD burden score in the development study.[214] 
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The MRI CAA burden score was developed in symptomatic participants with 
pathologically proven CAA, however it was designed to assess the total CAA 
SVD burden in patients without pathological CAA assessment, and showed 
an independent association with the severity of pathological CAA-associated 
features. Therefore, I applied it in all participants with adequate MRI brain 
scans, regardless of ICH location or Boston criteria classification. 
Image analysis training  
I have completed four years of Clinical Radiology training, including one year 
of neuroradiology, and am a Fellow of the Royal College of Radiologist UK. 
Through my clinical radiology training, I am familiar with the range of SVD 
MRI biomarkers. In addition, I reviewed training materials for acute ischaemic 
stroke classification, WMH, atrophy, enlarged perivascular spaces and CMBs 
before rating the research MRI scans.[215]  
MRI rating  
I performed the visual ratings of the clinical and research brain MRI scans 
using Carestream Vue PACS version 11.3.2, Carestream Health, Inc, USA. I 
performed all assessments masked to clinical, genetic, CT, histopathological 
and outcome data. 
 
2.3 APOE genotyping 
APOE genotyping was performed using either peripheral blood or cerebellar 
brain tissue. 
2.3.1 Peripheral blood samples 
Two peripheral blood samples were taken by members of the RUSH 
research team using nine-millilitre ethylene-diamine-tetra-acetic acid (EDTA) 
tubes. Samples were anonymised with a unique four-digit study ID number 
and the participant’s date of birth and sent to the Edinburgh Wellcome Trust 
Clinical Research Facility (WTCRF, Western General Hospital, Edinburgh) 
for storage and future genotyping. 
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2.3.2 Brain tissue samples 
Many participants died before peripheral blood samples could be taken. 
Therefore cerebellar vermis brain tissue samples from the LINCHPIN brain 
bank were also sent to the Edinburgh WTCRF for APOE genotyping. The 
details of LINCHPIN research brain autopsies are described in section 2.4. 
2.3.3 DNA extraction 
WTCRF laboratory staff extracted DNA from whole blood using a Nucleon Kit 
(GenProbe) with the BACC3 protocol. DNA samples were re-suspended in 1 
ml TE buffer pH 7.5 (10mM Tris-Cl pH 7.5, 1mM EDTA pH 8.0). The yield of 
DNA was measured using picogreen and normalised to 10ng/μl before 
genotyping. 
WTCRF laboratory staff extracted DNA from fresh-frozen cerebellar brain 
tissue by homogenising using buffer ATL with proteinase K and incubating at 
56oC on a thermomixer at 1000 rpm then isolated using Qiagen DNeasy 
blood and tissue kit. DNA samples were resuspended in 200 μl of Qiagen 
elution buffer and normalised to 10ng/μl before genotyping.  
WTCRF laboratory staff extracted DNA from formalin fixed paraffin 
embedded cerebellar tissue brain tissue using the Covaris E220 Focused 
Ultra Sonicator and the truXTRAC FFPE DNA kit, following the genomic DNA 
extraction protocol. 20 μm tissue scrolls were deparaffinised by sonication for 
2 x 5 minute periods before overnight incubation on a thermomixer at 56oC 
with proteinase K. Crosslinking was reversed by incubation at 80oC for 1 hour 
before purification in spin columns, and elution in 50 μL of Covaris Buffer BE 
(5mM Tris HCl pH 8.5). 
2.3.4 APOE genotyping 
WTCRF laboratory staff determined genotypes for two APOE single-
nucleotide polymorphisms (rs429358 and rs7412) using TaqMan single-
nucleotide polymorphism genotyping assays (Applied Biosystems, Foster 
City, CA) on a ThermoFisher QuantStudio 12K Flex Real-Time PCR System 
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instrument with QuantStudio 12K Flex Software or Taqman Genotyper 
Software v1.3.  
WTCRF laboratory staff were masked to clinical, CT, MRI and pathological 
features.  
2.3.5 APOE genotype definition 
I used the two APOE single-nucleotide polymorphisms (rs429358 and 
rs7412) to determine alleles (Table 2.5).[216] APOE single-nucleotide 
polymorphisms (rs429358 (C;T) and rs7412 (C;T)) are ambiguous for 2/4 
and 1/3 genotypes. In such cases, I classified the genotype as 2/4 given 
that 1/3 is very uncommon. I classified APOE genotype as APOE2 
possession if participants had at least one 2 allele and APOE4 possession 
if they had at least one 4 allele.  
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Table 2.5 APOE genotypes and corresponding alleles 
rs429358 rs7412 Genotype 
C;C T;T Apo-1/1 
C;T T;T Apo-1/2 
C;T C;T Apo-2/4 
C;C C;T Apo-1/4 
T;T T;T Apo-2/2 
T;T C;T Apo-2/3 
T;T C;C Apo-3/3 
C;T C;C Apo-3/4 
C;C C;C Apo-4/4 
APOE = apolipoprotein E. 
 
2.4 LINCHPIN research brain autopsy 
LINCHPIN research autopsies were performed by one neuropathologist 
(Professor C Smith) according to a standard operating procedure.[217] The 
maximum interval from death to autopsy was five days. 
The cerebral hemispheres were sectioned in the coronal plane at 1 cm 
intervals, the first slice taken through the mammillary bodies. The cerebellum 
was sectioned in the sagittal plane and the brainstem axially. Tissue samples 
approximately 20 x 20 x 10 mm were taken from each cerebral hemisphere 
from the frontal parasagittal cortex (BA9); Broca’s area (BA44/45); temporal 
tip (BA38); caudate nucleus; basal ganglia; hippocampus; thalamus; frontal, 
temporal, parietal and occipital white matter; cerebellum; pons and medulla. 
Samples were bisected in the coronal plane, one block fixed in 10% 
unbuffered formalin for standard histological processing and the other frozen 
in nitrogen vapour at -150oC. 
2.4.1 SVDs assessment 
2.4.1.1 CAA 
CAA was sought in the cerebral and cerebellar lobe samples using 
immunohistochemistry with a monoclonal mouse antibody to human beta-
amyloid, (Clone 6F/3D, Dako, Copenhagen) at a concentration of 1:100.  
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Professor C Smith rated features of CAA in all cerebral and cerebellar lobes 
using a consensus rating scale.[36] This rates the presence and severity of 
parenchymal and meningeal CAA (0–3); the presence of capillary CAA (0 or 
1), and vasculopathy (0–2) in each location (Table 2.6). 
2.4.1.2 Non-CAA SVD 
Two neuropathologists (Professor C Smith and Dr C Humphreys) rated the 
presence and severity of non-CAA SVD (or “other SVD”) features in the left 
cerebral hemisphere (frontal, central, periventricular and occipital white 
matter, basal ganglia at level of mammillary bodies and thalamus at level of 
lateral geniculate body) only, as SVD is usually considered symmetrical,[77] 
using haematoxylin and eosin staining with a modified version of a published 
scale as follows:[218] 
 None: very mild, occasional arteriolosclerosis without media splitting 
or luminal narrowing 
 Mild: widespread mild or focal moderate arteriolosclerosis 
 Moderate: widespread moderate or focal severe arteriolosclerosis, 
with splitting of the media and narrowing of the lumen 
 Severe: widespread severe arteriolosclerosis, fibrinoid necrosis, 
lipohyalinosis, evidence of vascular occlusion with or without 
recanalization 
2.4.2 Non-SVDs neurodegenerative pathologies 
2.4.2.1 Alzheimer’s disease pathology 
-amyloid plaques and tau were sought in all cerebral and cerebellar lobes 
using immunohistochemistry with a monoclonal mouse antibody to human 
beta-amyloid, (Clone 6F/3D, Dako, Copenhagen) at a concentration of 1:100 
and a monoclonal mouse antibody to human tau, (Thermo Fisher Scientific, 
USA) at a concentration of 1:2500 respectively. -amyloid plaque and 
neurofibrillary tangle burden were rated in all cerebral and cerebellar lobe 
samples by Professor C Smith using validated scales (Thal phase and Braak 
stage respectively).[219, 220] 
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The Thal phase assesses the hierarchical deposition of -amyloid plaques in 
the brain in Alzheimer’s disease according to five phases.[219] Phase 1 is 
defined by -amyloid depoists in the frontal, parietal, temporal or occipital 
neocortex. Phase 2 has additional allocortical -amyloid deposits. Phase 3 
has additional -amyloid deposits in the diencephalic nuclei and striatum, 
phase 4 shows additional -amyloid in distinct brainstem nuclei (substantia 
nigra, red nucleus, central gray, superior and inferior collicle, inferior olivary 
nucleus, and intermediate reticular zone). In phase 5 there is -amyloid 
deposition in the cerebellum and additional brainstem nuclei (pontine nuclei, 
locus coeruleus, parabrachial nuclei, reticulo-tegmental nucleus, dorsal 
tegmental nucleus, and oral and central raphe nuclei). Absent -amyloid 
plaques were classified as Thal phase 0. 
The Braak stage assesses the severity and distribution of neurofibrillary 
tangles in the brain in Alzheimer’s disease according to six stages.[220] 
Stages 1 and 2 are characterised by modest or numerous neurofibrillary 
tangles in the cortex confined to the transentorhinal region respectively. 
Stage 3 is characterised by severe involvement of the superficial cellular 
(Pre-) layer in both the transentorhinal and entorhinal regions, with only a 
few neurofibrillary tangles in the Pri- and Pre- layers and only modest 
involvement of the hippocampal formation. In stage 4 the layer Pre- is very 
severely affected and there is also considerable involvement of layers Pri- 
and Pre-, plus numerous neurofibrillary tangles in the hippocampal 
formation. Stage 5 shows more severe involvement of the layers Pri-, Pre- 
and Pre-, all components of the hippocampal formation are involved and the 
isocortex is severely affect. Stage 6 shows the most pronounced changes 
with the isocortex severely affected and involvement of the extrapyramidal 





Table 2.6 Consensus histopathological rating scale for CAA and CAA-associated vasculopathy.[36] 
Score Parenchymal CAA Meningeal CAA Capillary CAA Vasculopathy 
0 Absent Absent Absent Absent 
1 Scant -amyloid deposition Scant -amyloid deposition Present Occasional vessel 







CAA = cerebral amyloid angiopathy. 
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2.5 Discussion 
2.5.1 Methodological strengths 
2.5.1.1 Study design, data collection and follow-up 
Both LATCH and LINCHPIN were prospective community-based inception 
cohort studies of ICH. Both studies used multiple overlapping sources of 
case ascertainment. These features help limit selection bias. Completeness 
of baseline clinical characteristics was high. 
The cause of the ICH was based on multidisciplinary consensus between 
neurologists, stroke physicians and neuroradiologists following review of all 
relevant diagnostic information.  
Both LATCH and LINCHPIN used multiple sources of follow-up information to 
identify relevant outcomes. A consultant neurologist with an interest in stroke 
adjudicated the outcomes after reviewing all relevant information. The studies 
have up to eight years of follow-up, and the completeness of follow-up is high 
(Sections 10.4.1.3 and 10.4.2.3). 
2.5.1.2 Brain imaging 
To limit information bias, I reformatted diagnostic non-contrast brain CT 
scans into standard planes, slice thickness and windowing. I systematically 
assessed ICH and features of SVDs on the diagnostic non-contrast brain CT 
scans using a standardised pro forma (Appendix 1) based on published 
approaches where possible.[77, 190, 191, 193-196]  
Research brain MRI scans were acquired using standardised parameters on 
one of two MRI scanners. I systematically assessed ICH and SVDs features 
using a standardised pro forma (Appendix 2) based on published approaches 
where possible.[77, 89, 194, 204-206] 
I performed all imaging ratings masked to clinical, genetic, pathological and 
outcome data. 
2.5.1.3 Research brain autopsy 
Research brain autopsies were performed according to a standard operating 
procedure and included extensive tissue sampling. CAA, non-CAA SVDs and 
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Alzheimer’s disease pathology were assessed by neuropathologists using 
published scales[36, 218-220] masked to clinical, imaging and genetic data. 
2.5.2 Methodological weaknesses 
Despite using a community-based approach, the sample size of the 
LINCHPIN study was modest, particularly for the research brain MRI (n=157) 
and brain autopsy components (n=126) (Figure 3.3). There was also 
selection bias for the research brain MRI and brain autopsy components as 
not all participants underwent these tests (Sections 3.4.2.3 and 4.4.2.2). 
However, this was the largest sample that could be achieved over six years 
using a methodologically rigorous approach, during which all eligible patients, 
where appropriate, were invited to consent to the LINCHPIN study. 
It was difficult to collect follow-up data on blood pressure control and 
antithrombotic drug use after hospital discharge. These factors can influence 
the occurrence of vascular outcomes, such as recurrent ICH and incident 
ischaemic stroke.[158, 159] 
Not all LATCH patients or LINCHPIN participants underwent vascular 
imaging or delayed MRI as part of their clinical workup. Therefore, some 
patients and participants classified as SVD-associated ICH may have had an 
undetected macrovascular or neoplastic cause for their ICH. However, this 
approach reflects clinical practice in the UK, making the results generalisable 
to routine clinical practice. There were no instances of ICHs related to 
moyamoya disease, vasculitis or reversible cerebral vasoconstriction 
syndrome identified during the clinical workup of patients in LATCH, which 
may relate to the rarity of these conditions or misidentification. 
I used soft landmarks, such as the posterior surface of the brainstem and the 
fastigium of the fourth ventricle, to realign the diagnostic non-contrast brain 
CT scans. These can be distorted by mass effect related to brainstem or 
cerebellar ICHs, potentially affecting the orientation of the realigned planes. 
However, the effect of this in my studies is limited as brainstem or cerebellar 
ICHs occurred in a minority of participants, and most of these ICHs were 
small, without significant mass effect on the above landmarks. Approaches 
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using bony landmarks for defining planes, such as the floor of the anterior 
cranial fossa and posterior margin of the clivus, also vary between people 
and therefore would also result in between participant variation in the 
realigned planes. 
As discussed in Section 2.2.3.3, there is ambiguity over the implementation 
of the Boston criteria. 
Firstly, the relevance of cerebellar haematomas and CMBs in the original and 
modified Boston criteria is unclear. I considered cerebellar haematomas and 
CMBs as compatible haemorrhagic foci for both probable CAA and possible 
CAA when using the original and modified Boston criteria. I did this because 
there is increasing evidence that superficial cerebellar haemorrhages are 
associated with clinically diagnosed and pathologically verified CAA.[221-
226] 
The authors of the Boston criteria recently published clarification on the 
implementation of the two sets of criteria. They state “Cerebellar 
hemorrhages can result from either CAA or hypertensive arteriopathy and are 
therefore not counted by the Boston criteria, either in favor or against a 
probable CAA diagnosis”.[167] However, this directly contradicts the 
published criteria, which state that cerebellar haemorrhages are permitted in 
the multiple haemorrhages criterion of probable CAA in both the original and 
modified Boston criteria. Furthermore, a recent commentary cited a personal 
communication from Dr Greenberg, co-author of the Boston criteria, 
explaining that a primary cerebellar ICH and two or more microbleeds or one 
microbleed and cortical superficial siderosis would be classified as probable 
CAA.[227] It, therefore, remains unclear whether cerebellar haemorrhages 
should be considered in the criteria or not. 
Secondly, it is unclear whether the proximity of cortical superficial siderosis to 
ICHs needs to be taken into account in the modified Boston criteria. I 
considered any focus of cortical superficial siderosis as a compatible 
haemorrhagic focus for probable or possible CAA in the modified Boston 
criteria as there was no location requirement of the cortical superficial 
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siderosis described in these criteria.[110] However, the recent article from the 
Boston criteria authors states that cortical superficial siderosis “near or 
directly connected to ICHs that have ruptured into the subarachnoid space” 
are not counted as separate haemorrhages.[167] What constitutes “near” is 
not defined. 
Different interpretations of the original and modified Boston criteria will lead 
to different study findings. Further clarification from the Boston criteria 
authors on their implementation is therefore desirable, and will hopefully be 
addressed in the next iteration of the criteria.[228] 
2.5.3 Relevance to later chapters 
I used the data from LATCH in a cross-sectional analysis of the clinical and 
CT features of ICH (Chapter 3) and to assess the prognostic value of CT 
SVD biomarkers for the risk of recurrent ICH and risk of death or disability 
(Chapter 10 and Chapter 11) in a community-based setting. LATCH provides 
an ideal opportunity to assess the utility of the modified Boston criteria, the 
current in vivo reference standard for CAA-associated ICH, in clinical 
practice, as well as quantifying selection bias in the LINCHPIN study 
(Chapter 3). 
I used data from LINCHPIN in a cross-sectional analysis of the MRI and 
pathological features of ICH (Chapter 3 and Chapter 4) and to assess the 
diagnostic value of MRI and CT SVD biomarkers for identifying the SVDs 
underlying ICH (Chapter 5 and Chapter 7-Chapter 9) in a community-based 
setting. I also used data from LINCHPIN to assess the prognostic value of CT 
SVD biomarkers the risk of recurrent ICH (Chapter 10). 
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Section C.  Cross-sectional studies of SVD-
associated ICH 
 
Chapter 3 Cross-sectional studies of SVD-associated ICH; baseline 
clinical characteristics, radiological features and APOE 
genotype 
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Chapter 3 Cross-sectional studies of SVD-
associated ICH; baseline clinical 




The type of SVDs underlying SVD-associated ICH varies according to ICH 
location. CAA almost exclusively affects cortical and leptomeningeal vessels, 
whereas arteriolosclerosis can affect small blood vessels anywhere in the 
brain.[1] Consequently, lobar ICH can be associated with both CAA and 
arteriolosclerosis while non-lobar ICH is almost exclusively associated with 
arteriolosclerosis.[1, 153, 229] Also, APOE 4 allele possession is associated 
with pathologically-proven CAA.[24] Therefore the baseline clinical 
characteristics, radiological features and APOE genotype in SVD-associated 
ICH may vary between lobar and non-lobar ICH locations because of the 
likely differences in underlying SVDs. 
The MRI-based modified Boston criteria [110] are the current non-invasive in 
vivo reference standard for identifying CAA-associated ICH.[167] The criteria 
rely on the identification of haemorrhagic foci to categorise the patient as 
probable CAA, possible CAA or no CAA, and are most accurate when MRI 
with blood-sensitive sequences has been performed. The criteria showed 
excellent sensitivity and good specificity in the development setting.[110] 
However, the utility of the modified Boston criteria in clinical practice is 
currently uncertain as MRI may not be available, and many patients with ICH 
may have contraindications to MRI. 
LATCH is ideal for performing observational epidemiology of SVD-associated 
ICH, allowing estimation of the incidence and assessment of the risk factors 
associated with SVD-associated ICH in a community-based study. LATCH 
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can also be used to assess the applicability of the modified Boston criteria in 
contemporary clinical practice in the UK. 
The community-based LINCHPIN study, which is nested within LATCH, 
included standardised research MRI brain scans and DNA sampling, thereby 
permitting the assessment of the MRI imaging biomarkers and APOE 
genotype associated with SVD-associated lobar and non-lobar ICH. 
 
3.2 Aims 
I aimed to: 
 Determine the incidence of first-ever SVD-associated ICH according to 
ICH location in a community-based cohort of ICH (LATCH). 
 Assess the distribution of clinical and diagnostic non-contrast brain CT 
features of first-ever SVD-associated ICH according to ICH location in 
a community-based cohort of ICH (LATCH). 
 Apply the modified Boston criteria in a community-based cohort of 
first-ever and recurrent SVD-associated ICH (LATCH) to assess their 
utility in clinical practice. 
 Compare clinical and baseline ICH features between ICH patients in 
LATCH who did and did not consent for the LINCHPIN study, to 
assess selection bias. 
 Assess the distribution of brain MRI SVD biomarkers in first-ever SVD-
associated ICH according to ICH location in the LINCHPIN study. 
 Assess the APOE genotype in first-ever SVD-associated ICH 
according to ICH location in the LINCHPIN study. 
 
3.3 Methods 
The study design, baseline data collection, diagnostic non-contrast brain CT 
and research brain MRI image acquisition and analysis, and APOE 
genotyping used in LATCH and LINCHPIN are described in Chapter 2. 
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I included consecutive adult participants (aged ≥16 years) living in the NHS 
Lothian Health Board region who had an ICH between 1st June 2010 and 31st 
May 2013 (LATCH) or 1st June 2010 and 31st May 2016 (LINCHPIN) 
inclusive. I excluded patients with exclusively extra-axial intracranial 
haemorrhage and ICH secondary to an underlying cause other than SVDs. 
I determined the location of the largest ICH using CHARTS when the ICH 
was diagnosed by brain CT or MRI,[190] or the pathology report when the 
ICH was diagnosed at autopsy. I measured the volume of the largest ICH 
using the modified ABC/2 approach on the diagnostic brain CT or MRI.[191] I 
was not able to quantify ICH volume in patients diagnosed at autopsy. 
I applied the modified Boston criteria[110] by reviewing all available clinical 
and research imaging performed in patients with an SVD-associated ICH 
during LATCH. For five patients there was no neuroimaging performed, 
instead their index ICH was diagnosed at the Procurator Fiscal autopsy. In 
these cases histopathological assessment for CAA was not performed. I 
therefore reviewed the pathology reports to quantify the number and location 
of ICHs to apply the modified Boston criteria. 
3.3.1 Statistical analysis 
I calculated 95% confidence intervals (95% CI) for crude incidence using a 
Poisson distribution. 
I used univariable analyses to compare the frequency of clinical, diagnostic 
non-contrast brain CT features, research brain MRI features and APOE 
genotype in participants with first-ever SVD-associated lobar ICH versus non-
lobar ICH using 2 test (or Fisher's exact test, where appropriate) for 
categorical variables. I used the t test or the Mann-Whitney U test for 
normally and non-normally distributed continuous variables respectively. I 
performed multivariable logistic regression to assess whether clinical and CT 
features were independently associated with ICH location. I pre-specified the 
baseline comorbidities, medications on admission, admission GCS score, 
ICH volume, the presence of multiple simultaneous ICHs, intraventricular 
haemorrhage, subarachnoid haemorrhage and subdural haemorrhage, and 
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CT SVD score (0 versus 1-3) to include into the multivariable model. As my 
conclusions were based on the pre-specified multivariable models, I did not 
control for multiple testing in the univariable analyses. 
I compared the frequency of clinical and diagnostic non-contrast brain CT 
features in LATCH patients who consented to the LINCHPIN study versus 
those who did not using 2 test (or Fisher's exact test, where appropriate) for 
categorical variables and the t test or the Mann-Whitney U test for normally 
and non-normally distributed continuous variables respectively. 
I performed statistical analyses using R statistical package version 3.4.4. 
3.3.2 Missing data 
 





3.4.1.1 Flow of patients 
There were 530 patients with a spontaneous ICH in the NHS Lothian Health 
Board region between 1st June 2010 and 31st May 2013 inclusive. Eighty-two 
patients had an ICH which was secondary to a structural cause other than 
SVDs. Of the 448 patients with ICH presumed related to SVDs, 419 were a 
first-ever ICH (Figure 3.1). 
3.4.1.2 The incidence of first-ever lobar and non-lobar SVD-associated 
ICH in LATCH 
The crude incidence of all first-ever SVD-associated ICH between 1st June 
2010 and 31st May 2013 was 20.2 per 100,000 per year (95% CI 18.3 to 
22.2). 
The crude incidence of first-ever SVD-associated lobar ICH was 10.0 per 
100,000 per year (95% CI 8.7 to 11.4) and non-lobar ICH was 10.2 per 
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100,000 per year (95% CI 8.8 to 11.6). The incidence of both lobar and non-
lobar ICH increased with age (Table 3.1) 
3.4.1.3 Locations of first-ever SVD-associated ICH in LATCH 
Three hundred and eighty-two (91%) of 419 patients with first-ever SVD-
associated ICH had a single index ICH, whereas 37 (9%) had multiple 
simultaneous index ICHs. The locations of the largest ICH are shown in 
Table 3.2. The largest ICH was lobar in 208 (50%) and non-lobar in 211 
(50%). The frontal lobe was the most frequent ICH epicentre in lobar ICH (97 
[47%]). 75% of non-lobar ICHs were supratentorial and were most frequently 
located in the basal ganglia (93 [44%]) or thalamus (64 [30%]). Of the 37 
patients with multiple index ICHs, 22 had multiple lobar ICHs, seven multiple 
non-lobar ICHs and eight mixed lobar and non-lobar ICHs. 
3.4.1.4 Baseline clinical features of first-ever lobar and non-lobar SVD-
associated ICH in LATCH 
The proportion with a pre-ICH diagnosis of hypertension was significantly 
higher in non-lobar ICH patients compared to those with a lobar ICH on 
univariable analysis, whereas pre-ICH dementia was more frequent in lobar 
ICH patients (Table 3.3). There were no other statistically significant 
univariable differences in pre-existing co-morbidities between the lobar and 
non-lobar ICH groups. Antiplatelet drug use at the time of ICH was 
significantly more common in lobar ICH compared with non-lobar patients. 
Lobar ICH patients had significantly larger ICH volumes. There was no 







Figure 3.1 Flowchart of patients in LATCH between 1st June 2010 and 31st May 2013 inclusive 
 
CT = computed tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of cerebral 






Table 3.1 Crude incidence of first-ever SVD-associated ICH by age and ICH location in LATCH 
Age groups 
(years) 
All ICH Non-lobar ICH Lobar ICH 
n Incidence (95% CI) n Incidence (95% CI) n Incidence (95% CI) 
16-59 65 4.2 (3.2-5.3) 37 2.4 (1.7-3.2) 28 1.8 (1.2-2.5) 
60-74 112 32.9 (27.2-39.4) 58 17.0 (13.0-21.8) 54 15.9 (12.0-20.5) 
75 and above 242 138.1 (121.4-156.3) 116 66.2 (54.9-79.0) 126 71.9 (60.1-85.2) 
Total 419 20.2 (18.3-22.2) 211 10.2 (8.8-11.6) 208 10.0 (8.7-11.4) 
Incidence expressed as n/100,000/year. ICH = Intracerebral haemorrhage. LATCH = Lothian Audit of the Treatment of 
Cerebral Haemorrhage. SVD = small vessel disease. 
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Table 3.2 Locations of first-ever SVD-associated ICHs in LATCH 
ICH epicentre Non-lobar ICH (n=211) Lobar ICH (n=208) 
Basal ganglia 93 (44) -  
Thalamus 64 (30) -  
Corpus callosum 2 (1) -  
Brainstem 18 (9) -  
Cerebellum 34 (16) -  
Frontal lobe -  97 (47) 
Parietal lobe -  57 (27) 
Temporal lobe -  38 (18) 
Occipital lobe -  15 (7) 
Holohemispheric -  1 (0) 
Data are n (%). ICH epicentre relates to the largest acute ICH if multiple ICHs 
were present at diagnosis. ICH = intracerebral haemorrhage. LATCH = 
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Table 3.3 Clinical characteristics of first-ever SVD-associated ICH in LATCH, 

























Co-morbidities*      
Hypertension 152 (72) 120 (58) 0.002 
Ischaemic stroke 42 (20) 27 (13) 0.053 
Transient ischaemic attack 25 (12) 20 (10) 0.450 
Dementia 15 (7) 37 (18) 0.001 
Diabetes 24 (11) 23 (11) 0.904 
Atrial fibrillation 51 (24) 39 (19) 0.169 
Myocardial infarction 18 (9) 19 (9) 0.839 



























































Pre-ICH modified Rankin scale; median 
(IQR) 
2 (1-3) 2 (1-3) 0.814 
Medications on admission      
Antiplatelet drug(s) 79 (37) 98 (47) 0.045 
Anticoagulant drug(s) 31 (15) 25 (12) 0.421 
Antihypertensive drug(s) 109 (52) 93 (45) 0.155 
Admission GCS; median (IQR) † 14 (10-15) 14 (10-15) 0.422 
ICH volume of the largest haematoma 
(ml); median (IQR) ‡ 
12 (4-29) 37 (12-85) <0.001 
Data are n (%) or median (IQR). * missing for 1 patient. † missing for4 
patients. ‡ missing for 5 patients diagnosed by autopsy. GCS = Glasgow 
coma scale. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the 
treatment of cerebral haemorrhage. SVD = small vessel disease.  
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3.4.1.5 Diagnostic brain CT scan features of first-ever lobar and non-
lobar SVD-associated ICH in LATCH 
Four hundred and four patients with first-ever SVD-associated ICH during 
LATCH were diagnosed by non-contrast brain CT (Figure 3.1). The median 
time between ICH onset and diagnostic brain CT was 0 days (IQR 0-1 days). 
The diagnostic non-contrast brain CT features of these patients are 
summarised in Table 3.4. Intraventricular haemorrhage was significantly 
more common in the non-lobar ICH group, whereas subarachnoid 
haemorrhage, subdural haemorrhage and finger-like projections were 
significantly more frequent in lobar ICH on univariable testing. The non-lobar 
ICH group had significantly more frequent old vascular lesions and more 
severe CT SVD score compared with lobar ICH. 
3.4.1.6 Multivariable analysis of baseline clinical features and diagnostic 
brain CT scan features of first-ever lobar and non-lobar SVD-
associated ICH in LATCH 
Multivariable analysis of patients with first-ever SVD-associated ICH 
diagnosed by CT showed no independent association between pre-existing 
co-morbidities and ICH location, including hypertension and dementia (Table 
3.5). ICH volume was significantly higher in patients with a lobar ICH 
compared with non-lobar ICH, while there was a borderline association 
between lobar ICH and higher admission GCS. Multiple simultaneous acute 
ICHs, subarachnoid haemorrhage and subdural haemorrhage were 
independently associated with lobar ICH, whereas intraventricular 
haemorrhage was associated with non-lobar ICH. 
3.4.1.7 Application of the modified Boston criteria during LATCH 
One hundred and twenty-seven patients out of 448 with SVD-associated ICH 
had MRI performed (28%) during routine clinical practice to diagnose or 
further assess their ICH, or as part of the LINCHPIN study (Figure 3.2). Of 
these, one hundred and twelve patients had MRI with blood-sensitive 
sequences, while no blood-sensitive sequences were performed in the other 
15 patients with brain MRI. Three hundred and sixteen patients had a 
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diagnostic brain CT scan without any clinical or research MRI performed 
(71%). Five patients had their ICH diagnosed at autopsy (1%). 
Patients who underwent a clinical or research MRI were significantly younger 
than those who did not have MRI on univariable testing, with significantly less 
frequent pre-ICH ischaemic stroke, dementia and myocardial infarction, and 
less pre-ICH disability (Table 3.6). Those who had an MRI had significantly 
higher admission GCS, smaller ICH volume and less frequent intraventricular 
haemorrhage. 
In total, 72 out of 448 patients with SVD-associated ICH were classified as 
probable CAA (16%), 166 as possible CAA (37%) and 210 as no CAA (47%) 
(Table 3.7). The proportion classified as probable CAA was highest in 
patients who underwent MRI with blood-sensitive imaging.  
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Table 3.4 Diagnostic non-contrast brain CT characteristics of first-ever SVD-
associated ICH in LATCH, stratified by ICH location 







Multiple simultaneous acute 
ICHs 
14 (7) 23 (12) 0.099 
Intraventricular haemorrhage 113 (55) 76 (38) 0.001 
Subarachnoid haemorrhage 31 (15) 145 (73) <0.001 
Subdural haemorrhage 1 (1) 41 (31) <0.001 
Finger-like projections 1 (1) 43 (22) <0.001 
Old vascular lesion 99 (48) 74 (37) 0.024 
Number of lacunes; median 
(IQR) 
0 (0-1) 0 (0-0) <0.001 




















































































































CT SVD score 
0 















Data are n (%) or median (IQR). CT = computed tomography. ICH = 
intracerebral haemorrhage. LATCH = Lothian audit of the treatment of 
cerebral haemorrhage. SVD = small vessel disease.  
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Table 3.5 Multivariable logistic regression model of baseline clinical and 
diagnostic non-contrast brain CT features associated with first-ever SVD-








Intercept -2.56 (1.31)   0.051 
Age (per year increase) 0.01 (0.01) 1.01 (0.99-1.04) 0.336 
Male sex -0.11 (0.31) 0.90 (0.49-1.64) 0.727 
Hypertension -0.71 (0.39) 0.49 (0.23-1.04) 0.066 
Ischaemic stroke -0.10 (0.44) 0.90 (0.37-2.12) 0.817 
Transient ischaemic attack -0.97 (0.50) 0.38 (0.14-1.00) 0.054 
Dementia 0.73 (0.50) 2.08 (0.79-5.70) 0.145 
Diabetes 0.21 (0.51) 1.23 (0.44-3.27) 0.682 
Atrial fibrillation -0.25 (0.45) 0.78 (0.31-1.86) 0.572 
Myocardial infarction 0.05 (0.58) 0.95 (0.30-2.88) 0.925 
Hyperlipidaemia -0.66 (0.41) 0.52 (0.23-1.14) 0.108 
Medications on admission      
Antiplatelet drug(s) 0.56 (0.38) 1.76 (0.84-3.74) 0.138 
Anticoagulant drug(s) -0.22 (0.52) 0.81 (0.29-2.23) 0.679 
Antihypertensive drug(s) -0.04 (0.39) 0.97 (0.45-2.10) 0.929 
Admission GCS (per unit 
increase) 
0.09 (0.05) 1.10 (1.00-1.21) 0.056 
ICH volume (per ml increase) 0.02 (0.01) 1.02 (1.01-1.04) <0.001 
Multiple simultaneous acute 
ICHs 
1.05 (0.50) 2.86 (1.07-7.72) 0.036 
Intraventricular haemorrhage -1.68 (0.38) 0.19 (0.09-0.38) <0.001 








CT SVD score 1-3 versus 0 -0.54 (0.33) 0.58 (0.31-1.11) 0.099 
1 patient excluded due to missing data. CT = Computed tomography. GCS = 
Glasgow coma scale. ICH = intracerebral haemorrhage. LATCH = Lothian au





Figure 3.2 Modified Boston criteria classification of SVD-associated ICH during LATCH 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of 
the treatment of cerebral haemorrhage. MRI = magnetic resonance imaging. SVD = small vessel disease.
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Table 3.6 Clinical and non-contrast brain CT features of LATCH patients with 
SVD-associated ICH who did and did not undergo brain MRI. 
Characteristics No MRI (n=321) MRI (n=127) p value 


















Co-morbidities*      
Hypertension 222 (69) 74 (58) 0.025 
Ischaemic stroke 64 (20) 9 (7) 0.001 
Transient ischaemic attack 43 (13) 12 (9) 0.247 
Dementia 57 (18) 3 (2) <0.001 
Diabetes 41 (13) 10 (8) 0.139 
Atrial fibrillation 76 (24) 21 (17) 0.095 
Myocardial infarction 35 (11) 4 (3) 0.009 




























































Pre-ICH modified Rankin scale; median 
(IQR) 
3 (2-4) 1 (1-2) <0.001 
Medications on admission      
Antiplatelet drug(s) 146 (46) 39 (31) 0.004 
Anticoagulant drug(s) 44 (14) 14 (11) 0.446 
Antihypertensive drug(s) 171 (53) 48 (38) 0.003 
Admission GCS; median (IQR) † 12 (8-14) 15 (14-15) <0.001 
Multiple simultaneous acute ICHs 34 (11) 5 (4) 0.038 
ICH volume of the largest haematoma 
(ml); median (IQR) ‡ 
29 (9-70) 9 (3-18) <0.001 
















Intraventricular haemorrhage 179 (56) 25 (20) <0.001 
Subarachnoid haemorrhage 148 (46) 47 (37) 0.080 
Subdural haemorrhage 37 (12) 9 (7) 0.163 
Data are n (%) or median (IQR). * missing for 1 patient. † missing for4 
patients. ‡ missing for 5 patients diagnosed by autopsy. GCS = Glasgow 
coma scale. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the 




















Probable CAA 37 (33) [25-42] 1 (7) [1-30] 34 (11) [8-15] 0 (0) [0-43] 72 (16) [13-20] 
Possible CAA 14 (13) [8-20] 5 (33) [15-58] 144 (46) [40-51] 3 (60) [23-88] 166 (37) [33-42] 
No CAA 61 (54) [45-63] 9 (60) [36-80] 138 (44) [38-49] 2 (40) [12-77] 210 (47) [42-52] 
Data are n (%) [95% CI]. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. 
LATCH = Lothian audit of the treatment of cerebral haemorrhage. MRI = magnetic resonance imaging. SVD = small vessel 
disease.
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3.4.2 LINCHPIN 
3.4.2.1 Flow of participants 
There were 612 patients with a spontaneous ICH presumed related to SVDs 
between 1st June 2010 and 31st May 2016. Three hundred fifty consented to 
the LINCHPIN study, of whom 337 presented with a first-ever ICH (Figure 
3.3). 
3.4.2.2 Comparison of LATCH patients with first-ever SVD-associated 
ICH who did and did not consent to any part of the LINCHPIN 
study 
Between 1st June 2010 and 31st May 2013 inclusive, 187 out of 448 LATCH 
patients with SVD-associated ICH consented to the LINCHPIN study, of 
whom 178 had a first-ever SVD-associated ICH (Figure 3.4). 
The age and sex distribution were similar between those who did and did not 
consent to any part of the LINCHPIN study on univariable testing (Table 
3.18). The proportion of patients with a previous history of ischaemic stroke 
or myocardial infarction was significantly lower in LINCHPIN consenters 
versus non-consenters. The frequency of other baseline co-morbidities was 
similar between the groups. Pre-ICH level of functioning was significantly 
better in LINCHPIN consenters. Admission GCS scores were significantly 
higher and intraventricular haemorrhage was significantly less frequent in 
those who consented to LINCHPIN. ICH volume tended to be smaller in 
consenters, but this did not reach statistical significance (Table 3.9). 
3.4.2.3 Research brain MRI 
Comparison of LATCH patients with first-ever SVD-associated ICH who did 
and did not undergo research brain MRI as part of the LINCHPIN study 
Eighty-three LATCH patients with first-ever SVD-associated ICH had a 
research brain MRI scan as part of LINCHPIN (Figure 3.4). Participants who 
had a research brain MRI were significantly younger and less likely to have a 
pre-ICH history of ischaemic stroke, dementia, diabetes or myocardial 
infarction than the rest of the patients with SVD-associated ICH in LATCH 
(Table 3.10). Also, those undergoing a research MRI had significantly better 
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pre-ICH functioning, higher admission GCS, smaller ICH volumes, were less 





Figure 3.3 Flowchart of participants in the LINCHPIN study between 1st June 2010 and 31st May 2016 inclusive 
 
* Two MRIs obtained but poor quality (too much movement) or no T2* sequence obtained (claustrophobia). 
APOE = apolipoprotein E. ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, 




Figure 3.4 Flowchart of LATCH patients recruited into the LINCHPIN study between 1st June 2010 until 31st May 2013 
inclusive 
 
* Two MRIs obtained but poor quality (too much movement) or no T2*-weighted GRE sequence obtained due to 
claustrophobia. APOE = apolipoprotein E. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of 
cerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological outcome. MRI = 
magnetic resonance imaging. SVD = small vessel disease. 
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Table 3.8 Baseline features of LATCH patients with first-ever SVD-



























Co-morbidities*      
Hypertension 111  (62) 161  (67) 0.316 
Ischaemic stroke 21  (12) 48  (20) 0.026 
Transient ischaemic attack 21  (12) 24 (10) 0.558 
Dementia 21 (12) 31 (13) 0.744 
Diabetes 14  (8) 33  (14) 0.060 
Atrial fibrillation 34  (19) 56  (23) 0.298 
Myocardial infarction 9  (5) 28  (12) 0.019 



























































Pre-ICH modified Rankin 
scale; median (IQR) 
2 (1-3) 3 (1-4) 0.007 
Medications on admission      
Antiplatelet drug(s) 75  (41) 102  (42) 0.969 
Anticoagulant drug(s) 22  (12) 34  (14) 0.603 
Antihypertensive drug(s) 83  (47) 119  (49) 0.578 
Admission GCS score; median 
(IQR) † 
14 (11-15) 13  (7-15) <0.001 
Data are n (%) or median (IQR). * missing for 1 patient. † missing for 4 
patients. GCS = Glasgow coma scale. ICH = intracerebral haemorrhage. 
LATCH = Lothian audit of the treatment of cerebral haemorrhage. LINCHPIN 
= Lothian intracerebral haemorrhage pathology, imaging and neurological 
outcome. SVD = small vessel disease.  
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Table 3.9 ICH location and diagnostic non-contrast brain CT features in 
LATCH patients with first-ever SVD-associated ICH who consented to the 
LINCHPIN study versus those who did not 



























ICH volume; median (IQR) ‡ 17  (5-40) 22  (6-62) 0.054 
Intraventricular haemorrhage 66  (37) 125  (52) 0.003 
Subarachnoid haemorrhage 78  (44) 101  (42) 0.696 
Subdural haemorrhage 17  (10) 25  (10) 0.782 



























Data are n (%) or median (IQR). ‡ missing for 5 patients diagnosed by 
autopsy. ¥ missing for 15 patients without a diagnostic CT. CT = computed 
tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the 
treatment of cerebral haemorrhage. LINCHPIN = Lothian intracerebral 
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Table 3.10 Baseline clinical features in first-ever SVD-associated ICH LATCH 
patients who had a LINCHPIN research brain MRI performed versus those 





No research MRI 
obtained (n=336) 
p value 


















Co-morbidities*      
Hypertension 47 (57) 225 (67) 0.071 
Ischaemic stroke 5 (6) 64 (19) 0.004 
Transient ischaemic attack 5 (6) 40 (12) 0.120 
Dementia 1 (1) 51 (15) 0.001 
Diabetes 4 (5) 43 (13) 0.038 
Atrial fibrillation 12 (15) 78 (23) 0.080 
Myocardial infarction 2 (2) 35 (10) 0.021 



























































Pre-ICH modified Rankin 
scale; median (IQR) 
1 (1-2) 3 (2-4) <0.001 
Medications on admission      
Antiplatelet drug(s) 24 (29) 153 (46) 0.006 
Anticoagulant drug(s) 10 (12) 46 (14) 0.694 
Antihypertensive drug(s) 33 (40) 169 (50) 0.085 
Admission GCS score; median 
(IQR) † 
15 (14-15) 13 (9-15) <0.001 
Data are n (%) or median (IQR). * missing for 1 patient. † missing for4 
patients. GCS = Glasgow coma scale. ICH = intracerebral haemorrhage. 
LATCH = Lothian audit of the treatment of cerebral haemorrhage. LINCHPIN 
= Lothian intracerebral haemorrhage pathology, imaging and neurological 
outcome. MRI = magnetic resonance imaging. SVD = small vessel disease.  
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Table 3.11 ICH location and diagnostic non-contrast brain CT features in 
first-ever SVD-associated ICH LATCH patients who had a LINCHPIN 
research brain MRI performed versus those who did not 

























ICH volume; median (IQR) ‡ 9  (3-20) 24  (7-63) <0.001 
Intraventricular haemorrhage 16  (19) 175 (52) <0.001 
Subarachnoid haemorrhage 31 (37) 148 (44) 0.269 
Subdural haemorrhage 6 (7) 36  (11) 0.344 



























Data are n (%) or median (IQR). ‡ missing for 5 patients diagnosed by 
autopsy. ¥ missing for 15 patients without a diagnostic CT. CT = computed 
tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the 
treatment of cerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. MRI = magnetic 
resonance imaging. SVD = small vessel disease. 
 
Brain MRI scan features of first-ever lobar and non-lobar ICH in LINCHPIN 
One hundred and fifty-seven LINCHPIN participants with first-ever SVD-
associated ICH had a research brain MRI (Figure 3.3). I excluded two 
participants due to poor quality MRI scans (one had too much motion artefact 
to allow accurate analysis; the other had no T2*-weighted GRE sequence 
obtained due to claustrophobia). Eighty-one (52%) of the remaining 155 
participants with research brain MRI had a non-lobar ICH and 74 (48%) had 
a lobar ICH. The median time between ICH onset and research brain MRI 
was 92 days (IQR 73-125 days). 
There was no statistically significant difference in the severity of WMH, 
atrophy or PVS between the groups (Table 3.12). Lobar ICH participants 
were more likely to have cortical superficial siderosis than the non-lobar ICH 
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group. When present, cortical superficial siderosis was more likely to be 
diffuse (i.e. both adjacent to and distant from the ICH) in those with a lobar 
ICH. Non-lobar ICH participants had more deep CMBs whereas there was no 
statistically significant difference in the number of lobar, cerebellar, brainstem 
or total CMBs between the groups. 
There was no significant difference in MRI SVD burden score[197] between 
the groups. The MRI CAA SVD burden score[214] was higher in lobar ICH 
participants. 
  
  Chapter 3 
94 
Table 3.12 Research brain MRI characteristics of SVD-associated ICH in the 

































Periventricular Fazekas score; median 
(IQR) 
2 (1-3) 3 (1-3) 0.262 




































































































Cortical atrophy; median (IQR) 2 (1-3) 2 (1-3) 0.267 































Basal ganglia PVS; median (IQR) 1 (1-2) 1 (1-2) 0.157 































Centrum semiovale PVS; median (IQR) 2 (1-2) 2 (1-3) 0.106 
Multiple ICH 11 (14) 12 (16) 0.645 








Cortical superficial siderosis 12 (15) 49 (66) <0.001 

















Cortical superficial siderosis location* 
Adjacent to ICH 




















Any lobar CMB 23 (28) 28 (38) 0.211 
Total lobar CMBs; median (IQR) 0 (0-1) 0 (0-2) 0.192 
Any deep CMB 28 (35) 12 (16) 0.009 
Total deep CMBs; median (IQR) 0 (0-1) 0 (0-0) 0.005 
Any cerebellar CMB 12 (15) 5 (7) 0.109 
Total cerebellar CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.105 
Any brainstem CMB 10 (12) 3 (4) 0.063 
Total brainstem CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.060 
Any CMB 39 (48) 32 (43) 0.540 
Total CMBs; median (IQR) 0 (0-4) 0 (0-2) 0.408 































MRI SVD burden score; median (IQR) 3 (2-4) 3 (2-4) 0.390 









































MRI CAA SVD burden score; median (IQR) 2 (1-2) 3 (2-4) <0.001 





















Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CMB = cerebral microbleed. ICH = intracerebral 
haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, 
imaging and neurological outcome. MRI = magnetic resonance imaging. PVS 
= perivascular space. SVD = small vessel disease.  
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3.4.2.4 APOE genotype 
Comparison of LATCH patients with first-ever SVD-associated ICH who did 
and did not undergo APOE genotyping as part of the LINCHPIN study 
One hundred and sixty LATCH patients with first-ever SVD-associated ICH 
had APOE genotyping performed on either a peripheral blood sample or 
autopsy brain tissue as part of LINCHPIN (Figure 3.4). Those who had DNA 
obtained for APOE genotyping had a significantly lower frequency of previous 
ischaemic stroke or myocardial infarction, less pre-ICH disability, higher 
admission GCS scores and less frequent intraventricular haemorrhage than 
the rest of the LATCH cohort on univariable testing (Table 3.13 and Table 
3.14). 
APOE genotype in first-ever lobar and non-lobar ICH in LINCHPIN 
Two hundred and ninety-one LINCHPIN participants had APOE genotyping 
performed (Figure 3.3). The genotype was undetermined in 14. Of the 
remaining 277 participants, 135 had a lobar ICH and 142 a non-lobar ICH. 
APOE 2 allele possession was significantly more common in lobar versus 
non-lobar ICH (37/135 [27%] versus 15/142 [11%] respectively, p<0.001). 
APOE 4 allele possession was more frequent in lobar ICH versus non-lobar 
ICH, but this did not reach statistical significance on univariable analysis 
(52/135 [39%] versus 41/142 [29%] respectively, p=0.089). APOE 2 
possession was independently associated with lobar ICH location after 
adjusting for baseline co-morbidities (Table 3.15). There was a borderline 
statistically significant association between APOE 4 possession with lobar 
ICH (OR 1.73 [95%CI 0.99-3.07]). 
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Table 3.13 Baseline features in first-ever SVD-associated ICH LATCH 
patients who had APOE genotyping performed as part of LINCHPIN versus 
those who did not 
Characteristics 
DNA for APOE 
genotype (n=160) 
No DNA for APOE 
genotype (n=259) 
p value 

















Co-morbidities*      
Hypertension 100  (63) 172 (67) 0.385 
Ischaemic stroke 19 (12) 50 (19) 0.045 
Transient ischaemic attack 19 (12) 26  (10) 0.564 
Dementia 18 (11) 34 (13) 0.571 
Diabetes 13 (8) 34 (13) 0.112 
Atrial fibrillation 30 (19) 60 (23) 0.276 
Myocardial infarction 7  (4) 30 (12) 0.011 



























































Pre-ICH modified Rankin 
scale; median (IQR) 
2 (1-3) 3 (1-4) 0.006 
Medications on admission      
Antiplatelet drug(s) 67 (42) 110 (43) 0.904 
Anticoagulant drug(s) 19 (12) 37  (14) 0.481 
Antihypertensive drug(s) 73 (46) 129  (50) 0.405 
Admission GCS score; median 
(IQR) † 
14 (11-15) 14  (8-15) 0.005 
Data are n (%) or median (IQR). * missing for 1 patient. ∞ missing for 22 
patients. † missing for4 patients. APOE = apolipoprotein E. GCS = Glasgow 
coma scale. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the 
treatment of cerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. SVD = small 
vessel disease.  
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Table 3.14 ICH location and diagnostic non-contrast brain CT features in 
first-ever SVD-associated ICH LATCH patients who had APOE genotyping 
performed as part of LINCHPIN versus those who did not 
 
DNA for APOE 
genotype 
(n=160) 























ICH volume; median (IQR) ‡ 17  (5-40) 20  (6-61) 0.272 
Intraventricular haemorrhage 63 (39) 128  (49) 0.045 
Subarachnoid haemorrhage 71 (44) 108  (42) 0.591 
Subdural haemorrhage 14  (9) 28  (11) 0.495 



























Data are n (%) or median (IQR). ‡ missing for 5 patients diagnosed by 
autopsy. ¥ missing for 15 patients without a diagnostic CT. APOE = 
apolipoprotein E. CT = computed tomography. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral 
haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, 
imaging and neurological outcome. SVD = small vessel disease. 
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Table 3.15 Multivariable logistic regression model of baseline clinical features 
and APOE genotype associated with first-ever SVD-associated lobar ICH 
during the LINCHPIN study 







Intercept -2.62 (0.91)   0.004 
Age (per year increase) 0.04 (0.01) 1.04 (1.02-1.07) 0.001 
Male sex -0.49 (0.27) 0.61 (0.36-1.05) 0.073 
Hypertension -0.72 (0.30) 0.49 (0.27-0.87) 0.016 
Ischaemic stroke -0.54 (0.43) 0.58 (0.25-1.33) 0.205 
Transient ischaemic attack -0.08 (0.47) 0.92 (0.37-2.31) 0.862 
Dementia 0.01 (0.47) 0.99 (0.40-2.49) 0.979 
Diabetes 0.21 (0.44) 1.23 (0.51-2.92) 0.642 
Atrial fibrillation 0.05 (0.37) 1.05 (0.51-2.18) 0.886 
Myocardial infarction 0.89 (0.53) 2.43 (0.88-7.26) 0.095 
Hyperlipidaemia -0.29 (0.39) 0.75 (0.34-1.60) 0.456 
APOE 2 allele possession 1.21 (0.37) 3.36 (1.67-7.06) <0.001 
APOE 4 allele possession 0.55 (0.29) 1.73 (0.99-3.07) 0.055 
APOE = apolipoprotein. ICH = intracerebral haemorrhage. LINCHPIN = 
Lothian intracerebral haemorrhage pathology, imaging and neurological 
outcome. SVD = small vessel disease. 
 
3.5 Discussion 
3.5.1 Main findings 
 The incidence of lobar and non-lobar first-ever SVD-associated ICH 
was similar and increased with age. 
 Baseline clinical and diagnostic CT findings in a community-based 
cross-sectional study of first-ever SVD-associated ICH (LATCH) 
o Pre-existing dementia was more frequent in patients with a 
lobar ICH, and pre-ICH hypertension more common in non-
lobar ICH patients, but these associations were not statistically 
significant after adjustment for other baseline clinical and non-
contrast CT brain features. 
o Patients with lobar ICH had statistically larger ICH volume and 
more frequent subarachnoid and subdural haemorrhage, while 
non-lobar ICH patients had more frequent intraventricular 
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haemorrhage after adjustment for other baseline clinical and 
non-contrast CT brain features. 
 Applying the modified Boston criteria in a population-based cross-
sectional study of SVD-associated ICH (LATCH) 
o Only 28% of patients underwent brain MRI as part of routine 
clinical practice or as part of the LINCHPIN study. 
o Those who had MRI were younger, had fewer co-morbidities, 
higher admission GCS scores, smaller ICH volumes and less 
frequent intraventricular haemorrhage compared with those 
who did not have an MRI. 
o Overall, 16% of patients were classified as probable CAA, 37% 
as possible CAA and 47% as no CAA. 
o In the 25% of patients who had MRI with blood-sensitive 
imaging, 33% were classified as probable CAA, 13% as 
possible CAA and 54% as no CAA. 
 Assessment of selection bias in LINCHPIN during a population-based 
cross-sectional study of first-ever SVD-associated ICH (LATCH) 
o Those who consented to any part of LINCHPIN were similar to 
non-consenters apart from being less likely to have had a 
previous ischaemic stroke or myocardial infarction, and having 
a higher admission GCS and less frequent intraventricular 
haemorrhage. 
o Those who had a research brain MRI were younger than the 
rest of the LATCH cohort, with less frequent pre-ICH ischaemic 
stroke, dementia, diabetes or myocardial infarction and less 
severe pre-ICH disability. Admission GCS was higher in those 
undergoing research brain MRI, and they had smaller ICHs, 
less frequent intraventricular haemorrhage and less severe CT 
SVD score. 
o Those who had DNA obtained for APOE genotyping had less 
pre-ICH disability, higher admission GCS and less frequent 
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intraventricular haemorrhage than the rest of the LATCH 
cohort. 
 Research MRI findings in a community-based cross-sectional study of 
first-ever SVD-associated ICH (LINCHPIN) 
o Cortical superficial siderosis was more frequent in lobar ICH 
while there were more deep CMBs in non-lobar ICH. 
o The severity of WMH, atrophy and PVS were similar between 
lobar and non-lobar ICH groups. 
 APOE genotype in a community-based cross-sectional study of first-
ever SVD-associated ICH (LINCHPIN) 
o APOE 2 possession was independently associated with lobar 
ICH location while APOE  allele possession showed a 
borderline independent association. 
3.5.2 Strengths of the study 
I have discussed the strengths of LATCH and the LINCHPIN study in section 
2.5.1. These include prospective, community-based inception cohort study 
designs, low levels of missing baseline clinical data and standardised 
approaches to assessing brain imaging to minimise information-bias. The 
nesting of LINCHPIN within the community-based LATCH study allowed me 
to examine selection biases in different components of this study. Also, I 
restricted my analyses of the clinical, imaging and genetic features in SVD-
associated ICH to those with a first-ever ICH to standardise the inception 
point. 
3.5.3 Weaknesses of the study 
The weaknesses of LATCH and the LINCHPIN study are discussed in 
section 2.5.2. The main weaknesses relate to the modest sample size and 
selection biases in the LINCHPIN study, particularly for those undergoing a 
research MRI (see section 3.5.4.4). 
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3.5.4 Comparison with other studies 
3.5.4.1 ICH incidence 
The overall incidence of first-ever SVD-associated ICH (20.2 per 100,000 
person-years) was similar to the incidence rate in a systematic review of 36 
population-based studies of ICH (24.6 per 100,000 person-years).[134] The 
incidence increased with age, which is consistent with other studies,[134] and 
is thought to be related to the higher incidence of CAA and hypertension with 
age and the use of antithrombotic drugs in this age group.[135] 
The overall incidence of lobar and non-lobar ICH was similar. This 
relationship persisted across all age groups. Other studies have shown a 
higher incidence of non-lobar ICH in younger patients compared with lobar 
ICH.[135, 230] This difference may, in part, be driven by ethnic background, 
with a higher frequency of non-lobar ICH found in blacks compared to 
whites.[231] In contrast, the patients in LATCH were almost entirely white. 
3.5.4.2 Cross-sectional clinical, imaging and genetic features in lobar 
versus non-lobar ICH 
Hypertension was common in the LATCH cohort, and more frequent in 
patients with non-lobar ICH compared to those with lobar ICH (72% versus 
58%). However, this difference was not statistically significant when I 
adjusted for other baseline clinical and diagnostic brain CT features. 
Hypertension is often considered a more important risk factor for non-lobar 
than lobar ICH.[232] A meta-analysis of studies comparing the frequency of 
hypertension between deep and lobar supratentorial ICH showed that while 
hypertension was more common in patients with deep ICH, this finding may 
be related to biases in study design.[141] Hypertension appears to be 
important in most SVD-associated ICH, regardless of ICH location, and so 
should not be used on its own to determine the likely underlying pathology. 
CAA is thought to be associated with lobar but not non-lobar ICH.[153] 
Autopsy studies of community-dwelling elderly have shown that CAA is 
associated with dementia during life, independent of Alzheimer’s disease 
pathology.[21, 233] Therefore, there may be an association between pre-ICH 
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dementia and lobar ICH. Pre-ICH dementia was more frequent in patients 
with a lobar ICH versus non-lobar ICH (18% versus 7%), although this did not 
remain significant in the multivariable analysis. 
There were no other statistically significant differences in baseline clinical 
characteristics of patients with lobar and non-lobar ICHs. 
Patients with a lobar ICH had a significantly larger ICH compared to non-
lobar ICH. This is consistent with previous studies,[234-236] and is probably 
related in part to anatomical factors; the cerebral lobes are less confined by 
the skull and dura than infratentorial non-lobar regions, and less confined by 
surrounding brain tissue than supratentorial non-lobar regions, especially if 
there is brain atrophy. Other features which may contribute to larger lobar 
ICH include more common pre-ICH use of antiplatelet drugs[235] and more 
frequent APOE 2 allele possession[236] in these patients. 
The higher frequency of subarachnoid and subdural haemorrhage with lobar 
ICH may reflect the likely underlying type of SVDs. CAA, which involves the 
leptomeningeal and cortical vessels,[1, 229] is thought to be associated with 
lobar but not non-lobar ICH.[153] Rupture of these vessels is likely to spread 
into the extra-axial spaces as well as the brain parenchyma. It may also be 
related to the anatomy, as an ICH in the cerebral lobes is closer to the 
cortical surface and tends to be larger,[237] increasing the chance of 
haemorrhage extension into the extra-axial spaces. The higher frequency of 
intraventricular haemorrhage with non-lobar ICH probably reflects the 
proximity of these haematomas to the ventricular system.[238, 239] 
The severity of WMH was similar between lobar and non-lobar ICH, which is 
in keeping with previous studies.[240, 241] ICHs are thought to represent late 
consequences of SVDs[170] and WMH occur in both CAA and 
arteriolosclerosis.[1, 77] Therefore, a high severity of WMH in both lobar and 
non-lobar ICH is not surprising. 
Cortical superficial siderosis was more frequent in patients with lobar ICH 
compared to non-lobar ICH. This is similar to a previous study,[241] and is 
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likely to reflect underlying CAA affecting the cortical and leptomeningeal 
vessels.[1, 118, 229] The higher frequency of diffuse cortical superficial 
siderosis and cortical superficial siderosis distant to the ICH in the lobar ICH 
group suggests this association is not simply due to direct extension of lobar 
ICH into the subarachnoid space. 
ICH and CMBs are haemorrhagic manifestations of both CAA and 
arteriolosclerosis.[1, 77] Previous studies have shown that the regional 
distribution of CMBs is associated with ICH location, [240, 242] which 
probably reflects the distribution of vessels involved by the underlying SVDs. 
In line with these studies, I found that the presence and number of deep 
CMBs were significantly higher in non-lobar versus lobar ICH. The presence 
and number of lobar CMBs were higher in the lobar ICH group, although 
these differences did not reach statistical significance. This may reflect the 
small sample size in my study. Also, the inclusion of cerebellar ICH in the 
non-lobar group may have increased the proportion with lobar CMBs given 
that cerebellar ICH can be caused by either CAA or arteriolosclerosis.[226] 
Lobar ICH location was independently associated with APOE 2 possession, 
and there was a borderline association with APOE 4 allele possession. 
These associations are consistent with a large genetic association 
study,[144] and are thought to be due to the presence of CAA-associated 
lobar ICH. Interestingly, a dose-dependent association between APOE 4 
and pathologically proven CAA was found in a meta-analysis, however, there 
was no overall association found between APOE 2 and CAA.[24] 
3.5.4.3 Application of the modified Boston criteria in clinical practice 
The modified Boston criteria are the non-invasive in vivo reference standard 
for identifying CAA-associated ICH and are frequently used in clinical 
practice.[110, 167] The criteria showed good diagnostic accuracy in the 
development setting. However, there are two unanswered questions 
regarding their diagnostic value. Firstly, the criteria have never been 
rigorously externally validated, meaning their true diagnostic accuracy is 
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uncertain. I investigated this question in chapter 5. Secondly, it is unclear 
how applicable these MRI-based criteria are in routine clinical practice. 
We offered all suitable SVD-associated ICH patients a research brain MRI 
during our community-based study of ICH. These scans were fully funded 
and performed on a dedicated research MRI scanner (i.e. not limited by 
clinical resources). Even so, only 28% of patients during LATCH had a brain 
MRI scan. This low uptake of MRI scanning is likely to reflect the high early 
fatality rate coupled with contraindications to MRI and survivors being unable 
to tolerate MRI. The proportion of SVD-associated ICH patients able to 
undergo brain MRI in other settings may be lower, particularly in middle- and 
low-income countries where access to MRI may be more limited. Therefore, 
MRI-based diagnostic and prognostic criteria are likely to have limited 
applicability in SVD-associated ICH. 
Overall, 16% of SVD-associated ICH patients in LATCH were classified as 
probable CAA and 37% as possible CAA on the modified Boston criteria. In 
comparison, 43% of participants in a hospital-based study of ICH were 
classified as probable CAA using MRI with blood-sensitive imaging, while 
27% were classified as possible CAA.[243] These differences may reflect 
selection biases in the hospital-based study, which only included participants 
who had had a brain MRI with blood-sensitive sequences. The increased 
sensitivity of blood-sensitive sequences for previous haemorrhagic foci is 
also likely to partially explain these differences. In line with this, I found that 
the proportion of patients classified as probable CAA varied according to 
whether or not MRI with blood-sensitive imaging was performed. Among the 
25% of LATCH patients with MRI and blood-sensitive imaging, 33% (95%CI 
25-42%) were classified as probable CAA, while 13% (95%CI 8-20%) were 
classified as possible CAA. In contrast, only 10% (95%CI 8-14%) of those 
without blood-sensitive MRI imaging were classified as probable CAA, while 
45% (95%CI 40-51%) were classified as possible CAA. A similar pattern was 
shown by Knudsen et al. where 50% with blood-sensitive MRI sequences 
were classified as probable CAA on the original Boston criteria, compared to 
22% without MRI and blood-sensitive sequences.[103]  
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3.5.4.4 Selection bias in the LINCHPIN study 
Few previous studies of SVD-associated ICH have assessed for selection 
bias. Therefore, it is difficult to know to which patients the results are 
applicable. The nesting of LINCHPIN within the community-based LATCH 
study allowed me to assess for selection bias. 
LATCH patients who consented to LINCHPIN were largely similar to those 
who did not consent. The main differences were lower admission GCS and 
more frequent intraventricular haemorrhage in non-consenters compared 
with consenters. This probably relates to the high early case fatality related to 
these factors,[152, 244, 245] which makes the discussion of and consent for 
research difficult.[246]  
LATCH patients who underwent a LINCHPIN research brain MRI were 
younger, had fewer pre-ICH co-morbidities and less pre-ICH disability, 
smaller ICHs and less severe CT SVD scores compared with the rest of the 
cohort. These differences occurred despite inviting all eligible and suitable 
ICH patients to consent to research MRI. They likely reflect the challenges of 
performing MRI in ICH, where the early fatality rate is high, and many of 
those who survive are disabled and unable to tolerate MRI scanning,[134] 
and are therefore more reflective of clinical practice. 
LATCH patients who had APOE genotyping performed had less severe pre-
ICH disability and less frequent intraventricular haemorrhage, which is 
probably related to the poorer prognosis associated with these 
variables.[151] Otherwise, they were largely similar to those who did not have 
APOE genotyping. 
3.5.5 Clinical implications 
The incidence of SVD-associated ICH increases dramatically with age. The 
overall incidence of SVD-associated ICH is therefore likely to increase as the 
population ages.[135, 136] The use of antithrombotic drugs in elderly patients 
needs careful consideration given the postulated link with the high ICH 
incidence.[135, 136] 
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Hypertension is a common co-morbidity in all SVD-associated ICH, 
regardless of ICH location. Preventing the development of hypertension, 
combined with its early detection and effective management, are important 
steps to reduce the incidence of ICH. 
The MRI-based modified Boston criteria for CAA are likely to have more 
limited applicability in clinical practice than in research settings for ICH given 
the difficulty in performing MRI in this patient group combined with limited 
clinical access to MRI. The diagnostic accuracy of the modified Boston 
criteria is likely to be worse in those without blood-sensitive MRI sequences. 
3.5.6 Future directions 
Future epidemiological studies should assess the influence of age, 
hypertension and antithrombotic drug use on the changing incidence of ICH. 
Some evidence of the change in incidence and aetiology of ICH is available 
from cohort studies from Oxfordshire[135] and Dijon.[136] However, future 
studies should include patients from high, middle and low-income countries 
and from different ethnic backgrounds. 
The risks and benefits of antithrombotic drugs in the elderly, as well as in 
those who have had an ICH need to be further studied given the risk of both 
haemorrhagic and vaso-occlusive events.[151, 247] A recent randomised 
controlled trial assessed the risk of recurrent ICH in SVD-associated ICH 
survivors who were taking an antiplatelet drug for the prevention of occlusive 
vascular disease at the time of ICH who were randomised to either restart or 
stop the antiplatelet agent. The group restarted on an antiplatelet agent 
actually had a borderline significantly lower risk of recurrent ICH compared 
with the group not restarted on an antiplatelet (adjusted hazard ratio 0·51, 
95% CI 0·25–1·03; p=0·060).[160] Several other ongoing randomised 
controlled trials are assessing whether antithrombotic drugs result in an 
overall benefit in serious vascular events after ICH.[248-251] 
Studies of the clinical and economic impact of the modified Boston criteria on 
clinical care, along with rigorous external validation of the criteria, are 
required to determine the clinical utility and accuracy of these criteria. 

  Chapter 4 
109 
Chapter 4 A cross-sectional study of SVD-
associated ICH; histopathological features 
 
4.1 Introduction 
Understanding the prevalence, severity and distribution of SVDs in SVD-
associated ICH is important. It helps relate research neuroimaging findings, 
such as the distribution of MRI SVD biomarkers or amyloid PET tracer 
uptake, to the underlying histopathology.[95, 252] It may also help inform 
clinical practice by inferring the likely cause of lobar and non-lobar ICH, 
which in turn can influence the outcome, such as the risk of recurrent ICH 
and post-ICH dementia.[59, 105]  
Histopathological assessment of brain tissue is the reference standard for 
assessing the severity and distribution of SVDs associated with ICH. Brain 
tissue can be sampled in different ways.  
During life, a cortical biopsy is the pathological reference standard for 
diagnosing CAA-associated ICH. However, it is at risk of sampling error. A 
false negative result can occur because of the patchy distribution of CAA and 
the small volume of tissue sampled.[27] A false positive result could occur 
due to the presence of coincidental CAA, which is a common finding in the 
elderly.[14] There are different histopathological approaches for grading CAA 
severity and defining CAA-associated ICH. The Vonsattel scale is one of the 
most widely used scales for grading CAA (Table 4.1). Both Vonsattel grade 
≥1 and ≥2 have been used to define a CAA-associated ICH.[164, 253] More 
recently a consensus rating scale for CAA was developed by Love et al 
(Table 2.6).[36] Quantifying the diagnostic accuracy of cortical biopsy using 
these different histopathological approaches is important for guiding clinical 
management as well as for research in ICH. 
After death, brain tissue can be acquired at autopsy. Multiple tissue samples 
are usually obtained either from one cerebral hemisphere or from the whole 
brain. Whole brain tissue sampling allows the most detailed assessment of 
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the severity and distribution of SVDs but is more time consuming and 
expensive to perform. However, the reliability of sampling one cerebral 
hemisphere is uncertain given that CAA is reported to have a patchy 
distribution within cerebral lobes.[27] Therefore, it is important to assess 
whether the presence and severity of CAA differs between unilateral cerebral 
hemisphere and whole brain autopsy sampling. 
 
Table 4.1 Vonsattel scale for grading CAA 
CAA severity Features 
Grade 0 Absence of amyloid-β staining in vessels 
Grade 1 
Presence of some patchy amyloid-β staining in an 
otherwise normal-appearing vessel 
Grade 2 
Complete replacement of the media by amyloid - wall is 
thickened 
Grade 3 
The vessel shows total replacement of the media with 
amyloid-β and cracking of the vessel wall that creates a 
“vessel-within-vessel” affecting at least 50% of the 
circumference of the vessel 
Grade 4 
Presence of an amyloid-laden vessel with scarring and 
fibrinoid necrosis 
The most advanced degree of CAA present in the specimen in used. CAA = 
cerebral amyloid angiopathy. 
 
CAA is common in the elderly.[14] Its prevalence increases with age[164] 
and with the presence of Alzheimer’s disease.[14] A large meta-analysis of 
24 studies (3520 participants) showed that there is a dose-dependent 
association of APOE 4 with histopathologically confirmed CAA.[254] The 
association between APOE 4 and CAA remained similar in those with and 
without dementia, suggesting that it is independent of the known association 
between APOE 4 and Alzheimer’s disease.[255, 256] There was a non-
significantly decreased odds of CAA with APOE 2 allele possession (OR 
0.73, 95% CI 0.53 to 1.00).[254]  
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Most of the studies assessing the clinical and genetic associations of 
histopathologically proven CAA were performed in non-ICH general hospital-
based autopsy series, autopsy studies of ageing or dementia brain banks, 
where CAA may have been incidental and asymptomatic. The associations of 
CAA in symptomatic ICH may be different, and they may also vary according 
to the type of vessel involved and with the severity of CAA. For example, 
there is evidence that APOE 4 is associated with CAA involving the 
capillaries (CAA-type 1) whereas APOE 2 is associated with CAA not 
affecting the capillaries (CAA-type 2).[257] The associations of CAA with age, 
Alzheimer’s disease, hypertension and APOE genotype in symptomatic ICH, 
accounting for the type of vessel affected (cortical and leptomeningeal 
arteries and capillaries) and severity of histopathological changes is therefore 
of interest. 
It is often cited that the occipital lobe is the brain region most frequently and 
severely affected by CAA.[18, 258] This feature has been used to explain a 
variety of neuroimaging findings in patients with CAA.[208, 252, 259-262] 
However, the literature on CAA distribution is conflicting, with some studies 
showing an occipital predominance of CAA, [28, 263, 264] while others do 
not.[265, 266] The topographical distribution CAA may also vary according to 
co-existent Alzheimer’s pathology.[267] Most of these studies were 
performed in non-ICH populations or hospital-based autopsy studies, where 
CAA may be incidental. Little is known about the distribution of CAA in 
symptomatic ICH, and the effect APOE genotype and Alzheimer’s disease 
have in this patient group. 
Participants in the community-based LINCHPIN study were invited to consent 
to a research brain autopsy in the event of their death. The LINCHPIN brain 
bank provides systematic and extensively sampled brain autopsy tissue, with 
standardised assessments for CAA and non-CAA SVD. The histopathology 
of SVDs in ICH can, therefore, be assessed in detail, using the LINCHPIN 
brain bank, and these histopathological findings can be related to the clinical 
characteristics and to neuroimaging features.  
  Chapter 4 
112 
4.2 Aims 
I aimed to: 
 Compare the clinical and diagnostic non-contrast brain CT features of 
first-ever SVD-associated ICH patients in LATCH consenting to and 
undergoing LINCHPIN research brain autopsy against those who did 
not consent, in order to determine selection bias. 
 Assess the diagnostic accuracy of CAA assessment in the left cerebral 
hemisphere against the reference standard of histopathological 
assessment using systematic whole brain autopsy samples in first-
ever SVD-associated ICH. 
 Assess the diagnostic accuracy of different histopathological CAA 
rating approaches in simulated cortical biopsies against the reference 
standard of histopathological assessment using systematic whole 
brain autopsy samples in first-ever SVD-associated lobar ICH. 
 Evaluate the severity and associations of histopathologically assessed 
CAA in participants with a first-ever SVD-associated lobar ICH. 
 Evaluate the distribution of histopathologically assessed CAA in 
participants with a first-ever SVD-associated lobar ICH. In particular, 
to evaluate whether CAA is more frequent and severe in the occipital 
lobes compared with the rest of the cerebral hemispheres (i.e. 
occipital predominance of CAA). 
 
4.3 Methods 
I used data from the prospective LINCHPIN study (Section 2.1.3.2). I 
included consecutive adult participants (aged ≥16 years) living in the NHS 
Lothian Health Board region who had a first-ever SVD-associated ICH 
between 1st June 2010 and 31st May 2016 inclusive and who underwent a 
subsequent research brain autopsy. 
I excluded patients with exclusively extra-axial intracranial haemorrhage and 
ICH secondary to an underlying cause other than SVDs. I excluded 
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LINCHPIN participants with a previous symptomatic ICH to standardise the 
inception point. 
4.3.1 Baseline data collection 
The RUSH team collected demographics and the presence of relevant co-
morbidities and medication use at the time of ICH by interviewing patients 
and their relatives and reviewing medical records as described in the 
methods chapter (Section 2.1.7). 
4.3.2 APOE genotyping 
APOE genotyping was performed on DNA extracted from peripheral blood or 
from brain tissue using standard techniques described in Section 2.3. I 
defined APOE 2 and APOE 4 possession if participants had at least one ɛ2 
allele or one ɛ4 allele respectively. 
4.3.3 Research brain autopsy 
Research brain autopsy was performed within five days of death according to 
a standard operating procedure (Section 2.4).[217] SVDs (CAA and non-CAA 
SVD) and Alzheimer’s pathology were assessed by neuropathologists as 
described in the methods (Section 2.4.1 and 2.4.2). 
There is no consensus approach for deriving a global cerebral CAA stage 
from the Love et al. CAA rating scale.[36] Therefore, to quantify the global 
cerebral burden of parenchymal and meningeal CAA, I separately summed 
the parenchymal and meningeal scores for each cerebral lobe and assigned 
a global parenchymal or meningeal CAA burden category (0=absent, 1-
8=mild, 9-16=moderate, and 17-24=severe). I selected these cut-offs based 
on the distribution of CAA severity ratings in the LINCHPIN brain bank 
(Figure 4.1). 
To make the CAA ratings compatible with the non-CAA SVD ratings derived 
from the left cerebral hemisphere, I separately summed the parenchymal and 
meningeal scores for each lobe in the left cerebral hemisphere and assigned 
a left cerebral hemisphere parenchymal or meningeal CAA burden category 
(0=absent, 1-4=mild, 5-8=moderate, and 9-12=severe, Figure 4.2). I 
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dichotomised the global cerebral and left cerebral hemisphere parenchymal 
and meningeal CAA burden categories (absent or mild versus moderate or 
severe) and the global cerebral and left cerebral hemisphere capillary CAA 
and vasculopathy ratings (present or absent) for analysis. 
For participants with a lobar ICH, I calculated the Vonsattel CAA grade based 
on the most advanced degree of parenchymal or meningeal CAA present 
within the cerebral lobe where the ICH was centred (Table 4.1).[164, 253]  
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Figure 4.1 Distribution of the summed CAA scores across all cerebral lobes 
in first-ever ICH LINCHPIN participants 
A) Parenchymal CAA. B) Meningeal CAA. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and 
neurological outcome.   
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Figure 4.2 Distribution of the summed CAA scores in the left cerebral 
hemisphere in first-ever ICH LINCHPIN participants 
A) Parenchymal CAA. B) Meningeal CAA. 
 
CAA = cerebral amyloid angiopathy. ICH – intracerebral haemorrhage. 
LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and 
neurological outcome.  
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4.3.4 Statistical analysis 
I used univariable analyses to compare the frequency of baseline clinical 
characteristics, diagnostic non-contrast brain CT features and APOE 
genotype between groups using 2 test (or Fisher's exact test, where 
appropriate) for categorical variables and the Mann-Whitney U test for non-
normally distributed continuous variables. 
I evaluated the diagnostic accuracy of different sampling approaches for 
histopathological CAA assessment (the left cerebral hemisphere or the 
cerebral lobe affected by ICH) against the reference standard of global 
cerebral CAA histopathological assessment using sensitivity and specificity 
and their 95% CI. I performed pre-specified sensitivity analyses of the 
diagnostic accuracy of CAA assessment using tissue from the cerebral lobe 
affected by ICH stratified by age tertiles, given that the specificity of 
simulated cortical biopsies for CAA was shown to decrease with age.[164] 
I used Firth's penalised likelihood logistic regression to assess whether 
APOE genotype and Thal phase were independently associated with left 
cerebral hemisphere parenchymal or meningeal CAA and vasculopathy in 
participants with first-ever lobar ICH because Thal phase showed complete 
separation between the outcome groups.[268] I performed multivariable 
logistic regression to assess whether APOE genotype and Thal phase were 
independently associated with left cerebral hemisphere capillary CAA in 
participants with first-ever lobar ICH. I pre-specified APOE genotype and 
Thal phase to include in multivariable models of CAA based on their previous 
associations with CAA.[254-256] I did not include other variables in these 
models to reduce overfitting. 
To assess the distribution of CAA, I calculated the relative risk (RR) and 95% 
confidence intervals of moderate or severe parenchymal or meningeal CAA, 
as well as the presence of capillary CAA or vasculopathy in the occipital 
lobes compared with the other cerebral lobes. 
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I performed statistical analyses using R statistical package version 3.4.4., 
except for the diagnostic accuracy statistics and RR, for which I used 
VassarStats Clinical Calculator 1.[269] 
4.3.5 Missing data 
 
The amount of missing data was low (Table 2.2). APOE genotyping was 
missing for one participant. I did not impute this missing data point. Instead, I 
excluded this participant from the relevant analyses. 
 
4.4 Results 
4.4.1 Flow of participants 
There were 612 patients with spontaneous ICH presumed related to SVDs 
between 1st June 2010 and 31st May 2016. Three hundred and fifty 
consented to the LINCHPIN study, including 233 with a first-ever ICH who 
consented to research brain autopsy (Figure 3.3). One hundred and twenty-
six of these participants died and underwent research brain autopsy, 
including 71 with a lobar ICH and 55 with a non-lobar ICH. The median time 
between ICH onset and research brain autopsy was 12 days (IQR 6-162 
days, range 1-2405 days). 
4.4.2 Comparison of first-ever ICH participants who had a research 
brain autopsy versus those who did not 
To assess for selection bias in the LINCHPIN brain bank, I compared the 
clinical and baseline imaging features between LINCHPIN participants 
recruited during the community-based LATCH cohort study (1st June 2010 
until 31st May 2013 inclusive) who consented to and underwent research 
brain autopsy against LATCH patients who did not consent to research brain 
autopsy. 
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4.4.2.1 Comparison of LATCH patients with first-ever SVD-associated 
ICH who did and did not consent to research brain autopsy 
During the community-based LATCH cohort study, 128 first-ever SVD-
associated ICH patients consented to research brain autopsy as part of 
LINCHPIN (Figure 3.4). Consenters were generally similar to the rest of the 
LATCH cohort, except that they were significantly less likely to have had a 
previous ischaemic stroke or myocardial infarction (Table 4.2). 
The frequencies of lobar ICH location and subarachnoid haemorrhage on the 
diagnostic brain CT were higher in those who consented to research brain 
autopsy compared with the rest of the LATCH cohort, while the proportion 
with infratentorial ICH was lower in research brain autopsy consenters (Table 
4.3). 
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Table 4.2 Baseline clinical features in first-ever SVD-associated ICH LATCH 


























Co-morbidities*      
Hypertension 76 (59) 196  (68) 0.105 
Ischaemic stroke 14 (11) 55  (19) 0.042 
Transient ischaemic attack 14  (11) 31  (11) 0.940 
Dementia 16 (13) 36 (12) 0.971 
Diabetes 12  (9) 35 (12) 0.422 
Atrial fibrillation 23 (18) 67 (23) 0.239 
Myocardial infarction 5 (4) 32 (11) 0.018 



























































Pre-ICH modified Rankin 
scale; median (IQR) 
2 (1-4) 2 (1-3) 0.134 
Medications on admission      
Antiplatelet drug(s) 55  (43) 122  (42) 0.842 
Anticoagulant drug(s) 13 (10) 43  (15) 0.200 
Antihypertensive drug(s) 56 (44) 146  (50) 0.226 
Admission GCS score; median 
(IQR) † 
14  (10-15) 14  (10-15) 0.129 
Data are n (%) or median (IQR). * missing for 1 patient. † missing for4 
patients. GCS = Glasgow coma scale. ICH = intracerebral haemorrhage. 
LATCH = Lothian audit of the treatment of cerebral haemorrhage. LINCHPIN 
= Lothian intracerebral haemorrhage pathology, imaging and neurological 
outcome. SVD = small vessel disease.  
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Table 4.3 ICH location and baseline imaging features between first-ever 
SVD-associated ICH LATCH patients who consented to research brain 

































ICH volume; median (IQR) ‡ 18  (6-49) 20  (5-55) 0.998 
Intraventricular haemorrhage 52 (41) 139  (48) 0.176 
Subarachnoid haemorrhage 64 (50) 115 (40) 0.046 
Subdural haemorrhage 10 (8) 32  (11) 0.317 



























Data are n (%) or median (IQR). ‡ missing for 5 patients diagnosed by 
autopsy.  ̂missing for 15 patients without a diagnostic CT. CT = computed 
tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the 
treatment of cerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. SVD = small 
vessel disease. 
 
4.4.2.2 Comparison of LATCH patient with first-ever SVD-associated ICH 
who did and did not undergo research brain autopsy 
Seventy-two LATCH patients with first-ever ICH died and underwent 
research brain autopsy (Figure 3.4). Donors were significantly older, more 
likely to have pre-ICH dementia and worse pre-ICH levels of functioning 
compared with the rest of the LATCH cohort (Table 4.4). They also had 
larger ICHs with more frequent subarachnoid haemorrhage (Table 4.5). 
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Table 4.4 Baseline clinical features in first-ever SVD-associated ICH LATCH 


























Co-morbidities*      
Hypertension 45 (63) 227 (66) 0.615 
Ischaemic stroke 10 (14) 59 (17) 0.511 
Transient ischaemic attack 8 (11) 37 (11) 0.917 
Dementia 14 (19) 38  (11) 0.047 
Diabetes 7 (10) 40  (12) 0.653 
Atrial fibrillation 19 (26) 71 (21) 0.270 
Myocardial infarction 5 (7) 32 (9) 0.531 


























































Pre-morbid modified Rankin 
scale; median (IQR) 
3 (2-4) 2 (1-3) 0.006 
Medications on admission      
Antiplatelet drug(s) 36 (50) 141 (41) 0.143 
Anticoagulant drug(s) 10 (14) 46 (13) 0.886 
Antihypertensive drug(s) 34 (47) 168 (48) 0.854 
Admission GCS score; median 
(IQR) † 
13  (10-14) 14 (10-15) 0.128 
Data are n (%), median (IQR) or mean (SD). * missing for 1 patient. † 
missing for4 patients. GCS = Glasgow coma scale. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral 
haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, 
imaging and neurological outcome. SVD = small vessel disease.  
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Table 4.5 ICH and baseline imaging features in first-ever SVD-associated 
ICH LATCH patients who underwent research brain autopsy versus those 
































ICH volume; median (IQR) ‡ 29  (12-68) 18  (5-52) 0.008 
Intraventricular haemorrhage 37 (51) 154 (44) 0.277 
Subarachnoid haemorrhage 40 (56) 139 (40) 0.016 
Subdural haemorrhage 8 (11) 34 (10) 0.736 


























Data are n (%), median (IQR) or mean (SD). ‡ missing for 5 patients 
diagnosed by autopsy.  ̂missing for 15 patients without a diagnostic CT. CT = 
computed tomography. ICH = intracerebral haemorrhage. LATCH = Lothian 
audit of the treatment of cerebral haemorrhage. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
SVD = small vessel disease. 
 
4.4.3 Histopathological assessment of CAA and vasculopathy in the 
left cerebral hemisphere versus systematic whole brain 
autopsy in first-ever SVD-associated ICH 
To determine whether the histopathological assessment of CAA in the left 
cerebral hemisphere is representative of total brain CAA, I compared the 
severity of CAA and vasculopathy in the left cerebral hemisphere against the 
reference standard of global cerebral CAA histopathological assessment in 
all 126 LINCHPIN brain bank participants with first-ever SVD-associated ICH, 
regardless of ICH location. 
  Chapter 4 
124 
4.4.3.1 Parenchymal CAA 
Figure 4.3 shows the parenchymal CAA severity in the left cerebral 
hemisphere compared with the global cerebral parenchymal CAA severity 
(reference standard). Seventy-three participants had absent or mild global 
cerebral parenchymal CAA, all of whom had absent or mild left cerebral 
hemisphere parenchymal CAA, resulting in a specificity of 100% (95% CI 94-
100). Fifty-three participants had moderate or severe global cerebral 
parenchymal CAA, 52 of whom had moderate or severe left cerebral 
hemisphere parenchymal CAA, giving a sensitivity of 98% (95 %CI 89-100). 
 
Figure 4.3 Bubble plot of left cerebral hemisphere parenchymal CAA severity 
against global cerebral parenchymal CAA severity in first-ever ICH 
participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
4.4.3.2 Meningeal CAA 
The meningeal CAA severity in the left cerebral hemisphere compared with 
the global cerebral meningeal CAA severity (reference standard) is shown in 
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Figure 4.4. Sixty-five participants had absent or mild global cerebral 
meningeal CAA, 63 of whom had absent or mild left cerebral hemisphere 
meningeal CAA, resulting in a specificity of 97% (95% CI 88-99). Sixty-one 
participants had moderate or severe global meningeal parenchymal CAA, 59 
of whom had moderate or severe left cerebral hemisphere meningeal CAA, 
resulting in a sensitivity of 97% (95% CI 88-99). 
 
Figure 4.4 Bubble plot of left cerebral hemisphere meningeal CAA severity 
against global cerebral meningeal CAA severity in first-ever ICH participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
4.4.3.3 Capillary CAA 
The presence or absence of capillary CAA in the left cerebral hemisphere 
compared with both cerebral hemispheres (reference standard) is shown in 
Figure 4.5. Eighty-seven participants had no capillary CAA on global cerebral 
assessment, all of whom had no capillary CAA in the left cerebral 
hemisphere, resulting in a specificity of 100% (95% CI 95-100). Thirty-nine 
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participants had capillary CAA present on global cerebral assessment, 32 of 
whom had capillary CAA present in the left cerebral hemisphere, resulting in 
a sensitivity of 82% (95% CI 66-92). 
 
Figure 4.5 Bubble plot of left cerebral hemisphere capillary CAA against 
global cerebral capillary CAA in first-ever ICH participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
4.4.3.4 Vasculopathy 
The presence or absence of vasculopathy in the left cerebral hemisphere 
compared with both cerebral hemispheres (reference standard) is shown in 
Figure 4.6. Eighty-eight participants had no vasculopathy on global cerebral 
assessment, all of whom had no vasculopathy in the left cerebral 
hemisphere, resulting in a specificity of 100% (95% CI 95-100). Thirty-eight 
participants had vasculopathy present on global cerebral assessment, 37 of 
whom had vasculopathy in the left cerebral hemisphere, resulting in a 
sensitivity of 97% (95% CI 85-100). 
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Figure 4.6 Bubble plot of left cerebral hemisphere vasculopathy against 
global cerebral vasculopathy in first-ever ICH participants. 
 
ICH = intracerebral haemorrhage. 
 
4.4.4 Histopathological assessment of CAA and vasculopathy in the 
cerebral lobe affected by ICH versus systematic whole brain 
autopsy in first-ever lobar ICH 
To simulate a cortical biopsy, I assessed the diagnostic accuracy of 
histopathological assessment of CAA and vasculopathy in the cerebral lobe 
affected by ICH using the Love et al[36] and Vonsattel[253] scales against 
the reference standard of global cerebral CAA histopathological assessment 
using the Love et al scale[36]. 
Seventy-one LINCHPIN participants who underwent a research autopsy had 
a first-ever SVD-associated lobar ICH. The ICH epicentre was located in the 
frontal lobe in 34 (48%), parietal lobe in 16 (23%), temporal lobe in 12 (17%) 
and the occipital lobe in 9 (13%). 
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4.4.4.1 Parenchymal CAA 
The parenchymal CAA severity in the cerebral lobe where the ICH epicentre 
was located compared with the global cerebral parenchymal CAA severity 
(reference standard) is shown in Figure 4.7. Twenty-eight participants had 
absent or mild global cerebral parenchymal CAA, 26 of whom had absent or 
mild parenchymal CAA in the cerebral lobe where the ICH epicentre was 
located, resulting in a specificity of 93% (95%CI 75-99). Forty-three 
participants had moderate or severe global cerebral parenchymal CAA, 36 of 
whom had moderate or severe parenchymal CAA in the cerebral lobe where 
the ICH epicentre was located, resulting in a sensitivity of 84% (95% CI 69-
93). 
 
Figure 4.7 Bubble plot of parenchymal CAA severity in the lobe containing 
the ICH epicentre against global cerebral parenchymal CAA severity in first-
ever lobar ICH participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
I performed a sensitivity analysis of the diagnostic accuracy of parenchymal 
CAA stratified by age at the time of the index ICH (Table 4.6 and Table 4.7).  
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Table 4.6 Cross-tabulations of parenchymal CAA severity in the lobe 
containing the ICH epicentre against the global cerebral parenchymal CAA 
severity, stratified by age at the time of the index ICH 
Age at time of index ICH 56 to 79 years 
Cerebral lobe affected 
by ICH parenchymal 
CAA (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Absent/mild 10 3 13 
Moderate/severe 0 12 12 
Total 10 15 25 
Age at time of index ICH 80 to 84 years 
Cerebral lobe affected 
by ICH parenchymal 
CAA (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Absent/mild 6 1 7 
Moderate/severe 0 15 15 
Total 6 16 22 
Age at time of index ICH 85 to 95 years 
Cerebral lobe affected 
by ICH parenchymal 
CAA (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Absent/mild 10 3 13 
Moderate/severe 2 9 11 
Total 12 12 24 
Data are number. CAA = cerebral amyloid angiopathy. ICH = intracerebral 
haemorrhage 
 
Table 4.7 Diagnostic test accuracy of moderate/severe parenchymal CAA 
severity in the lobe containing the ICH epicentre using moderate/severe 
global parenchymal CAA severity as the reference standard cut off, stratified 
by age at the time of the index ICH 
 Age at time of 
index ICH 56 to 79 
years 
Age at time of 
index ICH 80 to 84 
years 
Age at time of 
index ICH 85 to 95 
years 
Sensitivity 80 (51-95) 94 (68-100) 75 (43-93) 
Specificity 100 (66-100) 100 (52-100) 83 (51-97) 
Data are percentage (95% CI). CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage.  
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4.4.4.2  Meningeal CAA 
The meningeal CAA severity in the cerebral lobe where the ICH epicentre 
was located compared with the global cerebral meningeal CAA severity 
(reference standard) is shown in Figure 4.8. Twenty-three participants had 
absent or mild global meningeal parenchymal CAA, 21 of whom had absent 
or mild meningeal CAA in the cerebral lobe where the ICH epicentre was 
located, resulting in a specificity of 91% (95% CI 70-98). Forty-eight 
participants had moderate or severe global cerebral meningeal CAA, 44 of 
whom had moderate or severe meningeal CAA in the cerebral lobe where the 
ICH epicentre was located, resulting in a sensitivity of 92% (95% CI 79-97). 
 
Figure 4.8 Bubble plot of meningeal CAA severity in the lobe containing the 
ICH epicentre against global cerebral meningeal CAA severity in first-ever 
lobar ICH participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
I performed a sensitivity analysis of the diagnostic accuracy of meningeal 
CAA stratified by age at the time of the index ICH (Table 4.8 and Table 4.9).  
  Chapter 4 
131 
Table 4.8 Cross-tabulations of meningeal CAA severity in the lobe containing 
the ICH epicentre against the global cerebral meningeal CAA severity, 
stratified by age at the time of the index ICH 
Age at time of index ICH 56 to 79 years 
Cerebral lobe affected 
by ICH meningeal 
CAA (Index test) 
Global cerebral meningeal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Absent/mild 9 1 10 
Moderate/severe 1 14 15 
Total 10 15 25 
Age at time of index ICH 80 to 84 years 
Cerebral lobe affected 
by ICH meningeal 
CAA (Index test) 
Global cerebral meningeal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Absent/mild 5 2 7 
Moderate/severe 1 14 15 
Total 6 16 22 
Age at time of index ICH 85 to 95 years 
Cerebral lobe affected 
by ICH meningeal 
CAA (Index test) 
Global cerebral meningeal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Absent/mild 7 1 8 
Moderate/severe 0 16 16 
Total 7 17 24 
Data are number. CAA = cerebral amyloid angiopathy. ICH = intracerebral 
haemorrhage 
 
Table 4.9 Diagnostic test accuracy of moderate/severe meningeal CAA 
severity in the lobe containing the ICH epicentre using moderate/severe 
global meningeal CAA severity as the reference standard cut off, stratified by 
age at the time of the index ICH 
 Age at time of 
index ICH 56 to 79 
years 
Age at time of 
index ICH 80 to 84 
years 
Age at time of 
index ICH 85 to 95 
years 
Sensitivity 93 (66-100) 88 (60-98) 94 (69-100) 
Specificity 90 (54-99) 83 (36-99) 100 (56-100) 
Data are percentage (95% CI). CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage.  
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4.4.4.3 Capillary CAA 
The presence or absence of capillary CAA in the cerebral lobe where the ICH 
epicentre was located compared with both cerebral hemispheres (reference 
standard) is shown in Figure 4.9. Forty-two participants had no capillary CAA 
on global cerebral assessment, all of whom had no capillary CAA in the 
cerebral lobe where the ICH epicentre was located, resulting in a specificity 
of 100% (95% CI 90-100). Twenty-nine participants had capillary CAA 
present on global cerebral assessment, 12 of whom had capillary CAA 
present in the cerebral lobe where the ICH epicentre was located, resulting in 
a sensitivity of 41% (95% CI 24-61). 
 
Figure 4.9 Bubble plot of capillary CAA in the lobe containing the ICH 
epicentre against global cerebral capillary CAA in first-ever lobar ICH 
participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
I performed a sensitivity analysis of the diagnostic accuracy of capillary CAA 
stratified by age at the time of the index ICH (Table 4.10 and Table 4.11).  
  Chapter 4 
133 
Table 4.10 Cross-tabulations of capillary CAA in the lobe containing the ICH 
epicentre against the global cerebral capillary CAA, stratified by age at the 
time of the index ICH 
Age at time of index ICH 56 to 79 years 
Cerebral lobe affected 
by ICH capillary CAA 
(Index test) 
Global cerebral capillary CAA 
(Reference standard) 
 
Absent Present Total 
Absent 15 7 22 
Present 0 3 3 
Total 15 10 25 
Age at time of index ICH 80 to 84 years 
Cerebral lobe affected 
by ICH capillary CAA 
(Index test) 
Global cerebral capillary CAA 
(Reference standard) 
 
Absent Present Total 
Absent 12 5 17 
Present 0 5 5 
Total 12 10 22 
Age at time of index ICH 85 to 95 years 
Cerebral lobe affected 
by ICH capillary CAA 
(Index test) 
Global cerebral capillary CAA 
(Reference standard) 
 
Absent Present Total 
Absent 15 5 20 
Present 0 4 4 
Total 15 9 24 
Data are number. CAA = cerebral amyloid angiopathy. ICH = intracerebral 
haemorrhage. 
 
Table 4.11 Diagnostic test accuracy of capillary CAA presence in the lobe 
containing the ICH epicentre using global cerebral capillary CAA presence as 
the reference standard cut off, stratified by age at the time of the index ICH 
 Age at time of 
index ICH 56 to 79 
years 
Age at time of 
index ICH 80 to 84 
years 
Age at time of 
index ICH 85 to 95 
years 
Sensitivity 30 (8-65) 50 (20-80) 44 (15-77) 
Specificity 100 (75-100) 100 (70-100) 100 (75-100) 
Data are percentage (95% CI). CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage.  
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4.4.4.4 Vasculopathy 
The presence or absence of vasculopathy in the cerebral lobe where the ICH 
epicentre was located compared with both cerebral hemispheres (reference 
standard) is shown in Figure 4.10. Thirty-seven participants had no 
vasculopathy on global assessment, all of whom had no vasculopathy in the 
cerebral lobe where the ICH epicentre was located, resulting in a specificity 
of 100% (95% CI 88-100). Thirty-four participants had vasculopathy present 
on global cerebral assessment, 25 of whom had vasculopathy in the cerebral 
lobe where the ICH epicentre was located, resulting in a sensitivity of 74% 
(95% CI 55-86). 
 
Figure 4.10 Bubble plot of vasculopathy in the lobe containing the ICH 
epicentre against global cerebral vasculopathy in first-ever lobar ICH 
participants. 
 
ICH = intracerebral haemorrhage. 
 
I performed a sensitivity analysis of the diagnostic accuracy of vasculopathy 
stratified by age at the time of the index ICH (Table 4.12 and Table 4.13).  
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Table 4.12 Cross-tabulations of vasculopathy in the lobe containing the ICH 
epicentre against the global cerebral vasculopathy, stratified by age at the 
time of the index ICH 
Age at time of index ICH 56 to 79 years 
Cerebral lobe affected 
by ICH vasculopathy 
(Index test) 
Global cerebral vasculopathy 
(Reference standard) 
 
Absent Present Total 
Absent 11 4 15 
Present 0 10 10 
Total 11 14 25 
Age at time of index ICH 80 to 84 years 
Cerebral lobe affected 
by ICH vasculopathy 
(Index test) 
Global cerebral vasculopathy 
(Reference standard) 
 
Absent Present Total 
Absent 12 1 13 
Present 0 9 9 
Total 12 10 22 
Age at time of index ICH 85 to 95 years 
Cerebral lobe affected 
by ICH vasculopathy 
(Index test) 
Global cerebral vasculopathy 
(Reference standard) 
 
Absent Present Total 
Absent 14 4 18 
Present 0 6 6 
Total 14 10 24 
Data are number. CAA = cerebral amyloid angiopathy. ICH = intracerebral 
haemorrhage. 
 
Table 4.13 Diagnostic test accuracy of the presence of vasculopathy in the 
lobe containing the ICH epicentre using global cerebral vasculopathy as the 
reference standard cut off, stratified by age at the time of the index ICH 
 Age at time of 
index ICH 56 to 79 
years 
Age at time of 
index ICH 80 to 84 
years 
Age at time of 
index ICH 85 to 95 
years 
Sensitivity 71 (42-90) 90 (54-99) 60 (27-86) 
Specificity 100 (68-100) 100 (70-100) 100 (73-100) 
Data are percentage (95% CI). CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage.  
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4.4.4.5 Presence of any CAA (Vonsattel grade ≥1) 
The presence of any CAA in the cerebral lobe where the ICH epicentre was 
located (Vonsattel grade ≥1) compared with the global cerebral parenchymal 
CAA severity (reference standard) is shown in Figure 4.11. Twenty-eight 
participants had absent or mild global cerebral parenchymal CAA, 20 of 
whom had Vonsattel grade 0 in the cerebral lobe where the ICH epicentre 
was located, resulting in a specificity of 71% (95% CI 51-86). Forty-three 
participants had moderate or severe global cerebral parenchymal CAA, all of 
whom had Vonsattel grade ≥1 in the cerebral lobe where the ICH epicentre 
was located, resulting in a sensitivity of 100% (95% CI 90-100). 
 
Figure 4.11 Bubble plot of Vonsattel grade ≥1 in the lobe containing the ICH 
epicentre against global cerebral parenchymal CAA in first-ever lobar ICH 
participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
I performed a sensitivity analysis of the diagnostic accuracy of Vonsattel 
grade ≥1 stratified by age at the time of the index ICH (Table 4.14 and 4.15).  
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Table 4.14 Cross-tabulations of the Vonsattel grade of CAA in the lobe 
containing the ICH epicentre against the global cerebral parenchymal CAA 
severity, stratified by age at the time of the index ICH 
Age at time of index ICH 56 to 79 years 
Cerebral lobe affected 
by ICH (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Vonsattel grade 0 9 0 9 
Vonsattel grade ≥1 1 15 16 
Total 10 15 25 
Age at time of index ICH 80 to 84 years 
Cerebral lobe affected 
by ICH (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Vonsattel grade 0 5 0 5 
Vonsattel grade ≥1 1 16 17 
Total 6 16 22 
Age at time of index ICH 85 to 95 years 
Cerebral lobe affected 
by ICH (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Vonsattel grade 0 6 0 6 
Vonsattel grade ≥1 6 12 18 
Total 12 12 24 
Data are number. CAA = cerebral amyloid angiopathy. ICH = intracerebral 
haemorrhage. 
 
Table 4.15 Diagnostic test accuracy of Vonsattel grade ≥1 in the lobe 
containing the ICH epicentre using moderate/severe global parenchymal 
CAA severity as the reference standard cut off, stratified by age at the time of 
the index ICH 
 Age at time of index 
ICH 56 to 79 years 
Age at time of index 
ICH 80 to 84 years 
Age at time of index 
ICH 85 to 95 years 
Sensitivity 100 (75-100) 100 (76-100) 100 (70-100) 
Specificity 90 (54-99) 83 (36-99) 50 (22-78) 
Data are percentage (95% CI). CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage.  
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4.4.4.6 Presence of complete replacement of a vessel wall with amyloid-
 (Vonsattel grade ≥2) 
The presence of complete replacement of a vessel wall with -amyloid in the 
cerebral lobe where the ICH epicentre was located (Vonsattel grade ≥2) 
compared with the global cerebral parenchymal CAA severity (reference 
standard) is shown in Figure 4.12. Twenty-eight participants had absent or 
mild global cerebral parenchymal CAA, 22 of whom had Vonsattel grade <2 
in the cerebral lobe where the ICH epicentre was located, resulting in a 
specificity of 79% (95% CI 59-91). Forty-three participants had moderate or 
severe global cerebral parenchymal CAA, 41 of whom had Vonsattel grade 
≥2 in the cerebral lobe where the ICH epicentre was located, resulting in a 
sensitivity of 95% (95% CI 83-99). 
 
Figure 4.12 Bubble plot of Vonsattel grade ≥2 in the lobe containing the ICH 
epicentre against global cerebral parenchymal CAA in first-ever lobar ICH 
participants. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
I performed a sensitivity analysis of the diagnostic accuracy of Vonsattel 
grade ≥2 stratified by age at the time of the index ICH (Table 4.16 and 4.17).  
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Table 4.16 Cross-tabulations of the Vonsattel grade of CAA in the lobe 
containing the ICH epicentre against the global cerebral parenchymal CAA 
severity, stratified by age at the time of the index ICH 
Age at time of index ICH 56 to 79 years 
Cerebral lobe affected 
by ICH (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Vonsattel grade <2 9 1 10 
Vonsattel grade ≥2 1 14 15 
Total 10 15 25 
Age at time of index ICH 80 to 84 years 
Cerebral lobe affected 
by ICH (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Vonsattel grade <2 5 1 6 
Vonsattel grade ≥2 1 15 16 
Total 6 16 22 
Age at time of index ICH 85 to 95 years 
Cerebral lobe affected 
by ICH (Index test) 
Global cerebral parenchymal CAA 
(Reference standard) 
 
Absent/mild Moderate/severe Total 
Vonsattel grade <2 8 0 8 
Vonsattel grade ≥2 4 12 16 
Total 12 12 24 
Data are number. CAA = cerebral amyloid angiopathy. ICH = intracerebral 
haemorrhage. 
 
Table 4.17 Diagnostic test accuracy of Vonsattel grade ≥2 CAA severity in 
the lobe containing the ICH epicentre using moderate/severe global 
parenchymal CAA severity as the reference standard cut off, stratified by age 
at the time of the index ICH 
 Age at time of index 
ICH 56 to 79 years 
Age at time of index 
ICH 80 to 84 years 
Age at time of index 
ICH 85 to 95 years 
Sensitivity 93 (66-100) 94 (68-100) 100 (70-100) 
Specificity 90 (54-99) 83 (36-99) 67 (35-89) 
Data are percentage (95% CI). CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage.  
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4.4.5 Pathological severity and associations of SVDs in first-ever 
SVD-associated ICH 
In this section, I have used the histopathology ratings from the left cerebral 
hemisphere to assess the severity of SVDs in first-ever SVD-associated ICH 
for two reasons. Firstly, I wanted to make the CAA ratings similar to the non-
CAA SVD ratings, which were only performed in the left cerebral hemisphere. 
Secondly, I have shown in section 4.4.3 that the presence and severity of 
CAA and vasculopathy in the left cerebral hemisphere is representative of the 
global cerebral CAA assessment. 
4.4.5.1 Left cerebral hemisphere parenchymal CAA and non-CAA SVD 
severity in first-ever lobar versus non-lobar ICH 
Forty-five of the 55 (82%) participants with first-ever non-lobar ICH had 
moderate or severe non-CAA SVD and absent or mild parenchymal CAA in 
the left cerebral hemisphere (Figure 4.13). Nine (16%) had both moderate or 
severe non-CAA SVD and parenchymal CAA. One participant with a left 
lentiform nucleus ICH had no clear underlying cause of ICH (mild non-CAA 
SVD, absent parenchymal CAA and no macrovascular abnormality, 
coagulopathy or tumour). 
Twenty-six of the 71 (37%) participants with first-ever lobar ICH had 
moderate or severe non-CAA SVD and absent or mild parenchymal CAA 
(Figure 4.13). Thirty-two (45%) had both moderate or severe non-CAA SVD 
and parenchymal CAA in the left cerebral hemisphere, and 11 (15%) had 
moderate or severe parenchymal CAA and absent or mild non-CAA SVD. 
Two (3%) participants had no clear underlying cause of ICH (absent or mild 
parenchymal CAA, mild non-CAA SVD and no macrovascular abnormality, 
coagulopathy or tumour). 
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Figure 4.13 Pathological severity of left cerebral hemisphere CAA and non-
CAA SVD in first-ever ICH according to ICH location 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. SVD 
= small vessel disease. 
 
4.4.5.2 Associations of left cerebral hemisphere CAA and vasculopathy 
in first-ever lobar ICH 
Given that CAA is associated with lobar but not non-lobar ICH,[153] and the 
low frequency of moderate or severe CAA in non-lobar ICH shown in Figure 
4.13, I restricted my analyses assessing the associations of CAA to 
participants with first-ever lobar ICH. 
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Parenchymal CAA 
The severity of left cerebral hemisphere parenchymal CAA in first-ever lobar 
ICH is shown in Figure 4.14. Twenty-eight participants had absent or mild 
parenchymal CAA while 43 had moderate or severe parenchymal CAA. 
Those with moderate or severe parenchymal CAA were significantly more 
likely to possess APOE 2 or 4 alleles, and moderate or severe meningeal 
CAA, capillary CAA, vasculopathy and more severe Braak stage and Thal 
phase on univariable assessment (Table 4.18). There were no statistically 
significant differences in age and pre-ICH co-morbidities between those with 
moderate or severe parenchymal CAA and those with absent or mild 
parenchymal CAA. 
Moderate or severe left cerebral hemisphere parenchymal CAA was 
significantly associated with APOE 4 allele possession when adjusting for 
APOE 2 allele possession and Thal phase (Table 4.19). 
 
Figure 4.14 Severity of left cerebral hemisphere parenchymal CAA in first-
ever lobar ICH participants 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage.  
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Table 4.18 Clinical and histopathological characteristics of first-ever lobar 



























Co-morbidities      
Hypertension 21 (75) 26 (61) 0.206 
Ischaemic stroke* 4 (14) 6 (14) 1.000 
Transient ischaemic 
attack* 
2 (7) 3 (7) 1.000 
Dementia* 2 (7) 10 (23) 0.108 
Diabetes* 4 (14) 3 (7) 0.422 
Atrial fibrillation 11 (39) 10 (23) 0.148 
Myocardial infarction* 5 (18) 6 (14) 0.742 
Hyperlipidaemia* 14 (14) 5 (12) 0.732 
APOE 4 carrier† 2 (7) 21 (49) <0.001 


















Capillary CAA 1 (4) 23 (54) <0.001 






























































Data are n (%) or median (IQR). * Fisher’s exact test. † Data not available in 
1 case with absent/mild CAA. APOE = apolipoprotein E. CAA=cerebral 
amyloid angiopathy. ICH = intracerebral haemorrhage. SVD=small vessel 
disease.  
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Table 4.19 Multivariable Firth’s logistic regression model of first-ever lobar 
ICH associated with left cerebral hemisphere moderate or severe 
parenchymal CAA  
  Coefficient  
(standard error) 
Odds ratio (95%CI) 
p 
value 
Intercept -1.11 (0.53) 0.33 (0.09-0.86) 0.305 
APOE 4 carrier 1.71 (0.77) 5.51 (1.38-51.07) 0.027 
APOE 2 carrier 1.31 (0.74) 3.72 (0.95-24.29) 0.078 
Thal phase      
0/I -- -- Reference  
II/III 0.98 (0.61) 2.67 (0.84-10.49) 0.109 
IV/V 3.01 (1.64) 20.20 (1.79-Not reached) 0.066 
APOE = apolipoprotein E. CAA=cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage. 
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Meningeal CAA 
The severity of left cerebral hemisphere meningeal CAA in first-ever lobar 
ICH is shown in Figure 4.15. Twenty-two participants with first-ever lobar ICH 
had absent or mild meningeal CAA in the left cerebral hemisphere while 49 
had moderate or severe meningeal CAA. Those with moderate or severe 
meningeal CAA were more likely to have APOE 4 allele possession, and 
moderate or severe parenchymal CAA, capillary CAA, vasculopathy and 
more severe Braak stage and Thal phase on univariable assessment (Table 
4.20). There were no statistically significant differences in age and pre-ICH 
co-morbidities between those with moderate or severe meningeal CAA and 
those with absent or mild meningeal CAA. 
APOE 4, APOE 2 and Thal phase were not independently associated with 
moderate or severe left cerebral hemisphere meningeal CAA (Table 4.21). 
 
Figure 4.15 Severity of left cerebral hemisphere meningeal CAA in first-ever 
lobar ICH participants 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage.  
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Table 4.20 Clinical and histopathological characteristics of first-ever lobar 



























Co-morbidities      
Hypertension 17 (77) 30 (61) 0.186 
Ischaemic stroke* 4  (18) 6  (12) 0.488 
Transient ischaemic 
attack* 
1 (5) 4  (18) 1.000 
Dementia* 2 (9) 10 (20) 0.381 
Diabetes* 4 (18) 3 (6) 0.192 
Atrial fibrillation 9 (41) 12 (25) 0.161 
Myocardial infarction* 4 (18) 7 (14) 0.729 
Hyperlipidaemia* 3 (14) 6 (12) 1.000 
APOE 4 carrier† 3 (14) 20 (41) 0.030 


















Capillary CAA 1 (5) 23 (47) <0.001 






























































Data are n (%) or median (IQR). * Fisher’s exact test. † Data not available in 
1 case with absent/mild CAA. APOE = apolipoprotein E. CAA=cerebral 
amyloid angiopathy. ICH = intracerebral haemorrhage. SVD=small vessel 
disease.  
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Table 4.21 Multivariable Firth’s logistic regression model of first-ever lobar 
ICH associated with left cerebral hemisphere moderate or severe meningeal 
CAA  
  Coefficient 
(standard error) 
Odds ratio (95%CI) 
p 
value 
Intercept -0.26 (0.47) 0.77 (0.29-1.88) 0.577 
APOE 4 carrier 0.65 (0.70) 1.91 (0.52-10.72) 0.353 
APOE 2 carrier 0.72 (0.71) 2.06 (0.57-11.92) 0.305 
Thal phase      
0/I -- -- Reference  
II/III 0.84 (0.58) 2.33 (0.77-7.93) 0.145 
IV/V 2.69 (1.57) 14.68 (1.41-Not reached) 0.086 




Forty-seven participants with first-ever lobar ICH had no capillary CAA in the 
left cerebral hemisphere while 24 had capillary CAA present. Those with 
capillary CAA were more likely to have APOE 2 and 4 allele possession, 
and moderate or severe parenchymal CAA, moderate or severe meningeal 
CAA, vasculopathy and more severe Braak stage and Thal phase on 
histopathological assessment on univariable assessment (Table 4.22). Those 
without capillary CAA had more frequent pre-ICH hypertension. There were 
no other statistically significant differences in age and pre-ICH co-morbidities 
between those with and without capillary CAA. 
APOE 4, APOE 2 and Thal phase were not independently associated with 
capillary CAA (Table 4.23).  
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Table 4.22 Clinical and histopathological characteristics of first-ever lobar 

























Co-morbidities      
Hypertension 36 (77) 11 (46) 0.010 
Ischaemic stroke* 8 (17) 2 (8) 0.477 
Transient ischaemic 
attack* 
4 (9) 1 (4) 0.656 
Dementia* 6 (13) 6 (25) 0.315 
Diabetes* 5 (11) 2 (8) 1.000 
Atrial fibrillation 16 (34) 5 (21) 0.249 
Myocardial infarction* 9 (19) 2 (8) 0.312 
Hyperlipidaemia* 9 (19) 0 (0) 0.024 
APOE 4 carrier† 10 (22) 13 (54) 0.006 

































































































Data are n (%) or median (IQR). * Fisher’s exact test. † Data not available in 
1 case with absent/mild CAA. APOE = apolipoprotein E. CAA=cerebral 
amyloid angiopathy. ICH = intracerebral haemorrhage. SVD=small vessel 
disease.  
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Table 4.23 Multivariable logistic regression model of first-ever lobar ICH 
associated with left cerebral hemisphere capillary CAA 
  Coefficient 
(standard error) 
Odds ratio (95%CI) 
p 
value 
Intercept -2.39 (0.70) 0.09 (0.02-0.36) <0.001 
APOE 4 carrier 0.97 (0.61) 2.63 (0.80-8.69) 0.113 
APOE 2 carrier 1.17 (0.63) 3.23 (0.94-11.08) 0.062 
Thal phase      
0/I -- -- Reference  
II/III 1.25 (0.75) 3.50 (0.81-15.12) 0.093 
IV/V 1.89 (0.97) 6.61 (0.99-44.09) 0.051 




Thirty-eight participants with first-ever lobar ICH had no vasculopathy in the 
left cerebral hemisphere while 33 had vasculopathy present. Those with 
vasculopathy were more likely to have a pre-ICH diagnosis of dementia, 
lobar ICH location and APOE 4 allele possession, and moderate or severe 
parenchymal CAA, moderate or severe meningeal CAA, capillary CAA, and 
more severe Braak stage and Thal phase on univariable assessment (Table 
4.24). There were no statistically significant differences in age between those 
with and without vasculopathy 
Left cerebral hemisphere vasculopathy was significantly associated with Thal 
phase when adjusting for APOE 2 and 4 allele possession (Table 4.25). 
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Table 4.24 Clinical and histopathological characteristics of first-ever lobar 

























Co-morbidities      
Hypertension 29 (76) 18 (55) 0.052 
Ischaemic stroke* 6 (16) 4  (12) 0.742 
Transient ischaemic 
attack* 
3 (8) 2  (6) 1.000 
Dementia 3 (8) 9 (27) 0.030 
Diabetes* 5 (13) 2 (6) 0.438 
Atrial fibrillation 14 (37) 7 (21) 0.150 
Myocardial infarction 7 (18) 4 (12) 0.464 
Hyperlipidaemia* 6 (16) 3  (9) 0.489 
APOE 4 carrier† 7 (19) 16 (49) 0.009 

































































































Data are n (%). * Fisher’s exact test. † Data not available in 1 case with 
absent/mild CAA. APOE = apolipoprotein E. CAA=cerebral amyloid 
angiopathy. ICH = intracerebral haemorrhage. SVD=small vessel disease.  
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Table 4.25 Multivariable Firth’s logistic regression model of first-ever lobar 
ICH associated with left cerebral hemisphere vasculopathy  
  Coefficient 
(standard error) 
Odds ratio (95%CI) 
p 
value 
Intercept -2.09 (0.66) 0.12 (0.02-0.38) 0.002 
APOE 4 carrier 0.46 (0.65) 1.58 (0.42-6.19) 0.482 
APOE 2 carrier 1.10 (0.69) 3.00 (0.82-15.01) 0.109 
Thal phase      
0/I -- -- Reference  
II/III 1.72 (0.71) 5.61 (1.60-35.75) 0.014 
IV/V 4.58 (1.63) 97.08 (8.31-Not reached) 0.005 
APOE = apolipoprotein E. CAA=cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage. 
 
4.4.6 Pathological distribution of CAA in first-ever SVD-associated 
lobar ICH 
4.4.6.1 Parenchymal CAA 
The distribution and severity of global parenchymal CAA in 71 participants 
with first-ever lobar ICH is shown in Figure 4.16. Moderate or severe 
parenchymal CAA was present in the frontal lobes in 39 (55%) participants, 
the parietal lobes in 40 (56%), temporal lobes in 35 (49%), and the occipital 
lobes in 36 (51%) participants. In contrast, only five (7%) participants had 
moderate or severe parenchymal CAA in the cerebellum.  
51% of participants had moderate or severe parenchymal CAA in the 
occipital lobes while 54% had moderate or severe parenchymal CAA in the 
other cerebral lobes (frontal, parietal and temporal). The risk ratio of 
moderate or severe parenchymal CAA in the occipital lobes compared with 
the other cerebral lobes was 0.95 (95% CI 0.73-1.23). 
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Figure 4.16 Distribution and severity of parenchymal CAA in first-ever lobar 
ICH participants 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
4.4.6.2 Meningeal CAA 
The distribution and severity of global cerebral meningeal CAA in participants 
with first-ever lobar ICH is shown in Figure 4.17. Moderate or severe 
meningeal CAA was present in the frontal lobes in 46 (65%) participants, the 
parietal lobes in 44 (62%), temporal lobes in 44 (62%), and the occipital 
lobes in 46 (65%) participants. Forty-three (61%) participants had moderate 
or severe meningeal CAA in the cerebellum.  
65% of participants had moderate or severe meningeal CAA in the occipital 
lobes while 63% had moderate or severe meningeal CAA in the other 
cerebral lobes (frontal, parietal and temporal). The risk ratio of moderate or 
severe meningeal CAA in the occipital lobes compared with the other 
cerebral lobes was 1.03 (95%CI 0.84-1.26). 
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Figure 4.17 Distribution and severity of meningeal CAA in first-ever lobar ICH 
participants 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
4.4.6.3 Capillary CAA 
The distribution of global cerebral capillary CAA in participants with first-ever 
lobar ICH is shown in Figure 4.18. Capillary CAA was present in the frontal 
lobes in 8 (11%) participants, the parietal lobes in 14 (20%), temporal lobes 
in 11 (15%), and the occipital lobes in 28 (39%) participants. Nine (13%) 
participants had capillary CAA in the cerebellum. 
39% of participants had capillary CAA in the occipital lobes while 15% had 
capillary CAA in the other cerebral lobes (frontal, parietal and temporal). The 
risk ratio of capillary CAA in the occipital lobes compared with the other 
cerebral lobes was 2.55 (95% CI 1.66-3.90). 
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Figure 4.18 Distribution of capillary CAA in first-ever lobar ICH participants 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
4.4.6.4 Vasculopathy 
The distribution of global cerebral vasculopathy in participants with first-ever 
lobar ICH is shown in Figure 4.19. Vasculopathy was present in the frontal 
lobes in 27 (38%) participants, the parietal lobes in 24 (34%), temporal lobes 
in 21 (30%), and the occipital lobes in 23 (32%) participants. Five (7%) 
participants had vasculopathy in the cerebellum. 
32% of participants had vasculopathy in the occipital lobes while 34% had 
vasculopathy in the other cerebral lobes (frontal, parietal and temporal). The 
risk ratio of vasculopathy in the occipital lobes compared with the other 
cerebral lobes was 0.96 (95% CI 0.65-1.41). 
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Figure 4.19 Distribution of vasculopathy in first-ever lobar ICH participants 
 
ICH = intracerebral haemorrhage. 
 
4.4.6.5 Sensitivity analyses 
The occipital predominance of capillary CAA persisted regardless of age 
(Figure 4.20), APOE 2 genotype (Figure 4.21) or APOE 4 genotype (Figure 
4.22). The strength of the occipital capillary CAA predominance seemed to 
increase with increasing Thal phase. The risk ratio of capillary CAA presence 
in the occipital lobes compared with the other cerebral lobes was 1.68 
(95%CI 0.62-4.45) among the 22 participants with Thal phase 0 or I, 2.37 
(95%CI 1.34-4.18) among the 38 participants with Thal phase II or III and 
4.80 (95% CI 1.98-11.63) among the 11 participants with Thal phase IV or V 
(Figure 4.23).  
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Figure 4.20 Distribution of capillary CAA in first-ever lobar ICH participants 
stratified by age at the time of the index ICH 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. 
 
Figure 4.21 Distribution of capillary CAA in first-ever lobar ICH participants 
stratified by APOE 2 allele possession 
 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage. 
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Figure 4.22 Distribution of capillary CAA in first-ever lobar ICH participants 
stratified by APOE 4 allele possession 
 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage. 
 
Figure 4.23 Distribution of capillary CAA in first-ever lobar ICH participants 
stratified by Thal phase 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage.  
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There was no occipital predominance for moderate or severe parenchymal or 
meningeal CAA or vasculopathy when stratifying the analyses by age, APOE 
2 or 4 genotype or Thal phase (data not shown). 
The severity of parenchymal or meningeal CAA and the presence of capillary 
CAA or vasculopathy did not vary between the cerebral hemisphere or lobe 
affected by ICH compared with the contralateral unaffected cerebral 
hemisphere or lobe (data not shown). 
 
4.5 Discussion 
4.5.1 Main findings 
 Assessment of selection bias during the community-based LATCH 
cohort study 
o Those with a first-ever SVD-associated ICH who consented to 
research brain autopsy were similar to non-consenters apart 
from having less frequent pre-ICH ischaemic stroke or 
myocardial infarction, and more frequent lobar ICH locations 
and subarachnoid haemorrhage. 
o Those with a first-ever SVD-associated ICH who had a 
research brain autopsy were older with more frequent pre-ICH 
dementia and more severe pre-ICH disability than the rest of 
the LATCH cohort. They also had larger ICHs and more 
frequent subarachnoid haemorrhage. 
 Diagnostic accuracy of histopathological assessment of CAA and 
vasculopathy in the left cerebral hemisphere versus systematic whole 
brain autopsy 
o Histopathological assessment of parenchymal CAA, meningeal 
CAA and vasculopathy using the left cerebral hemisphere had 
excellent sensitivity and specificity (≥97%) compared with the 
global cerebral histopathological assessment. 
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o Histopathological assessment for the presence of capillary CAA 
in the left cerebral hemisphere had moderate sensitivity (82%) 
compared with global cerebral histopathological assessment. 
 Diagnostic accuracy of histopathological assessment of CAA and 
vasculopathy in the cerebral lobe affected by ICH (simulated cortical 
biopsy) versus systematic whole brain autopsy 
o Histopathological assessment of parenchymal CAA and 
meningeal CAA using the Love et al. grading system[36] in the 
cerebral lobe affected by ICH had good sensitivity and excellent 
specificity compared with the global cerebral histopathological 
assessment, regardless of the age at the time of index ICH. 
o Histopathological assessment for the presence of vasculopathy 
in the cerebral lobe affected by ICH had modest sensitivity, 
while the sensitivity for capillary CAA presence was poor. 
o The presence of any CAA (Vonsattel grade ≥1) was 100% 
sensitive compared with the global cerebral histopathological 
assessment. The specificity was modest (70%) and this 
decreased with age. 
o The presence of complete replacement of a vessel wall with 
amyloid- (Vonsattel grade ≥2) was 95% sensitive and 79% 
specific compared with global cerebral histopathological 
assessment. Again, the specificity decreased with age. 
 Pathological severity and associations of SVDs in first-ever SVD-
associated ICH 
o 98% of participants with a non-lobar ICH had moderate or 
severe non-CAA SVD. 
o 45% of participants with a lobar ICH had mixed moderate or 
severe CAA and non-CAA SVD, 37% had moderate or severe 
non-CAA alone, and 15% had moderate or severe CAA alone. 
o Moderate or severe parenchymal CAA was significantly 
associated with APOE 4 allele possession when adjusting for 
APOE 2 genotype and Thal phase. 
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o The presence of vasculopathy was independently associated 
with Thal phase but not APOE 2 or 4 genotype. 
 Pathological distribution of CAA in first-ever lobar ICH 
o There was no occipital predominance for parenchymal CAA, 
meningeal CAA or vasculopathy regardless of age, APOE 
genotype or Thal phase. 
o Capillary CAA showed an occipital predominance irrespective 
of age, APOE genotype or Thal phase. 
4.5.2 Strengths of the study 
The LINCHPIN brain bank is a unique dataset to study the histopathology of 
SVD-associated ICH.  
The RUSH team minimised selection bias by prospectively inviting all eligible 
participants to the study, regardless of clinical characteristics, imaging 
features or genotype. There were many similarities between ICH patients 
who consented to a research brain autopsy and non-consenters, as well as 
those who had a research brain autopsy versus non-donors. 
We minimised information bias through the use of a standardised approach 
for systematically acquiring the research brain autopsy[217] and assessing 
histopathological features of SVDs and Alzheimer’s pathology using 
published scales.[36, 219, 220] The histopathological assessors were 
masked to the clinical, imaging and genetic features. Finally, the amount of 
missing data was low, with only one participant not having APOE genotyping 
performed. 
4.5.3 Weaknesses of the study 
Although we tried to limit selection bias, those included in the study were 
older with more frequent pre-ICH dementia and more severe pre-ICH 
disability than those not included. They also had larger ICHs and more 
frequent subarachnoid haemorrhage. The older age and larger ICH volume 
of included participants probably reflect the increased likelihood of dying after 
ICH in such patients.[244] The more frequent subarachnoid haemorrhage is 
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probably related to the increased proportion of lobar ICH and the larger ICH 
volume of included participants, both of which are associated with 
subarachnoid haemorrhage.[40, 237] 
The time between ICH onset and autopsy was prolonged for some 
participants. The autopsy occurred over one year after the ICH for 25 
participants (20%) and over three years for eight participants (6%). Given 
that CAA is a progressive, age-related process, its severity may have 
increased in those with a long-delay between ICH and autopsy. I did not have 
sufficient power to adjust my analyses for the time between ICH and autopsy. 
However, the time interval between ICH and autopsy in most participants 
was short (median 12 days, IQR 6-162 days), making it easier to relate 
histopathological changes at autopsy to those likely present at the time of the 
index ICH. 
The sample size was modest, with 126 participants with first-ever SVD-
associated ICH, 71 of whom had a lobar ICH. The sample size limited the 
number of variables I could include in the multivariable analyses of CAA and 
vasculopathy. For example, I did not have sufficient power to adjust for age 
and sex. However, this is one of the largest brain banks of SVD-associated 
ICH worldwide. In comparison, the original Boston criteria were validated in 
39 lobar ICH participants who had brain tissue sampled. Only 14 of these 
participants had tissue from a full brain autopsy.[103] The modified Boston 
criteria were derived using data from 60 participants, 11 of whom did not 
have ICH. Only 19 of the participants had brain tissue from a full brain 
autopsy.[110] 
It was not possible to mask the histopathological assessors to the ICH 
location. Furthermore, the assessors were not masked to the location of the 
pathological samples. This may have biased assessment of CAA and non-
CAA SVD presence and severity. 
It would be interesting to assess the associations of CAA in non-lobar ICH in 
more detail. However, the CAA ratings were not performed in the basal 
ganglia, thalami or brainstem because previous studies have shown these 
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regions are rarely affected by CAA.[60, 267, 270] I was therefore unable to 
assess the frequency and severity of CAA in locations where most of the 
non-lobar ICHs occurred. Also, the severity of non-CAA SVD was quantified 
as an overall score in the left cerebral hemisphere rather than assessed 
separately in individual brain regions as it is usually considered to be a 
symmetrical process. Therefore I could not assess the distribution and 
severity of non-CAA SVD, which again would be interesting. 
I simulated cortical biopsies by using the ratings from the cerebral lobe 
affected by the index ICH. However, the histopathological ratings were based 
on sections from a tissue block taken at autopsy, rather than a tissue sample 
with the size and shape that is obtained by cortical biopsy. As a result, the 
amount of tissue available for histopathological assessment was probably 
larger than is available from a cortical biopsy. Also, the simulated biopsy 
samples were assessed along with sections from the other brain regions 
obtained at autopsy, rather than in isolation, as would occur with a cortical 
biopsy. These factors could increase the apparent diagnostic accuracy of the 
simulated cortical biopsies.[176] 
4.5.4 Comparison with other studies 
4.5.4.1 Selection bias 
The participants included in research studies should be representative of the 
population of interest to ensure the results are generalisable.[271] This is 
particularly important for brain autopsy studies given the declining autopsy 
rates.[272] Most previous autopsy studies of CAA did not provide an 
assessment of selection bias. The nesting of the LINCHPIN study within the 
community-based LATCH cohort study of ICH allows an accurate 
assessment of selection bias. Those who consented to research brain 
autopsy were generally similar to non-consenters, although those who 
underwent research brain autopsy differed from the rest of the cohort as 
described in 4.4.2.2. Many of these differences are likely to reflect their 
associations with death soon after ICH[244] and are thus difficult to avoid in 
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an autopsy study. However, being able to quantify the selection bias is 
important as it indicates to whom the results are generalisable. 
4.5.4.2 Diagnostic accuracy of simulated cortical biopsies for CAA-
associated lobar ICH 
A previous study assessed the diagnostic accuracy of simulated cortical 
biopsy from brain autopsies for CAA-associated ICH.[164] Vonsattel grade 
≥1 had a sensitivity of 100% and a specificity ranging from 95% for those 
aged 65-74 years to 77% for those ≥85 years. Using Vonsattel grade ≥2 as 
the cut-off resulted in a sensitivity of 93% and specificity ranging from 98% 
for those aged 65-74 years to 88% for those ≥85 years. The absence of 
amyloid- in the simulated cortical biopsy was said to show strong evidence 
against CAA-associated ICH. However, their study had several 
methodological limitations. There were only two participants with CAA-
associated ICH (defined as corticosubcortical ICH with severe CAA) and no 
participants with non-CAA-associated ICH. Fourteen simulated cortical 
biopsies were assessed from each of the two CAA-associated ICH 
participants. The authors treated these individual simulated biopsies as 
independent samples and used them to calculate the sensitivity. The 
specificity was calculated as 100% minus the percent likelihood of 
encountering the same degree of CAA in a brain sample from the general 
elderly population. These limitations make the results difficult to interpret. 
In contrast, I included 71 participants with lobar ICH, 43 of whom were 
classified as CAA-associated lobar ICH (moderate or severe global cerebral 
parenchymal CAA) and 28 as non-CAA–associated lobar ICH (absent or mild 
global cerebral parenchymal CAA). I calculated the sensitivity and specificity 
using standard approaches. Vonsattel grade ≥1 in the cerebral lobe affected 
by ICH had a sensitivity of 100% (95%CI 90-100) and a specificity of 71% 
(95%CI 51-86) for moderate or severe global cerebral parenchymal CAA. 
The specificity ranged from 90% in those aged 56-79 years to 50% in those 
aged 85-95 years (Table 4.15). Vonsattel grade ≥2 had a sensitivity of 95% 
(95%CI 83-99) and a specificity of 79% (95%CI 59-91). The specificity 
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ranged from 90% in those aged 56-79 years to 67% in those aged 85-95 
years (Table 4.17). 
My data are consistent with the prior work.[164] Together they suggest that 
cortical biopsy is highly sensitive for moderate or severe CAA, and Vonsattel 
grade <1 can be used to rule out CAA-associated ICH. The specificity of 
cortical biopsy for moderate or severe CAA decreases with age, and is 
highest in those aged age younger than 85 years and when using Vonsattel 
grade ≥2 as the positive cut off. 
4.5.4.3 Severity and associations of CAA in first-ever SVD-associated 
ICH 
Moderate or severe non-CAA SVD was present in all but one (98%) 
participants with first-ever non-lobar ICH. This finding is consistent with 
previous studies that have shown that non-lobar ICH, in particular those 
occurring in the basal ganglia and thalamus, are caused by 
arteriolosclerosis.[232, 273] Sixteen percent of participants with non-lobar 
ICH also had moderate or severe parenchymal CAA in the left cerebral 
hemisphere, which is similar to the population prevalence of CAA in this age 
group.[14]  
The most frequent SVD associated with first-ever lobar ICH in my study was 
non-CAA SVD, with moderate or severe non-CAA SVD occurring in 58 out of 
71 (82%) participants with lobar ICH. In contrast, 43 of the 71 participants 
(61%) with lobar ICH had moderate or severe parenchymal CAA. CAA and 
non-CAA SVDs frequently coexist in first-ever lobar ICH, with 45% of lobar 
ICH participants having both moderate or severe parenchymal CAA and non-
CAA SVD. Only a minority have “pure CAA” (15% with moderate or severe 
parenchymal CAA and mild non-CAA SVD) or “pure non-CAA SVD” (37% 
with moderate or severe non-CAA SVD and absent or mild parenchymal 
CAA). Previous retrospective autopsy studies of CAA-associated ICH have 
shown the coexistence of CAA and non-CAA SVDs pathologies, with up to 
57% of patients having both CAA and arteriolosclerosis.[214, 274-276] 
Therefore, in the context of lobar ICH, CAA and non-CAA SVDs should not 
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be considered as mutually exclusive disease processes. Whether and how 
CAA and non-CAA SVDs interact in the context of ICH remains to be 
established. 
I identified an independent association between moderate or severe 
parenchymal CAA and APOE 4 genotype, which is in keeping with previous 
meta-analyses.[25, 254] APOE 2 was more common in lobar ICH with 
moderate or severe parenchymal CAA, but this did not reach statistical 
significance (OR 3.72, 95% CI 0.95 to 24.29, p=0.078). There was no 
association between moderate or severe meningeal CAA, capillary CAA or 
vasculopathy and APOE genotype. The lack of significant association 
between capillary CAA and APOE 2 and 4 contradicts previous autopsy 
studies,[257, 277] which may reflect differences in the populations (ICH 
versus dementia/non-ICH) or the limited power in my study. 
There was no independent association between parenchymal CAA, 
meningeal CAA, capillary CAA or vasculopathy and Thal phase. Many 
previous studies have demonstrated an association between CAA and 
Alzheimer’s disease neuropathological changes.[278] However, the 
frequency of Alzheimer’s disease pathology has been shown to be lower in 
those with more severe CAA.[270] This may explain the findings in my study. 
Alternatively, the lack of an association may reflect the limited power in my 
multivariable analyses, especially as Thal phase IV/V showed a borderline 
significant association in all analyses. 
4.5.4.4 Distribution of CAA in lobar ICH 
It is commonly cited that the occipital lobe is the brain region most frequently 
and severely affected by CAA.[18, 258] The greater frequency of CAA in the 
occipital lobes has been used to explain a variety of neuroimaging findings in 
patients with CAA, such as the spatial clustering of haemorrhages,[208] 
reductions in brain connectivity[259] and vascular reactivity,[260] WMH 
distribution[261] and amyloid PET tracer uptake.[252, 262] However, the 
previous neuropathological studies assessing the distribution of CAA have 
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shown that parenchymal and meningeal CAA is generally widely distributed 
throughout the cerebral lobes without a consistent occipital predominance. 
Vinters et al. assessed the distribution of CAA in the cerebral cortex using 
Congo red in a hospital-based autopsy study regardless of clinical 
diagnosis.[28] They found that in 30 patients aged over 60 years, CAA of any 
severity was present in the occipital lobes in 65% of patients compared with 
44% in the other cerebral lobes (RR 1.48 (95%CI 1.16-1.90)). Severe CAA 
was present in the occipital lobes in 28% compared with 18% in the other 
cerebral lobes (RR 1.59 (95%CI 0.96.16-2.66)). Tomonaga assessed the 
distribution of CAA using Congo red in a non-selective hospital-based 
autopsy study in Tokyo, Japan. Seven patients of out 128 clinical autopsies 
aged 60-105 had overall severe CAA.[263] Moderate or severe CAA (defined 
as CAA involving at least 3 out of 10 vessels) was present in the occipital 
lobe in 100% compared with 86% in the other cerebral lobes (RR1.17 
(95%CI 0.98-1.39)). Neither of these studies reported the distribution of 
meningeal or capillary CAA. 
Nelson et al. performed a prospective autopsy study of normal ageing and 
Alzheimer’s disease in Kentucky, USA.[264] Parenchymal and meningeal 
CAA was assessed in the four cerebral lobes using immunohistochemistry in 
371 brains. Greater prevalence of severe parenchymal and meningeal CAA 
was found in the occipital lobes (19% and 41% respectively), compared with 
the other cerebral lobes (frontal, 9% and 21%; parietal, 12% and 23%; 
temporal, 11% and 23%). 
Xu et al. performed a retrospective hospital-based neuropathological study of 
362 autopsies of patients aged 60 to 95 years regardless of clinical diagnosis 
in Beijing, China.[265] CAA was identified in 114 cases using Congo red and 
immunohistochemistry, 27 of whom had severe CAA. The frontal lobe was 
most frequently affected by severe CAA (96%), followed by the occipital lobe 
(89%), parietal lobe (63%) and cerebellum (52%). The type of vessel 
involved was not specified. 
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Masuda et al. performed a prospective population-based autopsy study in 
Hisayama, Japan between 1971 and 1983 regardless of clinical 
diagnosis.[266] They identified CAA using Congo red in 91 out of 400 cases. 
CAA of any severity was present in the occipital lobes in 54% compared with 
65% in the other cerebral lobes (RR 0.83 (95%CI 0.67-1.02)). The type of 
vessel involved was not specified. 
In my community-based neuropathological study of first-ever lobar ICH, I 
found that parenchymal CAA, meningeal CAA and vasculopathy are all 
relatively evenly distributed throughout the cerebral lobes, even after 
accounting for participant age at the time of the index ICH, APOE genotype 
and Thal phase. 
In contrast, I found a strong occipital predominance for capillary CAA. This 
occurred regardless of age, APOE genotype or Thal phase. A recent large 
prospective population-based, non-selective neuropathological study also 
showed that capillary CAA was most frequently found in the occipital 
lobes.[279] The significance of this occipital predominance of capillary CAA is 
uncertain, especially in the context of ICH and the distribution of imaging 
findings previously described in CAA.[208, 252, 259-262] 
A recent phase 2 randomised controlled trial assessed the efficacy of 
immunotherapy with ponezumab, a monoclonal antibody against -amyloid1-
40, in patients with probable CAA according to the modified Boston 
criteria.[280] The primary outcome was change in the cerebrovascular 
reactivity in the visual cortex at 90 days. The hypothesis was that a treatment 
response to ponezumab would decrease vascular amyloid and improve 
vascular reactivity. However, the treatment group had a trend towards 
reduced cerebrovascular reactivity, which was opposite to the hypothesized 
direction. 
The reasons for this result are unclear. It may indicate that vascular amyloid 
was not sufficiently cleared, that clearance of vascular amyloid does not 
improve vasoreactivity or could even cause vascular damage, or the time 
point was too early. 
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Other possible explanations relate to the choice of occipital cerebrovascular 
reactivity as the outcome. Impaired occipital cerebrovascular in CAA is based 
on a few small case control studies, many of which used inappropriate 
control groups.[260, 281-283] Therefore, its validity as a biomarker of CAA is 
unclear. Furthermore, the pathophysiology of impaired occipital vascular 
reactivity in CAA is not understood. As discussed above, decreased occipital 
cerebrovascular reactivity is thought to reflect the occipital CAA 
predominance. However, given the lack occipital gradient for parenchymal 
and meningeal CAA and vasculopathy demonstrated in my study, occipital 
cerebrovascular reactivity may not reflect the overall CAA burden. Instead it 
may be related to capillary CAA, which did show a strong, consistent occipital 
predominance. Ponezumab is known to reduce CAA in leptomeningeal and 
brain vessels, but capillaries were removed from the samples as part of the 
processing. Its effect on capillary CAA is not known.[280] 
The frequency and severity of CAA in the cerebellum is unclear, with some 
studies showing little involvement,[263, 266] while others showing that the 
cerebellum is commonly affected.[226, 265] I found that the cerebellum was 
frequently affected by moderate or severe meningeal CAA, but rarely had 
parenchymal CAA, capillary CAA or vasculopathy. This is relevant because 
the cerebellar cortex is often used as the reference tissue for amyloid PET 
studies in ICH and CAA, based on the assumption it only has non-specific 
tracer binding.[284] However, this may not be the case given the frequent 
presence of moderate or severe meningeal CAA seen in my study. 
4.5.5 Clinical implications 
CAA assessed in cortical biopsies using the Vonsattel scale appears to have 
high sensitivity for CAA-associated lobar ICH, regardless of age. The 
absence of amyloid- in a cortical biopsy (Vonsattel grade 0) can, therefore, 
be used to rule out CAA-associated lobar ICH. The presence of complete 
replacement of a vessel wall with amyloid- (Vonsattel grade ≥2) in a cortical 
biopsy has good specificity for CAA-associated ICH in those aged under 85 
years and can be used to rule in CAA-associated ICH in this group. However, 
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its specificity is modest in those aged 85 years or above and may lead to 
false positive results. Assessment of capillary CAA in the cortex of the 
cerebral lobe affected by ICH has poor sensitivity for global cerebral capillary 
CAA due to the occipital predominance of this type of CAA. 
4.5.6 Future directions 
Dedica ted diagnostic test accuracy studies of CAA assessment in simulated 
cortical biopsies are needed to establish the true diagnostic accuracy. These 
studies should use tissue samples that reflect the size and shape of cortical 
biopsy samples obtained in clinical practice. The samples should be 
assessed masked to relevant features, including the rest of the brain autopsy 
to reduce diagnostic-review bias.[176] 
Further large neuropathological studies in ICH are needed to rigorously 
assess the clinical, genetic and histopathological associations of CAA and 
non-CAA SVDs in ICH with adjustment for potential confounders, such as 
age, time delay to autopsy and Alzheimer’s pathology. These studies should 
be prospective and unselective to ensure the results are representative of 
ICH. The pathological assessment should include both CAA and non-CAA 
SVDs in the different brain regions (cerebral lobes, deep grey matter, 
brainstem and cerebellum) to provide a comprehensive evaluation of SVDs. 
Particular attention should be paid to the significance of mixed CAA and non-
CAA SVDs compared with pure CAA and pure non-CAA SVD, as well as the 
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Chapter 5 Diagnostic test accuracy studies of the 
original and modified Boston criteria for 
CAA-associated ICH against a 
histopathological reference standard 
 
5.1 Introduction 
Multiple macrohaemorrhages and CMBs restricted to the lobar regions are 
the original imaging hallmarks of CAA,[253, 285] and form the basis of the 
Boston criteria for CAA (Table 1.1).[285, 286] The probable CAA category of 
the original Boston criteria had excellent specificity (100%, 95% CI 66-100) 
but limited sensitivity (45%, 95% CI 27-64) when assessed in 39 lobar ICH 
participants.[103] However, this study had several limitations, such as 
selection bias, variable index tests (CT and MRI with and without blood-
sensitive sequences) and different sources of tissue sampling as the 
reference standard. Restricting these analyses to the 16 participants with 
blood-sensitive MRI improved the sensitivity of probable CAA (73%, 95% CI 
39-93) with no reduction in the specificity. However, the numbers in this 
sensitivity analysis were small. Two studies have externally validated the 
original Boston criteria in the context of ICH,[95, 110] but both also had 
methodological limitations, such as small sample sizes, selection bias and 
partial verification bias, where the results of the index test influence whether 
the reference standard was performed. 
More recently, cortical superficial siderosis detected on blood-sensitive MRI 
has been shown to be associated with CAA.[108, 110, 111] The inclusion of 
cortical superficial siderosis as a separate lobar haemorrhagic lesion in the 
Boston criteria (Table 1.1) resulted in a non-significant increase in the 
sensitivity of the probable CAA category from 90% (95% CI 76-96) to 95% 
(95% CI 83-99), with the specificity remaining 81% (95% CI 62-93) in the 
study by Linn et al.[110] The so-called “modified Boston criteria” are now the 
non-invasive in vivo reference standard for diagnosing CAA-associated  
  Chapter 5 
174 
ICH[167] and are frequently used in clinical practice and in research to guide 
further, often invasive, investigations, treatment decisions and recruitment 
into studies.[167, 168] However, there were limitations in the development of 
the modified Boston criteria, such as selection bias, partial verification bias 
and no masking of the reference standard assessment. Furthermore, the 
modified Boston criteria have never been externally validated. Their 
diagnostic accuracy and their impact on patient care is therefore uncertain. 
 
5.2 Aim 
I aimed to perform separate diagnostic test accuracy studies of the original 
and modified Boston criteria (index tests) against a histopathological 




5.3.1 Study design and participants 
I used data from the prospective LINCHPIN study (Section 2.1.3.2). I 
included consecutive adult participants (aged ≥16 years) living in the NHS 
Lothian Health Board region who had an ICH (first-ever or recurrent) between 
1st June 2010 and 31st May 2016 inclusive, and who underwent a research 
brain MRI and subsequently died and had a research brain autopsy (Figure 
3.3). 
For the primary analysis I included participants regardless of the ICH location 
(lobar or non-lobar) as this was the approach used by Linn et al in the 
development of the modified Boston criteria.[110] However, there is no 
statistical association between CAA and deep ICH.[153] Furthermore, the 
original Boston criteria were developed in patients with only lobar ICH.[103] 
Therefore, I performed a sensitivity analysis excluding participants with non-
lobar ICH. 
  Chapter 5 
175 
I excluded patients with exclusively extra-axial intracranial haemorrhage, ICH 
secondary to an underlying cause other than SVDs, and those without 
research brain MRI with T2*-weighted GRE and research brain autopsy. 
5.3.2 Baseline data collection 
The RUSH team collected demographics and the presence of relevant co-
morbidities and medication use at the time of ICH by interviewing patients 
and their relatives and reviewing medical records as described in the 
methods chapter (Section 2.1.7). 
We determined APOE genotype from peripheral blood or cerebellar tissue as 
described in Section 2.3. 
5.3.3 Index test 
Research brain MRI was performed around six months after the index ICH 
using standardised parameters described in Section 2.2.3. 
I rated the brain MRI scans for the presence of SVD biomarkers using the 
standardised pro forma described within the methods chapter (Appendix 
2).[77] I classified the total brain MRI SVD burden using the MRI SVD burden 
score[197] and the MRI CAA SVD burden score[214] as described in Section 
2.2.3.3. I used the T2*-weighted GRE sequence to categorise scans as 
probable CAA, possible CAA or no CAA according to the original and 
modified Boston criteria (Table 1.1).[110, 285, 286] 
I pre-specified probable CAA as the positive index test result and possible 
CAA or no CAA as the negative index test result because probable CAA is 
the key diagnostic cut-off used in clinical practice and research.[103, 110, 
167] This cut-off will maximise the specificity of the criteria, and be most 
useful for ruling in CAA. 
I performed a pre-specified sensitivity analysis using no CAA as the negative 
index test result and possible CAA or probable CAA as the positive index test 
result as this cut-off will maximise the sensitivity of the criteria, and be most 
useful for ruling out CAA. 
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I performed all assessments masked to clinical, diagnostic brain CT, genetic 
and histopathological data. 
5.3.4 Reference standard 
Research brain autopsies were performed within five days of death according 
to a standard operating procedure as described in the methods chapter.[217] 
A single neuropathologist (Professor C Smith) assessed samples for CAA 
severity by using a consensus scale (Table 2.6).[36] Professor Smith 
performed all histopathological assessments masked to clinical, imaging and 
genetic data. 
I pre-specified the positive reference standard test result (CAA-associated 
ICH) as CAA severity of ≥2 on the Vonsattel scale (replacement of whole 
vessel wall by amyloid- in the most severely affected vessel in any brain 
sample)[253] as this was the cut-off used to develop the modified Boston 
criteria.[110] Vonsattel grade ≥2 corresponds to ≥2 (some circumferential 
amyloid-) parenchymal or meningeal CAA on the consensus scale 
developed by Love et al.[36] 
To assess the overall severity of CAA, I separately summed the meningeal 
CAA and parenchymal CAA scores for all cerebral lobes from the consensus 
scale developed by Love et al.[36] I graded summed scores to produce 
separate global cerebral meningeal CAA and parenchymal CAA scores 
(0=none, 1-8=mild, 9-16=moderate, 17-24=severe) as described in section 
4.3.3. 
5.3.5 Statistical analysis 
I compared the frequency of clinical and diagnostic non-contrast brain CT 
features, APOE genotype, and MRI SVD biomarkers in participants classified 
as positive on the histopathological reference standard (CAA-associated 
ICH) versus negative on the histopathological reference standard (not CAA-
associated ICH) using 2 test (or Fisher's exact test, where appropriate) for 
categorical variables and the Mann-Whitney U test for non-normally 
distributed continuous variables. 
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I assessed the diagnostic accuracy of the original and modified Boston 
criteria against the histopathological reference standard separately using 
sensitivity, specificity, likelihood ratios, and predictive values and their 95% 
CI. 
I performed statistical analyses using R statistical package version 3.4.4., 
except for the diagnostic accuracy statistics, for which I used VassarStats 
Clinical Calculator 1.[269] 
5.3.6 Missing data 
All included participants had the index test and reference standard available. 
5.3.7 Sample size 
I did not perform a sample size calculation. Instead, I used the largest sample 
possible from the on-going prospective LINCHPIN study over six years to 




5.4.1.1 Flow of participants 
Between 1st June 2010 and 31st May 2016 there were 612 patients with 
spontaneous ICH presumed related to SVDs (Figure 3.3). Three hundred and 
fifty consented to the LINCHPIN study, of whom 160 had a research MRI of 
adequate quality. I included 16 participants who died and had a research 
brain autopsy (Figure 5.1 and Figure 5.2). 
The median time between ICH and MRI (index test) was 92 days (IQR 55-
123 days, range 7-369 days) and between MRI (index test) and autopsy 
(reference standard) was 927 days (IQR 350-1659 days, range 28-2343 
days). There were no adverse events associated with the index test. 
5.4.1.2 Comparison of included versus excluded LINCHPIN participants 
Participants included in the study were older and more likely to have a pre-
ICH diagnosis of atrial fibrillation than LINCHPIN participants not included 
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(Table 5.1). Baseline clinical features were otherwise similar. Included 
participants tended to have a smaller ICH volume, less frequent 
intraventricular haemorrhage and finger-like projections and less severe CT 
SVD score (Table 5.2). However, these differences were not statistically 
significant. 
5.4.1.3 Comparison of participants with the index test who underwent the 
reference standard versus those who did not 
Participants who underwent both the index test (MRI) and reference standard 
(autopsy) were older with more frequent pre-ICH dementia and atrial 
fibrillation, a higher median pre-ICH modified Rankin scale score, more 
severe CT SVD score and more advanced atrophy compared with those who 
had the index test alone (Table 5.3, Table 5.4 and Table 5.5). The frequency 
of probable CAA according to both the original and modified Boston criteria 
was higher in those with both the index test and reference standard 
compared with those only undergoing the index test. 
 





Figure 5.1 Flow of participants in the original Boston criteria versus autopsy reference standard LINCHPIN DTA study 
 
CAA = cerebral amyloid angiopathy. DTA = diagnostic test accuracy. GRE = gradient recalled echo. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. MRI = magnetic resonance imaging.  





Figure 5.2 Flow of participants through the modified Boston criteria versus autopsy reference standard LINCHPIN DTA study 
 
CAA = cerebral amyloid angiopathy. DTA = diagnostic test accuracy. GRE = gradient recalled echo. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. MRI = magnetic resonance imaging
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Table 5.1 Baseline clinical characteristics in LINCHPIN participants with both 
MRI index test and histopathological reference standard (included in the 
study) versus those without (not included in the study). 
 
























Co-morbidities      
Hypertension 218  (65) 11  (69) 0.763 
Ischaemic stroke* 41  (12) 3  (19) 0.435 
Transient ischaemic attack* 39  (12) 1  (6) 1.000 
Dementia* 32  (10) 3  (19) 0.206 
Diabetes* 37  (11) 0  (0) 0.393 
Atrial fibrillation* 58  (17) 8  (50) 0.004 
Myocardial infarction* 22  (7) 2  (13) 0.300 























Pre-ICH modified Rankin 
scale; median (IQR) 
2 (1-3) 2 (1-3) 0.526 
Medications on admission      
Antiplatelet drug(s) 121  (36) 5  (31) 0.691 
Anticoagulant drug(s)* 47  (14) 4  (25) 0.266 
Antihypertensive drug(s) 159  (48) 8  (50) 0.843 
Admission GCS; median 
(IQR) 
14 (11-15) 14  (14-15) 0.207 
Data are n (%) or median (IQR). * Fisher’s exact test. GCS = Glasgow coma 
scale. ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. MRI = magnetic 
resonance imaging. SVD = small vessel disease.  
  Chapter 5 
182 
Table 5.2 ICH location and non-contrast diagnostic brain CT characteristics 
in LINCHPIN participants with both MRI index test and histopathological 
reference standard (included in the study) versus those without (not included 
in the study). 
 




























ICH volume; median (IQR) 16 (5-41) 10 (4-18) 0.095 
Intraventricular haemorrhage 132  (39) 3  (19) 0.097 
Subarachnoid haemorrhage 133  (40) 8  (50) 0.412 
Subdural haemorrhage* 30  (9) 0  (0) 0.379 
Finger-like projections 48  (15) 0 (0) 0.141 



























Data are n (%) or median (IQR). * Fisher’s exact test. CT = computed 
tomography. ICH = intracerebral haemorrhage. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
MRI = magnetic resonance imaging. SVD = small vessel disease.  
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Table 5.3 Baseline clinical features in LINCHPIN participants with research 









Age (years); median 
(IQR) 


















Co-morbidities      
Hypertension 85  (59) 11  (69) 0.451 
Ischaemic stroke* 13  (9) 3  (19) 0.203 
Transient ischaemic 
attack* 
9  (6) 1  (6) 1.000 
Dementia* 0  (0) 3  (19) <0.001 
Diabetes* 11  (8) 0  (0) 0.604 
Atrial fibrillation* 11  (8) 8  (50) <0.001 
Myocardial infarction* 4  (3) 2  (13) 0.111 























Pre-ICH modified Rankin 
scale; median (IQR) 
1 (1-1) 2  (1-3) 0.010 
Medications on 
admission 
     
Antiplatelet drug(s)* 42  (29) 5  (31) 1.000 
Anticoagulant drug(s)* 12  (8) 4  (25) 0.058 
Antihypertensive 
drug(s) 
57  (40) 8  (50) 0.421 
Admission GCS; median 
(IQR) 
15  (15-15) 14  (14-15) 0.161 
Data are n (%) or median (IQR). * Fisher’s exact test. GCS = Glasgow coma 
scale. ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. MRI = magnetic 
resonance imaging. SVD = small vessel disease. 
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Table 5.4 ICH location and non-contrast diagnostic brain CT characteristics 
in LINCHPIN participants with research MRI who had a research autopsy 
versus those who did not 
 
Index test only 
(n=144) 



























ICH volume; median (IQR) 9  (3-22) 10  (4-18) 0.903 
Intraventricular 
haemorrhage* 
31  (22) 3  (19) 1.000 
Subarachnoid 
haemorrhage 
47  (33) 8  (50) 0.165 
Subdural haemorrhage* 10  (7) 0  (0) 0.600 
Finger-like projections* 15  (11) 0  (0) 0.370 



























Data are n (%) or median (IQR). * Fisher’s exact test. CT = computed 
tomography. ICH = intracerebral haemorrhage. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
MRI = magnetic resonance imaging. SVD = small vessel disease. 
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Table 5.5 Research brain MRI features in LINCHPIN participants with 
research MRI who had a research autopsy versus those who did not 
 
Index test only 
(n=144) 





score; median (IQR) 
3 (2-4) 4 (3-4) 0.076 
Deep Fazekas score; 
median (IQR) 
3 (2-3) 3 (2-3) 0.936 
Central atrophy; median 
(IQR) 
3 (1-4) 3 (3-4) 0.034 
Cortical atrophy; median 
(IQR) 
2 (1-3) 3 (2-5) 0.008 
Basal ganglia PVS; median 
(IQR) 
1 (1-2) 2 (1-2) 0.427 
Centrum semiovale PVS; 
median (IQR) 
3 (2-4) 3 (2-3) 0.551 
Multiple ICH* 21  (15) 45 (31) 0.142 
Cortical superficial siderosis 56  (39) 10 (63) 0.069 
Any lobar CMB 48  (33) 7  (44) 0.405 
Any deep CMB* 38  (26) 3 (19) 0.763 
Any cerebellar CMB* 15  (10) 3 (19) 0.395 
Any brainstem CMB* 11  (8) 2 (13) 0.622 
Any CMB 67  (47) 8 (50) 0.792 
MRI SVD burden score; 
median (IQR) 
3  (2-4)  2 (2-4) 0.575 
MRI CAA SVD burden 
score; median (IQR) 
2  (2-3) 3 (2-4) 0.149 












































Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CMB = cerebral microbleed. ICH = intracerebral 
haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, 
imaging and neurological outcome. MRI = magnetic resonance imaging. PVS 
= perivascular space. SVD = small vessel disease. 
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5.4.1.4 Baseline clinical characteristics associated with the presence and 
absence of CAA on histopathology 
Eleven participants were classified as CAA-associated ICH by the reference 
standard and five as not CAA-associated ICH. There were no significant 
differences in demographics, co-morbidities or non-contrast diagnostic CT 
brain features between the CAA-associated ICH group compared with the 
non-CAA associated ICH group (Table 5.6 and Table 5.7). APOE 2 and 4 
allele possession occurred exclusively in the CAA-associated ICH, however 
these differences were only statistically significant for APOE 4. The time 
between ICH and MRI was significantly shorter for CAA-associated ICH 
(median 88 days, IQR 54-97) versus the non-CAA associated ICH group 
(median 123 days, IQR 123-129). There was no significant difference in the 
number of days between MRI and autopsy between CAA-associated and 
non-CAA-associated ICH groups (Table 5.6). 
Participants included in this study tend to be older than those included in the 
original[103] and modified[110] Boston criteria studies (Table 5.8). 
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Table 5.6 Baseline clinical characteristics in DTA study participants classified 


























Co-morbidities      
Hypertension* 5  (100) 6  (55) 0.119 
Ischaemic stroke* 0  (0) 3  (27) 0.509 
Transient ischaemic attack* 0  (0) 1  (9) 1.000 
Dementia* 0  (0) 3  (27) 0.509 
Diabetes 0  (0) 0  (0) NA 
Atrial fibrillation* 4  (80) 4  (36) 0.282 
Myocardial infarction* 2  (40) 0  (0) 0.083 























Pre-ICH modified Rankin scale; 
median (IQR) 
2 (1-3) 1 (1-3) 0.668 
APOE 2 possession* 0 (0) 6  (55) 0.093 
APOE 4 possession* 0 (0) 7  (64) 0.033 
Medications on admission      
Antiplatelet drug(s)* 3  (60) 2  (18) 0.245 
Anticoagulant drug(s)* 1  (20) 3  (27) 1.000 
Antihypertensive drug(s)* 3  (60) 5  (45) 1.000 


















Time between index ICH and 
MRI (days); median (IQR) 
123  (123-129) 88 (54-97) 0.042 
Time between MRI and autopsy 
(days); median (IQR) 
496  (357-1789) 993 (398-1482) 0.872 
Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. DTA = diagnostic test accuracy. GCS = Glasgow coma 
scale. ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. MRI = magnetic 
resonance imaging. SVD = small vessel disease.
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Table 5.7 ICH location and non-contrast diagnostic brain CT features in DTA 
study participants classified as CAA-associated versus non-CAA-associated 































ICH volume; median (IQR) 5  (3-11) 14  (5-19) 0.160 
Intraventricular 
haemorrhage* 
2  (40) 1  (9) 0.214 
Subarachnoid 
haemorrhage* 
2  (40) 6  (55) 1.000 
Subdural haemorrhage 0  (0) 0 (0) NA 
Finger-like projections 0  (0) 0  (0) NA 



























Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral amyloid 
angiopathy. CT = computed tomography. DTA = diagnostic test accuracy. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. SVD = small vessel disease. 
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Table 5.8 Baseline characteristics of participants included in the development 
studies of the original and modified Boston criteria 
 Original Boston criteria study† Modified Boston criteria study 
 No CAA (n=10) CAA (n=29) No CAA (n=22) CAA (n=38) 




























Co-morbidities         
Hypertension 7 (70) 16 (57) ? (-) ? (-) 
Dementia 2 (20) 7 (25) ? (-) ? (-) 
Medications on 
admission 
        
Antiplatelet drug 3 (30) 6 (21) 8 (36) 10 (26) 
Warfarin 6 (60) 9 (31) 3 (14) 2 (5) 
Data are n (%) or mean (SD).? = not reported; † Includes participants 
undergoing CT, MRI without blood-sensitive imaging or MRI with blood-sensitive 
imaging as the index test. CAA = cerebral amyloid angiopathy. CT = computed 
tomography. MRI = magnetic resonance imaging. 
 
5.4.1.5 MRI characteristics associated with CAA-associated and non-
CAA-associated ICH on histopathology 
Nine CAA-associated ICH cases had lobar ICH and two had a deep ICH 
(Table 5.9). There was no statistically significant difference in the number of 
ICHs, the presence of cortical superficial siderosis or the presence or number 
of lobar or deep CMB between CAA-associated and non-CAA-associated 
ICH. The severity of WMH, atrophy and PVS was similar between the 
groups. The median CAA SVD burden score was higher in CAA-associated 
ICH, although this did not reach statistical significance. 
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Table 5.9 MRI features (index test) in DTA study participants classified as 
CAA-associated versus non-CAA-associated ICH by the histopathological 






























Lobar CMB presence* 1 (20) 6 (55) 0.308 
Lobar CMBs; median (IQR) 0 (0-0) 1 (0-2) 0.259 
Deep CMB presence* 1 (20) 2 (18) 1.000 
Deep CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.803 
Cerebellar CMB presence* 2 (40) 1 (9) 0.214 
Cerebellar CMBs; median (IQR) 0 (0-2) 0 (0-0) 0.158 
Brainstem CMB presence* 1 (20) 1 (9) 1.000 
Brainstem CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.491 
Total CMB presence* 2 (40) 6 (55) 1.000 
Total CMBs; median (IQR) 0 (0-2) 1 (0-6) 0.809 
Cortical superficial siderosis* 3  (60) 7  (64) 1.000 

















Cortical superficial siderosis location* 
Adjacent to ICH 




















Periventricular Fazekas score; 
median (IQR) 
3 (3-4) 4 (3-4) 0.273 
Deep Fazekas score; median (IQR) 2 (2-3) 3 (2-3) 0.711 
Central atrophy; median (IQR) 3 (2-4) 3 (3-5) 0.769 
Cortical atrophy; median (IQR) 4 (2-5) 3 (2-4) 0.729 



























Severe basal ganglia PVS* 0 (0) 3 (27) 0.509 








































Severe centrum semiovale PVS* 0 (0) 2 (18) 1.000 
MRI SVD burden score; median 
(IQR) 
2 (1-4) 2 (2-4) 0.507 
MRI CAA SVD burden score; median 
(IQR) 
2 (1-3) 3 (3-5) 0.072 












































Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CMB = cerebral microbleed. DTA = diagnostic test 
accuracy. ICH = intracerebral haemorrhage. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
MRI = magnetic resonance imaging. MRI = magnetic resonance imaging. 
PVS = perivascular space. SVD = small vessel disease. 
 
5.4.1.6 Histopathological SVDs severity in CAA-associated and non-
CAA-associated ICH 
Ten participants with CAA-associated lobar ICH had moderate or severe 
global cerebral meningeal CAA on the Love et al. consensus scale, while the 
other participant had mild meningeal CAA. Nine participants also had 
moderate or severe global cerebral parenchymal CAA, while one participant 
had mild parenchymal CAA and in the other participant there was no 
parenchymal CAA. Eight participants had associated vasculopathic changes. 
Seven participants had moderate or severe non-CAA SVD while the 
remaining four participants had mild non-CAA SVD. 
All five participants with non-CAA-associated ICH had absent global cerebral 
parenchymal CAA. There was mild global cerebral meningeal CAA in two 
participants with non-CAA-associated ICH, while in the rest there was no 
meningeal CAA. None of them had vasculopathy. Four of the non-CAA-
associated ICH participants had severe non-CAA SVD, while the other 
participants had moderate non-CAA SVD. 
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5.4.2 Index test versus reference standard 
5.4.2.1 Original Boston criteria 
Table 5.10 shows the cross-tabulation of the original Boston criteria (index 
test) against the histopathological assessment for CAA (reference standard). 
Six out of the 11 CAA-associated ICH cases were classified as probable CAA 
by the original Boston criteria, resulting in a sensitivity of 55% (95% CI 25-82, 
Table 5.11). Three out of the five non-CAA-associated ICH controls were 
classified as either no CAA or possible CAA, resulting in a specificity of 60% 
(95% CI 17-93). 
Examples of true positive (Figure 5.3 and Figure 5.4) and true negative 
(Figure 5.5 and Figure 5.6) cases are shown below. The clinical and imaging 
features for the two false positive and five false negative cases using the 
original Boston criteria are summarised in Figure 5.7 and Figure 5.8 
respectively. 
In a sensitivity analysis using the no CAA category as the negative index test 
cut-off, the sensitivity increased to 73% (95% CI 39-93), with a decrease in 
the specificity to 40% (95% CI 7-83). 
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Table 5.10 Cross-tabulations of the original Boston criteria classifications 
using probable CAA or possible/probable CAA as the index test cut off 
against the histopathological reference standard 
Original Boston 




No CAA CAA Total 
No/possible CAA 3 5 8 
Probable CAA 2 6 8 
Total 5 11 16 
No CAA 2 3 5 
Possible/probable 
CAA 
3 8 11 
Total 5 11 16 
CAA = cerebral amyloid angiopathy. DTA = diagnostic test accuracy. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. 
 
Table 5.11 DTA statistics for the original Boston criteria CAA using probable 
CAA or possible/probable CAA as the index test cut off 





Sensitivity 55 (25-82) 73 (39-93) 
Specificity 60 (17-93) 40 (7-83) 
Positive likelihood ratio 1.4 (0.4-4.5) 1.2 (0.5-2.7) 
Negative likelihood ratio 0.8 (0.3-1.9) 0.7 (0.1-3.2) 
Positive predictive value 75 (36-96) 73 (39-93) 
Negative predictive value 38 (10-74) 40 (7-83) 
Data are percentage or ratio (95% CI). CAA = cerebral amyloid angiopathy. 
DTA = diagnostic test accuracy. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. 
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Figure 5.3 True positive result for the original and modified Boston criteria 
against the histopathological reference standard. 
Axial T2*-weighted GRE images showing 
A. Lobar ICH with its epicentre in the left frontal lobe (asterisk) and left frontal 
superficial siderosis (white arrows). 
B. Lobar ICH with its epicentre in the left frontal lobe (asterisk), left frontal 
superficial siderosis (white arrow) and right frontal lobar cerebral microbleed 
(dotted arrow). 
C. Two lobar cerebral microbleeds in the left temporal lobe (dotted arrows). 
The participant is classified as probable CAA by both the original Boston 
criteria (lobar ICH and lobar cerebral microbleeds) and the modified Boston 
criteria (lobar ICH, lobar cerebral microbleeds and cortical superficial 
siderosis). Histopathological assessment showed a CAA-associated ICH 
(grade 3 CAA on the Vonsattel scale). There was severe parenchymal and 
meningeal global cerebral CAA with vasculopathy on the Love et al scale. 
Mild non-CAA SVD was present. 
 
CAA = cerebral amyloid angiopathy. GRE = gradient recalled echo. ICH = 
intracerebral haemorrhage. MRI = magnetic resonance imaging. P = 
posterior. R = right. SVD = small vessel disease.  
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Figure 5.4 True positive result for the original and modified Boston criteria 
against the autopsy histopathological reference standard 
Axial T2*-weighted GRE images showing 
A. Lobar ICH with its epicentre in the right temporal lobe (asterisk). 
B. Second lobar ICH with its epicentre in the right frontal lobe (chevron). 
C. Second lobar ICH centred in the right frontal lobe (chevron) and right parietal 
cortical superficial siderosis (white arrow). 
D. Right parietal cortical superficial siderosis (white arrows). 
The participant is classified as probable CAA by both the original Boston criteria 
(two lobar ICHs) and the modified Boston criteria (two lobar ICHs and cortical 
superficial siderosis). Histopathology showed a CAA-associated ICH (grade 3 
CAA on the Vonsattel scale). There was severe parenchymal and meningeal 
global cerebral CAA with vasculopathy on to the Love et al scale. Moderate non-
CAA SVD was present. 
 
CAA = cerebral amyloid angiopathy. GRE = gradient recalled echo. ICH = 
intracerebral haemorrhage. MRI = magnetic resonance imaging. P = posterior. R 
= right. SVD = small vessel disease.  
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Figure 5.5 True negative result for the original and modified Boston criteria 
against the autopsy histopathological reference standard 
Axial T2*-weighted GRE image showing 
A. Deep ICH with its epicentre in the left caudate head nucleus (white arrow). 
The participant is classified as no CAA by both the original and modified 
Boston criteria (single deep ICH). Histopathological assessment showed a 
non-CAA-associated ICH (grade 0 CAA on the Vonsattel scale). There was 
absent parenchymal and meningeal global cerebral CAA and no 
vasculopathy on to the Love et al scale. Severe non-CAA SVD was present. 
 
CAA = cerebral amyloid angiopathy. GRE = gradient recalled echo. ICH = 
intracerebral haemorrhage. MRI = magnetic resonance imaging. P = 
posterior. R = right. SVD = small vessel disease. 
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Figure 5.6 True negative test result for the original and modified Boston 
criteria against the autopsy histopathological reference standard 
Axial T2*-weighted GRE images showing 
A. Lobar ICH with its epicentre in the left cerebellar hemisphere (asterisk). 
B. Lobar cerebral microbleeds in the left occipital and temporal lobes (white 
arrows). 
C. Lobar cerebral microbleed in the left occipital lobe (white arrow) and deep 
cerebral microbleeds in the thalami (white dotted arrows). 
The participant is classified as no CAA by both the original and modified Boston 
criteria (lobar haemorrhage and mixed lobar and deep cerebral microbleeds). 
Histopathological assessment showed a non-CAA-associated ICH (grade 0 CAA 
on the Vonsattel scale). There was absent parenchymal and meningeal global 
cerebral CAA and no vasculopathy according to the Love et al scale. Severe 
non-CAA SVD was present. 
 
CAA = cerebral amyloid angiopathy. GRE = gradient recalled echo. ICH = 
intracerebral haemorrhage. MRI = magnetic resonance imaging. P = posterior. R 






Figure 5.7 Discrepancies between the original and modified Boston criteria and the autopsy reference standard using probable 
CAA as the positive index test result 
A and B False positive index test result for both the original and modified Boston criteria 
C False positive index test result for the modified Boston criteria 
 
Clinical details MRI features 
Boston criteria 
classification 
Example T2*-weighted GRE images 
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APOE genotype 3/3 
Right cerebellar 












Modified – Probable 
CAA 
 












Severe non-CAA SVD 
 
Time from MRI to 
autopsy = 2343 days 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. GRE = gradient recalled echo. ICH = intracerebral 







Figure 5.8 Discrepancies between the original and modified Boston criteria and the autopsy reference standard using probable 
CAA as the positive index test result 
A - D False negative index test result for both the original and modified Boston criteria 
E False positive index test result for the original Boston criteria 
 
Clinical details MRI features 
Boston criteria 
classification 
Example T2*-weighted GRE images 
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Severe parenchymal 
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white matter (dashed 
arrow) 
 
No cortical superficial 
siderosis 
Original – No CAA 
 
 
Modified – No CAA 
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Severe parenchymal 




Severe non-CAA SVD 
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Histopathology 
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drug use (Admission 
INR 2.1) 
 
APOE genotype 3/4 
Left basal ganglia ICH 
(dashed arrow) 
 
Lobar microbleed (solid 
arrows) 
 
No deep microbleeds 
 
No cortical superficial 
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drug use (Admission 
INR 2.3) 
 
APOE genotype 3/3 



















global cerebral CAA 
 
Mild parenchymal 




Severe non-CAA SVD 
 
Time from MRI to 
autopsy = 466 days 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. GRE = gradient recalled echo. ICH = intracerebral 
haemorrhage. MRI = magnetic resonance imaging. SVD = small vessel disease. 
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5.4.2.2 Modified Boston criteria 
The inclusion of cortical superficial siderosis as a distinct haemorrhagic 
lesion (modified Boston criteria –Table 1.1) resulted in the upgrading from 
possible CAA to probable CAA in two participants. The cross-tabulation of 
the modified Boston criteria against histopathology reference standard is 
shown in Table 5.12. 
The sensitivity of the modified Boston criteria using the probable CAA 
category as the index test cut-off was 64% (95% CI 32-88) and its specificity 
40% (95% CI 7-83, Table 5.13). 
Examples of true positive (Figure 5.3 and Figure 5.4) and true negative 
(Figure 5.5 and Figure 5.6) cases are shown above. The clinical and imaging 
features for the three false positive and four false negative cases are 
summarised in Figure 5.7 and Figure 5.8 respectively. 
Using the no CAA category as the negative index test cut-off, the sensitivity 
and specificity of the modified Boston criteria were the same as the original 
Boston criteria (sensitivity 73% (95% CI 39-93), specificity 40% (95% CI 7-
83)). 
 
Table 5.12 Cross-tabulations of the modified Boston criteria classifications 
using probable CAA or possible/probable CAA as the index test cut off 
against the histopathological reference standard 
Modified Boston 




No CAA CAA Total 
No/possible CAA 2 4 6 
Probable CAA 3 7 10 
Total 5 11 16 
No CAA 2 3 5 
Possible/probable CAA 3 8 11 
Total 5 11 16 
CAA = cerebral amyloid angiopathy. DTA = diagnostic test accuracy. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome.  
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Table 5.13 DTA statistics for the modified Boston criteria CAA using probable 
CAA or possible/probable CAA as the index test cut off 





Sensitivity 64 (32-88) 73 (39-93) 
Specificity 40 (7-83) 40 (7-83) 
Positive likelihood ratio 1.1 (0.5-2.5) 1.2 (0.5-2.7) 
Negative likelihood ratio 0.9 (0.2-3.6) 0.7 (0.1-3.2) 
Positive predictive value 70 (35-92) 73 (39-93) 
Negative predictive value 33 (6-76) 40 (7-61) 
Data are percentage or ratio (95% CI). CAA = cerebral amyloid angiopathy. 
DTA = diagnostic test accuracy. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. 
 
5.4.3 Index test versus reference standard in lobar ICH 
In a sensitivity analysis I assessed the diagnostic accuracy of the original and 
modified Boston criteria in those with a lobar ICH. The sensitivity of both the 
original Boston criteria (Table 5.14 and Table 5.15) and the modified Boston 
criteria (Table 5.16 and Table 5.17) was higher, however there were no true 
negative cases in this small group of participants, resulting in a specificity of 
0%.  
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Table 5.14 Cross-tabulations of the original Boston criteria classifications 
using probable CAA or possible/probable CAA as the index test cut off 
against the histopathological reference standard in lobar ICH participants 
Original Boston 




No CAA CAA Total 
No/possible CAA 0 3 3 
Probable CAA 2 6 8 
Total 2 9 11 
No CAA 0 1 1 
Possible/probable 
CAA 
2 8 10 
Total 2 9 11 
CAA = cerebral amyloid angiopathy. DTA = diagnostic test accuracy. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. 
 
Table 5.15 DTA statistics for the original Boston criteria CAA using probable 
CAA or possible/probable CAA as the index test cut off in lobar ICH 
participants 





Sensitivity 67 (31-91) 89 (51-99) 
Specificity 0 (0-80) 0 (0-80) 
Positive likelihood ratio 0.7 (0.4-1.6) 0.9 (0.7-1.1) 
Negative likelihood ratio Inf (NaN-inf) Inf (NaN-Inf) 
Positive predictive value 75 (36-96) 80 (44-96) 
Negative predictive value 0 (0-69) 0 (0-95) 
Data are percentage or ratio (95% CI). CAA = cerebral amyloid angiopathy. 
DTA = diagnostic test accuracy. Inf = infinity. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
NaN = Not a number. 
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Table 5.16 Cross-tabulations of the modified Boston criteria classifications 
using probable CAA or possible/probable CAA as the index test cut off 
against the histopathological reference standard in lobar ICH participants 
Modified Boston 




No CAA CAA Total 
No/possible CAA 0 2 2 
Probable CAA 2 7 9 
Total 2 9 11 
No CAA 0 1 1 
Possible/probable 
CAA 
2 8 10 
Total 2 9 11 
CAA = cerebral amyloid angiopathy. DTA = diagnostic test accuracy. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. 
 
Table 5.17 DTA statistics for the modified Boston criteria CAA using probable 
CAA or possible/probable CAA as the index test cut off in lobar ICH 
participants 





Sensitivity 78 (40-96) 89 (51-99) 
Specificity 0 (0-80) 0 (0-80) 
Positive likelihood ratio 0.8 (0.5-1.1) 0.9 (0.7-1.1) 
Negative likelihood ratio Inf (NaN-inf) Inf (NaN-Inf) 
Positive predictive value 78 (40-96) 80 (44-96) 
Negative predictive value 0 (0-80) 0 (0-95) 
Data are percentage or ratio (95% CI). CAA = cerebral amyloid angiopathy. 
DTA = diagnostic test accuracy. Inf = infinity. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
NaN = Not a number. 
 
  Chapter 5 
210 
5.5 Discussion 
5.5.1 Main findings 
 The probable CAA category in the original Boston criteria showed 55% 
sensitivity and 60% specificity for CAA-associated ICH (Vonsattel 
grade ≥2 on research brain autopsy). 
 The combination of either possible or probable CAA categories in the 
original Boston criteria increased sensitivity to 73% for CAA-
associated ICH but lowered the specificity to 40%. 
 The inclusion of any cortical superficial siderosis as a distinct 
haemorrhagic lesion (modified Boston criteria) increased the 
sensitivity of probable CAA to 64% for CAA-associated ICH but 
decreased the specificity to 40%. 
 The combination of either possible or probable CAA categories in the 
modified Boston criteria increased sensitivity to 73% for CAA-
associated ICH without changing the specificity (40%). 
5.5.2 Strengths of the study 
I performed and reported the study accorded to the STARD guidelines for 
diagnostic accuracy studies.[173] Important strengths are: 
 We used prospective case ascertainment to reduce selection bias by 
inviting all potentially eligible patients to the study.[175, 287] 
 The index test and reference standard were acquired prospectively, 
and we optimised procedures for the study question.[175] 
 We performed the index test at a standardised time point after the 
index ICH for all participants. 
 The reference standard was offered to all eligible participants, 
regardless of clinical features or the results of the index test to reduce 
partial verification bias.[174, 176, 246] 
 All included participants underwent the same index test and reference 
standard to avoid differential verification bias.[174] 
 I minimised information bias by using a standard MRI acquisition 
protocol for all participants and I followed published guidance for rating 
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SVD biomarkers on MRI.[77] We also used a standardised approach 
for systematically acquiring the reference standard[217] and a 
validated scale to evaluate CAA.[36] Assessors of the index test and 
reference standard were masked to relevant features.[175, 176] 
 There were no missing data. 
 I pre-specified the sensitivity analysis using a different cut-off for index 
test positivity.[288] 
 I reported the flow of participants through the study and described the 
differences between those who did and did not undergo the reference 
standard to illustrate partial verification bias.[174, 175]  
 I described the baseline clinical and radiographic features and the 
distribution of CAA and non-CAA SVDs severity in the study groups to 
describe the spectrum of participants.[175, 176] 
5.5.3 Weaknesses of the study 
Although we tried to limit selection bias, those included in the study were 
older than those not included, and they tended to have a smaller ICH volume 
and a less severe CT SVD score. These variations in the spectrum of 
disease can bias the diagnostic accuracy of a test,[176] although the 
differences were small. The older age of included participants may relate to 
the increased likelihood of dying after ICH with increasing age[244] and thus 
undergoing the autopsy reference standard. The other differences probably 
reflect the feasibility of MRI scanning in this patient group. 
The sample size was small, which was related to the rigorous reference 
standard I used. Only 16 of the 160 participants who underwent the index 
test had the reference standard. Patients able to undergo MRI tend to be less 
severely affected by ICH than those not able to have MRI (Table 3.10). As a 
result, the fatality rate will be lower in participants with the index test versus 
those without. Acquisition of an autopsy reference standard in those with the 
index test was therefore infrequent. The small sample size results in less 
precise estimates of diagnostic accuracy and reduces generalisability.[289] 
The lack of power also prevented me from assessing independent 
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associations between clinical, genetic and MRI SVD biomarkers and 
pathologically-proven CAA. However, a further 79 participants who have 
undergone research MRI have consented to research brain autopsy, 67 of 
whom are still alive, so more data will become available with the passage of 
time. 
The use of an autopsy-based reference standard resulted in two further 
limitations. Firstly, most participants who had the index test did not undergo 
the reference standard (Figure 5.1 and Figure 5.2), resulting in a potential 
partial verification bias. Partial verification bias is common in studies using an 
invasive reference standard.[290] All LINCHPIN participants were invited to 
provide consent to research autopsy, and those who consented to this were 
similar to those who did not. However, those who underwent autopsy in this 
study were older with more frequent pre-ICH dementia compared to those 
only having the index test (Table 5.2). Although the index test result did not 
influence the reason for undergoing an autopsy, the prevalence and severity 
of CAA in my study is likely to be increased relative to the population of 
interest given the association between CAA and increasing age and 
dementia.[21, 27, 233, 258] In line with this, the ratio of positive to negative 
index test results according to both the original and modified Boston criteria 
was higher in those undergoing an autopsy. This is likely to bias the studies 
by increasing the sensitivity of the criteria.[174, 176, 291] 
Secondly, the use of autopsy leads to a time delay between the index test 
and reference standard. Ideally, the index test and reference standard should 
be performed at the same time or as close as possible.[173, 292] The 
median time between the MRI and autopsy was 927 days and ranged from 
44 days to 2405 days. CAA is a progressive, age-related condition.[27, 258] 
Therefore, a delay in performing the histopathological assessment may lead 
to a false positive reference standard classification due to the interval 
development of CAA after the index test was performed. This would reduce 
index test sensitivity. Four of the false negative index test results for the 
original Boston criteria when using probable CAA as the index test cut-off 
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occurred in elderly participants whose autopsy occurred over a year after the 
index test (Figure 5.8). Three of these participants were also false negative 
results in the modified Boston criteria diagnostic test accuracy study. 
5.5.4 Comparison with other studies 
The sensitivity of the original Boston criteria was 55% (95% CI 25-82) when I 
used the probable CAA category as the cut-off. This is lower than the original 
study characterising the Boston criteria by Knudsen et al. (73% (95% CI 39-
93))[103] and external validation studies by Charidimou et al. (77% (95% CI 
46-95))[95] and Linn et al. (90% (95% CI 76-96)).[110] However, the studies 
by Knudsen et al[103] and Charidimou et al[95] have confidence intervals 
which overlap the point estimate from my study. 
The probable CAA category is the highest level of diagnostic certainty and 
therefore should maximise specificity over sensitivity. When I performed a 
sensitivity analysis using possible or probable CAA categories as the cut-off, 
the sensitivity of both the original and modified criteria increased to 73% 
(95% CI 40-93). A similar result was found by Charidimou et al. (sensitivity 
92% (95% CI 62-100)).[95] As expected the specificity reduced with this cut-
off in both my study (40% (95% CI 7-83)) and the study by Charidimou et al. 
(63% (95% CI 25-92)).[95] 
In my study the specificity of the probable CAA category in the original 
Boston criteria was 60% (95% CI 17-93). This is lower than the original study 
characterising the Boston criteria (100% (95% CI 40-100))[103] and the 
external validation studies (88% (95% CI 47-100)[95] and 81% (95% CI 62-
93),[110] but the confidence intervals in these studies overlap with the point 
estimate from my study. 
The inclusion of cortical superficial siderosis as a distinct haemorrhagic 
lesion in the criteria (modified Boston criteria) increased the sensitivity of the 
probable CAA category from 55% to 64% (95% CI 32-88). However, the 
specificity reduced from 60% to 40% (95% CI 7-83). The only previous study 
assessing the modified Boston criteria also reported an increase in the 
sensitivity compared with the original Boston criteria (95% (95% CI 83-99) 
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versus 90% (95% CI 76-96) respectively), but the specificity remained 
unchanged at 81% (95% CI 62-93).[110] 
I included participants with both lobar and non-lobar ICH locations in my 
primary analysis as this was the approached used by Charidimou et al in 
their external validation of the original Boston criteria[95] and Linn et al in the 
development of the modified Boston criteria.[110] I performed a sensitivity 
analysis excluding participants with non-lobar ICH because there is thought 
to be no association between CAA and deep ICH[153] and the original 
Boston criteria were developed in patients with only lobar ICH.[103] As 
expected there were fewer false-negative results with both the original and 
modified Boston criteria when applied to only lobar ICH, resulting in a higher 
sensitivity. However there were only two non-CAA-associated lobar ICH 
cases, both of which were false positive results using the original and 
modified Boston criteria. 
There are several potential reasons relating to the study methodology and 
the design of the criteria to explain the differences in diagnostic accuracy 
between my study and the other studies. The weaknesses in my study and 
the likely effects on sensitivity and specificity are discussed in section 5.5.3, 
while those relating to the previous studies are described below. 
5.5.4.1 Limitations of previous studies 
All three previous studies were small (Knudsen et al. n = 15, Charidimou et 
al. n= 21, Linn et al. n=60) with wide 95% CI.[95, 103, 110] A pooled analysis 
of the data could improve the power and refine the estimates of diagnostic 
accuracy. However, as discussed below, there are major methodological 
limitations in all these studies, which would make it difficult to interpret any 
meta-analysis. 
The previous studies all identified potential participants through retrospective 
searches of pathology databases (i.e. the reference standard). This approach 
can affect the prevalence and severity of the target disease and alternative 
conditions compared with the population of interest, which can influence the 
apparent diagnostic accuracy.[287, 293] Indeed, the prevalence of CAA 
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cases in these studies ranged from 62-74% [95, 103, 110] compared with 
61% prevalence of CAA-associated lobar ICH in our LINCHPIN brain bank 
(Figure 4.13). The prevalence of CAA-associated ICH in my study was also 
high (69%). 
The reference standard was not obtained in all who underwent the index test 
in the previous studies. Instead, it was performed as part of the clinical 
management and may have been influenced by the likelihood and severity of 
CAA, based on the clinical features and the index test result. This leads to 
partial verification basis, where there is the preferential performance of the 
reference standard in those with a higher probability of the disease of interest 
and will result in biased estimates of diagnostic accuracy by falsely 
increasing sensitivity and decreasing specificity.[174, 176, 291] 
All the previous studies used more than one type of reference standard. The 
accuracy of detecting CAA will differ between brain biopsy, haematoma 
evacuation and autopsy due to the small volume of tissue sampled by the 
former two. Analysing the different reference standards together without 
accounting for this differential verification will result in biased accuracy 
estimates.[174, 294] 
The control groups in all three previous studies were younger than the cases. 
Given the increasing prevalence of CMBs with age,[99, 295, 296] the chance 
of false-positive results in such participants will be lower, which may have 
falsely increased specificity.[175] 
The previous studies by Charidimou et al[95] and Linn et al[110] included 
participants with non-lobar ICH as well as participants without ICH who had 
undergone the index test and reference standard. This heterogeneous case 
mix can affect diagnostic accuracy estimates. Also, the previous studies 
included participants with both first-ever and recurrent ICH. This could falsely 
increase sensitivity given that participants with a recurrent ICH are likely to 
have more severe underlying SVDs.[176, 297] 
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Finally, the studies performed by Charidimou et al[95] and Linn et al[110] did 
not report whether assessment of the reference standard was masked to 
clinical information or the index test, which can result in the reported 
diagnostic accuracy of the index test being too high.[294] The timing between 
the index test and reference standard can affect diagnostic accuracy, but this 
was not reported in any of the previous studies. 
5.5.4.2 Limitations of the Boston criteria 
The Boston criteria may have misclassified participants, affecting its 
sensitivity. One of the false negative results in my study of the original Boston 
criteria occurred in a participant classified as possible CAA. They had a 
single lobar ICH and no microbleeds. However, cortical superficial siderosis, 
which is known to be associated with CAA,[110] was also present. This 
negative case was correctly classified when I applied the modified Boston 
criteria, leading to an increase in the sensitivity. 
A difficulty with the original and modified Boston criteria relates to mixed 
location haemorrhagic foci. The SVDs underlying ICH are typically 
heterogeneous, with mixed CAA and non-CAA SVDs often present in lobar 
ICH (Figure 4.13). Any non-lobar haemorrhage results in a “no CAA” 
classification by both the original and modified Boston criteria, which is 
potentially problematic in cases where there are multiple lobar 
haemorrhages, suggestive of CAA, and a single deep CMB. One false 
negative result in my study occurred in a participant with lobar ICH and 
multiple lobar CMBs but a single deep CMB. This participant was classified 
as no CAA by both the original and modified Boston criteria. The autopsy 
showed severe CAA as well as severe non-CAA SVD. 
The lower specificity in my study may relate to misclassification by Boston 
criteria. One of the false positive results in my study occurred in a participant 
with a single lobar haemorrhage and two cortical cerebellar CMBs. On this 
basis, they were classified as probable CAA. However the autopsy showed 
mild meningeal and absent parenchymal CAA, but severe non-CAA SVD. 
Cerebellar haemorrhage can occur in both CAA and arteriosclerosis.[153, 
  Chapter 5 
217 
298] Therefore the validity of their inclusion as a separate lobar 
haemorrhagic focus in the Boston criteria is unclear, particularly when the 
severity of CAA in the cerebellum is often milder compared with the cerebrum 
(Figure 4.16).[167] 
5.5.5 Clinical implications 
The original and modified Boston criteria might be useful non-invasive 
approaches to rule in or rule out CAA-associated ICH. This would limit the 
need for invasive investigations to diagnose CAA, such as brain biopsy, and 
could help guide clinical management and inform prognosis after ICH.[59, 
105, 158] However, given the methodological limitations of the external 
validation studies of the original criteria and the lack of external validation of 
the modified criteria, their true diagnostic accuracy is uncertain. My 
preliminary data in a small cohort suggest that the diagnostic accuracy of the 
original and modified Boston criteria is lower than the published values. 
Therefore, these criteria should be used with caution in clinical practice. 
5.5.6 Future directions 
Future work should focus on rigorous external validation of the original and 
modified Boston criteria with a larger sample to quantify their diagnostic 
accuracy. The ideal external validation study would involve an unselected, 
population-based cohort study of first-ever lobar ICH comparing standardised 
MRI imaging with blood-sensitive sequences against a standardised 
histopathological reference standard acquired close to the index test. The 
index test result should not influence the decision to perform tissue sampling 
in order to limit partial verification bias. Imaging and histopathological 
assessments should be masked.[173] 
The Boston criteria have limitations when there are mixed location 
haemorrhages or a solitary lobar haemorrhage. Therefore, future studies 
should aim to improve the Boston criteria. This could be through the 
development of a multivariable prediction model for CAA. Such a model 
should include relevant clinical features, such as age and pre-existing 
dementia, APOE genotype and MRI biomarkers, such as the number of lobar 
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and non-lobar macrohaemorrhages and CMBs, the extent of cortical 
superficial siderosis and other more recently identified CAA-associated MRI 
biomarkers. This approach allows the probability of CAA to be predicted 
based on the presence and number of these predictors, helping to 
circumvent the problems described above. Simple criteria could be derived 
from this model, and relevant clinical cut-offs identified to rule in or out CAA. 
The LINCHPIN study contains many of the ideal characteristics of a 
diagnostic test accuracy study. Sixty-seven study participants who had a 
research MRI and consented to research autopsy are still alive. Repeating 
my analyses when these participants have died and donated brain tissue at 
research autopsy will provide a more robust assessment of the performance 
of the Boston criteria and an opportunity to develop a novel MRI-based 
prediction model for CAA-associated ICH. However, the sample size will still 
be modest. 
The International CAA Association is currently coordinating a multicentre 
study to validate and update the Boston criteria.[228] This study will include 
participants from different centres around the world and will be the largest 
study of its kind in CAA. It will have limitations, such as heterogeneous index 
tests (MRI field strength, scanner type and sequence parameters), 
heterogeneous reference standards (haematoma evacuation, brain biopsy 
and autopsy) and possible selection bias favouring participants with CAA. 
However, it will present a good opportunity to develop and validate MRI-
based diagnostic criteria for CAA. 
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The modified Boston criteria are the current non-invasive in vivo reference 
standard for diagnosing CAA.[110, 167] These criteria use the presence of 
haemorrhagic consequences of CAA on MRI (macrohaemorrhages, CMBs, 
and cortical superficial siderosis) to categorise a patient as probable CAA, 
possible CAA or no CAA. However, haemorrhages are thought to represent 
the late consequences of advanced CAA.[170] Therefore, those in the earlier 
stages of the disease spectrum, in whom haemorrhages have not yet 
occurred, may not be identified. In addition, multiple sites of haemorrhage are 
necessary to diagnose “probable” CAA on the modified Boston criteria, yet 
27% of ICH patients had a single lobar index ICH on MRI in a hospital-based 
study,[243] while 36% of patients in my population-based LATCH study have 
a single lobar index ICH identified on CT +/- MRI (Figure 3.2). The 
significance of this possible CAA category in relation to underlying CAA and 
risk of future haemorrhages is unclear. A more accurate diagnostic approach 
is therefore essential. 
In vivo molecular imaging with PET is a technique that may help identify 
CAA. The direct detection of perivascular β-amyloid with PET may allow 
accurate diagnosis of CAA even before haemorrhages have occurred.  
11C-Pittsburgh compound B (PiB), a benzothiazole dye that binds β-amyloid, 
was initially developed as a PET radioligand for fibrillar/parenchymal β-
amyloid in Alzheimer’s disease. PiB is now recognised to be a non-specific β-
amyloid ligand, binding with high affinity to both non-vascular parenchymal 
and perivascular β-amyloid.[171, 172] Three studies have demonstrated that 
PiB uptake in patients with possible CAA or probable CAA according to the 
modified Boston criteria (n=60) is significantly higher than healthy controls 
without ICH (n=87),[252, 262, 299] while other studies have shown PiB 
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uptake corresponds topographically to lobar microbleeds.[300, 301] The 
distribution of PiB uptake in possible CAA or probable CAA also differed from 
that observed in Alzheimer’s disease (n=22).[252, 262] In contrast, one study 
did not show a difference in PiB uptake between probable CAA-related ICH 
(n=11) and healthy controls (n=9).[302] These conflicting results perhaps 
reflect the small sample sizes combined with other methodological 
limitations, such as heterogeneous case groups including those with and 
without ICH, poorly matched control groups and variable techniques used for 
PET data analysis. 
The short half-life of 11C-PiB (20 minutes) restricts its use outside the 
research setting. The newer 18F-labelled amyloid PET ligands, such as 18F-
flutemetamol, have a half-life six times longer, making them more practical 
for clinical practice.  
Two recent studies have shown that uptake of florbetapir, an 18F-amyloid 
tracer, is significantly higher in probable CAA lobar ICH (n=25) versus deep 
ICH controls (n=27).[303, 304] Flutemetamol is a structural analogue of PiB, 
and the two compounds possess very similar in- and ex-vivo binding 
characteristics in Alzheimer’s disease and healthy controls.[305] Therefore, 
18F-flutemetamol is expected to be a non-specific β-amyloid ligand. However, 
whether it binds to perivascular -amyloid, and whether 18F-flutemetamol can 
identify CAA in vivo is uncertain. 
 
6.2 Aims 
I aimed to: 
 Assess whether 6-CN-flutemetamol, a fluorescent derivative of 
flutemetamol, labels perivascular (CAA) and non-vascular parenchymal -
amyloid using ex vivo brain tissue samples from participants with SVD-
associated ICH. 
 Perform a diagnostic test accuracy study of 18F-flutemetamol PET for 
CAA-associated ICH, comparing the visual classification of 18F-
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flutemetamol PET scans (index test) against the MRI-based modified 
Boston criteria (reference standard). 
 Compare visual evaluation of the 18F-flutemetamol PET scans against 
quantitative analysis of cortical standardised uptake value ratios (SUVr) in 
SVD-associated ICH. 
 Quantitatively assess the amount and distribution of 18F-flutemetamol 
uptake between probable CAA versus possible CAA or no CAA according 
to the modified Boston criteria in patients with ICH. 
 
6.3 Methods 
6.3.1 Ex vivo 6-CN-flutemetamol study 
6.3.1.1 Selection of cases 
I reviewed the histopathological ratings for CAA[36] and non-vascular 
(Alzheimer’s type) -amyloid (Thal phase)[219] in the LINCHPIN brain bank 
to identify four cases covering the extremes of CAA and non-vascular -
amyloid severity. 
 Absent parenchymal and meningeal CAA and absent non-vascular -
amyloid (Thal phase 0). 
 Absent parenchymal and meningeal CAA and severe non-vascular -
amyloid (Thal phase 5). 
 Severe parenchymal and meningeal CAA and absent non-vascular -
amyloid (Thal phase 0). 
 Severe parenchymal and meningeal CAA and severe non-vascular -
amyloid (Thal phase 5). 
6.3.1.2 Immunofluorescence 
The immunofluorescence was performed by Karina McDade (KM, Senior 
Research Technician, Centre for Clinical Brain Sciences, The University of 
Edinburgh) and Dr Juraj Koudelka (JK, Research Fellow, Centre for 
Discovery Brain Sciences, The University of Edinburgh). 
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KM cut one 8 m section from a formalin fixed paraffin embedded frontal 
convexity (BA46) tissue block from each participant using a microtome. She 
mounted the sections onto glass slides and fixed them by heating at 40oC 
overnight. The frontal cortex was selected as it is known to be affected by 
both CAA and non-vascular -amyloid. 
JK heated the sections to 60oC for 60 minutes to melt the wax. He 
deparaffinised the sections by washing in xylene twice (15 minutes per wash) 
and hydrated them in two changes of 100% ethanol (five minutes each), 90% 
ethanol for one minute and 70% ethanol for one minute. JK washed the 
sections using distilled water and then equilibrated them in phosphate 
buffered saline (PBS) for five minutes. 
JK performed antigen retrieval using citrate buffer heat retrieval. He placed 
the slides in a rack filled with 10mM citrate buffer brought to pH 6.0 using 2M 
NaOH then added 0.25 ml Tween 20. The rack was placed in an antigen 
retrieval machine (Biocare Decloaking Chamber NxGen, California, USA) 
and heated to 95oC for ten minutes. 
Once cooled, JK equilibrated the sections by washing in PBS twice (five 
minutes per wash) then PBS-Tween 20 (0.05%) twice (two minutes per 
wash) before blocking them with 0.5% bovine serum albumin (BSA) and 10% 
normal serum in PBS for one hour at room temperature. He then drained 
excess block and incubated the sections with primary antibodies for Collagen 
type IV to label the vascular basement membrane of blood vessels (Col IV; 
1:1000, 70R-CR013x; Fitzgerald Industries Intl, MA, USA) and -amyloid 
(6E10; 1:1000, SIG-39320; Signet/Covance, Dedham, MA, USA) at 4oC 
overnight in blocking buffer. 
On the next day, JK washed the sections twice in PBS-Tween 20 (0.05%) 
(ten minutes per wash) before incubating them for two hours at room 
temperature in the dark with fluorescent secondary antibodies (Col IV: goat 
anti-rabbit Alexa Fluor 546, Thermofisher; 6E10: goat anti-mouse Alexa Fluor 
488, Thermofisher, both diluted 1:500 in PBS) and 6-CN-flutemetamol 
(courtesy of Dr Milos Ikonomovic, University of Pittsburgh) (1 M solution 
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made with 0.1M KPBS). He then washed the sections twice in PBS (ten 
minutes per wash) and once in Tris Buffer (10 minutes). The sections were 
air-dried at room temperature for ten minutes. He mounted coverslips using 
VECTASHIELD Hardset (VECTOR Laboratories, UK) and sealed the edges 
with nail varnish.  
We imaged the sections using a laser scanning confocal microscope Zeiss 
LSM 710 (Oberkochen, Germany) using 10x and 20x lenses. 
6.3.2 In vivo 18F-flutemetamol MRI-PET studies 
6.3.2.1 Study design and participants 
I prospectively identified incident cases of ICH in NHS Lothian between 1st 
December 2015 and 26th September 2018 (Figure 6.1). I reviewed NHS 
Lothian’s electronic records system twice a week to identify all patients with 
ICH admitted to NHS Lothian stroke units, as well as those seen in 
stroke/TIA clinics. I included consecutive adults aged 40-95 years who had a 
first-ever ICH, were resident in the NHS Lothian Health Board region and 
provided consent. 
 
Figure 6.1 MRI-PET study timeline 
 
APOE = apolipoprotein E. ICH = intracerebral haemorrhage. MRI = magnetic 
resonance imagine. PET = positron emission tomography. 
 
I excluded patients with exclusively extra-axial intracranial haemorrhage, ICH 
secondary to an underlying cause other than SVDs, infratentorial ICH and 
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recurrent ICH. I also excluded patients if they had a contraindication to MRI, 
such as a non-MRI compatible implantable device or metallic foreign bodies 
in the eye, were unable to tolerate MRI-PET scanning because they were 
claustrophobic, unable to transfer independently onto the MRI scanner, 
unable to lie flat, too unwell or unable to fit into the scanner, and those with a 
known diagnosis of dementia. 
6.3.2.2 Baseline data collection 
I collected demographics, the presence of relevant co-morbidities and 
medication use at the time of ICH by interviewing participants and their 
relatives, and reviewing medical records as described in section 2.1.7. 
6.3.2.3 Cognitive assessment 
I used the mini mental state examination (MMSE), Montreal cognitive 
assessment (MoCA) and Addenbrooke’s cognitive examination (ACEIII) to 
assess cognition before the MRI-PET scan because cognitive impairment 
and dementia are associated with -amyloid deposition so they could be 
confounders for amyloid PET uptake associated with ICH location.[306, 307]  
6.3.2.4 Index test 
MRI-PET acquisition 
The Edinburgh Imaging Facility QMRI, The University of Edinburgh, 
performed 18F-flutemetamol brain MRI-PET scans using a hybrid 3T mMR 
Biograph (Siemens Medical Solutions, Erlangen, Germany) around six to 12 
months after the ICH. The Edinburgh Imaging Facility QMRI radiochemistry 
laboratories produced 18F-flutemetamol under good manufacturing practice 
conditions. 
The scan protocol consisted of simultaneous MRI and PET acquisition 
following the intravenous injection of 185MBq 18F-flutemetamol. The first 30-
minute scan started when a 185MBq bolus of 18F-flutemetamol was injected 
via an antecubital vein and included 30 minutes of dynamic PET emission 
scanning in 3D list mode (voxel size 2.3 x 2.3 x 5.0 mm, signal to noise ratio 
1). The following MRI sequences were performed simultaneously: MR 
Attenuation Correction (MRAC), MRAC-Ultrashort TE (UTE), Arterial Spin 
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Labelling (ASL), 3D T1-weighted, T2-weighted and FLAIR sequences, and 
SWI. 
The second 30-minute window started at 90 minutes after 18F-flutemetamol 
injection and included 30 minutes of dynamic PET emission scanning in 3D 
list mode as above plus simultaneous acquisition of the following MRI 
sequences: MRAC, MRAC-UTE, 3D T1-weighted, axial T2-weighted, FLAIR 
and T2*-weighted GRE, and DWI/diffusor tensor imaging (DTI) sequences. 
The MRI sequence parameters are shown in Table 6.1. 
I reconstructed 18F-flutemetamol PET scans with 3D iterative reconstruction 
with three iterations using the MRAC-UTE for attenuation correction. 








Table 6.1 MRI sequence parameters in the MRI-PET study 









Orientation AC-PC SAG SAG AC-PC SAG AC-PC AC-PC AC-PC AC-PC 
TE (ms) 11 2.26 294 117 398 133 20 19.9 81 
TR (ms) 2500 2400 2800 5500 5000 9000 28 620 8300 
TI (ms)  900   1800 2500    
Flip angle 
(degrees) 
90 8  90  130 9 20  
Field of view 
(mm2) 
192 256 250 220 250 220 240 220 250 
Slice thickness 
(mm) 
6 1 1 4 1 4 1.7 4 3 
Slice gap (mm)    0  4  4  
Diffusion 
directions 
        39 
b-value 1 (s/mm2)         0 
b-value 2 (s/mm2)         750 
AC-PC = anterior commissure-posterior commissure. DTI = diffusion-tensor imaging. FLAIR = fluid-attenuated inversion 
recovery. GRE = gradient echo. MRI = magnetic resonance imaging. SAG = sagittal. SWI = susceptibility weighted imaging. 
TE = echo time. TI = inversion time. TR = repetition time. 
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Qualitative flutemetamol PET image analysis (index test) 
Dr Gerard Thompson (consultant neuroradiologist) and I (trainee 
neuroradiologist) independently assessed 18F-flutemetamol uptake on the 
reconstructed and corrected PET images derived from the 90 to 120 minutes 
post-injection interval fused to the participant’s 3D T1-weighted images using 
Syngo Via software (Siemens Medical Solutions, Erlangen, Germany). We 
performed the assessments masked to clinical, CT and MRI features.  
We followed the guidance provided by GE Healthcare for 18F-flutemetamol 
visual assessment for image alignment, colour scales, and windowing, and 
completed the Vizamyl™ (flutemetamol F18) Electronic Training Programme 
before assessing the PET scans.[308]  
We re-aligned scans into standard planes (Figure 6.2) 
 Axial: Perpendicular to the frontal and occipital poles at the level of the 
anterior and posterior corpus callosum in the sagittal plane, and parallel to 
the inferior aspect of the temporal poles in the coronal plane. 
 Coronal: Parallel to the frontal and occipital poles in the sagittal plane and 
perpendicular to the interhemispheric fissure in the axial plane. 
 Sagittal: Parallel to the interhemispheric fissure in both coronal and axial 
planes. 
We used a rainbow-PET colour scale, with the pons as the high-intensity 
reference region set to 90% of maximum (Figure 6.3). We assessed the five 
standard regions (frontal lobe and anterior cingulate, posterior cingulate and 
precuneus, lateral temporal lobe, parietal lobe, and striatum) for flutemetamol 
uptake (Figure 6.4).[308] Also, we assessed uptake in the occipital lobe given 
the presumed posterior predominance of CAA.[27, 252, 262] We rated the 
left and right hemispheres separately. 
As shown in Figure 6.4, we rated the frontal lobe and anterior cingulate, 
lateral temporal, parietal and occipital lobes as positive if there was increased 
cortical uptake, resulting in a convex appearance with loss of the sulcal 
pattern and/or a steep gradient of intensities from the cortex to the 
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subarachnoid CSF. We rated the posterior cingulate and precuneus as 
positive if there was increased cortical uptake. We assessed the striatum as 
positive if there was contiguous increased uptake between the thalamus and 
frontal white matter (loss of the “striatal gap”) (Figure 6.4). We classified each 
region as either positive, negative or equivocal. We classified scans as 
positive overall if there was at least one positive region. Otherwise, we 
classified them as negative. We reviewed any cases where we disagreed 
and came to a consensus decision. I chose a visual assessment of the 
flutemetamol scans to define index test outcome as this reflects clinical 
practice. I used the consensus decision for overall positive/negative to 
determine index test positivity/negativity.  
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Figure 6.2 Realignment of fused 18F-flutemetamol-3D T1-weighted images 
into standard planes 
A-C. Axial, coronal and sagittal planes before realignment. 
D-F. Realigned axial, coronal and sagittal planes. The pink lines show the 
alignment of the axial plane, the purple lines the alignment of the coronal 







Figure 6.3 Scaling of the rainbow-PET colour scale - the pons is set to 90% of maximum. 
 






Figure 6.4 The five standard regions for flutemetamol uptake showing the features in each region required to make a positive 
scan classification. 
Frontal pole and lobe: the lack of a marked sulcal pattern (dotted lines) and/or sharp intensity gradient from grey matter to 
cerebrospinal fluid. Posterior cingulate and precuneus: presence of cortical uptake in the circled region. Lateral temporal lobe: 
heightened uptake throughout and loss of the gyral/sulcal pattern (dotted circles). Parietal lobe: high uptake and decreased 
sulcal pattern within the dotted circles. Striatum: >50% uptake in the dotted region between the thalamus and the frontal lobe 
(axial or sagittal view). Reproduced with permission from [309] 
 
.
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Quantitative flutemetamol PET image analysis 
I performed quantitative analysis of the 90 to 120-minute post-injection 
reconstructed and corrected PET images using PMOD version 3.8 (PMOD 
Technologies LCC, Zurich, Switzerland). 
I spatially normalised the 3D T1-weighted images acquired in the 90-120 
minute scanning window to a T1-weighted Montreal Neurological Institute 
(MNI) brain template. I used the same transformation to normalise the PET 
images to the T1-weighted MNI brain template. I segmented the normalised 
T1 images to produce grey matter, white matter and cerebrospinal fluid 
probability maps.  
I defined standard volumes of interest (VOIs) on the normalised PET images 
using automated anatomical labelling VOIs: frontal lobe, including the insula 
and anterior and mid cingulate gyrus, parietal lobe including the posterior 
cingulate gyrus, temporal lobe, occipital lobe and cerebellar cortex. I used the 
grey matter probability map with a threshold of 75% to restrict the cortical and 
cerebellar VOIs to grey matter. I created a global cortical VOI by summing all 
cerebral cortical VOIs. To avoid bias, I did not include any VOIs affected by 
ICH in this global cortical VOI. I calculated the occipital/global cortex, 
frontal/global cortex and occipital/frontal ratios to assess for an anterior-
posterior CAA gradient, as described in a previous study.[302] 
In my primary analysis I used the cerebellar cortex as the reference region to 
derive regional and global cortical SUVr. Because CAA can affect the 
cerebellum (Figure 4.16 and Figure 4.17), I compared the cerebellar cortical 
SUV between probable CAA and possible CAA or no CAA groups. I also 
manually defined a spherical VOI with a radius of 8mm in the centre of the 
pons on each scan, ensuring the VOI was contained entirely within the pons, 
and repeated the analyses using this as the reference region. 
6.3.2.5 Reference standard 
The ideal reference standard for CAA is a histopathological assessment. 
However, this is rarely performed during life. Instead, I used the modified 
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Boston criteria as the reference standard because they are the current non-
invasive in vivo reference standard for diagnosing CAA.[167]  
I rated the MRI brain scans for the presence of acute ICH and ischaemia, 
chronic ischaemic cortical infarcts, lacunes, chronic haemorrhage and SVD 
biomarkers using the standardised pro forma described in the methods 
chapter (Appendix 2). I used the SWI images to categorise scans as 
probable, possible or no CAA according to the modified Boston criteria.[110] I 
pre-specified the positive reference standard cut off as probable CAA (CAA-
associated ICH) and the negative reference standard cut-off as no CAA or 
possible CAA (non-CAA-associated ICH) as this is the key diagnostic cut-off 
used in clinical practice and in research.[110, 167] 
I performed all assessments masked to clinical and CT features. I performed 
the MRI ratings at least three months after the corresponding flutemetamol 
PET ratings to reduce bias. I performed MRI ratings using Carestream Vue 
PACS version 11.3.2, Carestream Health, Inc, USA. 
6.3.2.6 Statistical analysis 
I compared the frequency of clinical features in participants classified as 
CAA-associated ICH versus not CAA-associated according to the modified 
Boston criteria reference standard using 2 test (or Fisher's exact test, where 
appropriate) for categorical variables and the Mann-Whitney U test for non-
normally distributed continuous variables. 
I assessed inter-rater agreement of PET visual ratings using unweighted 
Cohen’s  coefficient. I evaluated the diagnostic accuracy of visual 
flutemetamol assessment using sensitivity, specificity, likelihood ratios, and 
predictive values and their 95% CI. I compared the regional and global SUVr 
between CAA-associated ICH and not CAA-associated ICH groups using the 
Mann-Whitney U test as the data were non-normally distributed. 
I performed statistical analyses using R statistical package version 3.4.4., 
except for the diagnostic accuracy statistics, for which I used VassarStats 
Clinical Calculator 1.[269] 
  Chapter 6 
234 
6.3.2.7 Missing data 
No data were missing. 
6.3.2.8 Sample size 
No studies have assessed the difference in 18F-flutemetamol binding 
between lobar and deep ICH. Previous studies comparing PiB uptake in 
patients with possible/probable CAA (as defined by the Boston criteria) and 
controls demonstrated statistically significant differences in mean global 
distribution volume ratio (DVR) of 0.14 to 0.16 between patients with 
possible/probable CAA and controls.[252, 299] The standard deviation of 
DVR for cases ranged from 0.06 to 0.2 and 0.1 to 0.29 for controls. 
Using a two-sided, two-sample test with a 5% level of significance, a total 
sample size of 45 and a ratio of 2:1 case: control [i.e. 30 lobar ICH:15 deep 
ICH], the minimum detectable difference in means will be 0.14 at 80% power 
and 0.16 at 90% power. Based on previous studies I expected the common 
standard deviation to be approximately 0.15. Therefore, I expected to have a 
sufficient sample size with 45 participants to identify any real differences 
between the groups. 
6.3.2.9 Regulatory approval 
The MRI-PET study was approved by the Scotland A Research Ethics 
Committee (16/SS/0111). I obtained written informed consent from all 
participants. 
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6.4 Results 
6.4.1 Ex vivo 6-CN-flutemetamol study 
The clinical and histopathological characteristics of the four LINCHPIN brain 
bank participants are described in Table 6.2. 
6-CN-flutemetamol labels both non-vascular -amyloid plaques (Figure 6.5 - 
no CAA and Thal phase 5 case and severe CAA and Thal phase 5 case) and 
perivascular -amyloid (Figure 6.5 – severe CAA and Thal phase 0 case and 
severe CAA and Thal phase 5 case). Both parenchymal and meningeal CAA 
are labelled by 6-CN-flutemetamol (Figure 6.5 - severe CAA and Thal phase 
0 case). There is little non-specific labelling with 6-CN-flutemetamol (Figure 
6.5 – no CAA and Thal phase 0 case).  
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Table 6.2 Clinical and histopathological features of LINCHPIN brain bank 













Age at index ICH (years) 56 53 79 81 
Sex Female Male Female Female 
Co-morbidities     
Hypertension No No Yes No 
Ischaemic stroke No No No No 
Transient ischaemic 
attack 
No No No No 
Dementia No No No No 
Diabetes No No No No 
Atrial fibrillation Yes No No No 
Myocardial infarction No No No No 
Hyperlipidaemia No No No No 
Medications on admission     
Antiplatelet drug(s) No No Yes No 
Anticoagulant drug(s) No No No No 
Antihypertensive drug(s) Yes No Yes No 
APOE genotype 3/3 3/3 2/2 3/4 
ICH details     
Previous ICH No No No No 
Multiple acute ICH Yes Yes No Yes 















Histopathology features     
Parenchymal CAA 
severity 
Absent Absent Severe Severe 
Meningeal CAA severity Absent Absent Severe Severe 
Non-CAA SVD severity Moderate Mild Mild Moderate 
Thal phase 0 5 0 5 
Braak Stage 0 6 0 6 
APOE = Apolipoprotein. CAA = cerebral amyloid angiopathy. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and eurological outcome. SVD = small vessel disease.  
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Figure 6.5 Representative immunofluorescence images for Collagen IV 
(blood vessels), 6E10 (-amyloid) and 6-CN-flutemetamol in the frontal 
convexity in four participants from the LINCHPIN brain bank. 
CN-flutemetamol labels perivascular (parenchymal (white arrowheads) and 
leptomeningeal (white arrows) CAA) and non-vascular -amyloid (white 
dashed arrows). 
 
Scale bar = 100 m. CAA = cerebral amyloid angiopathy. LINCHPIN = 
Lothian intracerebral haemorrhage pathology, imaging and neurological 
outcome.  
  Chapter 6 
238 
6.4.2 In vivo 18F-flutemetamol MRI-PET studies 
6.4.2.1 Participants 
Flow of participants 
I identified 198 patients with spontaneous ICH between 1st December 2015 
and 26th September 2018. Seventy-nine were eligible, of whom I included 20 
in the study (Figure 6.6). This is below the target sample size of 45. The 
predicted versus actual study recruitment is shown in Figure 6.7. 
The median time between ICH and MRI-PET (index test and reference 
standard) was 305 days (IQR 240-350 days, range 190-403 days). 
Baseline clinical characteristics of included participants  
The median age of participants was 71 years (IQR 62-74), and six (30%) 
were female. All participants were independent before the index ICH 
(modified Rankin scale 0 or 1) and presented with small symptomatic ICH 
(median ICH volume 4 cm3, IQR 2-17). Median admission GCS was 15 (IQR 
14-15) (Table 6.3). 
Baseline clinical characteristics associated with probable CAA (CAA-
associated ICH) versus no CAA or possible CAA (non-CAA-associated ICH) 
Seven participants were classified as probable CAA on the modified Boston 
criteria (“CAA-associated ICH”), 12 as no CAA plus one as possible CAA 
(grouped as “non-CAA-associated ICH”) (Table 6.4). 
The CAA-associated ICH group were slightly older (median age 73 versus 
69) and with a higher proportion of females (43% versus 23%) compared with 
non-CAA-associated ICH, although these differences did not reach statistical 
significance. The frequency of co-morbidities and antithrombotic drug use on 







Figure 6.6 Flow of participants through the 18F-flutemetamol PET versus the modified Boston criteria diagnostic test accuracy 
study 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. MRI = magnetic resonance imaging. PET = positron 






Figure 6.7 Target versus achieved recruitment to the 18F-flutemetamol MRI-PET study. 
 
MRI = magnetic resonance imaging. PET = positron emission tomography. 
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Table 6.3 Baseline clinical characteristics of study participants included in the 
in vivo 18F-flutemetamol MRI-PET study 
 All participants (n=20) 










Co-morbidities   
Hypertension 8 (40) 
Ischaemic stroke 3  (15) 
Transient ischaemic attack 0  (0) 
Dementia 0  (0) 
Diabetes 2  (10) 
Atrial fibrillation 1 (5) 
Myocardial infarction 1 (5) 













Pre-ICH modified Rankin scale; 
median (IQR) 
0 (0-0) 
Medications on admission   
Antiplatelet drug(s) 4 (20) 
Anticoagulant drug(s) 1 (5) 
Antihypertensive drug(s) 6 (30) 
Admission GCS; median (IQR) 15 (14-15) 
MMSE; median (IQR) 30 (29-30) 
MOCA; median (IQR) 28 (26-29) 
ACEIII; median (IQR) 96 (94-98) 
Time between ICH and cognitive 
assessment (days); median (IQR) 
245 (185-316) 
Time between ICH and MRI-PET scan 
(days); median (IQR) 
305 (240-350) 
Time between cognitive assessment 
and MRI-PET scan (days); median (IQR) 
41 (11-54) 
ACE = Addenbrooke’s cognitive examination. GCS = Glasgow coma scale. 
ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral 
haemorrhage pathology, imaging and neurological outcome. MMSE = mini 
mental state examination. MoCA = Montreal cognitive assessment. MRI = 







Table 6.4 Modified Boston criteria MRI features in the in vivo 18F-flutemetamol MRI-PET study participants 
ICH 
location 
Multiple ICH CMB count Cortical superficial siderosis Modified 
Boston criteria Lobar Non lobar Presence Location Extent Number of sulci 
Deep No 0 3 No  
  
No CAA 
Deep No 0 0 No  
  
Deep No 0 0 No  
  
Deep No 0 0 No  
  
Deep No 0 0 No  
  
Deep No 0 0 No  
  
Deep No 0 0 No  
  
Deep No 0 0 No  
  
Deep Yes (deep) 0 0 No  
  
Deep No 4 3 No  
  
Deep No 0 0 No  
  
Lobar No 14 1 Yes Adjacent to ICH Focal 1 
Lobar No 0 0 No  
  
Possible CAA 
Lobar No 102 0 Yes Adjacent & distant to ICH Diffuse 10 
Probable CAA 
Lobar No 0 0 Yes Adjacent & distant to ICH Diffuse 10 
Lobar No 0 0 Yes Adjacent to ICH Focal 1 
Lobar No 0 0 Yes Adjacent to ICH Focal 1 
Lobar No 9 0 Yes Adjacent & distant to ICH Focal 3 
Lobar No 241 0 Yes Adjacent & distant to ICH Diffuse 4 
Lobar Yes (lobar) 108 0 No  
  
CAA = cerebral amyloid angiopathy. CMB = cerebral microbleed. ICH = intracerebral haemorrhage. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. MRI = Magnetic resonance imaging. PET = Positron 
emission tomography.
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Table 6.5 Baseline clinical features and cognitive assessment in CAA-
associated versus non-CAA-associated ICH participants classified by the 


























Co-morbidities*      
Hypertension 6  (46) 2 (29) 0.642 
Ischaemic stroke 2  (15) 1 (14) 1.000 
Transient ischaemic attack 0  (0) 0 (0) N/A 
Dementia 0  (0) 0 (0) N/A 
Diabetes 1  (8) 1 (14) 1.000 
Atrial fibrillation 0  (0) 1 (14) 0.350 
Myocardial infarction 0  (0) 1  (14) 0.350 























Pre-ICH modified Rankin scale; 
median (IQR) 
0 (0-0) 0 (0-0) 0.648 
Medications on admission*      
Antiplatelet drug(s) 2 (15) 2  (29) 0.587 
Anticoagulant drug(s) 0 (0) 1  (14) 0.350 
Antihypertensive drug(s) 3 (23) 3  (43) 0.613 
Admission GCS; median (IQR) 15  (15-15) 14 (14-15) 0.086 
MMSE; median (IQR) 30 (29-30) 30 (30-30) 0.850 
MoCA; median (IQR) 28 (27-28) 26 (25-26) 0.064 
ACEIII; median (IQR) 97 (94-98) 95 (93-95) 0.139 
Time between ICH and cognitive 
assessment (days); median (IQR) 
257 (209-318) 209 (181-242) 0.245 
Time between ICH and MRI-PET 
scan (days); median (IQR) 
304  (247-345) 305 (232-345) 0.782 
Time between cognitive 
assessment and MRI-PET scan 
(days); median (IQR) 
30 (0-51) 49 (30-105) 0.088 
* Fisher’s exact test. ACE = Addenbrooke’s cognitive examination. CAA = 
cerebral amyloid angiopathy. GCS = Glasgow coma scale. ICH = intracerebral 
haemorrhage. MMSE = mini mental state examination. MoCA = Montreal 
cognitive assessment. MRI = Magnetic resonance imaging. PET = Positron 
emission tomography.  
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The time between ICH and MRI-PET scan was similar between CAA-
associated and non-CAA-associated ICH groups (median 305 days, IQR 
247-345, versus 304 days, IQR 232-345 respectively). All 20 participants 
tolerated the full MRI-PET scan. There were no reported adverse effects. 
 
Distribution of disease severity between CAA-associated and non-CAA-
associated ICH groups 
The CAA-associated ICH group had significantly more frequent cortical 
superficial siderosis and a higher number of lobar microbleeds than the non-
CAA-associated ICH group as expected (Table 6.6). There was no difference 
in the presence or number of deep or cerebellar microbleeds, or the severity 
of WMH, atrophy or enlarged perivascular spaces between the groups. The 
median MRI CAA SVD burden score was higher in the CAA-associated ICH 
group. 
6.4.2.2 Qualitative flutemetamol PET assessment 
Inter-rater agreement 
Inter-rater agreement of visual evaluation of the flutemetamol PET scans was 
almost perfect for overall positivity ( 0.90, Table 6.7). Agreement for 
standard regions was substantial to perfect for all regions except the right 
parietal lobe, where there was moderate agreement. Agreement for the 
occipital lobe, which is not part of the standard assessment, was the poorest 
( 0.41 to 0.49). 
Index test versus reference standard 
Table 6.8 shows the consensus visual classification of flutemetamol PET 
scans (index test) against the modified Boston criteria classification 
(reference standard). Six of the seven probable CAA cases had a positive 
flutemetamol PET scan resulting in a sensitivity of 86% (95% CI 42% to 99%, 
Figure 6.8 and Figure 6.9). Ten of the 13 participants classified as no CAA or 
possible CAA had a negative flutemetamol PET scan, resulting in a 
specificity of 77% (95% CI 46 to 94%, Figure 6.10 and Figure 6.11, Table 
6.9). 
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The clinical and imaging features of the one false negative and three false 
positive cases are summarised in Figure 6.12 and Figure 6.13 to Figure 6.15 
respectively. 
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Table 6.6 MRI characteristics in participants classified as CAA-associated 
ICH versus non-CAA-associated ICH by the MRI-based modified Boston 





























































Periventricular Fazekas score; 
median (IQR) 
3 (2-4) 4 (2-4) 0.507 
Deep Fazekas score; median (IQR) 2 (2-3) 3 (2-3) 0.614 
Central atrophy; median (IQR) 3 (2-3) 3 (3-5) 0.116 
Cortical atrophy; median (IQR) 1 (1-1) 1 (1-3) 0.144 
Basal ganglia PVS; median (IQR) 1 (1-2) 1 (1-1) 0.276 
Centrum semiovale PVS; median 
(IQR) 
3 (2-3) 2 (2-3) 0.413 
Cortical superficial siderosis* 1 (8) 6  (86) 0.001 
Any lobar CMB* 2 (15) 4 (57) 0.122 
Lobar CMBs; median (IQR) 0 (0-0) 9 (0-104) 0.032 
Any deep CMB* 3 (23) 0 (0) 0.521 
Deep CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.180 
Any cerebellar CMB* 0 (0) 1 (14) 0.350 
Cerebellar CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.173 
Any brainstem CMB* 0 (0) 0 (0) N/A 
Brainstem CMBs; median (IQR) 0 (0-0) 0 (0-0) N/A 
Any  CMB* 3 (25) 4 (57) 0.326 
Total CMBs; median (IQR) 0 (0-1) 9 (0-105) 0.071 
MRI SVD burden score; median 
(IQR) 
2 (1-4) 3 (3-3) 0.683 
MRI CAA SVD burden score; 
median (IQR) 
2 (1-2) 3 (3-6) 0.003 
* Fisher’s exact test. CAA = cerebral amyloid angiopathy. CMB = cerebral 
microbleed. ICH = intracerebral haemorrhage. MRI = Magnetic resonance 
imaging. PET = Positron emission tomography. PVS = perivascular space. 
SVD = small vessel disease.  
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Table 6.7 Inter-rater agreement for visual assessment of 18F-flutemetamol 
PET scans 
Region 
Frequency positive, n (%) Inter-rater 
agreement,  
 (95% CI) 
Rater 1 Rater 2 
Right frontal pole 7 (35) 9 (45) 0.79 (0.70-0.89) 
Left frontal pole 7 (35) 8 (40) 0.89 (0.82-0.96) 
Right posterior cingulate & precuneus 8 (40) 8 (40) 1.00 (1.00-1.00) 
Left posterior cingulate & precuneus 8 (40) 8 (40) 1.00 (1.00-1.00) 
Right lateral temporal lobe 7 (35) 6 (30) 0.66 (0.54-0.78) 
Left lateral temporal lobe 7 (35) 6 (30) 0.89 (0.81-0.96) 
Right parietal lobe 7 (35) 3 (15) 0.49 (0.36-0.63) 
Left parietal lobe 7 (35) 4 (20) 0.63 (0.51-0.76) 
Right striatum 8 (40) 7 (35) 0.89 (0.82-0.96) 
Left striatum 8 (40) 7 (35) 0.89 (0.82-0.96) 
Right occipital 6 (30) 2 (10) 0.41 (0.27-0.56) 
Left occipital 7 (35) 3 (15) 0.49 (0.36-0.63) 
Overall 8  (40) 9 (45) 0.90 (0.70-1.00) 
PET = positron emission tomography 
 
Table 6.8 Cross-tabulations of the consensus visual 18F-flutemetamol PET 





Modified Boston criteria 
(Reference standard) 
 
Probable CAA No/possible CAA Total 
Positive 6 3 9 
Negative 1 10 11 
Total 7 13 20 
MRI = magnetic resonance imaging. PET = positron emission tomography.  
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Table 6.9 Diagnostic test accuracy statistics for the consensus visual 18F-
flutemetamol PET scan classification against the MRI-based modified Boston 
criteria 
 Flutemetamol visual classification 
Sensitivity 86 (42-99) 
Specificity 77 (46-94) 
Positive likelihood ratio 3.7 (1.3-10.5) 
Negative likelihood ratio 0.2 (0.0-1.2) 
Positive predictive value 67 (31-91) 
Negative predictive value 91 (57-100) 
MRI = magnetic resonance imaging. PET = positron emission tomography. 
 
Figure 6.8 True positive 18F-flutemetamol PET scan versus the modified 
Boston criteria 
A. Axial 18F-flutemetamol PET image showing loss of the normal sulcal 
pattern and a sharp intensity gradient from grey matter to cerebrospinal fluid 
in the frontal pole (arrows). 
B. Axial SWI showing a lobar ICH centred in the right frontal lobe (asterisk), 
diffuse cortical superficial siderosis (dashed arrows) and multiple lobar 
microbleeds (arrowheads). Classified as probable CAA on the modified 
Boston criteria. 
 
CAA = cerebral amyloid angiopathy. MRI = magnetic resonance imaging. 
PET = positron emission tomography. SWI = susceptibility-weighted imaging.  
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Figure 6.9 True positive 18F-flutemetamol PET scan versus the modified 
Boston criteria 
A. Axial 18F-flutemetamol PET image showing loss of the normal sulcal pattern 
and a sharp intensity gradient from grey matter to cerebrospinal fluid in the 
frontal pole (arrows) and lateral temporal lobes (arrowheads) plus loss of the 
normal strial gap (chevrons). 
B. Coronal 18F-flutemetamol image PET showing loss of the normal sulcal 
pattern and a sharp intensity gradient from grey matter to cerebrospinal fluid in 
the parietal (dashed arrows) and lateral temporal lobes (arrows). 
C. Axial SWI showing a lobar ICH centred in the left temporal lobe (asterisk) and 
multiple lobar microbleeds (dashed arrows). Classified as probable CAA on the 
modified Boston criteria. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. MRI = 
magnetic resonance imaging. PET = positron emission tomography. SWI = 
susceptibility-weighted imaging.  
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Figure 6.10 True negative 18F-flutemetamol PET scan versus the modified 
Boston criteria 
A - C. Axial, coronal and sagittal 18F-flutemetamol PET images showing the 
normal sulcal pattern and a gradual intensity gradient from grey matter to 
cerebrospinal fluid in the frontal pole (arrows), parietal lobe (arrows) and lateral 
temporal lobes (arrowheads). The normal striatal gap is present (dotted circle). 
D. Axial SWI showing a single deep ICH centred in the right thalamus (dashed 
arrow). There were no microbleeds or cortical superficial siderosis. Classified as 
no CAA on the modified Boston criteria. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. MRI = 
magnetic resonance imaging. PET = positron emission tomography. SWI = 
susceptibility-weighted imaging.  
  Chapter 6 
251 
Figure 6.11 True negative 18F-flutemetamol PET scan versus the modified 
Boston criteria 
A. Axial 18F-flutemetamol PET image showing the normal sulcal pattern and 
a gradual intensity gradient from grey matter to cerebrospinal fluid in the 
frontal pole (arrows) and lateral temporal lobes (dashed arrows). 
B. Axial SWI showing a single lobar ICH centred in the right frontal lobe 
(asterisk). There were no microbleeds or cortical superficial siderosis. 
Classified as possible CAA on the modified Boston criteria. 
 
CAA = cerebral amyloid angiopathy. ICH = intracerebral haemorrhage. MRI = 
magnetic resonance imaging. PET = positron emission tomography. SWI = 
susceptibility-weighted imaging 
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Figure 6.12 False negative 18F-flutemetamol PET scan versus the modified 
Boston criteria 
55 year-old male with first-ever symptomatic ICH. No pre-ICH history of 
hypertension or anthithrombotic drug use. MMSE 30/30, MoCA 29/30, ACE III 
93/100. 
A and B. Axial and coronal 18F-flutemetamol PET images showing the normal 
sulcal pattern and a gradual intensity gradient from grey matter to cerebrospinal 
fluid in the frontal pole (arrows), parietal lobe (dashed arrows) and lateral 
temporal lobes (arrowheads). 
C and D. Axial SWI images showing a single lobar ICH centred in the left 
temporal lobe (asterisk) and focal cortical superficial siderosis but no 
microbleeds. Classified as probable CAA on the modified Boston criteria. 
 
ACE = Addenbrooke’s cognitive examination. CAA = cerebral amyloid 
angiopathy. ICH = intracerebral haemorrhage. MoCA = Montreal cognitive 
assessment. MMSE = mini mental state exam. MRI = magnetic resonance 
imaging. PET = positron emission tomography. SWI = susceptibility-weighted 
imaging.  
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Figure 6.13 False positive 18F-flutemetamol PET scan versus the modified 
Boston criteria 
53 year-old female with first-ever symptomatic ICH. Pre-ICH history of 
hypertension. No pre-ICH anthithrombotic drug use. MMSE 30/30, MoCA 29/30, 
ACE III 100/100. 
A. Axial and coronal 18F-flutemetamol PET images showing loss of the normal 
sulcal pattern and a sharp intensity gradient from grey matter to cerebrospinal 
fluid in the frontal pole (arrows), lateral temporal lobes (arrowheads) and the 
parietal lobes (dashed arrows). 
C. Axial SWI showing a single deep ICH in the right basal ganglia (dashed 
arrow). No microbleeds or cortical superficial siderosis. Classified as no CAA on 
the modified Boston criteria. 
 
ACE = Addenbrooke’s cognitive examination. CAA = cerebral amyloid 
angiopathy. ICH = intracerebral haemorrhage. MoCA = Montreal cognitive 
assessment. MMSE = mini mental state exam. MRI = magnetic resonance 
imaging. PET = positron emission tomography. SWI = susceptibility-weighted 
imaging.  
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Figure 6.14 False positive 18F-flutemetamol PET scan versus the modified 
Boston criteria 
75 year-old male with first-ever symptomatic ICH. Pre-ICH history of 
hypertension. No pre-ICH anthithrombotic drug use. MMSE 29/30, MoCA 30/30, 
ACE III 97/100. 
A and B. Sagittal 18F-flutemetamol PET images showing loss of the normal 
striatal gap (dashed circle) and the presence of cortical uptake in the precuneus 
(arrow). 
C. Axial SWI showing a single deep ICH in the right basal ganglia (dashed 
arrow). No microbleeds or cortical superficial siderosis. Classified as no CAA on 
the modified Boston criteria. 
 
ACE = Addenbrooke’s cognitive examination. CAA = cerebral amyloid 
angiopathy. ICH = intracerebral haemorrhage. MoCA = Montreal cognitive 
assessment. MMSE = mini mental state exam. MRI = magnetic resonance 
imaging. PET = positron emission tomography. SWI = susceptibility-weighted 
imaging.  
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Figure 6.15 False positive 18F-flutemetamol PET scan versus the modified 
Boston criteria 
80 year-old male with first-ever symptomatic ICH. Pre-ICH history of 
hypertension and antiplatelet drug use. MMSE 30/30, MoCA 29/30, ACE III 
97/100. 
A. Axial and coronal 18F-flutemetamol PET images showing loss of the normal 
sulcal pattern and a sharp intensity gradient from grey matter to cerebrospinal 
fluid in the frontal pole (arrows), lateral temporal lobes (arrowheads) and the 
parietal (dashed arrows) lobes. 
C and D. Axial SWI showing a single lobar ICH in the right occipital lobe 
(asterisk). Multiple lobar microbleeds (arrows) and focal cortical superficial 
siderosis (arrowhead). A single deep microbleed is present in the right thalamus 
(dashed arrow). Classified as no CAA on the modified Boston criteria. 
 
ACE = Addenbrooke’s cognitive examination. CAA = cerebral amyloid 
angiopathy. ICH = intracerebral haemorrhage. MoCA = Montreal cognitive 
assessment. MMSE = mini mental state exam. MRI = magnetic resonance 
imaging. PET = positron emission tomography. SWI = susceptibility-weighted 
imaging.  
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6.4.2.3 Quantitative flutemetamol PET analysis 
Comparison of qualitative and quantitative analyses 
We classified nine out of 20 flutemetamol scans as positive by consensus 
visual assessment. The global cortical SUVr in these cases (median 1.68 
[IQR 1.63-1.88]) was significantly higher than those classified as negative 
(median 1.24 [IQR 1.22-1.28], p=0.0001). However, the global cortical SUVr 
overlapped between two positive and three negative cases (SUVr 1.29 to 
1.41) (Figure 6.16). 
 
Figure 6.16 Boxplots showing 18F-flutemetamol consensus visual 
classification against global cortical SUVr 
 
SUVr = standardised uptake value ratio. 
 
Flutemetamol scans are classified as positive on visual assessment if at least 
one cortical region is positive. Therefore, I compared the SUVr of individual 
cortical VOIs between the nine visual positive and the 11 visual negative 
scans (Figure 6.17). The maximum cortical regional SUVr of the scans 
classified as positive by visual rating (median 1.88 [IQR 1.78-2.07; range 
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1.55-2.17]) was significantly higher than those classified as negative (median 
1.31 [IQR 1.28-1.35; range 1.27-1.45], p<0.0001), without any overlap 
(Figure 6.18). 
 
Figure 6.17 Line plots showing global and regional cortical 18F-flutemetamol 
SUVr stratified by consensus visual flutemetamol classification 
 
SUVr = standardised uptake value ratio. 
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Figure 6.18 Boxplots showing 18F-flutemetamol consensus visual 
classification against the maximum cortical SUVr 
 
SUVr = standardised uptake value ratio. 
 
Quantitative flutemetamol PET analysis associated with CAA-associated ICH 
versus non-CAA-associated ICH 
The median global cortical SUVr was higher in CAA-associated ICH than 
non-CAA-associated ICH, although this did not reach statistical significance 
(median 1.63 [IQR 1.33-1.91] versus 1.26 [IQR 1.23-1.41], p=0.097, Figure 
6.19). The maximum regional cortical SUVr in CAA-associated ICH was 
significantly higher than the non-CAA-associated ICH group (median 1.78 
[IQR 1.60-2.08] versus 1.35 [IQR 1.29-1.45] respectively, p = 0.046, Figure 
6.20). The occipital/global cortex ratio was significantly lower in CAA-
associated ICH compared with the non-CAA-associated ICH group (median 
0.95 [IQR 0.91-0.98] versus 1.01 [IQR 0.96-1.01] respectively, p=0.037), 
while there was no difference in the frontal/global cortex ratio between CAA-
associated ICH and non-CAA-associated ICH (median 1.04 [IQR 1.03-1.14] 
versus 1.02 [IQR 1.02-1.06] respectively, p=0.393).  
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Figure 6.19 Boxplots showing modified Boston criteria classification against 
global cortical 18F-flutemetamol SUVr 
 
SUVr = standardised uptake value ratio. 
 
Figure 6.20 Boxplots showing modified Boston criteria classification against 
the maximum cortical SUVr 
 
SUVr = standardised uptake value ratio.  
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There was no difference in cerebellar SUVr using the pons as the reference 
region between the groups (CAA-associated ICH median 0.38 [IQR 0.37-
0.39] versus non-CAA-associated ICH median 0.39 [IQR0.37-0.40], p=0.643) 
(Figure 6.21). Repeating the global and maximum cortical SUVr analyses 
with the pons as the reference region showed similar significance, direction, 
and magnitude to the analyses using the cerebellar cortex as the reference 
region (Figure 6.22 and Figure 6.23). 
 
Figure 6.21 Boxplots showing the cerebellar SUVr using the pons as the 
reference standard stratified by the modified Boston criteria classification 
 
SUVr = standardised uptake value ratio.  
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Figure 6.22 Boxplots showing modified Boston criteria classification against 
global cortical 18F-flutemetamol SUVr using the pons as the reference region 
 
SUVr = standardised uptake value ratio. 
 
Figure 6.23 Boxplots showing modified Boston criteria (reference standard) 
classification against the maximum cortical SUVr using the pons as the 
reference region 
 
SUVr = standardised uptake value ratio.  
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6.5 Discussion 
6.5.1 Main findings 
 6-CN-flutemetamol labels both perivascular (CAA) and non-vascular -
amyloid in ex vivo brain tissue. 
 Overall visual assessment of flutemetamol scans between two trained 
observers was almost perfect ( 0.90). 
 Flutemetamol PET was positive by visual assessment in 6 out of 7 
participants with probable CAA on the modified Boston criteria (“CAA-
associated ICH”), and negative in 10 out of 13 participants with possible 
CAA or no CAA on the modified Boston criteria (“non-CAA-associated 
ICH”), resulting in 86% sensitivity and 77% specificity. 
 Visual assessment of flutemetamol scans correlated with maximum 
cortical SUVr with no overlap between positive and negative visual 
classifications. 
 Global cortical SUVr was higher in CAA-associated ICH versus non-CAA-
associated ICH, although this difference did not reach statistical 
significance. 
 Maximum cortical SUVr was significantly higher in CAA-associated ICH 
versus non-CAA-associated ICH, however there was overlap between the 
groups. 
 
6.5.2 Strengths of the studies 
6.5.2.1 Ex vivo 6-CN-flutemetamol study 
I selected cases from the LINCHPIN brain bank to represent the extremes of 
non-vascular parenchymal and perivascular -amyloid severity, based on 
systematic histopathological assessment using validated scales.[36, 219] We 
prepared and analysed all sections together, using the same reagents and 
parameters to minimise processing variability. We co-stained each section 
with markers for blood vessels (Col IV) and -amyloid (6E10) to allow 
accurate localisation of 6-CN-flutemetamol labelling. 
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6.5.2.2 In vivo 18F-flutemetamol MRI-PET studies 
I performed and reported the 18F-flutemetamol diagnostic accuracy study 
according to the STARD guidelines.[173] Important strengths are: 
 I formulated the study questions and designed the study before 
performing the index test and reference standard.[175] 
 I used prospective case ascertainment to minimise selection bias by 
inviting all potentially eligible patients to the study.[175, 287] 
 I only included participants with first-ever ICH to provide a standard 
inception point. 
 I used an appropriate control group with a similar distribution of vascular 
risk factors, cognition and MRI features of SVDs to the cases. 
 I performed the index test and reference standard during a standard 
timeframe after the index ICH. 
 All participants underwent the same index test and reference standard to 
avoid partial and differential verification biases.[174, 176] 
 I minimised information bias by using a standard MRI-PET acquisition 
protocol for all participants, following manufacturer guidance for 
assessment of the index test, including completing the manufacturer’s 
Electronic Training Programme before assessing PET scans,[308] using a 
validated scale to evaluate the reference standard[110] and masking 
assessors.[175]  
 There were no missing data. 
 I reported the flow of participants through the study, their baseline clinical 
and radiographic features and the distribution of disease severity in the 
study groups to illustrate selection bias.[175, 176] 
 I used an image analysis protocol to standardise the quantitative PET 
analysis, including defining standard VOIs on the normalised PET images 
using automated anatomical labelling.  
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6.5.3 Limitations of the studies 
6.5.3.1 Ex vivo 6-CN-flutemetamol study 
I showed that 6-CN-flutemetamol labels both non-vascular parenchymal and 
perivascular -amyloid when incubated with formalin fixed paraffin embedded 
section for two hours. However, this approach is clearly different to the 
mechanisms involved with in vivo 18F-flutemetamol PET scanning. In 
particular, I was unable to assess the distribution of 18F-flutemetamol from 
the vascular system through the blood-brain barrier into the brain 
parenchyma. However, previous studies have assessed the bio-distribution 
of 18F-flutemetamol and demonstrated that it is rapidly distributed throughout 
the body, including the brain.[310] Also, the sample size I used for this 
exploratory study was small and the cases represented the extremes of non-
vascular parenchymal and perivascular -amyloid. 
6.5.3.2 In vivo 18F-flutemetamol MRI-PET studies 
Despite using a prospective ascertainment approach, there is a substantial 
selection bias. Those included in the study tended to be relatively young, with 
little pre-ICH disability, small ICH volumes and high admission GCS 
compared with the community-based LATCH study of ICH (Table 3.3). This 
bias has implications for the generalisability of the study findings and the 
applicability of flutemetamol MRI-PET in clinical practice. However, studying 
patients with milder ICHs who may have less severe SVDs and who make a 
good functional recovery is clinically relevant, as this group have the most to 
gain from modifying the SVD process and preventing future haemorrhagic 
and vaso-occlusive events. 
The sample size was small. Performing 18F-flutemetamol PET-MR was 
difficult for several reasons. Firstly, the proportion of potentially eligible 
participants I included was low (20/198 = 10.1%). These findings are similar 
to a recent study assessing florbetapir PET in ICH, which included only 
10.7% potentially eligible participants.[303] The other studies of amyloid PET 
in ICH did not describe the flow of participants.[252, 262, 299, 302, 304, 311] 
Over 60% of patients with ICH were excluded, mainly because they died 
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within six months (n=29), had pre-existing dementia (n=15) or a non-MRI 
compatible medical device (n=7). Over 40% of eligible participants were 
unable to tolerate MRI-PET scanning because they could not lie flat, were 
claustrophobic or not independently mobile. These reasons for exclusion are 
similar to the recent florbetapir PET study.[303] 
Secondly, 18F labelled PET tracers, such as flutemetamol, are produced on 
the day of the scan due to their 120-minute half-life. The production process 
has several steps, takes five to six hours and the final tracer has to meet 
strict quality control checks.[312] If there is a problem with flutemetamol 
production, the scan has to be postponed as there is insufficient time to 
remanufacture the tracer. During my study, I had to reschedule a total of 15 
MRI-PET scans for seven participants due to problems with tracer 
production. This equates to a 57% (95% CI 41-72%) success rate for 
flutemetamol production. 
My interim analysis includes less than half the pre-specified sample size and 
increases the risk of a type II error. The lack of power prevented me from 
adjusting the analyses for known confounders of amyloid PET uptake, such 
as age and cognitive impairment. Such analyses are particularly important 
given the slight differences in age and cognition between the CAA-associated 
ICH and non-CAA-associated ICH groups (Table 6.5). 
The emission PET data should be corrected for spurious or missing events. 
In particular correction for the absorption or scatter of -rays by intervening 
tissue is important to allow accurate qualitative and quantitative analysis. A -
ray transmission or low-dose CT scan are usually used to produce an 
attenuation map to correct for -ray attenuation. However, the small bore in 
hybrid MRI/PET systems cannot permit either of these approaches. There 
are several MRI-based attenuation correction approaches, such as template-
based, atlas-based and direct segmentation-based and sequence-based, 
each with its advantages and disadvantages.[313, 314] I chose to use 
MRAC-UTE, a sequence-based approach for two reasons. In brain imaging, 
the bone and air-filled cavities are the most important “tissue” types for 
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attenuation correction.[313] UTE sequences were developed to differentiate 
tissues such as bone and air based on their very short T2 relaxation 
times.[315, 316] I chose not to use template-, atlas- or direct-segmentation 
methods as these are all based on tissue-dependent attenuation coefficients 
derived from reference datasets, which are unlikely to include participants 
with previous ICH. The participants in my study all had a previous ICH, which 
may distort the normal anatomy and alters the attenuation coefficient of brain 
parenchyma. 
The input concentration of the tracer delivered to the tissue of interest should 
be estimated to perform quantitative PET analysis. Arterial blood sampling is 
the most accurate method but is invasive and not commonly performed in 
clinical PET studies.[317] Instead I used the cerebellar cortex as a tissue 
reference region, which is a common approach in the studies of amyloid-PET 
in ICH.[252, 262, 299, 300, 302-304] The ideal reference region is tissue with 
similar tracer kinetic properties to the target tissue (cerebral cortex) with 
negligible specific binding.[317] In Section 4.4.6 I demonstrated that the 
cerebellum is affected by CAA, especially meningeal CAA. The presence of 
CAA in cerebellar cortex could affect SUVr measures. However, I found 
similar results when I repeated the analyses using the pons as the reference 
region, and there was no difference in cerebellar SUVr(pons) between the 
CAA-associated ICH and non-CAA-associated ICH groups. 
The ideal reference standard is systematic histopathological assessment for 
CAA and other SVDs, however, none of the participants had this. Instead, I 
used the MRI-based modified Boston criteria as the reference standard.[110] 
While the modified criteria are considered the in vivo clinical reference 
standard, they have moderate specificity in the development setting, and the 
sensitivity was less than 100%. The performance of the criteria in other 
settings is likely to be worse (Chapter 5). Therefore, their use as a reference 
standard in the study presents challenges for interpreting the diagnostic 
accuracy of flutemetamol PET. Are false negative or positive results due to 
misclassification by the index test or reference standard? 
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The single false negative flutemetamol case was a 55-year male who had no 
history of hypertension and did not take any antithrombotic drugs before his 
ICH. His cognition was normal after ICH. He was classified as probable CAA 
by the reference standard due to a single temporal macrohaemorrhage and 
focal cortical superficial siderosis affecting one sulcus, but no microbleeds. 
One false positive case was an 80-year-old male with a history of 
hypertension who took an antiplatelet agent before the index ICH. His 
cognition was normal. His MRI showed a single occipital macrohaemorrhage, 
focal cortical superficial siderosis, 14 lobar microbleeds. However, the 
presence of a single deep microbleed in the thalamus resulted in 
classification by the reference standard as non-CAA-associated ICH. The 
modified Boston criteria have a lower diagnostic certainty in these 
situations.[243] It is unclear whether the index test or reference standard 
wrongly classified this participant. 
The two other false positive cases both had a history of hypertension, were 
not taking any antithrombotic drugs at the time of ICH and had normal 
cognition after-ICH. They both had a deep ICH affecting the lentiform nucleus 
without cortical superficial siderosis or microbleeds. Given the lack of 
association between deep ICH and CAA,[27, 28, 153] their positive 
flutemetamol PET results are likely to reflect the background rate of 9-35% 
flutemetamol positivity in cognitively normal older adults.[318, 319] This 
presumably indicates asymptomatic Alzheimer’s disease or incidental CAA. 
6.5.4 Comparison with other studies 
6.5.4.1 Ex vivo 6-CN-flutemetamol study 
Previous in vitro experiments have shown that flutemetamol binds to fibrillary 
 amyloid in human Alzheimer brain homogenate assays and that 6-CN-
flutemetamol binding correlates significantly with fibrillary amyloid in 
human autopsy brain tissue samples.[310] Clinical studies have shown that 
cortical uptake of 18F-flutemetamol on PET correlates with the percent of 
biopsy specimen area staining for fibrillary amyloid in patients with normal 
pressure hydrocephalus.[320] A study of 106 end-of-life participants showed 
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that in vivo 18F-flutemetamol PET can identify fibrillary -amyloid identified on 
autopsy histopathology.[321]  
The binding of Thioflavin-T derivatives, such as flutemetamol, is not specific 
to -amyloid fibrils, and can also bind to insoluble -amyloid such as CAA 
and diffuse plaques.[322, 323] No previous study has directly assessed 
flutemetamol binding to CAA in ICH. In the study of 106 end-of-life 
participants undergoing in vivo 18F-flutemetamol PET and subsequent 
autopsy, three participants had CAA in the absence of Alzheimer’s disease 
on histopathological assessment. However, two had a negative in vivo 18F-
flutemetamol PET, one of whom had minimal and focal CAA. The authors 
stated that no firm conclusion relating to the contribution of CAA to 18F-
flutemetamol PET uptake could be made due to the small numbers. 
However, they did show indirect evidence that CAA may contribute to cortical 
18F-flutemetamol retention in several cases with a positive 18F-flutemetamol 
PET scan and borderline low levels of non-vascular -amyloid but associated 
CAA.[321, 324] In my studies, I showed clear evidence that 6-CN-
flutemetamol labels both non-vascular -amyloid as well as perivascular -
amyloid (CAA). 
6.5.4.2 In vivo 18F-flutemetamol MRI-PET studies 
Visual 18F-flutemetamol PET assessment 
The overall agreement between the two raters was almost perfect ( = 0.90). 
The one discrepancy was rated positive (based on a single positive right 
frontal/anterior cingulate region) by one rater but negative by the other. 
The raters had different levels of neuroradiology experience; I am a radiology 
trainee with an interest in neuroradiology while Dr Thompson is a consultant 
neuroradiologist. We both underwent the Vizamyl™ Electronic Training 
Programme before assessing PET scans, but neither of us had clinical 
experience reporting flutemetamol PET images. 
This high level of inter-rater agreement is similar to a previous study 
validating the Vizamyl™ Electronic Training Programme.[309] This study 
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assessed the reliability of flutemetamol visual assessment by newly trained 
readers using the electronic training programme. The study participants 
included healthy volunteers and those with varying degrees of cognitive 
decline. Inter-rater agreement was very high with most  scores more than 
0.8. Amyloid PET inter-rater agreement may be different in participants with 
structurally abnormal and asymmetric brains, such as those with ICH. 
However, my results are similar to the two recent studies assessing 
florbetapir in ICH, which both showed perfect agreement for visual 
rating.[303, 304] 
Flutemetamol scans are classified visually as positive if a single region is 
deemed positive. This correlates with the finding that overall visual 
flutemetamol assessments correlated better with the maximal regional SUVr 
than global cortical SUVr (Figure 6.16 to Figure 6.18). 
The high inter-rater agreement, coupled with perfect discrimination of visual 
assessment by maximal regional SUVr indicate that visual rating is a reliable 
and accurate approach for assessing flutemetamol PET scans in ICH. 
Therefore quantitative analysis may not be necessary for clinical practice. 
Diagnostic accuracy of 18F-flutemetamol PET in ICH 
The sensitivity of flutemetamol scans rated by visual assessment for 
probable CAA was 86% (95%CI 42-99). A negative flutemetamol PET scan 
had a high negative predictive value (91%) and low negative likelihood ratio 
(0.2), and can effectively rule out advanced CAA.[325] In contrast, a positive 
scan has moderate specificity 77% (95%CI 46-94), with a positive predictive 
value of 67% and positive likelihood ratio of 3.7. A positive flutemetamol scan 
could indicate advanced CAA, Alzheimer’s disease or both given the non-
specific -amyloid binding. These estimates are similar to the two recent 
studies assessing florbetapir for CAA in ICH (pooled sensitivity 90% [95%CI 
76-100], specificity 88% [95%CI 74-100]).[326] 
Quantitative 18F-flutemetamol uptake in ICH 
Previous studies have consistently shown increased global cortical amyloid 
uptake in CAA-associated ICH versus deep ICH controls.[303, 304, 311] In 
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my study, global cortical SUVr was higher in the CAA-associated ICH group 
versus the non-CAA-associated ICH group, although this did not reach 
statistical significance. This may be because the study is currently 
underpowered, with only 20 out of the pre-specified 45 sample size included 
or could reflect misclassifications of the lobar ICH cases by the reference 
standard as described in 6.5.3.2. 
Global cortical SUVr provides a composite measure of flutemetamol uptake, 
but one can argue that the maximum SUVr is what matters. For example, 
severe CAA in one region is theoretically sufficient to result in CAA-
associated ICH even if globally the burden of CAA is less severe. In line with 
this, the maximal cortical SUVr in CAA-associated ICH was significantly 
higher than the non-CAA-associated ICH group. 
The significantly reduced occipital/global ratio may be a spurious finding 
given that a meta-analysis of other amyloid PET studies comparing CAA-
associated ICH against deep ICH did not demonstrate a similar 
association,[327] and this type of regional CAA gradient was not 
demonstrated in the LINCHPIN brain bank (4.4.6). 
6.5.5 Future directions 
6.5.5.1 Ex vivo 6-CN-flutemetamol study 
My findings need to be replicated in a larger sample. Also, I used participants 
with absent or severe -amyloid to assess 6-CN-flutemetamol labelling. 
Repeating the analyses with tissue from participants with a range of CAA and 
parenchymal -amyloid severity will be important to assess whether 6-CN-
flutemetamol can label less severe CAA. The extent of 6-CN-flutemetamol 
labelling in cases of differing CAA severity could be quantified by measuring 
the fluorescence intensity. 
6.5.5.2 In vivo 18F-flutemetamol MRI-PET studies 
Although this is an interim analysis of a diagnostic test accuracy study, the 
findings show the potential diagnostic value of flutemetamol PET in ICH. It is 
important to continue the study recruitment to reach the pre-specified sample 
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size. This will allow refinement of the diagnostic test statistics and permit 
multivariable analysis of SUVr between CAA-associated lobar ICH versus 
non-CAA-associated ICH groups with adjustment for important confounders, 
such as age and cognitive status. Finally, there may be sufficient numbers to 
allow comparison of global cortical SUVr between probable CAA, possible 
CAA and no CAA categories. 
The use of the modified Boston criteria is a pragmatic reference standard in 
this type of study. However, it will result in misclassification. Assessing 
amyloid PET uptake against a histopathological reference standard will be a 
crucial step to determine its true diagnostic accuracy. Currently, 14 of the 20 
participants have consented to a research brain autopsy in the event of their 
death. Comparing the in vivo flutemetamol PET to the severity and 
distribution of CAA at autopsy and ex vivo flutemetamol binding will be 
necessary. There are however challenges to this approach. All the 
participants recruited to the study were mildly affected by ICH. The time 
between the index test and autopsy reference standard is therefore likely to 
be long, and it may be difficult to relate the histopathological changes to the 
index test. Brain biopsy may, therefore, be a more appropriate source of 
tissue for future studies of amyloid PET, but it is invasive, infrequently 
performed and at risk of sampling errors.[164] 
Future studies should focus on assessing the value of amyloid PET in clinical 
practice. A diagnostic accuracy study of the modified Boston MRI criteria, 
Edinburgh CT-based criteria (Chapter 7) and amyloid PET against a 
histopathological reference standard is needed to establish the role of these 
different imaging approaches for diagnosing CAA. It will be important to 
include ICH participants with a range of pre- and post-ICH disability to 
evaluate the generalisability of amyloid PET in clinical practice. 
One of the limitations of current amyloid PET tracers for clinical practice is 
the lack of molecular specificity, binding with high affinity to both perivascular 
and non-vascular β-amyloid.[171, 172] This means a positive scan may 
relate to Alzheimer’s disease, CAA or a combination of the two. Being able to 
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differentiate CAA from Alzheimer’s pathology is vital to improve the specificity 
of PET in ICH. This cannot be reliably achieved using the distribution of 
amyloid PET uptake.[327] Research is ongoing to develop a PET tracer 
which is selective for CAA.[328] Assessment of such a tracer in ICH would be 
an important further step. 
One of the key questions of amyloid PET is whether it can diagnose CAA at 
an early stage before any haemorrhagic consequences have developed. 
Longitudinal studies with repeat amyloid PET and MRI scanning will be 
required to answer this. There are longitudinal amyloid PET studies, such as 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI),[329] which include 
repeat amyloid PET and MRI scanning in cognitively normal participants. 
However, the prevalence of severe CAA in non-demented persons aged 70-
79 years was only 3% in one community-based neuropathological study,[233] 
meaning very large sample sizes and long follow up will be required to 
assess this. An alternative approach would be to study hereditary CAA. In 
contrast to sporadic CAA, hereditary CAA usually occurs at a young age in 
selected families carrying specific mutations which are inherited in an 
autosomal dominant fashion.[18] Amyloid PET and MRI in pre-symptomatic 
mutation carriers and non-mutation carriers, with longitudinal follow-up for the 
development of haemorrhagic consequences of CAA, would be feasible in 
this setting. 
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Chapter 7 The Edinburgh CT and genetic criteria for 
lobar ICH associated with CAA: model 




The MRI-based modified Boston criteria are the current non-invasive in vivo 
reference standard for diagnosing CAA and are commonly used in clinical 
practice.[110, 167] However, patient contraindications to MRI coupled with 
limited access to MRI scanners in many parts of the world restrict the 
usefulness of these criteria in ICH. Similarly, the limited availability of PET 
scanning restricts the value of -amyloid PET for diagnosing CAA-associated 
ICH in clinical practice. More easily obtained tests for diagnosing CAA-
associated ICH are required. 
Non-contrast brain CT is the most widely available neuroimaging modality 
and usually the first test to diagnose ICH (Figure 3.1). A recent systematic 
review identified certain imaging features on brain CT, such as subarachnoid 
haemorrhage and an irregular, lobulated ICH border, are frequently identified 
in patients with pathologically proven CAA-associated ICH (Section 
1.3.4.1).[166] APOE genotyping can be performed using a peripheral blood 
sample, making it potentially widely available. The presence of an APOE 4 
allele is the strongest genetic association with pathologically proven sporadic 
CAA, showing a dose-dependent association.[24, 25] 
Non-contrast brain CT and APOE genotype may therefore be useful for 
diagnosing CAA-associated lobar ICH, however their diagnostic accuracy is 
unknown. 
In this chapter I describe the development and internal validation of 
multivariable diagnostic prediction models for identifying CAA-associated 
lobar ICH using CT brain features with and without APOE genotype, and the 
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diagnostic accuracy of simple diagnostic criteria derived from these models. I 
helped conceive the study design and collect the data. I analysed and 
interpreted the data and drafted the manuscript. 
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7.2 Conclusion 
The CT-only and CT-APOE diagnostic prediction models showed excellent 
discrimination and were well calibrated for CAA-associated lobar ICH. The 
related Edinburgh criteria were able to accurately rule in or rule out CAA-
associated lobar ICH. These diagnostic models and simple diagnostic criteria 
may be useful in routine clinical practice for diagnosing or ruling out CAA-
associated lobar ICH, however their accuracy needs to be assessed in large, 
rigorous external validation studies. 
There were no participants in the development study with finger-like 
projections but absent subarachnoid haemorrhage. Based on the logistic 
regression models, this combination of features is classified as intermediate 
CAA probability. However, I was unable to assess the models’ calibration for 
this potential group. The diagnostic accuracy of the Edinburgh criteria for this 
combination of predictors should be assessed in larger external validation 
studies. 
I did not include an age cut-off as part of the Edinburgh criteria, as age was 
similar between participants with absent or mild CAA (median 84 years; IQR 
78-88) and those with moderate or severe CAA (median 82 years; IQR 79-
85). However, CAA is an age-related condition and unlikely to occur in those 
younger than 50 years. Indeed, although I included all adults with first-ever 
spontaneous lobar ICH in my development study, the youngest participant 
with lobar ICH was 56 years, and the youngest with CAA-associated lobar 
ICH was 67 years. The validity of the Edinburgh criteria in lobar ICH patients 
younger than this is unclear, and should be specifically addressed in external 
validation studies. 
Reliable implementation of diagnostic criteria is a key determinate of their 
clinical utility. In this development study there was moderate inter-rater 
agreement for finger-like projections and good agreement for subarachnoid 
haemorrhage. To improve the inter-rate agreement for these key imaging 
features, I have developed a series of online training materials for 
implementing the Edinburgh criteria.[330] These training materials are 
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available to any clinician or researcher. They include a series of test cases, 
which will allow me to assess the inter-rater agreement of the Edinburgh 
criteria across a wide range of raters of differing background and experience. 
The prognostic value of the Edinburgh criteria, for the risk of recurrent ICH 
and the development of post-stroke dementia in ICH survivors will also be 
important to assess. 
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Chapter 8 External validation studies of the 
Edinburgh CT-only and CT-APOE 
diagnostic models and criteria for CAA-
associated lobar ICH 
 
8.1 Introduction 
The diagnostic models for CAA-associated lobar ICH which I have developed 
using non-contrast CT brain features, and APOE 4 genotype when 
available, showed excellent discrimination and good calibration in the 
development setting.[229] The models had little optimism after internal 
validation, confirming their reproducibility and validity in the development 
setting. The related Edinburgh diagnostic criteria were able to rule out or rule 
in CAA. However, external validation is required to determine whether the 
diagnostic models and criteria are reliable in other settings.[331] 
External validation is the process of evaluating prediction models in datasets 
not used in model development.[331] External validation can be temporal 
(more recently affected individuals from the same geographical location as 
the development cohort), geographic (individuals from geographically distinct 
areas compared with the development cohort) or mixed. It permits the 
assessment of model performance in new individuals, allowing more 
accurate quantification of model optimism. Also, the use of plausibly similar 
individuals from other geographical regions and with different disease 
severity (different case-mix) allows the generalisability of the model to be 
determined. 
The diagnostic models I have developed used participants from the NHS 
Lothian Health Board region of Scotland who had died after ICH and who 
underwent a research autopsy. As a result, the participants tended to be 
white British. Also, they were older, had larger ICHs, more advanced CT SVD 
biomarkers, and usually died soon after their ICH compared with those not 
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included in the study.[229] Therefore external validation in other geographic 




I aimed to perform international, multi-centre external validation studies of the 
Edinburgh CT-only and CT and APOE diagnostic models for CAA-associated 
lobar ICH, and assess the diagnostic accuracy of the related Edinburgh 
criteria against a histopathological reference standard. I wanted to include 
participants from different geographic regions to assess the generalisability. 
Also, I aimed to allow brain biopsy, as well as autopsy, as the 
histopathological reference standard to determine whether the models and 
criteria are valid in less severe ICH. 
 
8.3 Methods 
I performed an international, multicentre external validation study of the 
Edinburgh diagnostic models and criteria according to a pre-specified study 
protocols (Appendix 3). I performed and reported the study according to the 
TRIPOD and STARD guidelines.[173, 332] 
8.3.1 Sources of data 
I identified potential collaborators using two approaches. 
Firstly, I contacted the International CAA Association, which is coordinating 
an update study of the modified Boston criteria. Through this, they have 
identified research groups with imaging and subsequent histopathology for 
CAA in spontaneous ICH. Dr Andreas Charidimou, who is coordinating this 
project, reviewed all groups invited to join the Boston criteria update study 
against the eligibility criteria in my study protocol (Section 8.3.2 and Appendix 
3). He identified 14 groups with potentially relevant data for my study. 
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Secondly, I used our recent systematic review of the imaging features of 
CAA-associated ICH to identify groups who had published studies comparing 
CT imaging against histopathological assessment of CAA in ICH.[166] I re-
ran the search strategy from this systematic review on 01/06/2018 to identify 
relevant new studies and abstracts. I reviewed all the papers and abstracts 
according to the eligibility criteria (Section 8.3.2 and Appendix 3) and 
identified 11 groups with potentially relevant data.  
Six groups were identified by both the International CAA Association and by 
my systematic review (Edinburgh, Boston, Lille, Calgary, Porto and 
Kanazawa). Therefore in total, I identified 19 individual research groups with 
potentially relevant data. 
In June 2018, I emailed the corresponding author from all 19 individual 
research groups inviting them to collaborate in this study (Appendix 4). I sent 
a reminder email in August 2018 to those who had not replied to my initial 
invitation. Twelve groups responded to my email invitation. Nine (47% of the 
studies) were able to contribute data from their cohorts (Table 8.1), five of 
which were identified by the International CAA Association and four by both 
the International CAA Association and my systematic review. 
8.3.2 Study design and participants 
I included data from all nine cohorts. Details of the study design, study setting 
and location of the centres are included in Table 8.1. The study design varied 
between collaborating centres, although most were hospital-based case-













































































































































































































































APOE = apolipoprotein E. CT = computed tomography
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I included adult patients (aged ≥16 years) with a first-ever lobar ICH 
diagnosed by non-contrast brain CT who had a subsequent histopathological 
assessment for CAA. 
I defined lobar ICH as described in Section 2.1.5.[190] 
I excluded patients with exclusively extra-axial intracranial haemorrhage, 
non-lobar ICH, ICH secondary to an underlying cause other than SVDs, and 
those without diagnostic quality non-contrast brain CT and histopathological 
samples for CAA assessment. 
These inclusion and exclusion criteria were the same as those I used for 
developing the Edinburgh diagnostic criteria.[229] 
In addition to the above, I excluded all participants included in the 
development of the Edinburgh diagnostic criteria (i.e. Edinburgh LINCHPIN 
cohort with ICH onset date between 1st June 2010 and 10th February 
2016).[229] 
For the external validation of the CT and genetic model and criteria, I 
excluded all cases without APOE genotyping. 
8.3.3 Baseline data collection 
Collaborators collected demographics, the presence of relevant co-
morbidities and medication use at the time of ICH by interviewing patients 
and/or reviewing medical records (Appendix 3). 
8.3.4 Index tests 
I reformatted non-contrast brain CT volume datasets into standard axial, 
coronal and sagittal planes as described in Section 2.2.1.2.[229] I assessed 
all available brain CT planes. When a volume dataset was not available, I 
reviewed the axial plane acquisition. 
I assessed the presence, number and location of acute ICH. I calculated the 
volume of the largest ICH using a modified ABC/2 approach as described in 
Section 2.2.1.3.[191] I rated the presence or absence of extra-axial 
haemorrhage (subarachnoid, subdural or intra-ventricular spaces) and finger-
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like projections arising from the largest haematoma. I defined finger-like 
projections in the same way as I did in the development study as elongated 
extensions arising from the haematoma, longer than they are wide, 
regardless of whether they extended to the cortex or not.[229] I rated finger-
like projections from the largest ICH if multiple acute ICHs were present on 
the CT scan. 
I developed and undertook online training materials for implementing the 
Edinburgh criteria before assessing the brain CT images.[330] I performed 
brain CT assessments masked to clinical, genetic and pathological data. 
Collaborators performed APOE genotyping on DNA extracted from peripheral 
blood or brain tissue using standard techniques, masked to radiological, 
clinical and pathological data. I defined APOE 2 and APOE 4 possession if 
a participant had at least one 2 or 4 allele respectively, as described in 
Chapter 7.[229]  
I used the same definitions for predictors (subarachnoid haemorrhage, finger-
like projections and APOE 4 possession) as I did during the development of 
the criteria. 
8.3.5 Reference standard 
The outcome of interest was CAA-associated lobar ICH defined by 
histopathological assessment of brain biopsy or autopsy material using 
Congo red and/or -amyloid immunohistochemistry. I defined CAA-
associated lobar ICH when the severity of CAA in any tissue sample was ≥2 
on the Vonsattel scale.[253]  
The sources of tissue and reference standard definition differed from the 
approach I took in the development of the Edinburgh diagnostic models and 
criteria. 
In the development study, I restricted the reference standard to research 
autopsy. In this external validation study, I included both brain biopsy and 
autopsy as sources of pathological tissue. I did this because I wanted to 
assess if the Edinburgh diagnostic models and criteria were applicable in a 
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wider range of ICH severity, rather than predominantly acutely fatal ICH 
which I used in the development study. While brain biopsy may be more 
prone to sampling error in comparison to autopsy, I have shown in Section 
4.4.4 that simulated brain biopsies from the lobe affected by ICH have 
excellent sensitivity and good specificity for global CAA severity identified on 
full autopsy. These results are similar to a previously published simulated 
biopsy study.[164] 
In the development study, a single neuropathologist assessed CAA severity. 
In line with the International CAA Association’s external validation and update 
of the modified Boston criteria, the histopathological reference standard in 
this external validation study was assessed locally by experienced 
neuropathologists. Sending pathological tissue to a central centre for rating 
by a single neuropathologist was not practical for logistical and regulatory 
approval reasons in this multi-centre study. 
In the development study, the CAA severity was assessed using a 
consensus scale.[36] In this external validation study, the severity of CAA 
was evaluated using the Vonsattel scale[253] for two reasons. Firstly, the 
Vonsattel scale was used as the reference standard in the update of the 
modified Boston criteria study. Many of the centres involved in that study 
were included in this external validation study. Therefore, I wanted to 
harmonise reference standards to minimise additional workload for 
collaborators. Secondly, the Vonsattel scale has been in use for over 25 
years, making it familiar to many neuropathologists. 
I chose a cut-off of ≥2 on the Vonsattal scale (complete replacement of the 
media by -amyloid) to define CAA-associated ICH as this definition is the 
closest to the cut off I used on the CAA consensus scale during the 
development study (some circumferential -amyloid), and resulted in the best 
sensitivity and specificity against the consensus scale ratings (Section 
4.4.4).[36] 
The histopathological assessments were performed masked to CT, clinical 
and genetic data.  
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8.3.6 Sample size 
I did not perform a formal sample size calculation as there is no generally 
accepted approach for this in validation studies.[333] General guidance is to 
include at least 100 cases and 100 controls to be able to detect modest 
changes in model performance measures.[334, 335] I included all available 
data from the collaborators I had identified through the International CAA 
association and through systematically reviewing the literature to maximise 
power. 
8.3.7 Missing data 
I excluded any cases with missing predictors as specified in the study 
protocol. It is difficult to assess the presence of subarachnoid haemorrhage 
or finger-like projections if an acute ICH is not visible on the diagnostic CT 
scan. I did not think it was appropriate to impute these data as they form the 
main predictors in the diagnostic models. Similarly, APOE 4 is one of only 
three predictors in the CT and genetic diagnostic model, so I decided not to 
impute the missing values. All cases had the reference standard available. 
8.3.8 Statistical analysis 
I compared the frequency of clinical, genetic, and CT characteristics in 
participants with and without CAA-associated lobar ICH according to the 
reference standard using 2 test (or Fisher's exact test, where appropriate) 
for categorical variables and the Mann-Whitney U test for non-normally 
distributed continuous variables.  
To assess the performance of the Edinburgh diagnostic models, I first 
calculated the risk score of moderate/severe CAA using the regression 
equations for the CT-only and CT and APOE models (Chapter 7, [229]) as 
follows: 
CT-only model risk score = 1·71 x subarachnoid haemorrhage + 2·89 
x finger-like projections -1·24 
CT and APOE model risk score = 3.11 x APO4 possession + 2.31 x 
subarachnoid haemorrhage + 3.20 x finger-like projections -2.55 
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The predictor values are one when present and zero when absent. 
I then calculated the predicted probability of moderate/severe CAA using the 
following formula: 
Predicted probability = 1/(1 + exp- risk score) 
I evaluated model calibration using calibration plots to assess the agreement 
between the model predicted and the observed frequency of CAA-associated 
ICH and calculated the intercept and the calibration slope. The intercept 
relates to calibration-in-the-large (a comparison of the mean of all predicted 
risks and the mean observed risk).[336] The calibration slope is related to 
shrinkage of regression coefficients during model development. A perfectly 
calibrated model will have an intercept of 0 and a calibration slope of 1. 
Miscalibration results in an intercept either above or below 0 and a calibration 
slope less than 1. I evaluated model discrimination using ROC curves and 
quantified the performance of the models using the concordance (c) statistic. 
I assessed the net benefit of the model using decision curve analysis.[337] 
To determine the performance of the Edinburgh diagnostic criteria I classified 
participants as low, intermediate or high risk of CAA-associated lobar ICH 
using the cut-offs defined in the development study (Chapter 7).[229] I then 
assessed diagnostic accuracy statistics (sensitivity, specificity, likelihood 
ratios and predictive values) between low versus intermediate/high risk (rule 
out criteria) and high versus low/intermediate risk groups (rule in criteria). 
I performed a pre-specified sensitivity analysis of the CT-only diagnostic 
model and criteria’s performance stratifying the reference standard according 
to the source of tissue (brain biopsy versus autopsy) given the differing 
sensitivity and specificity of these approaches for CAA (Section 4.4.4).[164] I 
also performed an exploratory sensitivity analysis by stratifying participants 
by ICH volume (less than median ICH volume (56 ml) versus greater than or 
equal to the median ICH volume) and time between diagnostic CT and tissue 
sampling based on my review of false negative cases. 
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I did not perform sensitivity analyses of the CT and APOE diagnostic model 
and criteria due to the small sample size in this part of the study. 
 
8.4 Results 
8.4.1 External validation of the Edinburgh CT-only diagnostic model 
and criteria 
8.4.1.1 Flow of participants 
There were 164 potentially eligible participants identified by the nine 
collaborating groups. After unavoidable exclusions, I included 146 (Figure 
8.1). 
8.4.1.2 Comparison of participants included in the external validation 
study with those in the development study 
Participants in the external validation cohort were younger compared with 
those in the development cohort (Table 8.2). Pre-ICH history of ischaemic 
stroke and of atrial fibrillation were less common in the external validation 
cohort than in the development cohort, whilst hyperlipidaemia was more 
common in the external validation cohort. The frequency of other 
comorbidities was similar between the cohorts. Fewer participants in the 
external validation cohort were taking an antiplatelet drug at the time of ICH. 
Admission GCS and ICH volume were similar between the external validation 
and development cohorts (Table 8.3). 
Subarachnoid haemorrhage and finger-like projections were more frequent in 
the external validation cohort than the development cohort (Table 8.3). 
All participants in the development study had died, whereas 45% of those in 
the external validation study were still alive. 
Autopsy was used as the reference standard for 34% of the external 
validation cohort compared with all participants in the development cohort. 
Overall, the median time between diagnostic CT and tissue sampling was 
shorter in the external validation cohort (3 days, IQR 0-13, range 0-2601) 
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compared with the development cohort (11 days, IQR 6-136, range 1-999). 
For those undergoing autopsy in the external validation study, the median 
time between diagnostic CT and tissue sampling was 12 days (IQR 5-516, 
range 0-2601). Sixty six percent of the external validation cohort were 
classified as CAA-associated lobar ICH by the reference standard compared 
with 58% in the development study. 
8.4.1.3 Baseline clinical and diagnostic CT brain characteristics in the 
external validation study of CAA-associated versus non-CAA-
associated lobar ICH on histopathology 
Ninety seven (66%) participants were classified as CAA-associated lobar ICH 
and 49 (34%) as non-CAA-associated lobar ICH. Pre-ICH dementia was 
more common in the CAA-associated lobar ICH group, although this did not 
reach statistical significance (Table 8.4). Non-CAA-associated lobar ICH 
participants were more likely to have a pre-ICH history of hypertension. 
Participants with CAA-associated lobar ICH were more likely to have 
subarachnoid haemorrhage and finger-like projections as well as more 







Figure 8.1 Flow of participants through the Edinburgh CT only CAA criteria external validation study 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. Edinburgh CT-only CAA criteria: Low risk = no 
subarachnoid haemorrhage or finger-like projections; Intermediate risk = subarachnoid haemorrhage or finger-like projections; High risk = subarachnoid 
haemorrhage and finger-like projections
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Table 8.2 Baseline clinical characteristics of the Edinburgh CT criteria 
development versus external validation cohorts 





























































































































































Time between ICH and diagnostic CT 
























Time between diagnostic CT scan and 
tissue (days); median (IQR) 
11 (6-136) 3 (0-13) 
CAA-associated lobar ICH 36 (58) 97 (66) 
Death 62 (100) 80 (55) 
Data are n (%) or median (IQR). * Relates to the largest ICH. APOE = 
Apolipoprotein. CAA = cerebral amyloid angiopathy .CT = computed tomography. 
GCS = Glasgow coma scale. ICH = intracerebral haemorrhage.  
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Table 8.3 Non-contrast diagnostic brain CT characteristics in the Edinburgh 




































ICH volume (ml)*; median 
(IQR) 
60 (20-118) 56 (33-86) 
Strictly lobar ICH 58 (94) 137  (94) 
Intraventricular 
haemorrhage 
31 (50) 55 (38) 
Subarachnoid haemorrhage 43 (69) 118 (81) 
Subdural haemorrhage 12 (19) 37  (25) 
Finger-like projections* 14 (23) 61 (42) 


















































































Data are n (%) or median (IQR). * Relates to the largest ICH. CT = computed 
tomography. ICH = intracerebral haemorrhage.  
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Table 8.4 Baseline clinical and non-contrast diagnostic brain CT 
characteristics in external validation study participants classified as CAA-







lobar ICH (n=97) 
p value 


















Co-morbidities      
Hypertension 37 (77) 53 (55) 0.011 
Ischaemic stroke 7 (14) 8 (8) 0.275 
Transient ischaemic attack^ 1 (2) 8 (9) 0.272 
Dementia 3 (9) 21 (24) 0.064 
Diabetes 7 (15) 11 (12) 0.609 
Atrial Fibrillation 7 (15) 16 (17) 0.747 























Medications on admission      
Antiplatelet drug(s) 15 (31) 28 (30) 0.827 
Anticoagulant drug(s) 13 (27) 15 (16) 0.101 
Admission GCS; median (IQR) 13 (8-15) 12 (8-15) 0.437 
Time between ICH and 




























Time between diagnostic CT 












Death 14 (29) 66 (68) <0.001 
Data are n (%) or median (IQR). *Relates to the largest ICH. ^Fisher’s exact 
test. CAA = cerebral amyloid angiopathy .CT = computed tomography. GCS 
= Glasgow coma scale. ICH = intracerebral haemorrhage.  
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Table 8.5 Non-contrast diagnostic brain CT characteristics in external 
validation study participants classified as CAA-associated versus non-CAA-






lobar ICH (n=97) 
p value 

































ICH volume (ml)*; median (IQR) 50 (20-70) 60 (38-93) 0.082 
Strictly lobar ICH 44 (90) 93 (96) 0.149 
Intraventricular haemorrhage 18 (37) 37 (38) 0.868 
Subarachnoid haemorrhage 33 (67) 85 (88) 0.003 
Subdural haemorrhage 13 (27) 24 (25) 0.815 
Finger-like projections* 8 (16) 53 (57) <0.001 



















































































































Data are n (%) or median (IQR). *Relates to the largest ICH. ^Fisher’s exact 
test. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SVD = small vessel disease.  
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Participants with a CAA-associated lobar ICH were more likely to have 
undergone an autopsy and have a longer period between diagnostic CT 
scanning and tissue sampling than the non-CAA-associated lobar ICH group. 
The time between ICH onset and diagnostic non-contrast brain CT ranged 
from 0 to 7 days. Table 8.6 compares the distribution of brain CT features 
according to the time between symptom onset and CT scanning. Those 
scanned on the same day as the symptom onset were more likely to have 
multiple simultaneous acute ICHs than those scanned on day one onwards. 
The frequency of subarachnoid haemorrhage and finger-like projections was 
similar between the two groups. 
 
Table 8.6 Diagnostic non-contrast brain CT features stratified by the timing of 
the scan relative to ICH symptom onset 
 
CT day 0 (n=131) 





































Strictly lobar ICH 123 (94) 14 (93) 0.932 
ICH volume (ml); 
median (IQR) 
58 (36-89) 38 (9-67) 0.057 
Intraventricular 
haemorrhage 
52 (40) 3 (20) 0.136 
Subarachnoid 
haemorrhage 
106 (81) 12 (80) 0.932 
Subdural haemorrhage 35 (27) 2 (13) 0.259 
Finger-like projections 53 (41) 8 (53) 0.338 
Data are n (%). CT = computed tomography. ICH = intracerebral 
haemorrhage.  
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8.4.1.4 Edinburgh CT-only diagnostic model performance 
Figure 8.2 shows the model calibration in the external validation cohort. The 
intercept, which compares the mean predicted risks against observed risks, 
is 0.15 (95CI -0.59 to 0.27). The calibration slope is 0.49 (95% CI 0.27 to 
0.71). The model shows good discrimination (c statistic 0.71, 95% CI 0.63 to 
0.79, Figure 8.3). 
The net benefit of the model is shown in the decision curves (Figure 8.4). The 
threshold probability is the level of diagnostic certainty above which a patient 
or clinician would choose treatment. Equally, it could be used by a researcher 
to identify patients eligible for inclusion in a randomised controlled trial or for 
a case-control study. The threshold probability is low in situations where we 
want to avoid false negatives (e.g. when trying to rule out CAA-associated 
lobar ICH), and high when false positives are to be avoided (e.g. when trying 
to rule in CAA-associated lobar ICH). The net benefit is the difference 
between those expected to benefit (true positives identified using the strategy 
– expected benefit) and those expected to be harmed (false positives 
identified using the strategy multiplied by a weighting factor based on the 
threshold probability – expected harm). The curves which maximise net 
benefit represent the optimal strategy for the associated threshold 
probabilities. The solid black line indicates a policy of treating no one (i.e. 
assume none have CAA-associated lobar ICH), the grey line a policy of 
treating all (i.e. assume all have CAA-associated lobar ICH). 
For low threshold probabilities (0-0.4), where harm of unnecessary treatment 
is limited and false negatives avoided (i.e. useful for ruling out CAA-
associated lobar ICH), the line for treat all is above the subarachnoid 
haemorrhage alone line. Therefore the strategy of treat all maximises net 
benefit in this situation. For high threshold probabilities (0.6-0.90), where 
there is harm of overtreatment, and false positives should be avoided, the 
criteria of subarachnoid haemorrhage AND finger-like projections maximises 
net benefit (i.e. for ruling in CAA-associated lobar ICH).  
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Figure 8.2 Calibration plot of predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model versus the observed 
frequency of CAA-associated lobar ICH 
 
The red line indicates perfect calibration, the model's calibration is shown by 
the black line. The grey shaded area represents the 95%CI. Triangles 
represent the three different risk groups produced by the prediction model. 
Vertical lines at the bottom of the plot represent the distribution of model 
predicted probabilities stratified by endpoint (CAA-associated ICH above the 
x-axis, non-CAA-associated ICH below the x-axis). CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage.  
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Figure 8.3 ROC curve for the predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model 
 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of 
the AUC based on 2000 bootstrap replicates. The grey line indicates a non-
informative AUC of 0.50 for comparison. AUC = area under the curve. CAA = 
cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. ROC = receiver operating characteristic. 
 
Figure 8.4 Decision curves of classifications of CAA-associated lobar ICH 
using the Edinburgh CT only prediction model 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SAH = subarachnoid haemorrhage.  
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8.4.1.5 Edinburgh CT-only criteria diagnostic accuracy 
The cross-tabulation of Edinburgh CT-only diagnostic criteria against the 
reference standard is shown in Table 8.7. The presence of subarachnoid 
haemorrhage had a sensitivity of 88% (95% CI 79 to 93) for CAA-associated 
ICH (Table 8.8), while the combination of subarachnoid haemorrhage and 
finger-like projections had a specificity of 84% (95% CI 70 to 93). 
There were 12 false negative cases for the rule out criteria of subarachnoid 
haemorrhage (Table 8.7), eight of which had an ICH volume less than 20ml 
and/or tissue sampling performed more than 1000 days after the ICH 
resulting in study inclusion. There were eight false positive cases for the rule 
in criteria of subarachnoid haemorrhage and finger-like projections, all of 
which were based on brain biopsy. 
 
Table 8.7 Cross-tabulations of the Edinburgh CT-only diagnostic criteria for 
CAA-associated lobar ICH against the Vonsattel reference standard 
Diagnostic criteria (index 
test) 
Subarachnoid haemorrhage 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 85 33 118 
Negative 12 16 28 
Total 97 49 146 
Diagnostic criteria (index 
test) 
Subarachnoid haemorrhage 
& finger-like projections 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 53 8 61 
Negative 44 41 85 
Total 97 49 146 







Table 8.8 Diagnostic accuracy statistics for the Edinburgh CT-only diagnostic criteria for CAA-associated lobar ICH in the 
development and external validation studies 











Sensitivity 89 (73-96) 39 (24-56) 88 (79-93) 55 (58-74) 
Specificity 58 (37-76) 100 (84-100) 33 (20-48) 84 (70-92) 
Positive likelihood 
ratio 
2.1 (1.3-3.3) Inf (NaN-Inf) 1.3 (1.0-1.6) 3.4 (1.7-6.5) 
Negative likelihood 
ratio 
0.2 (0.1-0.5) 0.6 (0.5-0.8) 0.4 (0.2-0.7) 0.5 (0.4-0.7) 
Positive predictive 
value 
74 (59-86) 100 (73-100) 72 (63-80) 87 (75-94) 
Negative predictive 
value 
79 (54-93) 54 (39-68) 57 (37-75) 48 (37-59) 
Data are percentage or ratio (95% confidence interval). CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH 
= intracerebral haemorrhage. Inf = infinity. NaN = not a number – calculation cannot be performed because one of the values 
includes a zero.
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Sensitivity analysis – stratifying analyses by tissue source 
Table 8.9 and Table 8.10 compare the baseline clinical and non-contrast CT 
brain characteristics of those undergoing autopsy versus brain biopsy in the 
external validation study. Those who had a biopsy were significantly younger 
compared with those undergoing autopsy, with less severe white matter 
lucencies and less central atrophy. The frequency of dementia, 
intraventricular haemorrhage and finger-like projections was also lower in the 
biopsy group, but none of these reached statistical significance. Admission 
GCS and ICH volume were similar between the groups. The time between 
diagnostic CT and tissue sampling was significantly longer in those 
undergoing autopsy (median 12 days (IQR 5-516, range 0-2601) versus 1 
day until brain biopsy (IQR 0-4, range 0-2455), p<0.001), while the frequency 
of CAA-associated lobar ICH was higher in the autopsy group. 
The Edinburgh CT-only diagnostic model performance in those who had a 
brain biopsy reference standard and those who had autopsy, are shown in 
Figure 8.5 to Figure 8.10. Model discrimination was better in the autopsy 
group compared with the brain biopsy group (c statistic 0.83 versus 0.71 
respectively). The diagnostic accuracy of the associated Edinburgh CT-only 
diagnostic criteria according to the tissue source of the reference standard is 
shown in Table 8.11 to Table 8.14. The rule out criteria (subarachnoid 
haemorrhage) have better sensitivity in the brain biopsy group, whereas the 
rule in criteria (subarachnoid haemorrhage and finger-like projections) were 
more specific in the autopsy group.  
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Table 8.9 Baseline clinical characteristics in external validation study 
participants who underwent autopsy versus brain biopsy reference standard 
 Autopsy (n=50) Brain biopsy (n=96) p value 
Age (years); median 
(IQR) 

















Co-morbidities     
Hypertension 32 (64) 58 (62) 0.786 
Ischaemic stroke 4  (8) 11 (12) 0.525 
Transient ischaemic 
attack^ 
4  (8) 5 (5) 0.493 
Dementia 13  (27) 11 (15) 0.090 
Diabetes 5  (10) 13 (14) 0.494 
Atrial Fibrillation 8  (16) 15 (16) 0.997 
























     
Antiplatelet drug(s) 12 (25) 31 (33) 0.293 




11 (8-14) 13 (8-15) 0.345 
APOE genotype 26 (52) 39 (41) 0.189 
APOE 2 possession 10 (39) 11 (28) 0.386 
APOE 4 possession 13 (50) 15 (39) 0.357 
CAA-associated lobar 
ICH 
45 (90) 52 (54) <0.001 
Time between diagnostic 
CT scan and tissue 
(days); 
Median (IQR) 
12 (5-516) 1 (0-4) <0.001 
Dead 50 (100) 30 (31) <0.001 
Data are n (%) or median (IQR). * Relates to the largest ICH. ^ Fisher’s exact 
test. APOE = Apolipoprotein. CAA = cerebral amyloid angiopathy .CT = 
computed tomography. GCS = Glasgow coma scale. ICH = intracerebral 
haemorrhage.  
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Table 8.10 Non-contrast diagnostic brain CT characteristics in external 
validation study participants who underwent autopsy versus brain biopsy 
reference standard 
 Autopsy (n=50) Brain biopsy (n=96) p value 

































Strictly lobar ICH 46 (92) 91 (95) 0.506 
ICH volume 
Median (IQR) 
55 (21-79) 57 (39-91) 0.321 
Intraventricular haemorrhage 22  (44) 33 (34) 0.255 
Subarachnoid haemorrhage 39 (78) 79 (82) 0.532 
Subdural haemorrhage 11 (22) 26 (27) 0.503 
Finger-like projections 26 (52) 35 (37) 0.071 




















































































































Data are n (%) or median (IQR). * Relates to the largest ICH. ^ Fisher’s exact 
test. CT = computed tomography. ICH = intracerebral haemorrhage. SVD = 
small vessel disease.  
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Figure 8.5 Calibration plot of predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model versus the observed 
frequency of CAA-associated lobar ICH for those who had a brain biopsy 
 
The red line indicates perfect calibration, the model's calibration is shown by 
the black line. The grey shaded area represents the 95%CI. Triangles 
represent the three different risk groups produced by the prediction model. 
Vertical lines at the bottom of the plot represent the distribution of model 
predicted probabilities stratified by endpoint (CAA-associated ICH above the 
x-axis, non-CAA-associated ICH below the x-axis). CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage.  
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Figure 8.6 ROC curve for the predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model for those who had a brain 
biopsy 
 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of 
the AUC based on 2000 bootstrap replicates. The grey line indicates a non-
informative AUC of 0.50. AUC = area under the curve. CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. ROC = 
receiver operating characteristic. 
 
Figure 8.7 Decision curves of predictions and classifications of CAA-
associated lobar ICH using the Edinburgh CT only prediction model in 
participants who had a brain biopsy reference standard 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SAH = subarachnoid haemorrhage.  
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Figure 8.8 Calibration plot of predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model versus the observed 
frequency of CAA-associated lobar ICH for those who had an autopsy 
 
The red line indicates perfect calibration, the model's calibration is shown by 
the black line. The grey shaded area represents the 95%CI. Triangles 
represent the three different risk groups produced by the prediction model. 
Vertical lines at the bottom of the plot represent the distribution of model 
predicted probabilities stratified by endpoint (CAA-associated ICH above the 
x-axis, non-CAA-associated ICH below the x-axis). CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage.  
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Figure 8.9 ROC curve for the predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model for those who had an 
autopsy 
 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of 
the AUC based on 2000 bootstrap replicates. The grey line indicates a non-
informative AUC of 0.50. AUC = area under the curve. CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. ROC = 
receiver operating characteristic. 
 
Figure 8.10 Decision curves of predictions and classifications of CAA-
associated lobar ICH using the Edinburgh CT only prediction model in 
participants who had an autopsy reference standard 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SAH = subarachnoid haemorrhage  
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Table 8.11 Cross-tabulations of the Edinburgh CT-only diagnostic criteria for 
CAA-associated lobar ICH against the Vonsattel reference standard in those 
who underwent brain biopsy 




Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 48 31 79 
Negative 4 13 17 
Total 52 44 96 
Diagnostic criteria (index 
test) 
Subarachnoid 
haemorrhage & finger-like 
projections 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 27 8 35 
Negative 25 36 61 
Total 52 44 96 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. 
 
Table 8.12 Diagnostic accuracy statistics for the Edinburgh CT-only 
diagnostic criteria for CAA-associated lobar ICH in those who underwent 
brain biopsy 







Sensitivity 92 (81-98) 53 (38-66) 
Specificity 30 (17-45) 82 (67-91) 
Positive likelihood ratio 1.3 (1.1-1.6) 2.9 (1.5-5.6) 
Negative likelihood ratio 0.3 (0.1-0.7) 0.6 (0.4-0.8) 
Positive predictive value 61 (49-71) 77 (59-89) 
Negative predictive value 77 (50-92) 59 (46-71) 
Data are percentage or ratio (95% confidence interval). CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage.  
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Table 8.13 Cross-tabulations of the Edinburgh CT-only diagnostic criteria for 
CAA-associated lobar ICH against the Vonsattel reference standard in those 
who underwent autopsy 




Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 37 2 39 
Negative 8 3 11 
Total 45 5 50 
Diagnostic criteria (index 
test) 
Subarachnoid 
haemorrhage & finger-like 
projections 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 26 0 26 
Negative 19 5 24 
Total 45 5 50 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. 
 
Table 8.14 Diagnostic accuracy statistics for the Edinburgh CT-only 
diagnostic criteria for CAA-associated lobar ICH in those who underwent 
autopsy 







Sensitivity 82 (67-92) 58 (42-72) 
Specificity 60 (17-93) 100 (46-100) 
Positive likelihood ratio 2.1 (0.7-6.1) Inf (NaN-Inf) 
Negative likelihood ratio 0.3 (0.1-0.7) 0.4 (0.3-0.6) 
Positive predictive value 95 (81-99) 100 (84-100) 
Negative predictive value 27 (7-61) 21 (8-43) 
Data are percentage or ratio (95% confidence interval). CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. Inf = infinity. NaN = not a number – calculation cannot be 
performed because one of the values includes a zero.  
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8.4.1.6 Sensitivity analysis – stratifying analyses by ICH volume 
Figure 8.11 to Figure 8.16 show the Edinburgh CT-only diagnostic model 
performance stratified by the median ICH volume. In the group with smaller 
ICHs, the model underestimated the frequency of CAA-associated lobar ICH 
for the low predicted model probabilities and showed modest discrimination 
(c statistic 0.66). In the group with larger ICHs, the model showed good 
calibration across all model predicted probabilities and good discrimination (c 
statistic 0.73). The diagnostic accuracy of the associated Edinburgh CT-only 
diagnostic criteria is shown in Table 8.15 to Table 8.18. The sensitivity of the 
rule out criteria (subarachnoid haemorrhage) was best in the larger ICH 
group, whereas the rule in criteria (subarachnoid haemorrhage and finger-like 
projections) were more specific in the smaller ICH group. 
 
Figure 8.11 Calibration plot of predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model versus the observed 
frequency of CAA-associated lobar ICH for those with an ICH volume below 
56 ml 
 
The red line indicates perfect calibration, the model's calibration is shown by the 
black line. The grey shaded area represents the 95%CI. Triangles represent the 
three different risk groups produced by the prediction model. Vertical lines at the 
bottom of the plot represent the distribution of model predicted probabilities stratified 
by endpoint (CAA-associated ICH above the x-axis, non-CAA-associated ICH below 
the x-axis). CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage.   
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Figure 8.12 ROC curve for the predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model for those with an ICH 
volume below 56 ml 
 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of 
the AUC based on 2000 bootstrap replicates. The grey line indicates a non-
informative AUC of 0.50. AUC = area under the curve. CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. ROC 
receiver operating characteristic. 
 
Figure 8.13 Decision curves of predictions and classifications of CAA-
associated lobar ICH using the Edinburgh CT only prediction model in 
participants patients who had an ICH volume below 56 ml 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SAH = subarachnoid haemorrhage   
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Figure 8.14 Calibration plot of predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model versus the observed 
frequency of CAA-associated lobar ICH for those with an ICH volume above 
56 ml 
 
The red line indicates perfect calibration, the model's calibration is shown by 
the black line. The grey shaded area represents the 95%CI. Triangles 
represent the three different risk groups produced by the prediction model. 
Vertical lines at the bottom of the plot represent the distribution of model 
predicted probabilities stratified by endpoint (CAA-associated ICH above the 
x-axis, non-CAA-associated ICH below the x-axis). CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage.   
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Figure 8.15 ROC curve for the predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT-only prediction model for those with an ICH 
volume above 56 ml 
 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of 
the AUC based on 2000 bootstrap replicates. The grey line indicates a non-
informative AUC of 0.50. AUC = area under the curve. CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. ROC = 
receiver operating characteristic. 
 
Figure 8.16 Decision curves of predictions and classifications of CAA-
associated lobar ICH using the Edinburgh CT only prediction model in 
participants who had an ICH volume above 56 ml 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SAH = subarachnoid haemorrhage.  
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Table 8.15 Cross-tabulations of the Edinburgh CT-only diagnostic criteria for 
CAA-associated lobar ICH against the Vonsattel reference standard in those 
with ICH volume less than 56 ml 




Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 35 18 53 
Negative 10 10 20 
Total 45 28 73 
Diagnostic criteria (index 
test) 
Subarachnoid 
haemorrhage & finger-like 
projections 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 17 2 19 
Negative 28 26 54 
Total 45 28 73 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage.  
 
Table 8.16 Diagnostic accuracy statistics for the Edinburgh CT-only 
diagnostic criteria for CAA-associated lobar ICH in those with ICH volume 
less than 56 ml 





haemorrhage & finger-like 
projections 
Sensitivity 78 (63-89) 38 (24-54) 
Specificity 36 (19-56) 93 (75-99) 
Positive likelihood ratio 1.2 (0.9-1.7) 5.3 (1.3-21) 
Negative likelihood ratio 0.6 (0.3-1.2) 0.7 (0.5-0.9) 
Positive predictive value 66 (52-78) 90 (66-98) 
Negative predictive value 50 (28-72) 48 (35-62) 
Data are percentage or ratio (95% confidence interval). CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage.  
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Table 8.17 Cross-tabulations of the Edinburgh CT-only diagnostic criteria for 
CAA-associated lobar ICH against the Vonsattel reference standard in those 
with ICH volume more than 56 ml 




Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 49 15 64 
Negative 2 6 8 
Total 51 21 72 
Diagnostic criteria (index 
test) 
Subarachnoid 
haemorrhage & finger-like 
projections 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 36 6 42 
Negative 15 15 30 
Total 51 21 72 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. 
 
Table 8.18 Diagnostic accuracy statistics for the Edinburgh CT-only 
diagnostic criteria for CAA-associated lobar ICH in those with ICH volume 
more than 56 ml 





haemorrhage & finger-like 
projections 
Sensitivity 96 (86-99) 69 (55-80) 
Specificity 29 (12-52) 71 (48-88) 
Positive likelihood ratio 1.4 (1.0-1.8) 2.4 (1.2-4.9) 
Negative likelihood ratio 0.1 (0.0-0.7) 0.4 (0.3-0.7) 
Positive predictive value 77 (65-86) 86 (71-94) 
Negative predictive value 75 (36-96) 58 (31-67) 
Data are percentage or ratio (95% confidence interval). CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage.  
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8.4.1.7 Sensitivity analysis – restricting analyses to those where tissue 
sampling occurred within 100 days of the diagnostic CT scan 
There are difficulties relating findings on the diagnostic brain CT to the 
severity of CAA on a delayed brain tissue sample due to the potential interval 
development and progression of CAA with time. This could cause a false 
positive reference standard result. So, I assessed the diagnostic accuracy of 
the CT-only criteria in the 125 participants who had tissue sampling within 
100 days of the diagnostic CT (Table 8.19 and Table 8.20). The sensitivity of 
the rule out criteria (subarachnoid haemorrhage) was higher in this subgroup 
compared with the entire cohort (94% versus 88% respectively), while the 
specificity was similar (83% versus 84%). 
 
Table 8.19 Cross-tabulations of the Edinburgh CT-only diagnostic criteria for 
CAA-associated lobar ICH against the Vonsattel reference standard in those 
where pathology tissue was acquired within 100 days of the CT scan 




Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 73 32 105 
Negative 5 15 20 
Total 78 47 125 
Diagnostic criteria (index 
test) 
Subarachnoid 
haemorrhage & finger-like 
projections 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 45 8 53 
Negative 33 39 72 
Total 78 47 125 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. 
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Table 8.20 Diagnostic accuracy statistics for the Edinburgh CT-only 
diagnostic criteria for CAA-associated lobar ICH in those where pathology 
tissue was acquired within 100 days of the CT scan 





haemorrhage & finger-like 
projections 
Sensitivity 94 (85-98) 58 (46-69) 
Specificity 32 (20-47) 83 (69-92) 
Positive likelihood ratio 1.4 (1.1-1.7) 3.4 (1.8-6.6) 
Negative likelihood ratio 0.2 (0.1-0.5) 0.5 (0.4-0.7) 
Positive predictive value 70 (60-78) 85 (72-93) 
Negative predictive value 75 (51-90) 54 (42-66) 
Data are percentage or ratio (95% confidence interval). CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. 
 
8.4.2 External validation of the Edinburgh CT and APOE diagnostic 
model and criteria 
8.4.2.1 Flow of participants 
Only 65 (45%) of the 146 participants included in the external validation of 
the CT-only diagnostic model and criteria had APOE genotyping available 
(Figure 8.17). 
8.4.2.2 Comparison of participants with APOE genotyping in the external 
validation study versus those without APOE genotyping 
Participants with APOE genotyping had similar demographic and baseline 
clinical and non-contrast CT brain characteristics to those without APOE 
genotyping. Histopathologically defined CAA-associated ICH was more 
frequent in those with available APOE genotype (75% versus 59%, p=0.040) 
( Table 8.21 and Table 8.22). 
8.4.2.3 Comparison of participants included in the external validation 
study with those in the development study 
Participants in the CT and APOE external validation cohort tended to be 
younger than those in the development cohort (Table 8.23), with a lower 
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frequency of previous ischaemic stroke and of atrial fibrillation. 
Hyperlipidaemia was more common in the external validation cohort. The 
frequency of other comorbidities was similar between the external validation 
and development cohorts. Fewer participants in the external validation cohort 
were taking an antiplatelet drug at the time of ICH. Admission GCS and ICH 
volume were similar between the external validation and development 
cohorts (Table 8.24). 
Subarachnoid haemorrhage and finger-like projections were more frequent in 
the external validation cohort than in the development cohort (Table 8.24). 
An autopsy was used as the reference standard for only 40% of the external 
validation cohort compared with all participants in the development cohort. 
The median time from diagnostic CT until tissue sampling was two days (IQR 
1-16, range 0-2601) in the external validation cohort compared with 11 days 
(IQR 6-136, range 1-999) in the development cohort. 75% of the external 
validation cohort were classified as CAA-associated lobar ICH by the 
reference standard compared with 58% in the development study. 
8.4.2.4 Baseline clinical and diagnostic CT brain characteristics in the 
external validation study of CAA-associated versus non-CAA-
associated lobar ICH on histopathology 
Forty nine (75%) participants were classified as CAA-associated lobar ICH 
and 16 (25%) as non-CAA-associated lobar ICH. Pre-ICH dementia, strictly 
lobar ICH, subarachnoid haemorrhage and finger-like projections were more 
common in the CAA-associated lobar ICH group, although these did not 








Figure 8.17 Flow of participants through the Edinburgh CT and APOE CAA criteria external validation study 
 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. 
Edinburgh CT & APOE CAA criteria: Low risk = no subarachnoid haemorrhage, APOE 4 or finger-like projections; Intermediate risk = either 
subarachnoid haemorrhage or APOE 4; High risk = subarachnoid haemorrhage and (APOE 4 and/or finger-like projections)  




Table 8.21 Baseline clinical and non-contrast diagnostic brain CT 
characteristics in those with and without APOE genotyping 
























Co-morbidities      
Hypertension 53  (67) 37  (57) 0.210 
Ischaemic stroke 8  (10) 7  (11) 0.900 
Transient ischaemic 
attack^ 
5 (7) 4  (6) 1.000 
Dementia 12 (21) 12  (19) 0.756 
Diabetes 12 (15) 6 (9) 0.269 
Atrial Fibrillation 14 (18) 9  (14) 0.510 























Medications on admission      
Antiplatelet drug(s) 27 (35) 16  (25) 0.194 
Anticoagulant drug(s) 18 (23) 10  (15) 0.264 
Admission GCS; median 
(IQR) 
13  (8-15) 11 (8-14) 0.649 
CAA-associated lobar ICH 48  (59) 49  (75) 0.040 
Time between diagnostic CT 
scan and tissue (days); 
median (IQR) 
3  (0-10) 1 (1-16) 0.613 
Dead 36  (44) 44 (68) 0.005 
Data are n (%) or median (IQR). * Relates to the largest ICH. ^ Fisher’s exact 
test. APOE = Apolipoprotein. CAA = cerebral amyloid angiopathy .CT = 
computed tomography. GCS = Glasgow coma scale. ICH = intracerebral 
haemorrhage.  




Table 8.22 Non-contrast diagnostic brain CT characteristics between those 








































Strictly lobar ICH 77 (95) 60  (92) 0.492 
ICH volume (ml); median (IQR) 58  (30-95) 55  (37-81) 0.615 
Intraventricular haemorrhage 30 (37) 25  (39) 0.860 
Subarachnoid haemorrhage 65 (80) 53  (82) 0.844 
Subdural haemorrhage 22 (27) 15  (23) 0.573 
Finger-like projections* 36 (44) 25  (39) 0.466 




















































































































Data are n (%) or median (IQR). * Relates to the largest ICH. ^ Fisher’s exact 
test. APOE = apolipoprotein E. CT = computed tomography. ICH = 
intracerebral haemorrhage. SVD = small vessel disease.  




Table 8.23 Baseline clinical and non-contrast diagnostic brain CT 
characteristics in the Edinburgh CT and APOE criteria development versus 






















































































































































Time between ICH and diagnostic 
























Time between diagnostic CT scan 









CAA-associated lobar ICH 36 (58) 49 (75) 
Death 62 (100) 44 (68) 




Data are n (%) or median (IQR). * Relates to the largest ICH. APOE = 
Apolipoprotein E. CAA = cerebral amyloid angiopathy .CT = computed 
tomography. GCS = Glasgow coma scale. ICH = intracerebral haemorrhage. 
Table 8.24 Non-contrast diagnostic brain CT characteristics in the Edinburgh 






































ICH volume (ml)*; median (IQR) 60 (20-118) 55 (37-81) 
Strictly lobar ICH 58 (94) 60 (92) 
Intraventricular haemorrhage 31 (50) 25 (39) 
Subarachnoid haemorrhage 43 (69) 53 (82) 
Subdural haemorrhage 12 (19) 15 (23) 
Finger-like projections* 14 (23) 25 (39) 
















































































Data are n (%) or median (IQR). * Relates to the largest ICH. APOE = 
apolipoprotein E. CT = computed tomography. ICH = intracerebral 
haemorrhage. SVD = small vessel disease.  




Table 8.25 Baseline clinical and non-contrast diagnostic brain CT 
characteristics in participants classified as CAA-associated versus non-CAA-






lobar ICH (n=49) 
p value 

















Co-morbidities      
Hypertension 10 (63) 22 (45) 0.604 
Ischaemic stroke^ 3 (19) 4 (8) 0.350 
Transient ischaemic attack^ 0 (0) 4 (8) 0.565 
Dementia^ 1 (6) 11 (22) 0.262 
Diabetes^ 2 (13) 4 (8) 0.631 
Atrial Fibrillation^ 2 (13) 7 (14) 1.000 






















Medications on admission      
Antiplatelet drug(s)^ 2 (13) 14 (29) 0.318 
Anticoagulant drug(s)^ 2 (13) 8 (16) 1.000 
Admission Glasgow Coma 
Scale 
14 (7-15) 11 (8-14) 0.858 
APOE 2 possession 3 (19) 18 (37) 0.182 
APOE 4 possession 8 (50) 20 (41) 0.520 
Time between ICH and 
diagnostic CT scan (days) 

















Time between diagnostic CT 










Death 6 (38) 38 (78) 0.003 
Data are n (%) or median (IQR). * Relates to the largest ICH. ^ Fisher’s exact 
test. APOE = Apolipoprotein. CAA = cerebral amyloid angiopathy .CT = 
computed tomography. GCS = Glasgow coma scale. ICH = intracerebral 
haemorrhage.  




Table 8.26 Non-contrast diagnostic brain CT characteristics in participants 
classified as CAA-associated versus non-CAA-associated ICH by the 





lobar ICH (n=49) 
p 
value 

































ICH volume (ml) 49 (23-70) 54.7 (38-85) 0.433 
Strictly lobar ICH 13 (81) 47 (96) 0.056 
Intraventricular haemorrhage 6 (38) 19 (39) 0.927 
Subarachnoid haemorrhage^ 10 (63) 43 (88) 0.057 
Subdural haemorrhage^ 2 (25) 11 (22) 1.000 
Finger-like projections 3 (19) 22 (45) 0.062 



















































































































Data are n (%) or median (IQR). * Relates to the largest ICH. ^ Fisher’s exact test. 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed 
tomography. ICH = intracerebral haemorrhage. SVD = small vessel disease.  




Participants with CAA-associated lobar ICH had more severe white matter 
lucencies than the non-CAA-associated lobar ICH group. CAA-associated 
participants were more likely to have undergone an autopsy. The median 
time between diagnostic CT scanning and tissue sampling was longer in the 
CAA-associated lobar ICH group, although this did not reach statistical 
significance. 
8.4.2.5 Edinburgh CT and APOE diagnostic model performance 
Figure 8.18 shows the model calibration. The model shows modest 
discrimination (c statistic 0.64, 95% CI 0.48 to 0.80, Figure 8.19). The net 
benefit of the model is shown in the decision curves (Figure 8.20). 
 
Figure 8.18 Calibration plot of predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT and APOE prediction model versus the 
observed frequency of CAA-associated lobar ICH. 
 
The red line indicates perfect calibration, the model's calibration is shown by the black line. 
The grey shaded area represents the 95%CI. Triangles represent the three different risk 
groups produced by the prediction model. Vertical lines at the bottom of the plot represent 
the distribution of model predicted probabilities stratified by endpoint (CAA-associated ICH 
above the x-axis, non-CAA-associated ICH below the x-axis). APOE = apolipoprotein E. 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage.  




Figure 8.19 ROC curve for the predicted probability of CAA-associated lobar 
ICH using the Edinburgh CT and APOE prediction model.  
 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of the AUC 
based on 2000 bootstrap replicates. The grey line indicates a non-informative AUC of 0·50 
for comparison. AUC = area under the curve. APOE = apolipoprotein E. CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. ROC = 
receiver operating characteristic. 
 
Figure 8.20 Decision curves of predictions and classifications of CAA-
associated lobar ICH using the Edinburgh CT and APOE prediction model 
 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed tomography. 
FLP = finger-like projection. ICH = intracerebral haemorrhage. SAH = subarachnoid 
haemorrhage.  




8.4.2.6 Edinburgh CT and APOE criteria diagnostic accuracy 
The cross-tabulation of Edinburgh CT and APOE diagnostic criteria against 
the reference standard is shown in Table 8.27. The presence of 
subarachnoid haemorrhage or APOE 4 possession had a sensitivity of 94% 
(95% CI 82 to 98) for CAA-associated ICH (Table 8.28). The combination of 
subarachnoid haemorrhage and APOE 4 possession and/or finger-like 
projections had a specificity of 63% (95% CI 36 to 84). 
There were three false negative cases for the rule out criteria of 
subarachnoid haemorrhage or APOE 4 possession (Table 8.27), two of 
which had an ICH volume less than 20ml and/or tissue sampling performed 
more than 1000 days after the ICH. There were six false positive cases for 
the rule in criteria of subarachnoid haemorrhage and APOE 4 possession 
and/or finger-like projections, all of which were based on brain biopsy. 
There were too few participants to do sensitivity analyses by the reference 
standard tissue source, ICH volume or time between CT and tissue sampling. 
 
Table 8.27 Cross-tabulations of the Edinburgh CT and APOE diagnostic 
criteria for CAA-associated lobar ICH against the Vonsattel scale 
Diagnostic criteria (index test) 
Subarachnoid haemorrhage 
or APOE 4+ 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 46 13 59 
Negative 3 3 6 
Total 49 16 65 
Diagnostic criteria (index test) 
Subarachnoid haemorrhage & 
(APOE4+ and/or finger-like 
projections) 
Vonsattel grade ≥2 
(Reference standard) 
 
Positive Negative Total 
Positive 31 6 37 
Negative 18 10 28 
Total 49 16 65 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = 
computed tomography. ICH = intracerebral haemorrhage. 





Table 8.28 Diagnostic accuracy statistics for the Edinburgh CT and APOE diagnostic criteria for CAA-associated lobar ICH in 
the development and external validation studies 
















Sensitivity 100 (88-100) 64 (46-79) 94 (82-98) 63 (48-76) 
Specificity 54 (34-73) 96 (78-100) 19 (5-46) 63 (36-84) 
Positive likelihood ratio 2.2 (1.4-3.3) 16.6 (2.4-115) 1.2 (0.9-1.5) 1.7 (0.9-3.3) 
Negative likelihood ratio 0 (0-NaN) 0.4 (0.2-0.6) 0.3 (0.1-1.7) 0.6 (0.4-0.9) 
Positive predictive value 75 (60-86) 96 (77-100) 78 (65-87) 84 (67-93) 
Negative predictive value 100 (73-100) 66 (49-80) 22 (13-35) 16 (7-33) 
Data are percentage or ratio (95% confidence interval). APOE = apolipoprotein. CAA = cerebral amyloid angiopathy. CT = 
computed tomography. ICH = intracerebral haemorrhage. NaN = not a number – calculation cannot be performed because 
one of the values includes a zero 
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8.5 Discussion 
8.5.1 Main findings 
External validation of the Edinburgh CT-only diagnostic criteria and model 
 Participants were younger than those I included in the Edinburgh CT 
diagnostic models and criteria development study. The predictors 
(subarachnoid haemorrhage and finger-like projections) and outcome 
(CAA-associated ICH) were more frequent than in the development 
setting. 
 The frequency of CT predictors (subarachnoid haemorrhage and 
finger-like projections) was similar between those scanned on the day 
of symptom onset versus those scanned on day one onwards. 
 Overall CAA-associated ICH was more frequent than predicted by the 
Edinburgh CT-only diagnostic model (intercept 0.15). The model 
shows good calibration for those with an intermediate predicted risk of 
CAA-associated ICH but underestimated the frequency in the low-risk 
group and over-estimated it in the high-risk group.  
 The model shows good discrimination (c statistic 0.71) 
 The Edinburgh CT-only rule out criteria of no subarachnoid 
haemorrhage or finger-like projections had a sensitivity of 88% 
compared with 89% in the development study. 
 Edinburgh CT-only rule in criteria of subarachnoid haemorrhage and 
finger-like projections had a specificity of 84% compared with 100% in 
the development study. 
 The sensitivity of the rule out criteria was lower in those with an 
autopsy reference standard, while the specificity of the rule in criteria 
was lower in those with a brain biopsy reference standard. 
 The rule out criteria were most sensitive in those with an ICH volume 
above the median (56 ml) and the rule in criteria most specific in those 
with an ICH volume below the median. 
External validation of the Edinburgh CT and APOE diagnostic criteria and 
model 
  Chapter 8 
377 
 Participants were younger than those I included in the Edinburgh CT 
and APOE diagnostic models and criteria development study. The CT 
predictors (subarachnoid haemorrhage and finger-like projections) and 
outcome (CAA-associated ICH) were more frequent than in the 
development setting. 
 The Edinburgh CT and APOE diagnostic model showed limited 
calibration, particularly for those with the lowest predicted risk of CAA-
associated ICH, and modest discrimination (c statistic 0.64). 
 The Edinburgh CT and APOE rule out criteria of no subarachnoid 
haemorrhage, APOE 4 possession or finger-like projections were 
94% sensitive compared with 100% in the development study 
 The rule in criteria of subarachnoid haemorrhage and either APOE 4 
possession or finger-like projections had a specificity of 63% 
compared with 96% in the development study. 
8.5.2 Strengths of the study 
I performed and reported the study according to the TRIPOD guidelines for 
multivariable prediction models,[332] and the STARD guidelines for 
diagnostic accuracy studies.[173] Important strengths are: 
 I identified as many research groups with relevant data as possible by 
liaising with the International CAA Association and systemically 
reviewing the literature. 
 Participants were from different countries and healthcare settings, 
increasing the generalisability of the results. 
 I only included participants with first-ever ICH to provide a standard 
inception point. 
 I used both autopsy and brain biopsy as the reference standard to 
include younger participants with non-fatal ICH compared with the 
development cohort, increasing the generalisability of the results. 
 I minimised information bias for predictor assessment by standardising 
imaging format, using the same definition for CT predictors as I used 
in the development study, undertaking online training for predictor 
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assessment before rating the CT scans, and performing the ratings 
masked to clinical, genetic and histopathological data. 
 Reference standard assessment was performed by experienced 
neuropathologists masked to clinical, CT, genetic and outcome data, 
using a validated scale for CAA.[253] I pre-specified the reference 
standard definition. 
 There were no missing predictor or outcome data for the external 
validation of the CT-only model and criteria. 
 I described the baseline clinical and radiographic features and the 
distribution of CAA and non-CAA SVD severity in the study groups to 
describe the spectrum of participants.[175, 176] 
8.5.3 Limitations of the study 
The main limitations relate to selection bias and the time delay to obtaining 
the reference standard. 
The sources of data I used introduced a selection bias. Participants were 
often part of hospital-based case series identified by collaborators rather than 
part of a community-based consecutive sample, as was the case with the 
development cohort. In most of the contributing cohorts the decision to 
perform APOE genotyping, and brain biopsy or autopsy was made by the 
treating medical team rather than being offered to all. In such cases, the 
decision to perform these procedures seemed to have been influenced by the 
clinical suspicion of CAA based on clinical history and imaging findings. This 
results in a partial verification bias, where the reference standard is 
preferentially performed in those most likely to have the outcome of interest. 
In line with this, the prevalence of subarachnoid haemorrhage, finger-like 
projection and CAA-associated ICH was higher in this external validation 
study compared with the development cohort. CAA-associated ICH was 
significantly more frequent in participants with APOE genotype (75%) 
compared to those without (59%). Therefore the external validation cohort is 
likely to be enriched for CAA-associated lobar ICH and not representative of 
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general clinical practice, particularly those with APOE genotype. This is likely 
to bias the results by falsely increasing the reported sensitivity of the criteria. 
The time between the index test and tissue sampling for the reference 
standard was long for some participants (over a year in 16 participants, and 
over five years in eight). CAA is a progressive, age-related condition, so its 
presence in delayed tissue samples does not necessarily reflect the 
pathological changes at the time of the CT scan following the index ICH, 
leading to false positive reference standard classifications. The prevalence of 
CAA when the reference standard was obtained over one year after the index 
ICH was 88%, compared with 64% obtained within a year. Therefore some of 
the participants may have been misclassified by the reference standard. 
There were several other limitations, which are likely to have smaller effects 
on the results. 
Despite CAA and ICH being common and the source studies coming from 
research groups with special interest in CAA and ICH, the available sample 
size was relatively small. Therefore the study did not reach the pre-specified 
sample size of 100 cases and 100 controls. In particular, the CT and APOE 
external validation cohort only included 49 CAA-associated ICH cases and 
16 non-CAA-associated ICH controls. This leads to a risk of a type II error. 
However, it was the largest sample I could achieve by approaching all 
potential research groups and using both autopsy and brain biopsy as the 
reference standard. In addition, the sample size of the CT-only external 
validation cohort is twice that of the development cohort. 
Baseline data collection was performed retrospectively in some cohorts. 
However, the proportion of missing baseline data was low apart from 
admission GCS, which was missing in 25%. CT predictors and the outcome 
were available for all included participants.  
I performed all CT ratings. Assessment by other raters from different centres 
and with different levels of experience is important to assess the inter-rater 
agreement of the CT predictors. 
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The reference standard I used was different to that used in the development 
cohort. In the development study, a single consultant neuropathologist 
performed systematic research autopsies and rated the tissue using a 
consensus CAA scale.[36] We classified a CAA-associated ICH where there 
was moderate or severe parenchymal CAA in the left cerebral hemisphere. In 
this study, I included both brain biopsy and autopsy in the reference 
standard. Brain biopsy is prone to sampling errors leading to false negative 
and false positive results compared with autopsy (Section 4.4.4).[164] 
Histopathological samples were assessed locally by experienced 
neuropathologists using the Vonsattel scale.[253] Participants were classified 
as having CAA-associated lobar ICH if there was Vonsattel grade ≥2 in any 
tissue sample. These factors may introduce variability in the classification of 
the reference standard between centres and with the development study. 
However, the Vonsattel CAA scale is a familiar, widely used scale. 
Furthermore, the cut-off of Vonsattel grade ≥2 correlates closely with the 
definition we used in the development study, even when applied in a biopsy 
sample (Section 4.4.4.6). 
8.5.4 Study findings 
8.5.4.1 External validation of the Edinburgh CT-only diagnostic model 
and criteria 
The Edinburgh CT-only diagnostic model showed good calibration for 
intermediate predicted probability (subarachnoid haemorrhage) of CAA-
associated lobar ICH (model predicted risk 62%, observed frequency 56%). 
The model underestimated the frequency of CAA-associated ICH for the low 
predicted risk cases (model predicted risk 23%, observed frequency 43%) 
and overestimated the frequency of CAA-associated ICH for high predicted 
risk cases (model predicted risk 97%, observed frequency 87%). The positive 
intercept (0.15) indicates that model predictions are systematically too low 
(calibration-in-the-large). The calibration slope (0.49) is less than 1, reflecting 
that the model predictions are too extreme (low predicted risk too low and 
vice versa).[336] The discriminative value of the model remained good (c 
statistic 0.71), although this was less than in the development setting (c 
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statistic 0.82). The combination of subarachnoid haemorrhage and finger-like 
projections maximises net benefit for high threshold probabilities (0.6-0.9) 
where false-positive results are to be avoided. For low threshold probabilities 
(0-0.4), the subarachnoid haemorrhage line is below the approach of 
considering all as having CAA-associated ICH, and is therefore not as useful 
for minimising false-negatives or ruling out CAA-associated ICH. 
The rule out criterion of no subarachnoid haemorrhage showed similarly high 
sensitivity for CAA-associated ICH in the external validation setting (88% 
95% CI 79 to 93) compared with the development study (89% 95% CI 73 to 
96). The rule in criteria of subarachnoid haemorrhage and finger-like 
projections had a specificity of 84% (95% CI 70 to 92) compared with 100% 
(95% CI 84 to 100) in the development cohort. 
Performance of a predictive model and diagnostic criteria in other settings 
depends on the quality of the prediction model, the characteristics of the 
external validation cohort and the accuracy of the reference standard.[334] 
Prediction models can be overfitted during development. This is especially 
true if the development sample is small.[338, 339] Overfitting results in 
predictions that are too extreme (low predicted risk too low and vice versa) at 
external validation, reducing discrimination and clinical usefulness.[334] I 
developed the Edinburgh diagnostic criteria on a small cohort of 62 
participants, so there is a chance the model is overfitted. To limit overfitting 
during model development, I only included two predictors in the CT-only 
model (13 events per variable). There was minimal optimism during internal 
validation, suggesting little overfitting.[340] I did not shrink the regression 
coefficients because the Firth's penalised likelihood logistic regression results 
in conservative coefficients. However, shrinkage of the regression 
coefficients would further reduce overfitting.[338] 
Even if the model is not overfitted, there are likely to be true differences in 
regression coefficients between the development and external validation 
populations related to the case mix and outcome definition. The frequency of 
CAA-associated ICH was higher in the external validation population 
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compared with the development cohort. This may relate to partial verification 
bias, where selection of patients for tissue sampling favoured those with a 
higher clinical suspicion of CAA, and the outcome definition as only one 
tissue sample needed to be classified as Vonsattel ≥2 for the participant to 
be classified as CAA-associated lobar ICH. A higher proportion with the 
outcome increases the intercept and reduces the net benefit.[334] The effect 
of the outcome incidence on model performance is highlighted by the 
sensitivity analyses based on the source of tissue. The frequency of CAA-
associated ICH in the autopsy group was 90%, and the intercept is high 
(1.81), whereas only 54% of the biopsy group were CAA-associated and the 
intercept was low (-0.40). 
The frequency of subarachnoid haemorrhage and finger-like projections were 
higher in the external validation cohort compared with the development 
study, resulting in fewer participants with low predicted probabilities of CAA 
and more with high predicted probabilities of CAA. The mean predicted 
probability of CAA-associated ICH in the external validation cohort was 
higher (69%) than in the development setting (58%), whilst the spread of 
prediction was similar in both cohorts. This will have reduced the c statistic 
and the net benefit.[334] The spread of predicted probabilities was greater 
when I restricted the analyses to the autopsy cases, and there was an 
increase in the c statistic in this subgroup (0.83). 
Assessment of diagnostic performance depends on accurate classification by 
the reference standard. The eight participants with a high predicted 
probability of CAA-associated ICH but classified as negative by the reference 
standard were all based on brain biopsy.  Brain biopsy is prone to sampling 
bias and false negative results.[164] Five of the 12 participants with a low 
predicted risk but classified as positive by the reference standard had tissue 
sampling performed over 1000 days after the diagnostic CT scan. Delayed 
tissue sampling increases the chance of the interval development of CAA, 
and therefore a false positive histopathological assessment. 
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The presence of subarachnoid haemorrhage is related to ICH volume.[237] 
Finger-like projections were also more frequent in larger ICH volumes in both 
the development and external validation cohorts.  I therefore assessed the 
performance of the diagnostic model and criteria stratifying by ICH volume.  
The model showed better calibration and discrimination when restricted to 
those with an ICH volume above the median (Figure 8.14 and Figure 8.15). 
The presence of subarachnoid haemorrhage was most sensitive for CAA-
associated ICH (96%, 95% CI 85 to 99%) in those with an ICH volume above 
the median, suggesting the absence of subarachnoid haemorrhage in this 
group can confidently rule out CAA-associated ICH. Conversely, the 
sensitivity of subarachnoid haemorrhage in the low ICH volume group was 
78% (95% CI 63 to 89). The presence of subarachnoid haemorrhage and 
finger-like projections was most specific in those with an ICH volume below 
the median (93%, 95% CI 75 to 99). Therefore the presence of these two 
features in this group can be used to rule in the diagnosis. In contrast, the 
specificity of these findings in the high ICH volume group was 71% (95% CI 
48 to 88). 
8.5.4.2 External validation of the Edinburgh CT and APOE diagnostic 
model and criteria 
The Edinburgh CT and APOE diagnostic model showed reasonable 
calibration for the intermediate predicted probability (APOE 4 possession) 
and high predicted probability of CAA-associated ICH. The model 
underestimated the frequency of CAA-associated ICH for the low predicted 
and intermediate (subarachnoid haemorrhage) probability cases. The 
positive intercept (0.30) indicates that model predictions are systematically 
too low (calibration-in-the-large). The calibration slope (0.19) is less than 1, 
reflecting the model predictions are too extreme.[336] The model showed 
only modest discrimination (c statistic 0.64). 
The rule out criteria of no subarachnoid haemorrhage or APOE 4 
possession showed high sensitivity for CAA-associated ICH (94% 95% CI 82 
to 98) compared with 100% (95% CI 88 to 100) in the development setting. 
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The rule in criteria of subarachnoid haemorrhage and APOE 4 possession 
or finger-like projections had limited specificity (63%, 95% CI 36 to 84) 
compared with 96% (95% CI 78 to 100) in the development cohort. 
As described above, there are several possible reasons for poor external 
validation of the model. In the CT and APOE external validation study, each 
of these is amplified. 
Overfitting in the development study is possible given that I included three 
variables (8.7 events per variable) and did not shrink the regression 
coefficients. However, two of the variables were pre-specified, and there was 
minimal optimism after internal validation. 
The frequency of CAA-associated ICH was much higher in the external 
validation (75%) compared to the development cohort (58%). This may relate 
to partial verification bias, where selection of patients for APOE genotyping 
favoured those with a higher clinical suspicion of CAA. This will increase the 
intercept and reduce net benefit.[334] 
The frequency of predictors was also higher in the external validation cohort 
than in the development cohort. The mean predicted probability of CAA-
associated ICH was 72% in the external validation cohort compared with 
57% in the development cohort, with less spread of the predictions (standard 
deviation 31% versus 35% respectively). These factors will reduce the 
discrimination and net benefit of the model.[334] 
There were few participants classified as non-CAA-associated lobar ICH, 
which will impact on the specificity of the rule out criteria.[176] 
8.5.5 Clinical implications 
This study assessed the external validity of the Edinburgh CT-only model in a 
heterogeneous group of participants. The CT-only criteria showed good 
sensitivity and specificity for ruling out and ruling in CAA-associated lobar 
ICH. The CT-only criteria were most sensitive for CAA-associated ICH in 
larger ICH (≥56 ml) and could be used to rule out CAA-associated ICH in this 
group reliably. The CT-only criteria were most specific for CAA-associated 
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ICH when applied to smaller ICH (<56 ml). Therefore, the criteria can be 
used to reliably rule in CAA-associated ICH in this setting. This potentially 
obviates the need for further investigations, such as MRI, -amyloid PET or 
brain biopsy, which are more costly and less available than CT, and carry 
potential complications. 
The external validation study of the Edinburgh CT and APOE model was 
small with significant partial verification bias. It is therefore difficult to draw 
firm conclusions. 
8.5.6 Future directions 
Larger studies with unbiased routes to data collection are needed to refine 
the estimates of the Edinburgh CT-only model performance and to determine 
the external validity of the Edinburgh CT and APOE model and criteria. 
Samples should ideally be unselected and representative to establish 
generalisability in clinical practice,[334] and include APOE genotyping where 
possible. APOE genotyping and tissue sampling (brain biopsy or autopsy) 
should be offered to all participants to reduce the effect of partial verification 
bias.  
The current study included participants from Europe and North America. 
Assessment of the criteria in other geographical settings and participants of 
different ethnicities is needed to assess their wider generalisability. 
The CT ratings need to be performed by raters of different experience to 
determine whether the criteria can be reliably implemented by others. 
Imaging data in this study are currently being rated by Dr Andreas 
Charidimou, a neurology trainee in Boston, to assess inter-rater agreement. I 
have also developed online training materials for the Edinburgh criteria to 
hopefully improve inter-rater agreement.[330] Users can log into the website 
and rate a series of cases, which allows rater-agreement from a diverse 
group of raters to be assessed. 
Tissue sampling should be performed as close to the index ICH as possible, 
to limit the chance of false positive histopathological findings. The use of 
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systematically acquired autopsy provides the most robust reference 
standard, however, brain biopsy allows the criteria to be assessed in non-
fatal ICH cases. Assessment of both CAA and non-CAA SVD is important, 
given that patients with ICH may have CAA in isolation or mixed with non-
CAA SVD (Figure 4.13).[229] Differentiating these categories from pure non-
CAA SVD may be informative for prognosis. 
Finally, further work is needed to assess the impact of the Edinburgh criteria 
on clinical management and outcome of ICH patients. 
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Chapter 9 Diagnostic test accuracy studies of the 
Edinburgh diagnostic criteria for CAA-




The MRI-based modified Boston criteria are the non-invasive in vivo 
reference standard for diagnosing CAA-associated ICH [110] and are often 
used in clinical practice when MRI is available and in CAA research.[167, 
168] However, access to MRI may be limited in many parts of the world. 
Even in settings where MRI is available, many patients with ICH may not be 
able to tolerate an MRI scan. In the three-year community-based LATCH 
study of ICH in the NHS Lothian Health Board region, less than 30% of 
patients underwent a research brain MRI scan (Figure 3.4). Those who 
underwent MRI tended to be younger, with less pre-ICH disability and less 
frequent pre-ICH dementia, have a smaller ICH and less severe SVD 
features on CT. More widely available diagnostic tests for CAA-associated 
ICH are therefore needed. 
The Edinburgh criteria for CAA-associated lobar ICH are based primarily on 
CT, which is the most widely available neuroimaging modality, and usually 
the first test performed to diagnose ICH (Figure 3.1). The criteria can also 
incorporate APOE genotype which is performed on a peripheral blood test 
and is therefore potentially available worldwide, although not currently used 
routinely in the clinical setting. The Edinburgh CT-only criteria showed good 
sensitivity and specificity for diagnosing CAA-associated lobar ICH in the 
development setting (Chapter 7, [229]) and in an external validation study 
(Chapter 8). The Edinburgh CT and APOE criteria had excellent sensitivity 
and specificity for CAA-associated lobar ICH in the development setting 
(Chapter 7, [229]). However, how the Edinburgh criteria relate to the more 
established modified Boston criteria is unknown. 




I aimed to: 
 Perform diagnostic test accuracy studies of the Edinburgh CT-only 
and CT-APOE diagnostic criteria for CAA-associated lobar ICH (index 
tests) against the MRI-based modified Boston criteria (reference 
standard). 
 Compare the Edinburgh CT-only and CT-APOE criteria for CAA-
associated lobar ICH and the modified Boston criteria against a 
histopathological reference standard. 
 
9.3 Methods 
9.3.1 Study design and participants 
I used data from the prospective LINCHPIN study (section 2.1.3.2). I included 
consecutive adult participants (aged ≥16 years) living in the NHS Lothian 
Health Board region who had a first-ever lobar ICH between 1st June 2010 
and 31st May 2016 inclusive diagnosed by non-contrast brain CT who had a 
subsequent research brain MRI scan. Some of the LINCHPIN participants 
were included in the development and external validation studies of the 
Edinburgh diagnostic criteria. 
I defined lobar ICH as described in section 2.1.5.[190] 
I excluded patients with exclusively extra-axial intracranial haemorrhage, 
non-lobar ICH, ICH secondary to an underlying cause other than SVDs, 
recurrent ICH and those without diagnostic quality non-contrast brain CT and 
research brain MRI with T2*-GRE sequence. I did not exclude participants 
used in the development or external validation of the Edinburgh criteria. 
9.3.2 Baseline data collection 
We collected demographics, the presence of relevant co-morbidities and 
medication use at the time of ICH as described in the section 2.1.7. 
  Chapter 9 
389 
9.3.3 Index tests 
I reformatted the first diagnostic non-contrast brain CT and assessed them 
using a standardised pro forma as described in Section 2.2. I performed brain 
CT assessments masked to clinical, genetic, MRI and pathological data. 
APOE genotyping was performed on DNA extracted from peripheral blood or 
brain tissue using standard techniques described in Chapter 7, masked to 
radiological, clinical and pathological data. I defined APOE 2 and APOE 4 
allele possession if participants had at least one ɛ2 allele or one ɛ4 allele 
respectively, as described in Chapter 7. 
I pre-specified the low-risk Edinburgh criteria categories (CT-only: no 
subarachnoid haemorrhage or finger-like projections; CT-APOE: no 
subarachnoid haemorrhage, no APOE 4 allele possession and no finger-like 
projections) as the negative index test results as these cut-offs maximise the 
sensitivity of the criteria, and are the most useful for ruling out CAA. 
I pre-specified the high-risk Edinburgh criteria categories (CT-only: 
subarachnoid haemorrhage and finger-like projections; CT-APOE: 
subarachnoid haemorrhage plus APOE 4 allele possession and/or finger-
like projections) as the positive index test results as these cut-offs maximise 
the specificity of the criteria, and are the most useful for ruling in CAA. 
9.3.4 Reference standards 
9.3.4.1 MRI-based Modified Boston criteria 
I used the modified Boston criteria as the reference standard because it is 
the current non-invasive in vivo reference standard for diagnosing CAA.[167] 
I pre-specified the “probable CAA” category as CAA-associated lobar ICH 
and “possible CAA” or “no CAA” categories as non-CAA-associated lobar 
ICH given the high sensitivity (95% 95%CI 83-99) and moderate specificity 
(81% 95%CI 62-93) of this cut-off for CAA.[110] Probable CAA is also the 
key diagnostic cut-off used in clinical practice and in research.[167] 
I rated the research brain MRI scans for the presence of acute ICH and 
ischaemia, chronic ischaemic infarcts, lacunes of presumed vascular origin, 
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chronic haemorrhage and SVD biomarkers using the standardised pro forma 
described in the methods section (Appendix 2). I used the T2*-GRE 
sequence to categorise scans as probable CAA, possible CAA or no CAA 
according to the modified Boston criteria.[110] I performed all assessments 
masked to clinical, CT, genetic and pathological data. I performed the MRI 
ratings at least six months after the corresponding diagnostic non-contrast 
brain CT assessment to reduce diagnostic-review bias.[176] 
9.3.4.2 Research autopsy 
Where available, I compared the Edinburgh CT and modified Boston criteria 
against a research brain autopsy reference standard. Research brain 
autopsies were performed within five days of death according to a standard 
operating procedure. [217] A single neuropathologist (Professor C Smith) 
assessed samples for CAA severity using a consensus scale developed by 
Love et al[36] as described in Section 4.3.3.[229] I classified lobar ICH cases 
as CAA-associated using two cut-offs. First, if there was moderate or severe 
parenchymal CAA in the left cerebral hemisphere on the Love et al 
consensus scale[36] as used in the development of the Edinburgh criteria 
(Section 4.3.3 and Chapter 7).[229] And second, if the severity of CAA in any 
tissue sample was ≥2 on the Vonsattel scale as used in the development of 
the modified Boston criteria (Section 8.3.5).[110, 253] 
9.3.5 Statistical analysis 
I compared the frequency of clinical, genetic, CT and MRI characteristics 
between groups using 2 test (or Fisher's exact test, where appropriate) for 
categorical variables and the Mann-Whitney U test for non-normally 
distributed continuous variables.  
To determine the performance of the Edinburgh CT-only and CT-APOE 
diagnostic criteria I classified participants as low, intermediate or high risk of 
moderate/severe CAA using the cut-offs defined in the development study 
(chapter 7).[229] I assessed the diagnostic accuracy of the Edinburgh CT-
only and CT and APOE rule in criteria (high versus low/intermediate risk 
groups) and rule out (low versus intermediate/high risk) criteria separately 
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against the probable CAA category on the modified Boston criteria reference 
standard using sensitivity, specificity, likelihood ratios, and predictive values 
and their 95% CI. 
I performed statistical analyses using R statistical package version 3.4.4., 
except for the diagnostic accuracy statistics, for which I used VassarStats 
Clinical Calculator 1.[269] 
9.3.6 Missing data 
I excluded any participants with missing APOE 4 genotype from the CT and 
APOE criteria analysis. I did not to impute these missing values as APOE 4 
is one of only three predictors in the Edinburgh CT and APOE diagnostic 
model. I excluded participants with missing or poor quality research MRI 
scans as this was the reference standard, and I felt it was inappropriate to 
impute any missing data. 
9.3.7 Sample size 
I was unable to calculate the sample size required for a diagnostic test 
accuracy study because no studies have previously compared the Edinburgh 
and modified Boston criteria. Therefore, I used the largest sample possible 
from the prospective LINCHPIN study. 
 
9.4 Results 
9.4.1 Edinburgh CT-only criteria versus the modified Boston criteria 
diagnostic test accuracy study 
9.4.1.1 Flow of participants 
There were 612 patients with spontaneous ICH presumed related to SVD 
between 1st June 2010 and 31st May 2016. One hundred and sixty-five 
patients with a first-ever lobar ICH consented to the LINCHPIN study, of 
whom 161 had a diagnostic non-contrast brain CT. There were no reported 
adverse effects with the index test. I included 70 participants who had a 






Figure 9.1 Flow of participants through the Edinburgh CT-only versus modified Boston criteria diagnostic test accuracy study 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. MRI = magnetic resonance imaging. 
Edinburgh CT-only CAA criteria: Low risk = no subarachnoid haemorrhage or finger-like projections; Intermediate risk = subarachnoid 
haemorrhage or finger-like projections; High risk = subarachnoid haemorrhage and finger-like projections.
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9.4.1.2 Comparison of participants with the index test who underwent the 
MRI-based reference standard versus those who did not 
Participants who underwent both the index test (diagnostic non-contrast brain 
CT) and reference standard (research brain MRI) were younger with less 
frequent pre-ICH dementia, atrial fibrillation and ischaemic stroke and had a 
lower median pre-ICH modified Rankin scale score compared with LINCHPIN 
participants who only had the index test (Table 9.1). Those with both the 
index test and reference standard also had higher admission GCS, a smaller 
ICH volume, less frequent intraventricular haemorrhage and a lower CT SVD 
score compared with those who only had the index test (Table 9.2). The 
frequency of subarachnoid haemorrhage and finger-like projections was also 
lower in those who underwent both the index test and reference standard, 
although these differences did not reach statistical significance. 
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Table 9.1 Baseline clinical features of first-ever lobar ICH participants with a 
diagnostic non-contrast brain CT (index test) who also had a research brain 









Age (years); median 
(IQR) 


















Co-morbidities      
Hypertension 58 (64) 35 (50) 0.080 
Ischaemic stroke 13 (14) 2 (3) 0.013 
Transient ischaemic 
attack 
11 (12) 3 (4) 0.082 
Dementia 16 (18) 1 (1) 0.001 
Diabetes 10 (11) 6 (9) 0.611 
Atrial fibrillation 25 (28) 10  (14) 0.044 
Myocardial infarction 11 (12) 3 (4) 0.082 























Pre-ICH modified Rankin 
scale; median (IQR) 
2 (2-4) 1 (1-1) <0.001 
Medications on 
admission 
     
Antiplatelet drug(s) 46 (51) 24 (34) 0.039 
Anticoagulant drug(s) 16 (18) 9 (13) 0.412 
Antihypertensive 
drug(s) 
53 (58) 27 (39) 0.013 
Admission GCS; median 
(IQR) 
12 (10-14) 15 (14-15) <0.001 
Data are n (%) or median (IQR). * Fisher’s exact test. CT = computed 
tomography. GCS = Glasgow coma scale. ICH = intracerebral haemorrhage. 
LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and 
neurological outcome. MRI = magnetic resonance imaging.  
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Table 9.2 Non-contrast diagnostic brain CT features of first-ever lobar ICH 
participants with a diagnostic non-contrast brain CT (index test) who also had 
a research brain MRI (reference standard) versus those who did not 
 
Index test only 
(n=91) 




ICH volume (ml); median 
(IQR) 
55 (20-95) 18 (7-33) <0.001 
Intraventricular 
haemorrhage 
42 (46) 10 (14) <0.001 
Subarachnoid haemorrhage 65 (71) 46 (66) 0.437 
Subdural haemorrhage 20 (22) 9 (13) 0.135 
Finger-like projections 28 (31) 13 (19) 0.078 

















































Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, 
imaging and neurological outcome. MRI = magnetic resonance imaging. SVD 
= small vessel disease. 
 
9.4.1.3 Baseline clinical and diagnostic non-contrast brain CT 
characteristics in CAA-associated and non-CAA-associated lobar 
ICH groups 
Forty-three participants were classified as probable CAA on the modified 
Boston criteria reference standard (“CAA-associated lobar ICH”) while 27 
were classified as “non-CAA-associated lobar ICH” (8 possible CAA and 19 
no CAA). The frequency of co-morbidities and antithrombotic drug use and 
the time between diagnostic CT and research MRI were similar between the 
groups (Table 9.3). Subarachnoid haemorrhage and finger-like projections 
were significantly more frequent in the CAA-associated lobar ICH participants 
compared with the non-CAA-associated group (Table 9.4).  
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Table 9.3 Baseline clinical features of participants classified as CAA-






























Co-morbidities      
Hypertension 14 (52) 21 (49) 0.806 
Ischaemic stroke* 1 (4) 1 (2) 1.000 
Transient ischaemic 
attack* 
0 (0) 3 (7) 0.279 
Dementia* 0 (0) 1 (2) 1.000 
Diabetes* 1 (4) 5 (12) 0.394 
Atrial fibrillation* 5 (19) 5 (12) 0.493 
Myocardial infarction* 2 (7) 1 (2) 0.555 























Pre-ICH modified Rankin 
scale; median (IQR) 
1 (1-2) 1 (1-1) 0.539 
Medications on admission      
Antiplatelet drug(s) 8 (30) 16 (37) 0.515 
Anticoagulant drug(s)* 4 (15) 5 (12) 0.726 
Antihypertensive drug(s) 11 (41) 16 (37) 0.768 
Admission GCS; median 
(IQR) 
15 (14-15)  15 (14-15)  0.415 
Days between index ICH & 
CT; median (IQR) 
1 (0-2) 1 (0-2) 0.727 
Days between CT & MRI; 
median (IQR) 
74 (66-105) 92 (73-118) 0.466 
Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CT = computed tomography. GCS = Glasgow coma 
scale. ICH = intracerebral haemorrhage. MRI = magnetic resonance imaging.  
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Table 9.4 Non-contrast diagnostic brain CT features of participants classified 












ICH volume (ml); median 
(IQR) 
14 (3-22) 19 (14-34) 0.106 
Intraventricular 
haemorrhage* 
5 (19) 5 (12) 0.493 
Subarachnoid haemorrhage 11 (41) 35 (81) <0.001 
Subdural haemorrhage* 1 (4) 8 (19) 0.139 
Finger-like projections 1 (4) 12 (28) 0.011 

















































Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. SVD = small vessel disease. 
 
9.4.1.4 Distribution of MRI SVD-biomarkers between CAA-associated 
and non-CAA-associated lobar ICH groups 
Cortical superficial siderosis was present in 37 out of 43 participants with 
CAA-associated lobar ICH, compared with 11 out of 27 with non-CAA-
associated lobar ICH (Table 9.5). Participants with CAA-associated lobar ICH 
also had a significantly higher median MRI CAA SVD burden score. There 
was no statistically significant difference in the severity of WMH, atrophy or 
PVS between the groups. The presence and number of lobar CMBs were 
also similar between the groups.  
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Table 9.5 MRI characteristics of participants classified as CAA-associated 












score; median (IQR) 
3 (1-3) 3 (2-3) 0.401 
Deep Fazekas score; median 
(IQR) 
2 (1-2) 2 (1-2) 0.062 
Central atrophy; median 
(IQR) 
3 (2-4) 3 (2-4) 0.629 
Cortical atrophy; median 
(IQR) 
2 (1-3) 2 (1-3) 0.333 
Basal ganglia PVS; median 
(IQR) 
1 (1-2) 1 (1-2) 0.111 
Centrum semiovale PVS; 
median (IQR) 
2 (1-3) 2 (2-3) 0.425 
Cortical superficial siderosis 11 (41) 37  (86) <0.001 
Any lobar CMB 10 (37) 17 (40) 0.834 
Lobar CMBs; median (IQR) 0 (1-2) 0 (0-2) 0.772 
Any deep CMB* 12 (44) 0 (0) <0.001 
Deep CMBs; median (IQR) 0 (0-1) 0 (0-0) <0.001 
Any cerebellar CMB* 2 (7) 3 (7) 1.000 
Cerebellar CMBs; median 
(IQR) 
0 (0-0) 0 (0-0) 0.946 
Any brainstem CMB* 3 (11) 0 (0) 0.053 
Brainstem CMBs; median 
(IQR) 
0 (0-0) 0 (0-0) 0.027 
Any CMB 12 (44) 19 (44) 0.983 
Total CMBs; median (IQR) 0 (0-4) 0 (0-2) 0.609 
MRI SVD burden score; 
median (IQR) 
2 (1-3) 2 (1-2) 0.466 
MRI CAA SVD burden score; 
median (IQR) 
1 (1-2) 2 (1-4) 0.007 
Data are n (%) or median (IQR). * Fisher’s exact test. CAA = cerebral 
amyloid angiopathy. CMB = cerebral microbleed. CT = computed 
tomography. ICH = intracerebral haemorrhage. MRI = magnetic resonance 
imaging. PVS = perivascular space. SVD = small vessel disease.  
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9.4.1.5 Diagnostic accuracy of the Edinburgh CT-only criteria against the 
modified Boston criteria 
Table 9.6 shows the cross-tabulation of the Edinburgh CT-only criteria (index 
test) against the modified Boston criteria classification (reference standard). 
Thirty-five out of the 43 participants with CAA-associated lobar ICH had 
subarachnoid haemorrhage on CT, resulting in a sensitivity of 81% (95% CI 
66-91, Table 9.7) for the rule out Edinburgh CT-only criteria. One out of 28 
non-CAA-associated lobar ICH had both subarachnoid haemorrhage and 
finger-like projections on the Edinburgh CT-only criteria, resulting in a 
specificity of 96% (95%CI 79-100) for the rule in Edinburgh CT-only criteria. 
Table 9.6 Cross-tabulations of the Edinburgh CT-only criteria classifications 
against the modified Boston criteria 
Edinburgh CT-only 
criteria (Index test) 






Probable CAA Total 
Low 9 7 8 24 
Intermediate 9 1 23 33 
High 1 0 12 13 
Total 19 8 43 70 
Data are number. CAA = cerebral amyloid angiopathy. CT = computed 
tomography. MRI = magnetic resonance imaging. 
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Table 9.7 Diagnostic test accuracy statistics for the Edinburgh CT-only 
criteria using probable CAA on the modified Boston criteria as the reference 
standard cut off 
 Edinburgh CT-only criteria 
 
Subarachnoid haemorrhage 
(Intermediate or High risk) 
Subarachnoid haemorrhage 
and finger-like projections 
(High risk) 
Sensitivity 81 (66-91) 24 (13-38) 
Specificity 59 (40-77) 95 (72-100) 
Positive likelihood ratio 2.0 (1.2-3.2) 4.5 (0.6-32.1) 
Negative likelihood 
ratio 
0.3 (0.2-0.6) 0.8 (0.7-0.9) 
Positive predictive 
value 
76 (61-87) 92 (62-100) 
Negative predictive 
value 
67 (45-84) 32 (20-45) 
Data are percentage or ratio (95%CI). CAA = cerebral amyloid angiopathy. 
CT = computed tomography. ICH = intracerebral haemorrhage. 
 
Examples of true positive and true negative cases are shown in Figure 9.2 
and Figure 9.3 respectively. The clinical and imaging findings for the one 
false positive case for the rule in criteria and the eight false negative cases 
for the rule out criteria are summarised in Figure 9.4 and Figure 9.5 
respectively.  
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Figure 9.2 True positive result for the Edinburgh CT-only criteria against the 
modified Boston criteria 
A. Sagittal non-contrast diagnostic brain CT image showing a right frontal 
ICH with finger-like projections (black arrowheads) and subarachnoid 
haemorrhage (black arrow). The participant is classified as high risk for CAA 
on the Edinburgh CT-only criteria. 
B. Axial T2*-GRE image showing a right frontal ICH with diffuse cortical 
superficial siderosis (white arrows). The participant is classified as probable 
CAA on the modified Boston criteria. 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. GRE = 
gradient recalled echo. ICH = intracerebral haemorrhage. MRI = magnetic 
resonance imaging. 
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Figure 9.3 An example of a true negative index test result for the Edinburgh 
CT-only criteria against the MRI-based modified Boston criteria reference 
standard. 
A. Axial non-contrast diagnostic brain CT image showing a small left frontal 
ICH. There is no subarachnoid haemorrhage or finger-like projections. The 
participant is classified as low risk for CAA on the Edinburgh CT-only criteria. 
B. Axial T2*-GRE image showing lobar (white arrows) and deep (white 
arrowhead) cerebral microbleeds. The participant is classified as no CAA on 
the modified Boston criteria. 
 
CAA = cerebral amyloid angiopathy. CT = computed tomography. GRE = 







Figure 9.4 Discrepancies between the Edinburgh CT-only and CT-APOE criteria and the modified Boston criteria reference 
standard 
A. False positive index test result for both the Edinburgh CT-only and CT-APOE criteria. 
B to E. False positive index test results for the Edinburgh CT-APOE criteria alone. 
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B 43 year-old male 
 











Time from ICH to 
CT 1 days 
 
 


















Left parietal lobar 











criteria – No CAA 
 
Time from CT to 






 Clinical details CT features MRI features Example CT and T2*-GRE images 
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D 82 year-old female 
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 Clinical details CT features MRI features Example CT and T2*-GRE images 
E 83 year-old male 
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Time from CT to 
MRI 91 days  
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed tomography. GRE = gradient recalled echo. 






Figure 9.5 Discrepancies between the Edinburgh CT-only and CT-APOE criteria and the modified Boston criteria reference 
standard 
A to E. False negative index test results for the Edinburgh CT-only criteria alone. 
F to H. False negative index test results for both the Edinburgh CT-only and CT-APOE criteria. 
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 Clinical details CT features MRI features Example CT and T2*-GRE images 
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 Clinical details CT features MRI features Example CT and T2*-GRE images 
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 Clinical details CT features MRI features Example CT and T2*-GRE images 
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 Clinical details CT features MRI features Example CT and T2*-GRE images 
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 Clinical details CT features MRI features Example CT and T2*-GRE images 
H 82 year-old female 
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Time from CT to 
MRI 31 days 
 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed tomography. GRE = gradient recalled echo. 
ICH = intracerebral haemorrhage. MRI = magnetic resonance imaging. 
  Chapter 9 
416 
9.4.2 Edinburgh CT-APOE criteria versus the modified Boston 
criteria 
9.4.2.1 Flow of participants 
One hundred and thirty-two of the 165 LINCHPIN participants with a first-ever 
lobar ICH consented to the LINCHPIN study and had both a diagnostic non-
contrast brain CT and APOE genotyping. There were no reported adverse 
effects with the index tests. I included 58 participants who had a subsequent 
research brain MRI with T2*-GRE sequence (Figure 9.6). 
9.4.2.2 Comparison of participants with the index test who underwent the 
reference standard versus those who did not 
Participants who underwent both the index tests (diagnostic non-contrast 
brain CT and APOE genotyping) and reference standard (research brain 
MRI) were younger with less frequent pre-ICH dementia, atrial fibrillation, 
hypertension and ischaemic stroke and a lower median pre-ICH modified 
Rankin scale score compared with those who had only the index test (Table 
9.8). Those with both the index tests and reference standard also had higher 
admission GCS, a smaller ICH volume, less frequent intraventricular and 
subdural haemorrhage and a less severe CT SVD score compared with 
those who had only the index test (Table 9.9). The frequencies of 
subarachnoid haemorrhage and finger-like projections were lower in those 
who underwent both the index test and reference standard, while APOE 2 
and APOE 4 allele possession were more common, although these 
differences did not reach statistical significance. 
9.4.2.3 Baseline clinical and diagnostic non-contrast brain CT 
characteristics associated with CAA-associated and non-CAA-
associated lobar ICH groups 
Thirty-five participants were classified as probable CAA on the modified 
Boston criteria reference standard (“CAA-associated lobar ICH”), whereas 23 
were classified as “non-CAA-associated lobar ICH” (8 possible CAA and 15 
no CAA). The frequency of co-morbidities and antithrombotic drug use and 
the time between diagnostic CT and research MRI were similar between the 
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groups (Table 9.10). Subarachnoid haemorrhage was significantly more 
frequent in the CAA-associated lobar ICH participants compared with the 
non-CAA-associated lobar ICH group (Table 9.11). Finger-like projections 
were also more common in the CAA-associated lobar ICH group, although 






Figure 9.6 Flow of participants in the Edinburgh CT-APOE criteria versus modified Boston criteria diagnostic test accuracy 
study 
 
APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. MRI = 
magnetic resonance imaging. Edinburgh CT & APOE CAA criteria: Low risk = no subarachnoid haemorrhage, APOE 4 allele possession 
or finger-like projections; Intermediate risk = either subarachnoid haemorrhage or APOE 4 allele possession; High risk = subarachnoid 
haemorrhage plus APOE 4 allele possession and/or finger-like projections.
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Table 9.8 Baseline clinical features of first-ever lobar ICH participants with a 
diagnostic non-contrast brain CT scan and APOE genotyping (index test) 









Age (years); median 
(IQR) 


















Co-morbidities      
Hypertension 51 (69) 29 (50) 0.027 
Ischaemic stroke 12 (16) 1 (2) 0.006 
Transient ischaemic 
attack 
10 (14) 3 (5) 0.110 
Dementia 13 (18) 1 (2) 0.003 
Diabetes 8 (11) 5 (9) 0.675 
Atrial fibrillation 22 (30) 8 (14) 0.030 
Myocardial infarction 11 (15) 2 (3) 0.029 























Pre-ICH modified Rankin 
scale; median (IQR) 
2 (2-4) 1 (1-1) <0.001 
Medications on 
admission 
     
Antiplatelet drug(s) 40 (54) 19 (33) 0.015 
Anticoagulant drug(s) 11 (15) 8 (14) 0.862 
Antihypertensive 
drug(s) 
42 (57) 21 (36) 0.019 
Admission GCS; median 
(IQR) 
12 (9-14) 15 (14-15) <0.001 
Data are n (%) or median (IQR). * Fisher’s exact test. APOE = apolipoprotein 
E. CT = computed tomography. GCS = Glasgow coma scale. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. MRI = magnetic resonance 
imaging.  
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Table 9.9 Non-contrast diagnostic brain CT features and APOE genotype of 
first-ever lobar ICH participants with a diagnostic non-contrast brain CT scan 
and APOE genotyping (index test) who had a research brain MRI (reference 














19 (7-33) <0.001 
Intraventricular 
haemorrhage 
36 (49) 10 (17) <0.001 
Subarachnoid 
haemorrhage 
51 (69) 37 (64) 0.535 
Subdural haemorrhage 16 (22) 5 (9) 0.043 
Finger-like projections 19 (26) 9 (16) 0.157 



























APOE 2 allele 
possession 
17 (23) 20 (35) 0.144 
APOE 4 allele 
possession 
23 (31) 26 (45) 0.105 






















Data are n (%) or median (IQR). * Fisher’s exact test. APOE = apolipoprotein 
E. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. MRI = magnetic resonance 
imaging. SVD = small vessel disease.  
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Table 9.10 Baseline clinical features in participants classified as CAA-





























Co-morbidities      
Hypertension 12 (52) 17 (49) 0.788 
Ischaemic stroke* 0 (0) 1 (3) 1.000 
Transient ischaemic 
attack* 
0 (0) 3 (9) 0.270 
Dementia* 0 (0) 1 (3) 1.000 
Diabetes* 0 (0) 5 (14) 0.146 
Atrial fibrillation* 4 (17) 4 (11) 0.700 
Myocardial infarction* 1 (4) 1 (3) 1.000 























Pre-ICH modified Rankin 
scale; median (IQR) 
1 (1-2) 1 (1-1) 0.719 
Medications on admission      
Antiplatelet drug(s) 6 (26) 13 (37) 0.380 
Anticoagulant drug(s)* 4 (17) 4 (11) 0.700 
Antihypertensive drug(s) 9 (39) 12 (34) 0.707 
Admission GCS; median 
(IQR) 
15 (14-15) 15 (14-15) 0.596 
Days between index ICH & 
CT; median (IQR) 
1 (0-2) 1 (0-2) 0.987 









Data are n (%) or median (IQR). * Fisher’s exact test. APOE = apolipoprotein 
E. CAA = cerebral amyloid angiopathy. CT = computed tomography. GCS = 
Glasgow coma scale. ICH = intracerebral haemorrhage. MRI = magnetic 
resonance imaging.  
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Table 9.11 Non-contrast diagnostic brain CT features and APOE genotype in 
participants classified as CAA-associated versus non-CAA-associated lobar 











ICH volume (ml); median (IQR) 17 (4-35) 20 (13-33) 0.386 
Intraventricular haemorrhage* 5 (22) 5 (14) 0.496 
Subarachnoid haemorrhage 10 (44) 27 (77) 0.009 
Subdural haemorrhage* 0 (0) 5 (14) 0.146 
Finger-like projections* 1 (4) 8 (23) 0.073 



























APOE 2 allele possession 8 (35) 12 (34) 0.969 
APOE 4 allele possession 9 (39) 17 (49) 0.479 






















Data are n (%) or median (IQR). * Fisher’s exact test. APOE = apolipoprotein 
E. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. SVD = small vessel disease. 
 
9.4.2.4 Distribution of MRI SVD-biomarkers between probable CAA and 
no CAA/possible CAA participants 
Cortical superficial siderosis was present in 30 out of 35 participants with 
CAA-associated lobar ICH, compared with 9 out of 23 with non-CAA-
associated lobar ICH (Table 9.12). Participants with CAA-associated lobar 
ICH also had a higher median MRI CAA SVD burden score. There was no 
statistically significant difference in the severity of WMH, atrophy or PVS 
between the groups. The presence and number of lobar CMBs were also 
similar between the groups. 
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Table 9.12 MRI characteristics of participants classified as CAA-associated 











Periventricular Fazekas score; 
median (IQR) 
3 (2-4) 4 (3-4) 0.274 
Deep Fazekas score; median 
(IQR) 
2 (2-3) 3 (2-3) 0.083 
Central atrophy; median (IQR) 3 (2-4) 3 (2-4) 0.812 
Cortical atrophy; median (IQR) 2 (2-3) 2 (1-3) 0.249 
Basal ganglia PVS; median 
(IQR) 
1 (1-2) 1 (1-2) 0.174 
Centrum semiovale PVS; 
median (IQR) 
3 (2-4) 3 (3-4) 0.272 
Cortical superficial siderosis 9 (39) 30 (86) <0.001 
Any lobar CMB 8 (35) 11 (31) 0.790 
Lobar CMBs; median (IQR) 0 (0-2) 0 (0-1) 0.717 
Any deep CMB* 9 (39) 0 (0) <0.001 
Deep CMBs; median (IQR) 0 (0-1) 0 (0-0) <0.001 
Any cerebellar CMB* 2 (9) 3 (9) 1.000 
Cerebellar CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.987 
Any brainstem CMB* 2 (9) 0 (0) 0.153 
Brainstem CMBs; median (IQR) 0 (0-0) 0 (0-0) 0.078 
Any CMB 9 (39) 13 (37) 0.879 
Total CMBs; median (IQR) 0 (0-3) 0 (0-1) 0.471 
MRI SVD burden score; median 
(IQR) 
2 (1-3) 2 (1-2) 0.492 
MRI CAA SVD burden score; 
median (IQR) 
1 (0-2) 2 (1-3) 0.006 
Data are n (%) or median (IQR). * Fisher’s exact test. APOE = apolipoprotein 
E. CAA = cerebral amyloid angiopathy. CMB = cerebral microbleed. CT = 
computed tomography. MRI = magnetic resonance imaging. PVS = 
perivascular space. SVD = small vessel disease.  
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9.4.2.5 Diagnostic accuracy of the Edinburgh CT-APOE criteria against 
the modified Boston criteria  
Table 9.13 shows the cross-tabulation of the Edinburgh CT-APOE criteria 
(index test) against the modified Boston criteria classification (reference 
standard). Thirty-one out of the 35 participants classified as CAA-associated 
lobar ICH had subarachnoid haemorrhage or APOE 4 allele possession, 
resulting in a sensitivity of 89% (95% CI 72-96, Table 9.14) for the rule out 
Edinburgh CT-APOE criteria. Five out of 23 participants classified as non-
CAA-associated lobar ICH had subarachnoid haemorrhage plus APOE 4 
allele possession and/or finger-like projections on the Edinburgh CT-APOE 
criteria, resulting in a specificity of 78% (95%CI 56-92) for the rule in 
Edinburgh CT-APOE criteria. 
 
Table 9.13 Cross-tabulations of the Edinburgh CT-APOE criteria 













Low 4 5 4 13 
Intermediate 7 2 13 22 
High 4 1 18 23 
Total 15 8 35 58 
Data are number. APOE = apolipoprotein E. CAA = cerebral amyloid 
angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. 
MRI = magnetic resonance imaging. 
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Table 9.14 Diagnostic test accuracy statistics for the Edinburgh CT-APOE 
criteria using probable CAA on the modified Boston criteria as the reference 
standard cut off 
 Edinburgh CT-APOE criteria 
 
Subarachnoid 
haemorrhage or APOE 4+ 
(Intermediate or High risk 
Subarachnoid 
haemorrhage and (APOE 
4+ or finger-like 
projections) (High risk) 
Sensitivity 89 (72-96) 51 (34-68) 
Specificity 39 (20-61) 78 (56-92) 
Positive likelihood ratio 1.5 (1.0-2.1) 2.4 (1.0-5.5) 
Negative likelihood 
ratio 
0.3 (0.1-0.8) 0.6 (0.4-0.9) 
Positive predictive 
value 
69 (53-81) 78 (56-92) 
Negative predictive 
value 
69 (39-90) 51 (34-68) 
Data are percentage or ratio (95%CI). APOE = apolipoprotein E. CAA = 
cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. 
 
Examples of true positive and true negative cases are shown in Figure 9.7 
and Figure 9.8 respectively. The clinical and imaging findings for the five 
false positive cases for the rule in criteria and the four false-negative cases 
for the rule out criteria and are summarised in Figure 9.4 and Figure 9.5 
respectively. 
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Figure 9.7 True positive result for the Edinburgh CT-APOE criteria against 
the modified Boston criteria 
A. Axial non-contrast diagnostic brain CT image showing a left frontal ICH 
with subarachnoid haemorrhage (black arrow) but no finger-like projections. 
The APOE genotype is 2/4. The participant is classified as high risk for CAA 
on the Edinburgh CT-APOE criteria. 
B. Axial T2*-GRE image showing a left frontal ICH with diffuse cortical 
superficial siderosis (white arrows) and lobar microbleeds (white 
arrowheads). The participant is classified as probable CAA on the modified 
Boston criteria. 
 
APOE = apolipoprotein. CAA = cerebral amyloid angiopathy. CT = computed 
tomography. GRE = gradient recalled echo. ICH = intracerebral 
haemorrhage. MRI = magnetic resonance imaging. 
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Figure 9.8 True negative result for the Edinburgh CT-APOE criteria against 
the modified Boston criteria 
A. Axial non-contrast diagnostic brain CT image showing a right temporal 
lobar ICH. There is no subarachnoid haemorrhage or finger-like projections. 
The APOE genotype is 3/3.The participant is classified as low risk for CAA 
on the Edinburgh CT-APOE criteria. 
B. Axial T2*-GRE image showing right temporal (white arrow) and basal 
ganglia (white arrowhead) ICHs. The participant is classified as no CAA on 
the modified Boston criteria. 
 
APOE = apolipoprotein. CAA = cerebral amyloid angiopathy. CT = computed 
tomography. GRE = gradient recalled echo. ICH = intracerebral 
haemorrhage. MRI = magnetic resonance imaging. 
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9.4.3 Comparison of the Edinburgh and modified Boston criteria 
against a histopathological reference standard 
9.4.3.1 Flow of participants 
Nine of the 70 participants with a first-ever lobar ICH diagnosed by non-
contrast brain CT and subsequent research brain MRI with T2*-GRE 
sequence had a research brain autopsy. All nine participants also had APOE 
genotyping. 
9.4.3.2 Comparison of participants with brain CT and MRI who 
underwent research autopsy versus those who have not had a 
research autopsy 
Comparison of those who had a research autopsy and those did not is 
difficult due to the small numbers in the research autopsy group. Those 
underwent autopsy were significantly older than those without an autopsy 
(Table 9.15). The frequency of subarachnoid haemorrhage and APOE 4 
allele possession between the groups was similar. However, none of the 
autopsy group had finger-like projections (Table 9.16). 
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Table 9.15 Baseline clinical features in first-ever lobar ICH participants with a 
diagnostic non-contrast brain CT scan, APOE genotyping and research brain 
MRI who had a research brain autopsy (reference standard) versus those 


























Co-morbidities      
Hypertension* 31 (51) 4 (44) 1.000 
Ischaemic stroke* 2 (3) 0 (0) 1.000 
Transient ischaemic attack* 3 (5) 0 (0) 1.000 
Dementia* 0 (0) 1 (11) 0.129 
Diabetes* 6 (10) 0 (0) 1.000 
Atrial fibrillation* 8 (13) 2 (22) 0.607 
Myocardial infarction* 2 (3) 1 (11) 0.343 























Pre-ICH modified Rankin scale; 
median (IQR) 
1 (1-1) 1 (1-2) 0.405 
Medications on admission      
Antiplatelet drug(s)* 22 (36) 2 (22) 0.708 
Anticoagulant drug(s)* 8 (13) 1 (11) 1.000 
Antihypertensive drug(s)* 24 (39) 3 (33) 1.000 
Admission GCS; median (IQR) 15 (14-15) 14 (14-15) 0.151 
Days between index ICH & CT; 
median (IQR) 
1 (0-2) 1 (0-3) 0.567 
Days between CT & MRI; 
median (IQR) 
89 (71-110) 85 (55-112) 0.614 
Data are n (%) or median (IQR). * Fisher’s exact test. APOE = apolipoprotein 
E. CAA = cerebral amyloid angiopathy. CT = computed tomography. GCS = 
Glasgow coma scale. ICH = intracerebral haemorrhage. LINCHPIN = Lothian 
intracerebral haemorrhage pathology, imaging and neurological outcome. 
MRI = magnetic resonance imaging.  
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Table 9.16 Non-contrast diagnostic brain CT features and APOE genotype in 
first-ever lobar ICH participants with a diagnostic non-contrast brain CT scan, 
APOE genotyping and research brain MRI who had a research brain autopsy 








ICH volume; median (IQR) 19 (9-32) 16 (5-34) 0.498 
Intraventricular haemorrhage* 9 (15) 1 (11) 1.000 
Subarachnoid haemorrhage* 40 (66) 6 (67) 1.000 
Subdural haemorrhage* 9 (15) 0 (0) 0.592 
Finger-like projections* 13 (21) 0 (0) 0.193 



























APOE 2 allele possession†* 16 (33) 4 (44) 0.704 
APOE 4 allele possession†* 21 (43) 5 (56) 0.717 












































Data are n (%) or median (IQR). * Fisher’s exact test. † APOE genotype 
missing in 12 participants without research autopsy. APOE = apolipoprotein 
E. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. MRI = magnetic resonance 
imaging. SVD = small vessel disease. 
 
9.4.3.3 Comparison of the Edinburgh and modified Boston criteria 
against the histopathological assessment of CAA 
Three of the nine participants had absent or mild parenchymal CAA on 
histopathological assessment using the consensus Love et al. scale[36] (
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Figure 9.9). Two of these were classified as intermediate risk of CAA on both 
the CT-only and CT-APOE Edinburgh criteria and the other as low risk on 
both sets of Edinburgh criteria. All three were classified as probable CAA by 
the modified Boston criteria. 
Six of the nine participants had moderate or severe left hemisphere 
parenchymal CAA on histopathological assessment using the consensus 
Love et al. scale.[36] Two were classified as low risk and four as intermediate 
risk using the Edinburgh CT-only criteria. APOE 4 allele possession 
upgraded the classification in five, resulting in one low risk, one intermediate 
risk and four high risk for CAA using the CT-APOE Edinburgh criteria. Four of 
the participants were classified as probable CAA, one as possible and one as 
no CAA using the modified Boston criteria. 
Two participants had a Vonsattel grade <2. One was classified as 
intermediate risk of CAA on both the CT-only and CT-APOE Edinburgh 
criteria and the other as low risk on both sets of Edinburgh criteria. Both 
participants were classified as probable CAA by the modified Boston criteria. 
Seven participants had a Vonsattel grade ≥2. Two were classified as low risk 
and five as intermediate risk using the Edinburgh CT-only criteria. APOE 4 
possession upgraded the classification in five, resulting in one low risk, two 
intermediate risk and four high risk for CAA using the CT-APOE Edinburgh 
criteria. Five of the participants were classified as probable CAA, one as 
possible and one as no CAA using the modified Boston criteria. 
 





Figure 9.9 Clinical features and non-contrast CT and MRI brain scan features in participants with diagnostic brain CT, research 
brain MRI, APOE genotyping and research autopsy. 
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Time from MRI to 
autopsy = 321 
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Time from MRI to 
autopsy = 1712 
days 
APOE = apolipoprotein. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. 
MRI = magnetic resonance imaging. SVD = small vessel diseases.
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9.5 Discussion 
9.5.1 Main findings 
 The Edinburgh CT-only rule out criteria (no subarachnoid 
haemorrhage or finger-like projections) were 81% sensitive for 
probable CAA on the modified Boston criteria.  
 The Edinburgh CT-only rule in criteria (subarachnoid haemorrhage 
and finger-like projections) were 96% specific for probable CAA on the 
modified Boston criteria. 
 The Edinburgh CT-APOE rule out criteria (no subarachnoid 
haemorrhage, APOE 4 allele possession or finger-like projections) 
were 89% sensitive for probable CAA on the modified Boston criteria.  
 The Edinburgh CT-APOE rule in criteria (subarachnoid haemorrhage 
plus APOE 4 allele possession and/or finger-like projections) were 
78% specific for probable CAA on the modified Boston criteria. 
9.5.2 Strengths of the study 
I performed and reported the study accorded to the STARD guidelines for 
diagnostic accuracy studies.[173] Important strengths are: 
 We used prospective case ascertainment to reduce selection bias by 
inviting all potentially eligible patients to the study.[175, 287] 
 I only included participants with first-ever ICH to provide a standard 
inception point. 
 The reference standard was acquired prospectively, and we optimised 
procedures for the study question.[175] 
 The reference standard was offered to all eligible participants, 
regardless of clinical features or the results of the index test to reduce 
partial verification bias.[174, 176, 246] 
 All included participants underwent the same index test and reference 
standard to avoid differential verification bias.[174] 
 I minimised information bias for the diagnostic non-contrast brain CT 
index test by standardising imaging format, using the same definition 
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for CT predictors as I used in the development study, and performing 
the ratings masked to clinical, genetic and MRI data.[175, 176] 
 We minimised information bias for the brain MRI reference standard 
by performing it at a standardised time point after the index ICH and 
using a standard MRI acquisition protocol for all participants. I followed 
published guidance for rating SVD biomarkers on MRI,[77, 107] and 
performed the ratings masked to clinical, genetic and CT findings.[175, 
176] 
 I pre-specified the cut-offs for the index tests and reference standard 
 I reported the flow of participants through the study and described the 
differences between those who did and did not undergo the reference 
standard to illustrate selection bias.[174, 175]  
 I described the baseline clinical and radiographic features and the 
distribution of MRI SVD biomarkers in the study groups to describe the 
disease spectrum within the included participants.[175, 176] 
9.5.3 Limitations of the study 
Although I tried to limit selection bias, those undergoing the MRI reference 
standard were younger, with fewer pre-ICH co-morbidities, less pre-ICH 
disability and lower CT SVD scores (Table 9.1, Table 9.2, Table 9.8 and 
Table 9.9). They also had smaller ICH volumes, less frequent intraventricular 
haemorrhage and had a higher GCS on hospital admission. These 
differences probably reflect the feasibility of MRI scanning in this patient 
group and highlight the drawbacks of MRI-based diagnostic criteria in ICH. 
Importantly, we attempted to offer the MRI reference standard to all eligible 
participants. Therefore the decision to perform a research MRI was not 
influenced by clinical characteristics or index test results, thereby limiting 
partial verification bias. In line with this, the frequencies of subarachnoid 
haemorrhage, finger-like projections and APOE 4 allele possession were not 
significantly different between those who did and did not undergo the 
reference standard, as were the distribution of classifications using the CT-
only and CT-APOE Edinburgh criteria (Table 9.3, Table 9.4, Table 9.10 and 
Table 9.11). 
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The sample size in my studies is modest. Seventy participants had both 
diagnostic non-contrast brain CT and research brain MRI, while 58 had 
diagnostic non-contrast brain CT, APOE genotyping and research brain MRI. 
The modest sample sizes result in less precise estimates of diagnostic 
accuracy.[289]  
The ideal assessment of the Edinburgh and modified Boston criteria would 
be to compare them against histopathological assessment for CAA. 
Currently, there are only nine LINCHPIN participants with a first-ever lobar 
ICH, who had diagnostic non-contrast brain CT, research brain MRI and 
research autopsy, which precludes any conclusions being drawn. 
I performed all CT and MRI ratings. Assessment by other raters with different 
levels of experience is important to assess the diagnostic accuracy of the 
Edinburgh criteria in a wider setting. 
9.5.4 Study findings 
The presence of subarachnoid haemorrhage (intermediate and high-risk 
groups on the Edinburgh CT-only criteria) had good sensitivity (81% (95%CI 
66-91)) for probable CAA on the modified Boston criteria. There were eight 
false negatives, where no subarachnoid haemorrhage was present on the 
diagnostic CT, but the research MRI showed multiple lobar haemorrhagic foci 
resulting in a probable CAA classification on the modified Boston criteria 
(Figure 9.5). There are several possible reasons for this.  
The Edinburgh CT-only criteria rely solely on features of the acute 
haemorrhage on the diagnostic non-contrast brain CT scan. In contrast, the 
modified Boston criteria include features of previous haemorrhagic lesions, 
such as cortical superficial siderosis and lobar CMBs, which are not visible 
on CT. Therefore the modified Boston criteria may have a higher sensitivity 
for CAA. 
The sensitivity of the Edinburgh criteria for CAA-associated lobar ICH is likely 
to be reduced in certain patient groups. For three of the eight false negative 
results, the diagnostic CT was performed between 3 and 5 days after the 
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symptom onset. The sensitivity of the Edinburgh criteria in such situations 
may be lower than patients scanned acutely as subarachnoid haemorrhage 
will resolve and the haematoma shape can change with time as the blood 
products start to resorb.[229] Secondly, the participants included in this study 
tended to have small ICH volumes (median 18 ml, IQR 7-33) compared with 
the development study (median 60 ml, IQR 20-118) and the external 
validation study (median 56 ml, IQR 33-86). In Chapter 8 I showed that the 
sensitivity of the Edinburgh CT-only criteria was lower in those with smaller 
ICH volume. All of the eight false negatives had an ICH volume ≤50 ml, and 
for seven the ICH volume was ≤20 ml.  
Finally, the Edinburgh and modified Boston criteria were developed using 
different definitions of CAA-associated ICH. Therefore some discordance 
between them is to be expected. 
The combination of subarachnoid haemorrhage and finger-like projections 
(Edinburgh CT-only high-risk group) was extremely specific (96% (95%CI 79-
100)) for probable CAA on the modified Boston criteria. There was only one 
false positive using these Edinburgh CT-only rule in criteria. This occurred in 
a 78-year-old male who had a single lobar ICH, several lobar CMBs and 
cortical superficial siderosis, but one thalamic CMB (Figure 9.4). The 
participant is classified as “no CAA” by the modified Boston criteria given the 
single deep CMB. However, the relevance of a single deep haemorrhagic 
lesion in the presence of multiple lobar haemorrhagic lesions on a patient’s 
likelihood of CAA is unclear,[167] and may indicate coexisting CAA and non-
CAA SVDs (Figure 4.13).[229] 
The presence of subarachnoid haemorrhage or APOE 4 allele possession 
+/- finger-like projections (Edinburgh CT-APOE criteria intermediate and 
high-risk groups) increased the sensitivity for probable CAA on the modified 
Boston criteria to 89% (95%CI 72-96). The four false negative results using 
this cut-off are summarised in Figure 9.5. I have discussed the potential 
reasons for these above. In particular, three of the four false negatives had 
an ICH volume ≤5 ml. 
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The high-risk group on the Edinburgh CT-APOE criteria (subarachnoid 
haemorrhage plus APOE 4 allele possession and/or finger-like projections) 
had a specificity of 78% (95%CI 56-92) for probable CAA on the modified 
Boston criteria. The five false positive results using this cut-off are 
summarised in Figure 9.4. Three of these had multiple lobar haemorrhagic 
lesions but a single deep CMB or old haemorrhage. As discussed above, 
these participants are classified as “no CAA” by the modified Boston criteria. 
However, it is unclear whether this is appropriate when there are multiple 
lobar haemorrhagic lesions given the frequent co-existence of CAA and 
arteriolosclerosis (Figure 4.13).[167, 229] Another false positive occurred in a 
50-year-old female who had a frontal ICH and cortical superficial siderosis. 
She were classified as “no CAA” on the modified Boston criteria because she 
was less than 55 years old at the time of her ICH. Whilst CAA is an age-
related disease, the validity of a strict age cut-off for diagnosing CAA-
associated is uncertain. 
9.5.5 Future directions 
The Edinburgh CT-only and CT-APOE diagnostic criteria show good 
sensitivity and specificity for probable CAA on the modified Boston criteria. 
However the sample size in this study was modest. In particular, the number 
of participants with diagnostic CT, MRI and histopathology was too small to 
draw any conclusions. 
Future work should aim to assess the diagnostic accuracy of the Edinburgh 
criteria against the modified Boston criteria in a larger sample to allow more 
precise estimates. A larger sample size would also allow the diagnostic 
accuracy of the Edinburgh criteria to be assessed in relevant subgroups, 
such as those with a small ICH volume and those who have a delay between 
symptom onset and diagnostic non-contrast brain CT. The inclusion of 
participants who have been scanned on MRI scanners with different field 
strengths (1.5T and 3T) and different blood-sensitive sequences (T2*-GRE 
and SWI) will be important given the effects these factors have on the 
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sensitivity for detecting CMBs and cortical superficial siderosis.[109, 209, 
341-346]  
I am currently coordinating a multi-centre diagnostic test accuracy study of 
the modified Boston criteria and the Edinburgh CT-only and CT-APOE 
criteria against a histopathological reference standard. This study includes 
adults with first-ever lobar ICH with a diagnostic non-contrast brain CT, 
APOE genotype if available, subsequent brain MRI with blood-sensitive 
sequence and histopathology assessment (cortical biopsy or brain autopsy) 
for CAA. This is the ideal study design to assess the diagnostic test accuracy 
of the Edinburgh and modified Boston criteria, and will provide more precise 
information on the accuracy and concordance of the two sets of criteria. 
Another important area for future research is the risk of CAA-associated 
outcomes, such as recurrent ICH and post-stroke dementia, predicted by the 
Edinburgh and modified Boston criteria. Studies should assess whether the 
two sets of diagnostic criteria are additive for future risk of CAA-associated 
outcomes. For example, are patients classified as low risk of CAA on both 
the Edinburgh and modified Boston criteria at a lower risk of recurrent ICH 
than those classified as low risk on only one of the criteria? Conversely, are 
those classified as high risk by the Edinburgh criteria and probable CAA by 
the modified Boston criteria at the highest risk of recurrent ICH? What is the 
significance of discordant classifications by the two diagnostic criteria? 
Ultimately the question of whether the CT-based Edinburgh criteria can be 
used to identify patients who will or will not benefit from further assessment of 
SVD biomarkers using MRI will be important to investigate to inform the 
rational use of imaging in clinical practice. 
Finally, these data highlight some of the drawbacks of the modified Boston 
criteria. In particular, the presence of a single deep CMB in a patient with 
multiple lobar haemorrhagic foci results in a “no CAA” classification. 
However, given the frequent co-existence of CAA and non-CAA SVDs 
(Figure 4.13), this is likely to lead to misclassification. Rigorous external 
validation and revision of the modified Boston criteria is required. 
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Chapter 10 The association between the Edinburgh 
diagnostic criteria for CAA-associated 
lobar ICH and the risk of recurrent ICH 
 
10.1 Introduction 
Lobar ICH associated with MRI biomarkers of CAA seems to have a higher 
risk of recurrent ICH compared with other subtypes of ICH.[105] These 
biomarkers may also increase the risk of antithrombotic-related ICH.[158] 
Non-invasive diagnosis of CAA in lobar ICH may therefore be important to 
estimate prognosis and guide treatment decisions in clinical practice. 
The principal approach for non-invasive diagnosis of CAA uses the MRI-
based modified Boston criteria.[110] However, many patients with ICH 
cannot undergo MRI (Figure 3.4) because of contraindications or limited 
availability. This is particularly the case in low and middle-income countries 
where over 80% of worldwide deaths due to haemorrhagic stroke occur.[132] 
The Edinburgh diagnostic criteria for CAA-associated lobar ICH use two 
diagnostic CT features (subarachnoid haemorrhage and finger-like 
projections from the haematoma), along with APOE ɛ4 genotype if available, 
to predict the risk of moderate or severe CAA in lobar ICH (Chapter 7)[229] I 
have shown that in the development setting, the rule-out and rule-in 
diagnostic criteria showed excellent sensitivity and specificity for moderate or 
severe CAA respectively (Chapter 7). Furthermore, I have demonstrated that 
the Edinburgh CT-only criteria has good diagnostic accuracy for CAA in a 
large multi-centre external validation study (Chapter 8). 
The Edinburgh diagnostic criteria may be more widely applicable than the 
modified Boston criteria given the better availability of CT compared with 
MRI. However, the association between the Edinburgh diagnostic criteria and 
the risk of recurrent ICH is unknown. 
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10.2 Aims 
I aimed to investigate the association between the Edinburgh diagnostic 
criteria for CAA-associated lobar ICH (CT-only and CT and APOE criteria 
separately) and the risk of recurrent ICH in survivors of lobar ICH. 
 
10.3 Methods 
10.3.1 Study design and patients 
10.3.1.1 Edinburgh CT-only diagnostic criteria study 
I used data from the prospective, community-based LATCH study (section 
2.1.3.1). I included consecutive patients living in the NHS Lothian Health 
Board region who had a spontaneous ICH between 1st June 2010 and 31st 
May 2013 inclusive, diagnosed on non-contrast brain CT. Some of the 
LATCH patients were included in the development of the Edinburgh 
diagnostic criteria. 
As an external cohort, I used data from the Clinical Relevance of Microbleeds 
in Stroke (CROMIS-2) ICH study (ClinicalTrials.gov Identifier: 
NCT02513316).[347] This was a prospective case-control study of adult 
patients with and without oral anticoagulant-associated ICH conducted in 79 
UK centres. I included participants who had a spontaneous ICH between 
December 2010 and July 2015 inclusive, diagnosed on non-contrast brain CT 
(CROMIS-2 cohort). 
10.3.1.2 Edinburgh CT and APOE diagnostic criteria study  
I used data from the prospective LINCHPIN study (section 2.1.3.2). I included 
consecutive participants living in the NHS Lothian Health Board region who 
had a spontaneous ICH between 1st June 2010 and 31st May 2016 inclusive, 
diagnosed on non-contrast brain CT and had APOE genotyping. Some of the 
LINCHPIN participants were included in the development of the Edinburgh 
diagnostic criteria. 
As an external cohort, I included participants from the CROMIS-2 study who 
had a spontaneous ICH between December 2010 and July 2015 inclusive, 
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diagnosed on non-contrast brain CT and APOE genotyping (CROMIS-2-DNA 
cohort). 
10.3.1.3 Eligibility criteria 
I included adult patients (aged ≥16 years) who had a first-ever or recurrent 
ICH diagnosed by non-contrast brain CT and who survived at least 30 days. 
I excluded patients with exclusively extra-axial intracranial haemorrhage, ICH 
secondary to an underlying cause other than SVDs, and those without a 
diagnostic quality non-contrast brain CT. I also excluded those who had a 
recurrent ICH within the first 30 days after the index ICH. 
I excluded patients without APOE genotyping from the Edinburgh CT and 
APOE diagnostic criteria study. 
10.3.2 Baseline data collection 
Collaborators collected demographics, the date of index ICH symptom onset, 
the presence of pre-ICH co-morbidities and medication use at the time of ICH 
and on hospital discharge or at 30 days after ICH by interviewing patients 
and/or reviewing medical records (Appendix 5). 
The co-morbidities of interest were  
 Hypertension (defined as either a history of hypertension in medical 
records before ICH or taking antihypertensive medication at the time 
of the ICH) 
 Dementia (defined as either a diagnosis of dementia in medical 
records before ICH or if a relative or close friend completed the short 
form Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) and the score was ≥64[183]) 
 Prior ischaemic stroke or TIA 
 Myocardial infarction 
 Atrial fibrillation 
 Diabetes mellitus 
 Hyperlipidaemia 
 Smoking status 
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The medication use pre-ICH and at hospital discharge or at 30 days after ICH 
of interest were 
 Antiplatelet drug(s) 
 Anticoagulant drug(s) 
 Anti-hypertensive drug(s) 
10.3.3 Image analysis 
I reformatted the non-contrast brain CT volume datasets from the LATCH 
and LINCHPIN cohorts into standard axial, coronal and sagittal planes as 
described in section 2.2.1.2. A collaborator (Dr David Seiffge) performed the 
same reformatting of the non-contrast brain CT volume datasets from the 
CROMIS-2 participants. 
I rated the reformatted non-contrast brain CT scans from LATCH and 
LINCHPIN participants and Dr Seiffge assessed the reformatted non-contrast 
brain CT scans from CROMIS-2 participants. We assessed the location of 
the largest ICH,[190] the ICH volume using a modified ABC/2 approach,[191] 
and the presence or absence extra-axial haemorrhage (subarachnoid, 
subdural or intraventricular spaces) and finger-like projections arising from 
the largest haematoma. We calculated the CT SVD burden score[196] based 
on the presence and severity of white matter lucencies,[193] lacunes[77] and 
atrophy[195] as described in section 2.2.1.3. 
We performed the CT ratings masked to the clinical, genetic and outcome 
information. 
10.3.4 APOE genotyping 
Where available, collaborators performed APOE genotyping on DNA 
extracted from peripheral blood or brain tissue using standard techniques, 
masked to radiological, clinical and outcome data. I defined APOE 2 and 
APOE 4 possession if a participant had at least one 2 or 4 allele 
respectively, as described in Chapter 7.[229] 
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10.3.5 Follow up and outcome 
The RUSH team used multiple sources of information to follow-up 
participants in LATCH and LINCHPIN as described in section 2.1.8. 
The CROMIS-2 study team used multiple sources of information to follow-up 
participants in the CROMIS-2 study for recurrent ICH and death outcomes. 
The sources of follow-up information used in CROMIS-2 were not identical to 
those used in LATCH and LINCHPIN, and included postal questionnaires at 
six months to the participants and their GPs.[347] All outcome events were 
notified to the central CROMIS-2 study team by each participating hospital 
research team. The central study team was also notified of all deaths and 
hospital attendances in study participants from the Health and Social Care 
Information Centre; this includes data on all admitted patient care episodes, 
outpatient appointments, and emergency attendances in England. 
For this study, I censored follow-up data at three years after the index ICH or 
on 27th February 2018, whichever occurred first. 
I pre-specified the first recurrent ICH as the outcome of interest. I defined 
recurrent ICH as the onset of new neurological deficits or worsening of pre-
existing deficits, anatomically referable to evidence of new ICH on CT or MRI 
scans.  
I pre-specified death as a competing event. 
Both the outcome and the competing event were adjudicated by trained 
members of the RUSH or CROMIS-2 study teams using all available clinical 
and imaging information, masked to baseline clinical and imaging data. 
10.3.6 Sample size 
I was unable to calculate the sample size required to assess the association 
between the Edinburgh diagnostic criteria for CAA-associated lobar ICH and 
recurrent ICH as no previous studies have assessed this. Instead, I used 
data from the community-based LATCH and LINCHPIN studies, as well as 
data from the multi-centre CROMIS-2 study to maximise power. 
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10.3.7 Missing data 
I excluded any cases with missing predictor or outcome variables. I did not 
impute missing data. 
10.3.8 Statistical analysis 
I compared the frequency of clinical characteristics, diagnostic non-contrast 
brain CT features and APOE genotype between the cohorts using 2 test (or 
Fisher's exact test, where appropriate) for categorical variables and the 
Mann-Whitney U test for non-normally distributed continuous variables. 
10.3.8.1 Time to event analyses 
I quantified the follow-up time in each cohort using the median and 
interquartile range, and the completeness of follow-up by calculating the 
completeness index ([observed follow up/potential follow up]*100).[348] 
I performed time to event analyses with the first recurrent ICH as the 
outcome and treated death as a competing risk. A competing risk is an event 
which precludes the occurrence of the primary event of interest.[349] 
Traditional methods for analysing survival data, such as the Kaplan-Meier 
method and the Cox proportional hazards model assume that competing 
risks are absent. Their use in the presence of a competing event results in an 
overestimation of the probability of the outcome and misestimation of the 
magnitude of relative effects of predictors on the incidence of the event.[349-
351] Accounting for competing events is particularly important when the 
frequency of the competing event is high, as is the case with death after 
ICH.[350] 
Therefore, I used the cumulative incidence function (CIF) to estimate the 
incidence of recurrent ICH while taking account of the competing risk of 
death (univariable competing risk analysis). I performed multivariable 
regression analysis taking into account death as a competing risk using two 
approaches; the cause-specific hazard function[351, 352] and the 
subdistribution hazard of the CIF.[353] The cause-specific hazard 
function[351, 352] represents the instantaneous rate of occurrence of an 
event among participants who are still event free. The subdistribution hazard 
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function[353] represents the instantaneous rate of occurrence of the given 
event type in participants who have not yet experienced that event type.  
I performed the analyses in the internal and external cohorts (Edinburgh CT-
only study: LATCH and CROMIS-2 cohorts; Edinburgh CT and APOE study: 
LINCHPIN and CROMIS-2-DNA cohorts) separately before meta-analysis as 
described below. 
Edinburgh CT-only diagnostic criteria study 
 Primary analysis 
I estimated the cumulative incidence function and subdistribution hazard ratio 
of recurrent ICH in participants with a first-ever ICH as their index event, 
stratified by ICH location (lobar versus non-lobar) in LATCH and CROMIS-2 
separately. 
Next, I assessed univariable predictors of recurrent ICH in participants with a 
first-ever lobar ICH using cumulative incidence and subdistribution hazard 
ratio, according to sex, Edinburgh CT-only criteria (low versus intermediate 
versus high; low versus intermediate or high) and CT SVD score (0 versus 1, 
2 or 3), separately in the LATCH and CROMIS-2 cohorts. I used Schoenfeld 
residuals and covariate time interactions to assess whether the variables 
obeyed the proportional hazard subdistribution assumption. 
I then performed a two-step  individual participant data meta-analysis[354] of 
recurrent ICH risk in the LATCH and CROMIS-2 studies. First, I performed 
competing risks multivariable regression for recurrent ICH using 
subdistribution and cause-specific hazard models, adjusting for Edinburgh 
CT-only diagnostic criteria and CT SVD score separately in the LATCH and 
CROMIS-2 cohorts. Then I synthesised the study level aggregate data using 
a random effects model with DerSimonian-Laird weights.[355] I used a 
random effects model due to the differences in study design and baseline 
characteristics between the LATCH and CROMIS-2 studies.[356, 357] 
 Secondary analyses 
To maximise power, I performed a one-step individual participant data meta-
analysis[354] by pooling the LATCH and CROMIS-2 first-ever lobar ICH 
pooling and generating subdistribution and cause-specific hazard models for 
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recurrent ICH adjusting for Edinburgh CT-only diagnostic criteria and CT 
SVD score. 
After pooling data from LATCH and CROMIS-2, I calculated the univariable 
cumulative incidence of recurrent ICH in participants with first-ever and 
recurrent lobar ICH as their index event, stratified by previous history of ICH, 
hypertension and dementia, medication on hospital discharge, the individual 
components of the Edinburgh CT-only diagnostic criteria. I then generated 
competing risks multivariable regression models for recurrent ICH using 
subdistribution and cause-specific hazard models; one for the Edinburgh CT-
only diagnostic criteria and the second for subarachnoid haemorrhage and 
finger-like projections (the individual components of the Edinburgh CT-only 
diagnostic criteria). I adjusted both models for age and sex, history of 
previous ICH, antihypertensive drug use on discharge and CT SVD score. 
Edinburgh CT-APOE diagnostic criteria study 
 Primary analyses 
I assessed univariable predictors of recurrent ICH in participants with a first-
ever lobar ICH using the cumulative incidence and subdistribution hazard 
ratio, according to sex, Edinburgh CT-APOE (low versus intermediate versus 
high; low versus intermediate or high) and CT SVD (0 versus 1, 2 or 3), 
separately in the LINCHPIN and CROMIS-2-DNA cohorts. I assessed 
whether the variables obeyed the proportional hazards assumption using 
Schoenfeld residuals and assessing covariate time interactions. 
I performed competing risks multivariable regression for recurrent ICH using 
subdistribution and cause-specific hazard models, adjusting for Edinburgh 
CT-APOE diagnostic criteria and CT SVD score in the CROMIS-2-DNA 
cohort. I could not perform multivariable regression in the LINCHPIN cohort 
as the Edinburgh CT-APOE diagnostic criteria did not obey the proportional 
hazards assumption. 
 Secondary analyses 
I performed a one-step individual participant data meta-analysis[354] by 
pooling the LINCHPIN and CROMIS-2-DNA first-ever lobar ICH data and 
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generating subdistribution and cause-specific hazard models for recurrent 
ICH adjusting for Edinburgh CT-APOE diagnostic criteria and CT SVD score. 
I calculated the univariable cumulative incidence of recurrent ICH in 
participants with first-ever and recurrent lobar ICH as their index event, 
stratified by APOE 2 and APOE 4 allele possession. I then generated 
competing risks multivariable regression models for recurrent ICH using 
subdistribution and cause-specific hazard model; one for the Edinburgh CT-
APOE diagnostic criteria and the second for subarachnoid haemorrhage, 
finger-like projections and APOE 4 allele possession (the individual 
components of the Edinburgh CT-APOE diagnostic criteria). I adjusted both 
models for history of previous ICH, antihypertensive drug use on discharge, 
CT SVD score and APOE 2 allele possession. 
10.3.8.2 Confounders 
Blood pressure control and antithrombotic drug use are potential confounders 
for recurrent ICH.[158, 159] These variables were difficult to treat as time-
varying covariates due to the data collection methods in the cohorts. Instead, 
I took a descriptive approach, quantifying the use of antiplatelet, 
anticoagulant and antihypertensive drug use at hospital discharge or on day 
30 after ICH in key groups (recurrent ICH versus no recurrent ICH; Edinburgh 




10.4.1 Edinburgh CT-only diagnostic criteria for CAA-associated 
lobar ICH study 
10.4.1.1 Flow of patients 
LATCH 
There were 448 patients with an ICH presumed secondary to SVDs in the 
NHS Lothian Health Board region between 1st June 2010 and 31st May 2013 






Figure 10.1 Flowchart of SVD-associated ICH participants in the LATCH study inclusive who had a diagnostic non-contrast 
brain CT and survived at least 30 days. 
 
CT = computed tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of cerebral 
haemorrhage. SVD = small vessel disease.
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Four hundred and thirty-two had diagnostic non-contrast brain CT, of whom 
252 survived at least 30 days without having a recurrent ICH. 
CROMIS-2 
There were 1026 participants with an ICH presumed secondary to SVDs in 
the CROMIS-2 study between 8th December 2010 and 28th July 2015 (Figure 
10.2). Five had missing data for the outcome, while 70 died or had a 
recurrent ICH within 30 days of their index event. Therefore, I included 951 
participants, of whom 372 had a lobar ICH. 
10.4.1.2 Comparison of LATCH and CROMIS-2 participants with first-ever 
SVD-associated lobar ICH 
Participants with first-ever lobar ICH in LATCH and CROMIS-2 were of 
similar ages and had similar ICH volumes and frequency of finger-like 
projections (Table 10.1 and Table 10.2). CROMIS-2 had a significantly higher 
proportion of male participants. The frequency of pre-ICH diabetes, atrial 
fibrillation and hyperlipidaemia was higher in CROMIS-2. There was more 
frequent pre-ICH use of anticoagulant and antihypertensive drugs in 
CROMIS-2 but less frequent pre-ICH antiplatelet drug use. Subarachnoid 
haemorrhage and CT measures of SVDs were more frequent in LATCH, 
while more CROMIS-2 participants were classified as low risk by the 
Edinburgh CT-only diagnostic criteria. A higher proportion of LATCH 
participants had a recurrent ICH or died during follow up. 
10.4.1.3 Completeness of follow up 
The median duration of follow-up in LATCH was 1095 days (IQR 324-1095), 
with 99.8% completeness of follow-up. The median duration of follow-up in 
CROMIS-2 was 1094 days (IQR 687-1094), with 95.8% completeness of 
follow-up. 
10.4.1.4 Cumulative incidence of recurrent ICH in the presence of death 
as a competing event. 
The cumulative incidences of recurrent ICH and death in LATCH and 
CROMIS-2 participants with first-ever ICH and first-ever lobar ICH are shown 
in Figure 10.3. The cumulative incidence of death far exceeded that of 
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recurrent ICH at all time points in all cohorts, indicating that death is a 
substantial competing event for recurrent ICH. 
10.4.1.5 Risk of recurrent ICH stratified by ICH location in participants with 
first-ever SVD-associated ICH 
One hundred and seventeen (49%) LATCH participants had a first-ever non-
lobar ICH, 5 of whom suffered a recurrent ICH during follow up (3-year 
cumulative incidence rate 4.3%, 95%CI 1.6-9.1). One hundred and twenty 
(51%) LATCH participants had a first-ever lobar ICH, 17 of whom had a 
recurrent ICH during follow up (3-year cumulative incidence rate 14.2%, 
95%CI 8.6-21.1, p=0.009, Figure 10.4). The 3 year cumulative incidence of 
death in first-ever non-lobar ICH (38.5%, 95%CI 29.6-47.2) was similar to 







Figure 10.2 Flowchart of SVD-associated ICH participants in the CROMIS-2 study who had a diagnostic non-contrast brain CT 
and survived at least 30 days. 
 
CROMIS = clinical relevance of microbleeds in stroke. CT = computed tomography. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.
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Table 10.1 Baseline clinical and outcome in first-ever SVD-associated lobar 
ICH participants in the LATCH and CROMIS-2 cohorts 
 LATCH first-ever 
lobar ICH (n=120) 
CROMIS-2 first-ever 
lobar ICH (n=342) 
p value 





























































































































































































Medications on discharge      
Antiplatelet drug(s)* 





































































Data are n (%) or median (IQR). * = Fisher’s exact test. GCS = Glasgow coma scale. 
CROMIS = clinical relevance of microbleeds in stroke. ICH = intracerebral haemorrhage. 
LATCH = Lothian audit of the treatment of cerebral haemorrhage. SVD = small vessel 
disease.  
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Table 10.2 Non-contrast CT brain features in first-ever SVD-associated lobar 
ICH participants in the LATCH and CROMIS-2 cohorts 
 
LATCH first-ever 
lobar ICH (n=120) 
CROMIS-2 first-ever 
lobar ICH (n=342) 
p value 
Multiple acute ICH 10 (8) 5 (2) <0.001 
































ICH volume (ml); median (IQR) 17 (6-38) 15 (5-29) 0.173 
Intraventricular haemorrhage 28 (23) 44 (13) 0.007 
Subarachnoid haemorrhage 78 (65) 132 (39) <0.001 
Subdural haemorrhage 15 (13) 6 (2) <0.001 
Finger-like projections 20 (17) 78 (23) 0.157 
Number of lacunes; median (IQR) 0 (0-0) 0 (0-0) <0.001 



















































































































CT SVD score 1, 2 or 3 70 (58) 148 (43) 0.004 






















Edinburgh CT-only CAA criteria 
Intermediate/high 
78 (65) 165 (48) 0.002 
Data are n (%) or median (IQR). * = Fisher’s exact test. CAA = cerebral amyloid 
angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT = computed 
tomography. GCS = Glasgow coma scale. ICH = intracerebral haemorrhage. . LATCH = 
Lothian audit of the treatment of cerebral haemorrhage. SVD = small vessel disease.  
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Figure 10.3 Cumulative incidence of recurrent ICH and death during follow 
up. 
A. First-ever SVD-associated ICH in LATCH 
B. First-ever SVD-associated ICH in CROMIS-2 
C. First-ever SVD-associated lobar ICH in LATCH 
D. First-ever SVD-associated lobar ICH in CROMIS-2 
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CROMIS = clinical relevance of microbleeds in stroke. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral 
haemorrhage. SVD= small vessel disease. 
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Figure 10.4 Cumulative incidence of A. Recurrent ICH and B. Death in first-
ever SVD-associated ICH in LATCH according to the index ICH location 
 
ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of 
cerebral haemorrhage. SVD = small vessel disease. 
 
Five hundred and forty-six (61%) CROMIS-2 participants had a first-ever 
non-lobar ICH, 5 of whom suffered a recurrent ICH during follow up (3-year  
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Figure 10.5 Cumulative incidence of A. Recurrent ICH and B. Death in first-
ever SVD-associated ICH in CROMIS-2 according to the index ICH location 
 
CROMIS = clinical relevance of microbleeds in stroke. ICH = intracerebral 
haemorrhage. SVD = small vessel disease. 
cumulative incidence rate 1.0%, 95%CI 0.4-2.1). 342 (39%) CROMIS-2 
participants had a first-ever lobar ICH, 25 of whom had a recurrent ICH 
during follow up (3-year cumulative incidence rate 7.9%, 95%CI 5.2-11.1, 
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p<0.001, Figure 10.5). The 3 year cumulative incidence of death in first-ever 
non-lobar ICH (24.2%, 95%CI 20.6-28.0) was similar to first-ever lobar ICH 
(20.6%, 95%CI 16.3-25.3, p=0.244, Figure 10.5). 
In both LATCH and CROMIS-2, a lobar ICH location significantly increased 
both the relative incidence (subdistribution hazard ratio) and the rate (cause-
specific hazard ratio) of recurrent ICH, with no significant effect on the 
relative incidence and rate of death (Table 10.3). 
Given the low incidence of recurrent ICH in non-lobar ICH, I focused my 
further analyses on participants with first-ever lobar ICH. 
10.4.1.6 Risk of recurrent ICH in participants with first-ever SVD-
associated lobar ICH 
LATCH cohort 
Seventeen of the 120 LATCH participants with first-ever SVD-associated 
lobar ICH had a recurrent ICH, and 46 died during follow up. 
The 3 year cumulative incidence rate for recurrent ICH and death according 
to sex, CT SVD score and Edinburgh CT-only diagnostic criteria are shown in 
Table 10.4 and Figure 10.6. 
The 3 year cumulative incidence rate for recurrent ICH generally increased 
with the Edinburgh CT-only CAA criteria (low risk 4.8%, 95%CI 0.8-14.4); 
intermediate risk 17.2%, 95%CI 8.8-28.1; high risk 25.0%, 95%CI 8.6-45.6, 
p=0.054). Those classified as intermediate or high risk on the Edinburgh CT-
only criteria (19.3%, 95%CI 11.4-28.8) had a significantly higher 3 year 
cumulative incidence rate for recurrent ICH compared with low risk (4.8%, 
95%CI 0.8-14.4, p=0.029). The 3 year cumulative incidence of death was 
similar across the Edinburgh CT-only risk categories (Figure 10.6). 
There was no significant change in the 3 year cumulative incidence of 
recurrent ICH with the CT SVD score. The cumulative incidence of death was 
higher in those with a CT SVD score of 1, 2 or 3 versus CT SVD score 0, 
although this did not reach statistical significance (Table 10.4 and Figure 
10.6). 
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The univariable subdistribution and cause-specific hazard models for sex, CT 
SVD score and Edinburgh CT-only diagnostic criteria are shown in Table 
10.5. High risk and intermediate or high risk on the Edinburgh CT-only criteria 
significantly increased both the relative incidence (subdistribution hazard 
ratio) and the rate (cause-specific hazard ratio) of recurrent ICH relative to 
the low-risk category, with no significant effect on the relative incidence and 
rate of death. The CT SVD score had no significant effect on the 
subdistribution hazard ratio or the cause-specific hazard ratio of recurrent 
ICH. Those with a CT SVD score of 1, 2 or 3 tended to have an increased 
hazard of death. However, this did not reach statistical significance. 
In multivariable models adjusting for CT SVD score and Edinburgh CT-only 
criteria (Table 10.6), high risk on the Edinburgh CT-only criteria was 
associated with an increased risk (subdistribution hazard ratio 6.38, 95%CI 
1.23-33.3) and rate (cause-specific hazard ratio 7.78, 95%CI 1.51-40.2) of 






Table 10.3 Sub-distribution and cause-specific hazard models for recurrent ICH and death in LATCH and CROMIS-2 
participants with first-ever SVD-associated ICH according to index ICH location 
Data are hazard ratio (95%CI) or p values. CROMIS = clinical relevance of microbleeds in stroke. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. SVD= small vessel disease. 
  
 
Sub-distribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 














































































































Table 10.4 Three year cumulative incidence of recurrent ICH and death in 120 LATCH participants with first-ever SVD-
associated lobar ICH 
Data are% (95%CI). CAA – cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. 
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Figure 10.6 Cumulative incidence of recurrent ICH and death in first-ever 
SVD-associated lobar ICH in LATCH 
A & B. Recurrent ICH and death stratified by sex 
C & D Recurrent ICH and death stratified by CT SVD score 
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CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. CROMIS = clinical relevance of microbleeds in 
stroke. SVD = small vessel disease.





Table 10.5 Univariable sub-distribution and cause-specific hazard models for recurrent ICH and death in 120 LATCH 
participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. SVD = small vessel disease.  
 
Sub-distribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
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Table 10.6 Multivariable sub-distribution and cause-specific hazard models for recurrent ICH and death in 120 LATCH 
participants with first-ever SVD-associated lobar ICH  
Data are hazard ratio (95%CI). CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. SVD = small vessel disease.
 
Sub-distribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
CT SVD score  
0 
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CROMIS-2 cohort 
Twenty-five of the 342 CROMIS-2 participants with first-ever SVD-associated 
lobar ICH had a recurrent ICH, and 65 died during follow up. 
The 3 year cumulative incidence rate for recurrent ICH and death according 
to sex, CT SVD score and Edinburgh CT-only diagnostic criteria are shown in 
Table 10.7 and Figure 10.7. 
The 3 year cumulative incidence rate for recurrent ICH was significantly 
higher in those with CT SVD score of 1, 2 or 3 compared with a CT SVD of 0 
(11.4%, 95%CI 6.8-17.4 versus 5.2%, 95%CI 2.5-9.2, p=0.030). The 3 year 
cumulative incidence of death was also significantly higher in those with a CT 
SVD score of 1, 2 or 3. There was no significant change in the 3 year 
cumulative incidence of recurrent ICH with the Edinburgh CT-only diagnostic 
criteria, although the point estimate for high risk on the Edinburgh CT-only 
diagnostic criteria was nearly double the low and intermediate risk groups. 
The univariable subdistribution and cause-specific hazard models for sex, CT 
SVD score and Edinburgh CT-only diagnostic criteria are shown in Table 
10.8. CT SVD score 1, 2 or 3 significantly increased both the relative 
incidence (subdistribution hazard ratio) and rate (cause-specific hazard ratio) 
of recurrent ICH and of death. The Edinburgh CT-only criteria had no 
significant effect on the subdistribution hazard ratio or cause-specific hazard 
ratio of recurrent ICH. 
In multivariable models adjusting for CT SVD score and Edinburgh CT-only 
criteria (Table 10.9), CT SVD score of 1, 2 or 3 was associated with an 
increased risk (subdistribution hazard ratio 2.37, 95%CI 1.05-5.35) and rate 
(cause-specific hazard ratio 2.49, 95%CI 1.10-5.64) of recurrent ICH. The 
Edinburgh CT-only criteria had no significant effect on the subdistribution 






Table 10.7 Three year cumulative incidence of recurrent ICH and death in 342 CROMIS-2 participants with first-ever SVD-
associated lobar ICH 
Data are % (95%CI). CAA = cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT = 
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Figure 10.7 Cumulative incidence of recurrent ICH and death in first-ever 
SVD-associated lobar ICH in CROMIS-2 
A & B. Recurrent ICH and death stratified by sex 
C & D Recurrent ICH and death stratified by CT SVD score 
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CAA = cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. ICH = intracerebral 






Table 10.8 Univariable sub-distribution and cause-specific hazard models for recurrent ICH and death in 342 CROMIS-2 
participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT 
= computed tomography. ICH = intracerebral haemorrhage. SVD = small vessel disease.  
Variable 
Sub-distribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
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Table 10.9 Multivariable sub-distribution and cause-specific hazard models for recurrent ICH and death in 342 CROMIS-2 
participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT 
= computed tomography. ICH = intracerebral haemorrhage. SVD = small vessel disease. 
 
Sub-distribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
CT SVD score  
0 
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LATCH and CROMIS-2 meta-analysis 
Two-step random-effects meta-analysis of the LATCH and CROMIS-2 
multivariable models showed that participants classified as high risk on the 
Edinburgh CT-only diagnostic criteria had a higher risk of recurrent ICH 
compared with the low-risk group (subdistribution hazard ratio 2.99, 95%CI 
1.08-8.27, Figure 10.8). There was no significant association between 
intermediate risk on the Edinburgh CT-only criteria or CT SVD score 1, 2 or 3 
and recurrent ICH risk (Subdistribution hazard ratio 1.74, 95%CI 0.86-3.51). 
I performed a secondary analysis by pooling the LATCH and CROMIS-2 data 
(462 participants with first-ever SVD-associated lobar ICH) and then fitting 
multivariable models. This resulted in a similar direction and magnitude of 
associations with recurrent ICH as the two-step meta-analysis (Table 10.10). 
High risk on the Edinburgh CT-only diagnostic criteria was associated with 
increased risk (subdistribution hazard ratio 2.98, 95%CI 1.33-6.67) and rate 
(cause-specific hazard ratio 3.14, 95%CI 1.40-7.00) of recurrent ICH. CT 
SVD score of 1, 2 or 3 had a borderline significant association with recurrent 
ICH in the subdistribution hazard model, and a significant association in the 
cause-specific hazard model (HR 2.02, 95%CI 1.08-3.76). 
Secondary analyses 
I performed pre-specified secondary analyses assessing the effect of other 
relevant variables, including the individual components of the Edinburgh CT-
only diagnostic criteria, on the risk of recurrent ICH or death during follow up 
in LATCH and CROMIS-2 participants with SVD-associated lobar ICH. 
The 3-year cumulative incidence of recurrent ICH was higher in those with a 
previous symptomatic ICH, as well as those who were not taking an 
antihypertensive drug at hospital discharge although these differences were 
not statistically significant (Figure 10.9 and Table 10.11). Those with 
subarachnoid haemorrhage on the diagnostic non-contrast brain CT had a 
significantly higher cumulative incidence of recurrent ICH. The cumulative 
incidence of recurrent ICH was also higher in those with finger-like 






Figure 10.8 Pooled risks of recurrent intracerebral haemorrhage during follow up in LATCH and CROMIS-2 participants with 
first-ever lobar ICH 
 
Weights from random effects analysis are shown by the point estimate area. CAA = cerebral amyloid angiopathy. CI = 
confidence interval. CROMIS = clinical relevance of microbleeds in stroke. CT – computed tomography. LATCH = Lothian 






Table 10.10 Secondary analysis: Multivariable sub-distribution and cause-specific hazard models for recurrent ICH and death 
in 462 LATCH and CROMIS-2 participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). CAA = cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT 
= computed tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. 
SVD = small vessel disease.
 
Sub-distribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
CT SVD score  
0 
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Figure 10.9 Cumulative incidence of recurrent ICH in SVD-associated lobar 
ICH in the pooled LATCH and CROMIS-2 data 
A. History of previous ICH. B. History of hypertension. C. History of dementia. 
D-F. Antiplatelet, anticoagulant and antihypertensive drug use on discharge 
respectively. G. Subarachnoid haemorrhage. H. Finger-like projections.
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CROMIS = clinical relevance of microbleeds in stroke. ICH = intracerebral 
haemorrhage. LATCH = Lothian audit of the treatment of cerebral 






Table 10.11 Secondary analysis: Three year cumulative incidence of recurrent ICH and death in pooled LATCH and CROMIS-
2 participants with SVD-associated lobar ICH 
Data are % (95%CI). CROMIS = clinical relevance of microbleeds in stroke. ICH = intracerebral haemorrhage. LATCH = 
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Multivariable models adjusting for age and sex, history of previous ICH, 
antihypertensive drug use at hospital discharge, CT SVD score and the 
Edinburgh CT-only diagnostic criteria are shown in Table 10.12. I excluded 
42 participants due to missing data, leaving 460 participants, of whom 42 had 
a recurrent ICH, and 108 died during follow up. High risk on the Edinburgh 
CT-only criteria was associated with an increased risk (subdistribution hazard 
ratio 2.81, 95%CI 1.17-6.72) and rate (cause-specific hazard ratio 2.79, 
95%CI 1.19-6.57) of recurrent ICH relative to the low-risk category. 
Intermediate risk on the Edinburgh CT-only criteria was associated with a 
borderline significant increased risk of recurrent ICH (subdistribution hazard 
ratio 2.04, 95%CI 1.00-4.16) and a significantly increased rate of recurrent 
ICH (cause-specific hazard ratio 2.08, 95%CI 1.03-4.22). 
Finally, I refitted the above models using subarachnoid haemorrhage and 
finger-like projections in place of the Edinburgh CT-only criteria. In these 
models (Table 10.13), only subarachnoid haemorrhage was associated with 
an increased risk (subdistribution hazard ratio 2.15, 95%CI 1.13-4.12) and 
rate (cause-specific hazard ratio 2.18, 95%CI 1.13-4.21) of recurrent ICH. 
Confounders 
The proportion of first-ever SVD-associated lobar ICH LATCH participants on 
an antiplatelet, anticoagulant or antihypertensive drug at hospital discharge 
was similar between those with and without a recurrent ICH (Table 10.14), as 
well as the Edinburgh CT-only risk categories (Table 10.15). 
In CROMIS-2, the proportion of participants with a first-ever SVD-associated 
lobar ICH on an antihypertensive drug at hospital discharge was lower in 
those who had a recurrent ICH (54%) compared to those without a recurrent 
ICH (72%) (Table 10.16), and lower in those classified as high risk on the 
Edinburgh CT-only criteria (61%) compared to low risk (75%) (Table 10.17). 
The proportion taking an antiplatelet or anticoagulant drug at hospital 







Table 10.12 Secondary analysis: Multivariable subdistribution and cause-specific hazard models for recurrent ICH and death 
in 460 LATCH and CROMIS-2 participants with SVD-associated lobar ICH (42 recurrent ICH, 108 deaths) 
Data are hazard ratio (95%CI). CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT 
= computed tomography. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. 
SVD = small vessel disease.  
 Subdistribution hazard model Cause-specific hazard model 
 Recurrent ICH Death Recurrent ICH Death 
 Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
Age (per 10 year 
increase) 
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Table 10.13 Secondary analysis: Multivariable subdistribution and cause-specific hazard models for recurrent ICH and death 
in 460 LATCH and CROMIS-2 participants with SVD-associated lobar ICH (42 recurrent ICH, 108 deaths) 
Data are hazard ratio (95%CI). CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT = computed tomography. 
ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. SVD = small vessel disease.  
 Subdistribution hazard model Cause-specific hazard model 
 Recurrent ICH Death Recurrent ICH Death 
 Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
Age (per 10 year 
increase) 
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Table 10.14 Medication use at hospital discharge in LATCH participants with first-ever lobar ICH stratified by the outcome of 
recurrent ICH during follow-up 
 No recurrent ICH (n=103) Recurrent ICH (n=17) 
Antiplatelet at discharge* 2 (2%) 1 (7%) 
Anticoagulant at discharge* 2 (2%) 2 (14%) 
Antihypertensive at discharge* 44 (44%) 7 (50%) 
* Data is not available for six LATCH participants with first-ever lobar ICH who survived more than 30 days but died before 
hospital discharge. ICH = intracerebral haemorrhage. LATCH = Lothian audit of the treatment of cerebral haemorrhage. 
 
Table 10.15 Medication use at hospital discharge in LATCH participants with first-ever lobar ICH stratified by Edinburgh CT-
only criteria classification 
 
Low risk CT-only 
Edinburgh CAA criteria 
(n=42) 
Intermediate risk CT-only 
Edinburgh CAA criteria 
(n=58) 
High risk CT-only 
Edinburgh CAA criteria 
(n=20) 
Antiplatelet at discharge* 1 (2%) 1 (2%) 1 (7%) 
Anticoagulant at discharge* 0 (0%) 2 (4%) 2 (13%) 
Antihypertensive at discharge* 21 (50%) 22 (39%) 8 (53%) 
* Data is not available for six LATCH participants with first-ever lobar ICH who survived more than 30 days but died before 
hospital discharge. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = intracerebral haemorrhage. 







Table 10.16 Medication use at hospital discharge in CROMIS-2 participants with first-ever lobar ICH stratified by the outcome 
of recurrent ICH during follow-up 
 No recurrent ICH (n=317) Recurrent ICH (n=25) 
Antiplatelet at discharge* 14 (5%) 2 (8%) 
Anticoagulant at discharge† 12 (4%) 0 (0%) 
Antihypertensive at discharge† 217 (72%) 13 (54%) 
* Data is not available for 15 CROMIS-2 participants. † Data is not available for 16 CROMIS-2 participants. CROMIS = clinical 
relevance of microbleeds in stroke. ICH = intracerebral haemorrhage. 
 
Table 10.17 Medication use at hospital discharge in CROMIS-2 participants with first-ever lobar ICH stratified by Edinburgh 
CT-only criteria classification 
 Low risk CT-only 
Edinburgh CAA criteria 
(n=177) 
Intermediate risk CT-
only Edinburgh CAA 
criteria (n=120) 
High risk CT-only 
Edinburgh CAA criteria 
(n=45) 
Antiplatelet at discharge* 7 (4%) 7 (6%) 2 (5%) 
Anticoagulant at discharge† 6 (4%) 5 (4%) 1 (2%) 
Antihypertensive at discharge† 126 (75%) 79 (68%) 25 (61%) 
* Data is not available for 15 CROMIS-2 participants. † Data is not available for 16 CROMIS-2 participants. CAA = cerebral 
amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT = computed tomography. ICH = intracerebral 
haemorrhage. 
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10.4.2 Edinburgh CT-APOE diagnostic criteria for CAA-associated 
lobar ICH study 
10.4.2.1 Flow of patients 
LINCHPIN 
Three hundred and fifty participants with ICH presumed secondary to SVDs 
consented to the LINCHPIN study between 1st June 2010 and 31st May 2016 
inclusive. Two hundred and eighty-two had both a diagnostic non-contrast 
brain CT and APOE genotyping, of whom 197 survived at least 30 days 
without having a recurrent ICH (Figure 10.10). 
CROMIS-2-DNA 
Of the 1026 participants with an ICH presumed secondary to SVDs in the 
CROMIS-2 study, 861 had both a diagnostic non-contrast brain CT and 
APOE genotyping. Four had missing data for the outcome, while 51 died or 
had a recurrent ICH within 30 days of their index event. Therefore, I included 
806 participants, of whom 314 had a lobar ICH (Figure 10.11). 
10.4.2.2 Comparison of LINCHPIN and CROMIS-2-DNA participants with 
first-ever lobar ICH 
Participants in LINCHPIN and CROMIS-2-DNA were similar in age and had a 
similar frequency of finger-like projections (Table 10.18 and Table 10.19). 
CROMIS-2-DNA had a significantly higher proportion of male participants. 
The frequency of pre-ICH diabetes, atrial fibrillation and hyperlipidaemia were 
higher in CROMIS-2-DNA. There was more frequent pre-ICH use of 
anticoagulant and antihypertensive drugs in CROMIS-2-DNA but less 
frequent pre-ICH antiplatelet drug use. Subarachnoid haemorrhage and CT 
measures of SVDs were more frequent in LINCHPIN, while more CROMIS-2-
DNA participants were classified as low risk by the Edinburgh CT-APOE 
diagnostic criteria. A higher proportion of LINCHPIN participants had a 
recurrent ICH or died during follow up. 





Figure 10.10 Flowchart of SVD-associated ICH participants in the LINCHPIN study who had a diagnostic non-contrast brain 
CT, APOE genotyping and survived at least 30 days. 
 
APOE = apolipoprotein E. CT = computed tomography. DNA= deoxyribonucleic acid. ICH = intracerebral haemorrhage. LINCHPIN = 
Lothian intracerebral haemorrhage pathology, imaging and neurological outcome. SVD = small vessel disease.  





Figure 10.11 Flowchart of SVD-associated ICH participants in the CROMIS-2 study who had a diagnostic non-contrast brain 
CT, APOE genotyping and survived at least 30 days. 
 
APOE = apolipoprotein E. CROMIS = clinical relevance of microbleeds in stroke. CT = computed tomography. DNA= deoxyribonucleic 
acid. ICH = intracerebral haemorrhage. SVD = small vessel disease.
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Table 10.18 Baseline clinical features in first-ever SVD-associated lobar ICH 
participants in the LINCHPIN and CROMIS-2-DNA cohorts 
 LINCHPIN first-ever 
lobar ICH (n=91) 
CROMIS-2-DNA first-
ever lobar ICH (n=293) 
p value 





























































































































































































Medications on discharge      
Antiplatelet drug(s)* 





































































Data are n (%) or median (IQR). * = Fisher’s exact test. CROMIS = clinical relevance of 
microbleeds in stroke. DNA = deoxyribonucleic acid. GCS = Glasgow coma scale.  ICH 
= intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. SVD = small vessel disease.  
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Table 10.19 Non-contrast brain CT features and APOE genotype in first-ever 
SVD-associated lobar ICH participants in the LINCHPIN and CROMIS-2-
DNA cohorts 
 LINCHPIN first-ever 
lobar ICH (n=91) 
CROMIS-2-DNA first-
ever lobar ICH (n=293) 
p value 
APOE 4 allele possession 39 (43) 90 (31) 0.032 
APOE 2 allele possession 27 (30) 72 (25) 0.332 
Multiple acute ICH* 10 (11) 5 (2) <0.001 































ICH volume (ml); median (IQR) 19 (10-36) 14 (5-29) 0.007 
Intraventricular haemorrhage 19 (21) 37 (13) 0.051 
Subarachnoid haemorrhage 58 (64) 112 (38) <0.001 
Subdural haemorrhage* 9 (10) 5 (2) 0.001 
Finger-like projections 18 (20) 66 (23) 0.570 
Number of lacunes; median (IQR) 0 (0-0) 0 (0-0) <0.001 














































































































CT SVD score 1, 2 or 3 53 (58) 124 (42) 0.008 
































Data are n (%) or median (IQR). * = Fisher’s exact test. APOE = apolipoprotein E. 
CAA = cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in 
stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 
pathology, imaging and neurological outcome. SVD = small vessel disease.  
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10.4.2.3 Completeness of follow up 
The median duration of follow-up in LINCHPIN was 1027 days (IQR 545-
1095), with 97.7% completeness of follow-up. The median duration of follow-
up in CROMIS-2-DNA was 1094 days (IQR 702-1094), with 95.8% 
completeness of follow-up. 
10.4.2.4 Risk of recurrent ICH in participants with first-ever lobar ICH 
LINCHPIN cohort 
Fourteen of the 91 LINCHPIN participants with first-ever SVD-associated 
lobar ICH had a recurrent ICH, and 27 died during follow up. 
The 3-year cumulative incidence rate for recurrent ICH and death according 
to sex, CT SVD score and Edinburgh CT-APOE diagnostic criteria are shown 
in Table 10.20 and Figure 10.12. 
The 3 year cumulative incidence rate for recurrent ICH generally increased 
with the Edinburgh CT-APOE CAA criteria (low risk 4.5%, 95%CI 0.3-19.5); 
intermediate risk 13.1%, 95%CI 4.0-27.9; high risk 26.8%, 95%CI 12.7-43.2, 
p=0.063). The 3-year cumulative incidence of death was similar across the 
Edinburgh CT-only risk categories (Figure 10.12). 
There was no significant change in the 3-year cumulative incidence of 
recurrent ICH with the CT SVD score. The cumulative incidence of death was 
higher in those with a CT SVD score of 1, 2 or 3 versus CT SVD score of 0, 
which was borderline significant (Table 10.20 and Figure 10.12). 
The univariable subdistribution and cause-specific hazard models for sex, CT 
SVD score and Edinburgh CT-only diagnostic criteria are shown in Table 
10.21. High risk on the Edinburgh CT-APOE criteria increased the relative 
incidence (subdistribution hazard ratio) and the rate (cause-specific hazard 
ratio) of recurrent ICH relative to the low-risk category, although this 
difference was not significant in either model. The CT SVD score had no 
significant effect on the subdistribution hazard ratio or cause-specific hazard 
ratio of recurrent ICH, although those with a CT SVD score of 1, 2 or 3 






Table 10.20 Three year cumulative incidence of recurrent ICH and death in 91 LINCHPIN participants with first-ever SVD-
associated lobar ICH  
Data are % (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CT = computed tomography. ICH = 
intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological outcome. 
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Figure 10.12 Cumulative incidence of recurrent ICH and death in first-ever 
SVD-associated lobar ICH in LINCHPIN 
A & B. Recurrent ICH and death stratified by sex 
C & D Recurrent ICH and death stratified by CT SVD score 
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APOE = Apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = 
computed tomography. ICH = intracerebral haemorrhage. LINCHPIN = 
Lothian intracerebral haemorrhage pathology, imaging and neurological 






Table 10.21 Univariable subdistribution and cause-specific hazard models for recurrent ICH and death in 91 LINCHPIN 
participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CT = computed tomography. 
ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological 
outcome. SVD = small vessel disease.
 
Subdistribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
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The Edinburgh CT-APOE variable did not obey the proportional hazard 




Twenty-four of the 293 CROMIS-2-DNA participants with first-ever SVD-
associated lobar ICH had a recurrent ICH while 51 died during follow up. 
The 3-year cumulative incidence rate for recurrent ICH and death according 
to sex, CT SVD score and Edinburgh CT-only diagnostic criteria are shown in 
Table 10.22 and Figure 10.13. 
The 3-year cumulative incidence rate for recurrent ICH was significantly 
higher in those with CT SVD score of 1, 2 or 3 compared with a CT SVD 
score of 0 (13.6%, 95%CI 8.1-20.6 versus 5.2%, 95%CI 2.4-9.6, p=0.011). 
The 3-year cumulative incidence of death was also significantly higher in 
those with a CT SVD score of 1, 2 or 3. There was no significant change in 
the 3-year cumulative incidence of recurrent ICH with the Edinburgh CT-
APOE diagnostic criteria. 
The univariable subdistribution and cause-specific hazard models for sex, CT 
SVD score and Edinburgh CT-only diagnostic criteria are shown in Table 
10.23. CT SVD score of 1, 2 or 3 significantly increased the relative incidence 
(subdistribution hazard ratio) and the rate (cause-specific hazard ratio) of 
recurrent ICH and death. The Edinburgh CT-APOE criteria had no significant 
effect on the subdistribution hazard ratio or cause-specific hazard ratio of 
recurrent ICH. 
In multivariable models adjusting for CT SVD score and Edinburgh CT-APOE 
criteria (Table 10.24), CT SVD score of 1, 2 or 3 was associated with an 
increased risk and rate of recurrent ICH. The Edinburgh CT-APOE criteria 
had no significant effect on the subdistribution hazard ratio or cause-specific 
hazard ratio of recurrent ICH or death. 
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I performed a secondary multivariable analysis by pooling the LINCHPIN and 
CROMIS-2-DNA data (384 participants with first-ever SVD-associated lobar 
ICH) and then fitting multivariable models (Table 10.25). High risk on the 
Edinburgh CT-APOE diagnostic criteria was associated with increased risk of 
recurrent ICH (subdistribution hazard model), and borderline significantly 
increased rate of recurrent ICH (cause-specific hazard model). CT SVD 
score of 1, 2 or 3 had a significant association with recurrent ICH and death 







Table 10.22 Three year cumulative incidence of recurrent ICH and death in 293 CROMIS-2-DNA participants with first-ever 
SVD-associated lobar ICH  
Data are % (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. SVD = 
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Figure 10.13 Cumulative incidence of recurrent ICH and death in first-ever 
SVD-associated lobar ICH in CROMIS-2-DNA 
A & B. Recurrent ICH and death stratified by sex 
C & D Recurrent ICH and death stratified by CT SVD score 
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APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CROMIS = 
clinical relevance of microbleeds in stroke. CT = computed tomography. ICH 







Table 10.23 Univariable subdistribution and cause-specific hazard models for recurrent ICH and death in 293 CROMIS-2-DNA 
participants with first-ever SVD-associated lobar ICH  
Data are hazard ratio (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. SVD = 
small vessel disease.  
 
Subdistribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
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Table 10.24 Multivariable subdistribution and cause-specific hazard models for recurrent ICH and death in 293 CROMIS-2-
DNA participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. SVD = 
small vessel disease.  
 
Subdistribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
CT SVD score  
0 











































































































Table 10.25 Secondary analysis: Multivariable subdistribution and cause-specific hazard models for recurrent ICH and death 
in 384 LINCHPIN and CROMIS-2-DNA participants with first-ever SVD-associated lobar ICH 
Data are hazard ratio (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. 
LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological outcome. SVD = small vessel disease. 
 
Subdistribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
CT SVD score  
0 
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Secondary analyses 
I performed pre-specified secondary analyses assessing the effect of APOE 
2 and APOE 4 allele possession on the risk of recurrent ICH or death 
during follow up in 384 LINCHPIN and CROMIS-2-DNA participants with 
SVD-associated lobar ICH. Thirty-eight of the participants had a recurrent 
ICH, and 78 died during follow up. 
The 3-year cumulative incidence of recurrent ICH was higher in those who 
possessed an APOE 2 allele, although this was borderline significant 
(Figure 10.14 and Table 10.26). There was no significant difference in the 
cumulative incidence of recurrent ICH between those with and without an 
APOE 4 allele. 
Multivariable models adjusting for history of previous ICH, antihypertensive 
drug use at hospital discharge, CT SVD score and the Edinburgh CT-APOE 
diagnostic criteria and APOE 2 allele possession are shown in Table 10.27. 
CT SVD score 1, 2 or 3 and APOE 2 allele possession were associated with 
an increased risk (subdistribution hazard model) and rate (cause-specific 
hazard model) of recurrent ICH. High risk on the Edinburgh CT-APOE criteria 
was associated with a borderline significant increased risk and rate of 
recurrent ICH. 
Finally, I refitted the above models using subarachnoid haemorrhage, finger-
like projections and APOE 4 allele possession in place of the Edinburgh CT-
APOE criteria. In these models (Table 10.28), only CT SVD score 1, 2 or 3 
and APOE 2 allele possession were associated with an increased risk 
(subdistribution hazard model) and rate (cause-specific hazard model) of 
recurrent ICH. 
10.4.2.5 Confounders 
The proportion of first-ever SVD-associated lobar ICH LINCHPIN participants 
on an antiplatelet, anticoagulant or antihypertensive drug at hospital 
discharge was similar between those with and without a recurrent ICH (Table 
10.29), as well as in the Edinburgh CT-APOE risk categories (Table 10.30). 
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In CROMIS-2 DNA, the proportion of participants with a first-ever SVD-
associated lobar ICH on an antihypertensive drug at hospital discharge was 
lower in those who had a recurrent ICH (57%) compared to those without a 
recurrent ICH (72%) (Table 10.31), and lower in those classified as high risk 
on the Edinburgh CT-only criteria (67%) compared to low risk (71%) (Table 
10.32). The proportion taking an antiplatelet or anticoagulant drug at hospital 
discharge was similar across the groups. 
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Figure 10.14 Cumulative incidence of recurrent ICH in SVD-associated lobar 
ICH in the pooled LINCHPIN and CROMIS-2-DNA data 
A. APOE 2. B. APOE 4. 
 
APOE = apolipoprotein E. CROMIS = clinical relevance of microbleeds in stroke. 
ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage 







Table 10.26 Secondary analysis: Three year cumulative incidence of recurrent ICH and death in 410 LINCHPIN and CROMIS-
2-DNA participants with SVD-associated lobar ICH 
Data are % (95%). APOE = apolipoprotein E. CROMIS = clinical relevance of microbleeds in stroke. DNA = deoxyribonucleic 
acid. ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological 
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Table 10.27 Secondary analysis: Multivariable subdistribution and cause-specific hazard models for recurrent ICH and death 
in 381 LINCHPIN and CROMIS-2-DNA participants with SVD-associated lobar ICH 
Data are hazard ratio (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. 
LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological outcome. SVD = small vessel disease.  
 
Subdistribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
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Table 10.28 Secondary analysis: Multivariable subdistribution and cause-specific hazard models for recurrent ICH and death 
in 381 LINCHPIN and CROMIS-2-DNA participants with SVD-associated lobar ICH 
Data are hazard ratio (95%CI). APOE = apolipoprotein E. CAA – cerebral amyloid angiopathy. CROMIS = clinical relevance of 
microbleeds in stroke. CT = computed tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. 
LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and neurological outcome. SVD = small vessel disease.  
 
Subdistribution hazard model Cause-specific hazard model 
Recurrent ICH Death Recurrent ICH Death 
Hazard ratio p value Hazard ratio p value Hazard ratio p value Hazard ratio p value 
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Table 10.29 Medication use at hospital discharge in LINCHPIN participants with first-ever lobar ICH stratified by the outcome 
of recurrent ICH during follow-up 
 No recurrent ICH (n=77) Recurrent ICH (n=14) 
Antiplatelet at discharge* 2 (3%) 0 (0%) 
Anticoagulant at discharge* 2 (3%) 1 (8%) 
Antihypertensive at discharge* 42 (56%) 6 (50%) 
* Data is not available for four LINCHPIN participants with first-ever lobar ICH who survived more than 30 days but died before 
hospital discharge. ICH = intracerebral haemorrhage. LINCHPIN = Lothian intracerebral haemorrhage pathology, imaging and 
neurological outcome. 
 
Table 10.30 Medication use at hospital discharge in LINCHPIN participants with first-ever lobar ICH stratified by Edinburgh 
CT-APOE criteria classification 
 Low risk CT-APOE 
Edinburgh CAA criteria 
(n=22) 
Intermediate risk CT-APOE 
Edinburgh CAA criteria 
(n=33) 
High risk CT-APOE 
Edinburgh CAA criteria 
(n=36) 
Antiplatelet at discharge* 1 (5%) 0 (0%) 1 (3%) 
Anticoagulant at discharge* 0 (0%) 2 (3%) 2 (6%) 
Antihypertensive at discharge* 12 (57%) 14 (42%) 22 (67%) 
* Data is not available for four LINCHPIN participants with first-ever lobar ICH who survived more than 30 days but died before 
hospital discharge. APOE = apolipoprotein E. CAA = cerebral amyloid angiopathy. CT = computed tomography. ICH = 







Table 10.31 Medication use at hospital discharge in CROMIS-2-DNA participants with first-ever lobar ICH stratified by the 
outcome of recurrent ICH during follow-up 
 No recurrent ICH (n=269) Recurrent ICH (n=24) 
Antiplatelet at discharge* 10 (4%) 2 (8%) 
Anticoagulant at discharge† 12 (5%) 0 (0%) 
Antihypertensive at discharge† 186 (72%) 13 (57%) 
* Data is not available for 12 CROMIS-2-DNA participants. † Data is not available for 13 CROMIS-2-DNA participants. 
CROMIS = clinical relevance of microbleeds in stroke. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. 
 
Table 10.32 Medication use at hospital discharge in CROMIS-2-DNA participants with first-ever lobar ICH stratified by 
Edinburgh CT-APOE criteria classification 
 Low risk CT-APOE 
Edinburgh CAA criteria 
(n=110) 
Intermediate risk CT-APOE 
Edinburgh CAA criteria 
(n=116) 
High risk CT-APOE 
Edinburgh CAA criteria 
(n=67) 
Antiplatelet at discharge* 5 (5%) 3 (3%) 4 (6%) 
Anticoagulant at discharge† 6 (6%) 4 (4%) 2 (3%) 
Antihypertensive at discharge† 76 (71%) 81 (74%) 42 (67%) 
* Data is not available for 12 CROMIS-2-DNA participants. † Data is not available for 13 CROMIS-2-DNA participants. APOE = 
apolipoprotein E. CAA = cerebral amyloid angiopathy. CROMIS = clinical relevance of microbleeds in stroke. CT = computed 
tomography. DNA = deoxyribonucleic acid. ICH = intracerebral haemorrhage. 
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10.5 Discussion 
10.5.1 Main findings 
 The relative risk and rate of recurrent ICH were significantly higher in 
participants with first-ever lobar ICH compared with non-lobar ICH in 
both the LATCH and CROMIS-2 cohorts. 
 Edinburgh CT-only diagnostic criteria for CAA-associated lobar ICH 
o In multivariable models adjusting for CT SVD score and 
Edinburgh CT-only criteria in first-ever lobar ICH LATCH 
participants, high risk on the Edinburgh CT-only criteria was 
significantly associated with an increased relative risk and rate 
of recurrent ICH compared with the low-risk category. 
o In multivariable models adjusting for CT SVD score and 
Edinburgh CT-only criteria in first-ever lobar ICH CROMIS-2 
participants, the relative risk and rate of recurrent ICH were 
higher in participants classified as high risk on the Edinburgh 
CT-only criteria compared with low risk, although this did not 
reach significance. CT SVD score of 1, 2 or 3 was associated 
with an increased risk and rate of both recurrent ICH and death. 
o In a two-step random-effects meta-analysis of the 
subdistribution hazard models of the LATCH and CROMIS-2 
cohorts, participants classified as high risk on the Edinburgh 
CT-only criteria had a significantly higher subdistribution hazard 
ratio for recurrent ICH compared with the low-risk group. CT 
SVD score of 1, 2 or 3 was not associated with an increased 
subdistribution hazard ratio of recurrent ICH. 
o Secondary multivariable analyses assessing the individual 
components of the Edinburgh CT-only criteria showed that 
subarachnoid haemorrhage was associated with an increased 
relative risk and rate of recurrent ICH, while finger-like 
projections were associated with a non-significant increased 
risk of recurrent ICH. 
 Edinburgh CT-APOE diagnostic criteria for CAA-associated lobar ICH 
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o In multivariable models adjusting for CT SVD score and 
Edinburgh CT- APOE criteria in the CROMIS-2-DNA cohort, CT 
SVD score of 1, 2 or 3 was associated with an increased risk 
and rate of recurrent ICH and death. The Edinburgh CT-APOE 
criteria were not associated with a statistically significantly 
increased risk or rate of recurrent ICH. 
o The Edinburgh CT-APOE variable did not obey the proportional 
hazard assumption in the LINCHPIN cohort; therefore, I did not 
perform multivariable analyses in the LINCHPIN cohort. 
o In a secondary meta-analysis, pooling the LINCHPIN and 
CROMIS-2-DNA cohorts, participants classified as high risk on 
the Edinburgh CT-APOE criteria had significantly higher risk 
and rate of recurrent ICH compared with the low-risk group. CT 
SVD score of 1, 2 or 3 was also associated with an increased 
hazard of recurrent ICH and death. 
o Secondary multivariable analyses assessing the individual 
components of the Edinburgh CT-APOE criteria and APOE 2 
genotype showed that APOE 2 allele possession was 
independently associated with an increased risk and rate of 
recurrent ICH. Subarachnoid haemorrhage, finger-like 
projections and APOE 4 allele possession were not 
significantly associated with an increased risk of recurrent ICH. 
10.5.2 Strengths of the studies 
I used data from three prospective cohort studies of ICH. The LATCH and 
LINCHPIN studies are overlapping community-based cohort studies in the 
Lothian Health Board region of Scotland. The Edinburgh criteria were 
developed in the LINCHPIN study. The CROMIS-2 study is a large 
multicentre UK-based cohort study of ICH, which provided the opportunity to 
evaluate the prognostic value of the Edinburgh criteria in an external cohort. 
There were few missing baseline data. To minimise information bias, we 
rated the diagnostic non-contrast brain CT scans using a standardised pro 
forma, masked to baseline data and outcome information. All studies had 
  Chapter 10 
533 
comprehensive follow-up for recurrent ICH and death, with >95% 
completeness of follow up. 
I used appropriate statistical approaches to analyse the data. A competing 
event is one whose occurrence precludes the occurrence of the primary 
event.[349] When studying recurrent ICH as the primary outcome, death is a 
major competing event.  Traditional approaches to time-to-event analysis, 
such as the Kaplan-Meier method and the Cox proportional hazards model, 
assume that competing events are absent, and that censored participants 
would eventually have the outcome of interest if the study had continued for 
long enough. Using these approaches to analyse time-to-event data and 
censoring participants who have a competing event violates this assumption. 
This results in an overestimation of the probability of the outcome and 
misestimation of the magnitude of relative effects of predictors on the 
incidence of the event.[349-351] Many studies with competing events 
erroneously use these traditional approaches to time-to-event analysis.[358] 
Instead, I used competing risks time-to-event analyses to take into account 
the substantial competing event of death. I used the cumulative incidence 
function to estimate the incidence of recurrent ICH while accounting for death 
as a competing event.[349] I used two methods to calculate the hazard 
function. The subdistribution hazard function[353] represents the 
instantaneous rate of occurrence of the given event type in participants who 
have not yet experienced that event type. It estimates the effect of variables 
on the probability of events occurring over time and is recommended when 
assessing the impact of variables on the incidence of the outcome of interest 
or assessing prognosis.[351] The cause-specific hazard function[351, 352] 
represents the instantaneous rate of occurrence of an event among 
participants who are still event free. It is better for the assessment of 
aetiology of a disease process.[351] Reporting all three measures gives a 
better understanding of the effects of variables on the event of interest and 
on any competing event.[359] 
I pre-specified the primary and secondary analyses and restricted the 
number of variables in the models to ensure at least 7-10 outcomes per 
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variable, to help reduce over-fitting. I ensured variables obeyed the 
proportional hazard assumptions before including them in multivariable 
analyses. I restricted the primary analyses to first-ever lobar ICH, to 
standardise the inception point. I reported the cumulative incidence function 
as well as subdistribution and cause-specific hazard models for recurrent ICH 
and death.[359] 
10.5.3 Limitations of the studies 
Despite using three ICH cohorts, the sample sizes were modest. In LATCH, I 
included 120 participants with first-ever lobar ICH, 17 of whom had a 
recurrent ICH during follow up. In CROMIS-2, 342 participants had a first-
ever lobar ICH, 25 of whom had a recurrent ICH. The number of participants 
in the Edinburgh CT-APOE study with recurrent ICH was smaller (14 in 
LINCHPIN, 24 in CROMIS-2-DNA). The modest number of outcome events 
limited the number of variables I could include in the primary multivariable 
models. Therefore, I was unable to adjust for potentially important variables, 
such as age, and individual CT biomarkers of SVDs. 
I was unable to adjust for key confounders of recurrent ICH, such as blood 
pressure control and antithrombotic use because accurate data on these 
variables during follow-up was not available in the cohorts. Therefore, I 
cannot exclude the influence of residual confounding on my results. 
Descriptive analyses showed the use of antihypertensive and antithrombotic 
drug at hospital discharge was similar between the Edinburgh CT-only and 
CT-APOE risk categories in the LATCH, LINCHPIN and CROMIS-2-DNA 
cohorts. However, the use of antihypertensive drugs at hospital discharge 
was lower in the high-risk CT-only group compared to the low risk in the 
CROMIS-2 cohort. 
The non-contrast CT brain scans from the cohorts were assessed 
independently. There was no assessment of inter-rater agreement. 
Therefore, the differences in the magnitude of CT based predictors, such as 
CT SVD score and Edinburgh CT criteria found in the different cohorts may 
relate to differences in the rating of these features. 
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10.5.4 Study findings 
10.5.4.1 Lobar ICH location is associated with a higher risk of recurrent 
ICH 
In LATCH and CROMIS-2 participants with a first-ever SVD-associated ICH, 
a lobar index ICH location was associated with a significantly increased rate 
and incidence of recurrent ICH compared with a non-lobar index ICH location 
(Table 10.3, Figure 10.4 and Figure 10.5). The rate and incidence of death 
were similar between lobar and non-lobar ICH locations. Therefore, the effect 
of lobar ICH location on recurrent ICH is likely to represent a direct effect, 
rather than an indirect effect on the competing event of death. This finding is 
consistent with previous studies.[151] It is thought to reflect the likely 
underlying SVDs, with CAA, which is associated with approximately 60% of 
lobar ICH, understood to have a higher risk of recurrent ICH than 
arteriolosclerosis, which is associated with all non-lobar ICH, as well as a 
proportion of lobar ICH (Figure 4.13).[105, 154-157] To investigate this 
further, I assessed the association between the Edinburgh diagnostic criteria 
for CAA-associated lobar ICH and recurrent ICH. 
10.5.4.2 Edinburgh CT-only diagnostic criteria for CAA-associated lobar 
ICH and the risk of recurrent ICH 
In multivariable analyses of LATCH patients with first-ever lobar ICH, the 
Edinburgh CT-only CAA criteria high-risk group was associated with a 
significantly increased rate and incidence of recurrent ICH compared with the 
low-risk group (Table 10.8). There was no significant increase in the rate or 
incidence of death in the high-risk group, indicating that the effect on 
recurrent ICH is a direct effect, rather than an indirect effect on the competing 
event of death. The Edinburgh CT-only high-risk group showed a similar 
direction of effect in the multivariable models using CROMIS-2 participants 
with first-ever lobar ICH, although the associations were not statistically 
significant. In CROMIS-2, a CT SVD score of 1, 2 or 3 was associated with a 
significantly increased rate and incidence of both recurrent ICH and death 
(Table 10.9). It is difficult to determine if the effect on recurrent ICH is a direct 
or indirect effect through the competing event, given the similar magnitude of 
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effect on death. Two-step meta-analysis of the LATCH and CROMIS-2 
cohorts showed a significantly increased incidence of recurrent ICH in the 
high-risk Edinburgh CT-only group relative to the low-risk group 
(subdistribution hazard ratio 2.99, 95%CI 1.08-8.27, Figure 10.8). These 
results suggest that CT markers of CAA-associated lobar ICH may be able to 
identify lobar ICH patients at high risk of recurrent ICH. 
A recent meta-analysis assessed the risk of recurrent ICH in 1306 survivors 
of ICH, stratified by the likely underlying SVDs using MRI.[105] They 
compared participants with strictly lobar ICHs and CMBs (probable CAA and 
possible CAA on the original Boston criteria[103] – “CAA-related ICH”) 
against those with strictly deep or mixed ICHs and CMBs (“CAA-unrelated 
ICH”). Participants with CAA-related ICH had a seven-fold increase in the risk 
of recurrent ICH compared with CAA-unrelated ICH. In the CAA-related ICH 
group, the presence of lobar CMBs was associated with an increased risk of 
recurrent ICH. However, there were several limitations to this study, including 
selection bias, variable follow-up methods, few outcome events and possible 
confounding. The authors did not restrict their analyses to lobar ICH, nor to 
those with first-ever ICH. Also, no account was taken of the competing risk of 
death. Therefore, the probability of the outcome may have been 
overestimated. Nonetheless, this data support my findings that imaging 
biomarkers of CAA-associated lobar ICH may be helpful for identifying ICH 
patients at higher risk of recurrent ICH.  
In a pre-specified secondary analysis, I assessed the risk of recurrent ICH 
stratified by the individual components of the Edinburgh CT-only criteria. 
Subarachnoid haemorrhage significantly increased the rate and incidence of 
recurrent ICH, adjusting for age, sex, previous history of ICH, 
antihypertensive drug use on hospital discharge and CT SVD score (Table 
10.13). The presence of finger-like projections was associated with a non-
significant increase in the rate and incidence of recurrent ICH. 
Cortical superficial siderosis is an MRI biomarker of CAA.[107, 110] A recent 
meta-analysis of 443 CAA-associated lobar ICH survivors showed that 
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cortical superficial siderosis is an independent predictor for recurrent 
ICH.[116] This association persisted after adjusting for age, sex, previous 
lobar ICH history, WMH volume and CMBs. Cortical superficial siderosis 
may, therefore, be a strong predictor of recurrent lobar ICH. However, this 
study was small and prone to selection bias and confounding. The authors 
postulate that cortical superficial siderosis is a marker of increased cortical 
and leptomeningeal small vessel fragility, resulting in a high risk of recurrent 
ICH.[116, 360, 361] Subarachnoid haemorrhage is the putative acute 
manifestation of cortical superficial siderosis.[362] Therefore, the association 
in my study between subarachnoid haemorrhage and the risk of recurrent 
ICH supports the premise of CAA affecting the superficial cortical and 
leptomeningeal small vessels results in a high risk of recurrent ICH. 
10.5.4.3 Edinburgh CT-APOE diagnostic criteria for CAA-associated lobar 
ICH and the risk of recurrent ICH 
The Edinburgh CT-APOE diagnostic criteria variable did not obey the 
proportional hazards assumption in the LINCHPIN cohort, and there was 
insufficient power to allow me to include covariate time interaction terms. 
Therefore, I did not perform the primary two-step meta-analysis. In a pre-
specified one-step meta-analysis of the LINCHPIN and CROMIS-2-DNA 
cohorts, the high-risk group on the Edinburgh CT-APOE CAA criteria was 
significantly associated with an increased rate and incidence of recurrent ICH 
compared with the low-risk group (Table 10.19). There was no significant 
increase in the rate or incidence of death in the high-risk group, indicating 
that the effect on recurrent ICH is a direct effect, rather than an indirect effect 
of the competing event of death. A CT SVD score of 1, 2 or 3 was 
significantly associated with an increased rate and incidence of both 
recurrent ICH and death (Table 10.19). It is difficult to determine if the effect 
on recurrent ICH is a direct or indirect effect through the competing event, 
given the similar magnitude of effect on death. 
In a pre-specified secondary analysis, APOE 2 allele possession was 
significantly associated with an increased rate and incidence of recurrent 
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ICH, while the high-risk Edinburgh CT-APOE category had a borderline 
significant association with the risk of recurrent ICH (Table 10.21). 
It has been proposed that APOE 4 is associated with increased vascular 
deposition of amyloid- and APOE 2 promotes vasculopathic wall 
changes.[363-365] There is some evidence that APOE genotype is 
associated with the severity of CAA. A systematic review of pathologically 
proven CAA revealed a possible association of severe CAA with APOE 
4.[25] APOE 2 was associated with more severe CAA. However this did not 
reach significance, which may reflect the small numbers of participants in this 
part of the study.[25] The possession of an APOE 2 or 4 allele has been 
shown to be associated with increased risk of recurrent ICH,[366, 367] 
although these studies were prone to confounding and did not account for 
death as a competing risk. In line with these studies, my results suggest that 
APOE 2 allele possession is associated with an increased risk of recurrent 
ICH, while there may be a possible association between APOE 4 allele 
possession and recurrent ICH risk. However, the sample size in my study 
was limited. 
10.5.5 Clinical implications 
My results suggest that simple features on the diagnostic non-contrast brain 
CT (the Edinburgh CT-only criteria and CT SVD score) may be able to 
identify ICH patients at high and low risk of recurrent ICH. APOE genotype 
may also be associated with an increased risk of recurrent ICH. This 
information could help with prognosis and might help guide treatment 
decisions,[368-370] but only after the findings are replicated in larger cohorts 
of ICH. 
MRI biomarkers of CAA are potentially useful for identifying ICH patients with 
a higher risk of recurrent ICH.[105, 116] However, many ICH patients may 
not have access to or be able to tolerate MRI scanning. Therefore, predicting 
recurrent ICH risk using simple tests is important. Non-contrast brain CT is 
usually the first test to diagnose ICH and is the most widely available 
neuroimaging test. APOE genotype can be performed on a peripheral blood 
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sample. My studies indicate that non-contrast brain CT with or without APOE 
genotyping may be useful and easily available tests for identifying ICH 
patients at higher risk of recurrent ICH. 
10.5.6 Future directions 
These results need to be assessed in larger studies of ICH survivors with 
comprehensive follow-up for recurrent ICH and death. The time-to-event 
analyses should take into account the substantial competing risk of death. 
The analyses should be adjusted for important confounders, such as age, 
history of previous ICH and antithrombotic drug use and blood pressure 
control during follow-up. 
I am currently coordinating a multicentre study assessing the association 
between the Edinburgh CT-only and CT-APOE diagnostic criteria and the risk 
of recurrent ICH. There are eight European and North American contributing 
centres involved, with over 2000 participants with first-ever lobar ICH, 
diagnostic non-contrast brain CT and follow-up for recurrent ICH and death. 
Around 1700 participants also have APOE genotyping. This large multicentre 
study should provide sufficient power to assess the prognostic value of the 
Edinburgh diagnostic criteria while adjusting for important confounders. 
The collaborators in this multicentre study are assessing the diagnostic brain 
CTs in their own cohorts for the Edinburgh criteria. Before rating the imaging, 
they are undertaking the online training for the Edinburgh criteria which I 
have developed.[330] This will hopefully improve the reliability of the ratings. 
Also, there are 60 practice cases within the training materials, which will 
allow me to assess inter-rater agreement between the collaborators, as well 
as any other researchers who have undertaken the training.  
ICH survivors are at risk of future ischaemic events, as well as recurrent 
ICH,[151] and may therefore benefit from antithrombotic drugs. However, the 
risk of antithrombotic-associated recurrent ICH in survivors of CAA-
associated lobar ICH is uncertain. Biffi et al. assessed the associations with 
risk of recurrent ICH in CAA-associated lobar ICH.[158] They showed that a 
previous lobar ICH, two or more lobar CMBs, posterior white matter lucencies 
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on CT and aspirin use after the index ICH were independently associated 
with the risk of recurrent ICH. However, this was a single centre cohort study. 
Only those who underwent a MRI were included, which is likely to introduce a 
selection bias. The sample size was modest, with only 29 recurrent ICHs 
during follow-up, and the regression models were over-fitted. The authors did 
not account for death as a competing risk, which will overestimate the 
strength of the reported associations. Finally, the results may be the result of 
confounding as this was not a randomised study. In particular, the authors 
did not account for blood pressure control during follow-up, which is known to 
affect the risk of recurrent ICH.[159] In contrast, a recent randomised 
controlled trial assessing the risk of recurrent ICH between SVD-associated 
ICH survivors showed that the group restarted on aspirin had a borderline 
significantly lower risk of recurrent ICH compared with the group not restarted 
on aspirin.[160] Furthermore, there was also no statistically significant 
association between CT or MRI markers of CAA and treatment group effect, 
suggesting that the finding of imaging biomarkers of CAA does not increase 
the risk of antithrombotic-associated ICH. However, the power of these 
subgroup analyses was limited, and there is likely to be selection bias in the 
study.[161] It is therefore unclear whether aspirin increases the risk of 
recurrent ICH in survivors of lobar ICH when imaging biomarkers of CAA are 
present. Sufficiently powered randomised controlled studies should aim to 
address whether imaging biomarkers of CAA are associated with increased 
risk of recurrent antithrombotic-associated ICH. 
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Chapter 11 Prediction models for death and disability 




Accurately predicting outcomes in SVD-associated ICH is important. It can 
help improve communication between clinicians, be used by clinicians to 
discuss prognosis with patients and their relatives and may help guide 
treatment decisions. Such information can also be used to select patients for 
clinical trials.[371-373] Prediction models may help improve prognostication 
beyond informal clinical assessment through rigorous development and 
external validation. Many prognostic tools have been developed for ICH,[373-
376] of which the ICH score is the most commonly used.[244] 
The ICH score is a simple ordinal grading scale based on five categorical 
predictors (age [<80 versus ≥80 years], admission GCS [3-4, 5-12 or 13-15], 
infratentorial ICH location, ICH volume [<30 ml versus ≥30 ml] and presence 
of intraventricular haemorrhage). It was derived from a logistic regression 
model for 30-day fatality developed in a retrospective single centre cohort 
consisting of 152 participants with ICH.[244] It has been externally validated 
for short (≤1 month)[245, 377-384] and long term (≥1 month)[380, 385] 
fatality, as well as short (≤1 month)[382, 386] and long term functional 
outcome(≥1 month)[380, 385-390] in a variety of healthcare settings.  
Whilst the ICH score has many strengths, there are some limitations. Firstly, 
it was developed on a relatively small Californian cohort from the 1990s. The 
magnitude of the included predictor associations may be different in ICH 
patients from the UK, and they may have changed in the intervening 20 
years. Also, new predictors have been identified that are associated with 
outcome after ICH,[151] such as white matter lucencies and other CT 
features of SVD.[195, 391] However, the prognostic value of CT SVD 
biomarkers in ICH is not fully understood. Some of the approaches the 
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authors took to model development, such as only including significant 
variables and converting continuous variables into categorical predictors, will 
have had a detrimental effect on predictive power.[334] Finally, the ICH score 
was specifically developed to predict short term fatality after ICH. 30-day 
fatality is high after ICH, around 40%,[133] and therefore a useful outcome to 
predict. However, fatality after ICH continues to increase beyond the short 
term, with population studies showing that it reaches 54% by one year.[151] 
The ICH-score shows good discrimination for 30-day mortality (pooled c 
statistic of the ICH score is 0.81, 95%CI 0.76-0.86)[375] and moderate 
discrimination for 90-120-day mortality (pooled c statistic 0.79, 95%CI 0.70-
0.88).[375] However, functional outcome is probably a more relevant clinical 
outcome than fatality; patients, relatives and medical practitioners are usually 
more interested in the chances of functional recovery rather than just survival 
after ICH.[371, 392] 
Several prediction models, such as the FUNC score,[152] modified ICH 
score[393] and Essen ICH score,[394] have been developed to specifically 
assess long term functional outcome (≥1 month). These scores are based on 
similar predictors to the ICH score, such as age, neurological status, ICH 
location and ICH volume, with reclassification of some of these and/or 
additional predictors included. They all have methodological limitations, such 
as selection bias and relatively high levels of missing outcome data. Also, 
they were all derived on cohorts from the 1990s or early 2000s. Finally, they 
were developed to assess functional outcome between 90-180 days, 
however functional recovery continues to evolve beyond the acute and 
intermediate phases, with changes occurring throughout the first year after 
ICH.[387] The ICH Functional Outcome Score (ICH-FOS) was developed to 
predict one-year functional outcome after ICH and performed well against 
existing scores.[390] However, this study excluded relevant ICH participants, 
such as those with pre-ICH disabilities. It was developed in a large cohort in 
China, and the demographics and some of the ICH characteristics of those 
included differ to patients in LATCH. Therefore, its relevance to patients with 
ICH in the UK is unclear. 
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Developing a prognostic prediction model for ICH in a large, unselected 
contemporary ICH cohort using a rigorous methodological approach to 
prediction modelling is important. In addition to the established clinical and 
radiological predictors of survival, CT biomarkers of SVD severity may add 
prognostic value and their incremental value should be assessed. The most 
clinically relevant model outcomes are fatality and functional recovery beyond 
the short term. Comparison of the performance of any novel prediction model 
against the ICH score is important since the ICH score is the most 
extensively validated prognostic score in ICH and there is a lack of evidence 
of superior predictions by other prognostic models.[395] 
The LATCH cohort is a large, representative ICH cohort with low levels of 
missing baseline data and comprehensive follow-up for death and functional 
status. It, therefore, provides an excellent dataset for developing a clinically 
relevant prediction model for death and disability after SVD-associated ICH. 
  
11.2 Aims 
I aimed to: 
 Assess survival in first-ever SVD-associated ICH. 
 Develop multivariable logistic regression prognostic models to predict 
the risk of death and death or disability at one year after first-ever 
SVD-associated ICH and to compare these against logistic regression 
models based on the ICH score.[244]  
 Perform a pragmatic update to the ICH score by incorporating the CT 
SVD score, and to compare its performance against the original ICH 
score for predicting death and death or disability at one year after first-
ever SVD-associated ICH. 
 
11.3 Methods 
I performed and reported the study according to the TRIPOD guidelines.[332] 
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11.3.1 Study design and patients 
I used data from the prospective, community-based LATCH study (section 
2.1.3.1). I included consecutive adult patients (aged ≥16 years) living in the 
NHS Lothian Health Board region who had a first-ever spontaneous ICH 
between 1st June 2010 and 31st May 2013 inclusive. 
I excluded those with exclusively extra-axial intracranial haemorrhage and 
ICH secondary to an underlying cause other than SVDs. I also excluded 
patients with a previous symptomatic ICH. 
11.3.1.1 Treatments 
Patients received standard clinical care, including admission to a dedicated 
stroke unit where possible, rehabilitation and secondary prevention through 
treatment of hypertension with antihypertensive drugs.[177, 178] Decisions 
regarding do not attempt resuscitation orders and withdrawal of active care 
were made by the clinical team and the patient and their relatives based on 
clinical information and patient/relative wishes; there were no local guidelines 
for these interventions.  
11.3.2 Predictors 
The RUSH team collected demographics and the presence of relevant co-
morbidities and medication use at the time of ICH as described in section 
2.1.7. 
I assessed the diagnostic non-contrast brain CT using a standardised pro 
forma, as described in section 2.2.1.3. I evaluated the presence, number and 
location of acute ICHs,[190] the volume of each ICH using a modified ABC/2 
approach,[191] and the presence or absence of extra-axial haemorrhage 
(subarachnoid, subdural or intraventricular spaces) and finger-like projections 
arising from the largest haematoma. I calculated the CT SVD burden 
score[196] based on the presence and severity of white matter 
lucencies[193] and cerebral atrophy[195], the number of lacunes[77] and CT 
SVD burden score[196] as described in the methods (2.2.1.3). 
I performed the CT ratings masked to clinical, MRI and outcome information. 
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11.3.3 Outcome 
The RUSH team used multiple sources of information to follow-up patients in 
LATCH as described in section 2.1.8. For this study, I censored follow-up 
data at five years after the index ICH or on 27th February 2018, whichever 
occurred first. 
I pre-specified the outcomes of interest in this study: 
1. Death from any cause at one year after the index ICH  
2. Death from any cause or disability, defined as a modified Rankin 
Scale 4-6,[185] at one year after the index ICH. 
I chose the outcome of death from any cause at one year after the index ICH 
because ICH is associated with high fatality.[133] Case fatality is highest in 
the early post-ICH period but continues to increase during the first year after 
ICH.[151] Therefore one-year fatality is likely to be a more useful outcome 
than 30-day fatality.  
I chose the combined outcome of death or disability at one year after the 
index ICH because the functional outcome is probably a more relevant 
clinical outcome than fatality alone.[371, 392] I chose the one year time point 
because functional outcome continues to evolve throughout the first year 
after ICH.[387] I dichotomised this outcome (modified Rankin Scale 0-3 
versus 4-6) to increase the power for analysis and to allow me to compare 
my results with other studies.[386-388] 
Deaths were adjudicated by a consultant neurologist with an interest in stroke 
medicine (Prof R Al-Shahi Salman) using the death certificate and GP and 
hospital records to confirm the cause and date of death. Adjudication was 
performed masked to the CT ratings, including the CT SVD score. 
The one year modified Rankin Scale was ascertained in surviving patients 
through a postal questionnaire sent to the patients’ GPs. The GPs used all 
available clinical information to derive the modified Rankin Scale. The GPs 
were not aware of this study when assessing the modified Rankin Scale. 
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11.3.4 Sample size 
I did not perform a sample size calculation because there is no generally 
accepted approach to estimating sample size in prediction modelling.[333] 
Instead, I used the largest sample size possible from the three-year 
community-based LATCH study to maximise power and generalisability. I 
reduced overfitting by following the general guidance of pre-specifying 
predictors, having at least 10 outcome events per predictor and at least 100 
events.[333] 
11.3.5 Missing data 
I excluded 15 patients with first-ever SVD-associated ICH because they did 
not have a diagnostic non-contrast CT brain scan. Information about pre-ICH 
history of diabetes was missing for one patient, and the admission GCS was 
not available for two patients. The modified Rankin scale at one year after the 
index ICH was missing in 10 patients. I excluded patients with missing 
predictors or outcomes from the relevant analyses. I did not impute any 
missing data. 
11.3.6 Statistical analysis 
11.3.6.1 Survival analysis 
I quantified the follow-up time using the median and interquartile range, and 
the completeness of follow-up by calculating the completeness index 
([observed follow up/potential follow up]*100).[348] 
I performed univariable Cox regression to assess for associations between 
survival time and pre-specified variables (age, sex, pre-ICH diagnosis of 
dementia, pre-ICH diagnosis of diabetes, antiplatelet use at the time of the 
ICH, anticoagulant use at the time of the ICH, admission GCS, ICH location 
(lobar versus non-lobar), ICH volume, intraventricular haemorrhage and CT 
SVD score ≥1) associated with long-term survival and functional outcome in 
ICH.[151, 152, 195, 391] I used Kaplan-Meier plots to show the survival 
curves for categorical predictors. I dichotomized the CT SVD score 0 versus 
≥1 for analyses for two reasons. First, I wanted to differentiate those without 
evidence of severe SVD on CT (CT SVD score 0) from those with severe CT 
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SVD (≥1). Secondly, I wanted to maximise power in my analyses, and very 
few participants had CT SVD score of 3. 
11.3.6.2 Prediction modelling and performance 
For the two outcomes, death and death or disability at one year after ICH, I 
compared the frequency of clinical characteristics and diagnostic non-
contrast brain CT features between groups using 2 test (or Fisher's exact 
test, where appropriate) for categorical variables and the Mann-Whitney U 
test for non-normally distributed continuous variables. 
I developed three separate prediction models for each outcome using logistic 
regression. For the first model (“full pre-specified model”) I included 11 pre-
specified predictors. Ten of these (age, sex, pre-ICH diagnosis of dementia, 
pre-ICH diagnosis of diabetes, antiplatelet use at the time of the ICH, 
anticoagulant use at the time of the ICH, admission GCS, ICH location (lobar 
versus non-lobar), ICH volume and intraventricular haemorrhage) were 
based on the variables most frequently associated with long-term survival 
and functional outcome in ICH.[151, 152] I also included the predictor CT 
SVD score ≥1 based on recent evidence of an association between CT SVD 
biomarkers and outcome in ICH.[195, 391] I modelled the continuous 
predictors age, GCS on admission and ICH volume as linear associations as 
there was no evidence of nonlinearity. There was no evidence of interactions 
between ICH location, ICH volume and CT SVD score. 
For the second model (“ICH-SVD score model”) I included six pre-specified 
predictors. Five were based on the variables included in the logistic 
regression model used to derive the ICH score (age, admission GCS, 
infratentorial ICH location, ICH volume and presence of intraventricular 
haemorrhage).[244] The other variable was CT SVD score (0 or ≥1). I 
dichotomised age (<80 or ≥80 years), but kept GCS and ICH volume as 
continuous linear variables, as this was the approach taken by Hemphill et al. 
in their logistic regression model.[244] 
I wanted to compare my new prediction models against the ICH score model. 
However, the logistic regression equation for the ICH score was not included 
in the published paper[244] nor was it available after contacting the 
  Chapter 11 
548 
corresponding author. Therefore, I fitted logistic regression models for death 
and death or disability at one year in the LATCH data using the ICH score 
variables used in the original ICH score logistic regression model, as 
described in the above paragraph (“ICH score model”). 
Predictions from multivariable models can be improved for new subjects by 
shrinkage of the regression coefficients to reduce variance.[334, 396, 397] I 
used penalised maximum likelihood estimation, which uses a penalty factor 
in the estimation of coefficients, to shrink the logistic regression coefficients 
of the prediction models. The optimal penalty factor was determined by the 
Akaike information criterion (AIC).[398] 
For each shrunken model, I evaluated its overall performance using 
Nagelkerke’s R2, the Brier score and AIC.[339] The AIC assesses model fit 
while taking into account the number of predictors in the model. The lower 
the AIC, the better the model fit. It can be used to compare the fit of different 
logistic regression models. I assessed model discrimination with the c 
statistic and displayed this graphically using ROC plots. I assessed model 
calibration using calibration plots. 
I internally validated each shrunken prediction model with bootstrapping by 
drawing 2000 random bootstrap samples with replacement, constructed 
models on each of these bootstrap samples and derived optimism-adjusted 
measures of performance.[339, 399] 
11.3.6.3 ICH score and ICH-SVD score 
I developed a modified ICH score (ICH-SVD score) by adding the predictor 
CT SVD score to the ICH score. I assigned one point to a CT SVD score ≥1 
based on the magnitude of its coefficient relative to the other variables in the 
ICH-SVD score logistic regression model. My ICH-SVD score therefore 
ranged from 0 to a maximum of 7. 
I compared the ICH-SVD score against the original ICH score for the two 
outcomes (death at one year and death or disability at one year) using the c 
statistic and displayed this graphically using ROC plots. 
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11.4 Results 
11.4.1 Flow of patients 
There were 530 patients with a spontaneous ICH in the NHS Lothian Health 
Board region between 1st June 2010 and 31st May 2013 inclusive. Four 
hundred nineteen had a first-ever SVD-associated ICH. I included 404 who 
had a diagnostic non-contrast brain CT (Figure 3.1). 
11.4.2 Survival analysis 
Three hundred and four of the 404 (75.2%) patients died during follow-up. 
The median duration of follow-up was 156 days (IQR 4-1547), with 98.1% 
completeness of follow-up. 
By 30 days, 168 patients (42%, 95%CI 37-46%) had died (Figure 11.1). This 
increased to 225 patients (56%, 95%CI 51-60%) at one year and 304 
patients (75%, 95%CI 71-80%) at five years. The Kaplan-Meier survival 
curves for the pre-specified categorical variables are shown in Figure 11.2. 
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Figure 11.1 Kaplan-Meier survival curve for first-ever SVD-associated ICH 
 
ICH = intracerebral haemorrhage. SVD = small vessel disease. 
 
Of the 11 pre-specified predictors, all except sex, anticoagulant use at the 
time of the index ICH and ICH location were associated with death on 
univariable Cox regression (Table 11.1). 
11.4.3 Prognostic models for death at one year after first-ever SVD-
associated ICH 
11.4.3.1 Baseline clinical and diagnostic CT brain characteristics  
Two hundred and twenty-five patients (56%) were dead at one year after 
their index ICH whilst 179 patients were alive. Those who died were older, 
with a more frequent history of pre-ICH ischaemic stroke or dementia, had 
higher pre-ICH modified Rankin scale scores and lower GCS on admission 
(Table 11.2). Larger ICH volume and more frequent intraventricular 
haemorrhage, subarachnoid haemorrhage, subdural haemorrhage and 
finger-like projections were also associated with death at one year, as was 
more severe CT SVD score (Table 11.3). There was no univariable 
association between sex, pre-ICH diabetes, antiplatelet or anticoagulant drug 
use at the time of ICH and ICH location and death at one year.  
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Figure 11.2 Kaplan-Meier survival curves for pre-specified categorical 
variables in first-ever SVD-associated ICH. 
A. Sex, B. Pre-ICH dementia, C. Pre-ICH diabetes, D. Antiplatelet use at the time of 
ICH, E. Anticoagulant use at the time of ICH, F. ICH location, G. intraventricular 
haemorrhage and H. CT SVD score. 
 
CT = computed tomography. ICH = intracerebral haemorrhage. IVH = 
intraventricular haemorrhage. SVD = small vessel disease.  
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Glasgow coma scale (per 
unit change) 
 0.82 0.79-0.84 <0.001 















































CT = computed tomography. ICH = intracerebral haemorrhage. SVD = small 
vessel disease. 
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Table 11.2 Baseline clinical features in first-ever SVD-associated ICH 
patients who were alive at one year after the index ICH versus those who 
were dead 
 Alive at 1 year 
(n=179) 
Dead at 1 year 
(n=225) 
p value 


















Co-morbidities      
Hypertension 113 (63) 153 (68) 0.276 
Ischaemic stroke† 20 (11) 48 (21) 0.006 
Transient ischaemic attack† 16 (9) 29 (13) 0.204 
Dementia 16 (9) 36 (16) 0.035 
Diabetes† 16 (9) 30 (13) 0.162 
Atrial fibrillation† 39 (22) 50 (22) 0.898 
Myocardial infarction 11 (6) 26 (12) 0.059 



























































Pre-ICH modified Rankin 
scale; median (IQR) 
2 (1-3) 3 (2-4) <0.001 
Medications on admission      
Antiplatelet drug(s) 72 (40) 103 (46) 0.263 
Anticoagulant drug(s) 22 (12) 32 (14) 0.571 
Antihypertensive drug(s) 87 (49) 111 (49) 0.884 
Admission GCS score; median 
(IQR)* 
14 (14-15) 11 (6-14) <0.001 
Data are n (%), median (IQR) or mean (SD). † data missing in 1 patient . * 
data missing in 2 patients. ‡ data missing in 34. GCS = Glasgow coma scale.  
ICH = intracerebral haemorrhage. SVD = small vessel disease. 
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Table 11.3 Non-contrast brain CT features in first-ever SVD-associated ICH 
patients who were alive at one year after the index ICH versus those who 
were dead 
 
Alive at 1 year 
(n=179) 

























ICH volume (ml); median (IQR) 10 (3-22) 38 (13-83) <0.001 
Intraventricular haemorrhage 48 (27) 141 (63) <0.001 
Subarachnoid haemorrhage 65 (36) 111 (49) 0.009 
Subdural haemorrhage 12 (7) 30 (13) 0.030 
Finger-like projections 11 (6) 33 (15) 0.006 
Number of lacunes; median 
(IQR) 
0 (0-1) 0 (0-1) 0.653 




















































































































Data are n (%), median (IQR) or mean (SD). CT = computed tomography. 
ICH = intracerebral haemorrhage. SVD = small vessel disease.  
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11.4.3.2 Multivariable logistic regression prediction models 
I excluded one patient because of missing data for pre-ICH diabetes and two 
for missing admission GCS score. Therefore, I included 401 patients who 
had complete data for all predictors and the outcome. 
Full pre-specified model 
The full prediction model for death included 11 pre-specified predictors and is 
shown in Table 11.4. The variance inflation factor values ranged from 1.06 to 
1.50, confirming no evidence of multicollinearity between the predictors. 
The shrunken model calculates the predicted probability of death at one year 
after index ICH as follows: 
𝑅𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 = −2.41 + 0.04 ∗ (𝑎𝑔𝑒) + 0.59 ∗ (𝑚𝑎𝑙𝑒 𝑠𝑒𝑥) − 0.06
∗ (𝑝𝑟𝑒 − 𝐼𝐶𝐻 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎) + 0.31 ∗ (𝑝𝑟𝑒 − 𝐼𝐶𝐻 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠) − 0.32
∗ (𝑎𝑛𝑡𝑖𝑝𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑢𝑠𝑒) − 0.01 ∗ (𝑎𝑛𝑡𝑖𝑐𝑜𝑎𝑔𝑢𝑙𝑎𝑛𝑡 𝑢𝑠𝑒) − 0.20
∗ (𝐺𝐶𝑆) + 0.50 ∗ (𝑛𝑜𝑛 𝑙𝑜𝑏𝑎𝑟 𝐼𝐶𝐻 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛) + 0.02
∗ (𝐼𝐶𝐻 𝑣𝑜𝑙𝑢𝑚𝑒 ) + 0.63 ∗ (𝑖𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 ℎ𝑎𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒)
+ 0.76 ∗ (𝐶𝑇 𝑆𝑉𝐷 𝑠𝑐𝑜𝑟𝑒 ≥ 1) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒𝑥𝑝−𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 
 
The categorical predictor values are 1 when present and 0 when absent, age 
is the age at the time of the index ICH in years, GCS is the GCS score on 
hospital admission and ICH volume is the volume of the largest ICH in ml. 
ICH score model 
The logistic regression prediction model for the variables used in the ICH 
score logistic regression model is shown in Table 11.5. The variance inflation 
factor values ranged from 1.01 to 1.13, confirming no evidence of 
multicollinearity between the predictors. 
The shrunken model calculates the predicted probability of death at one year 
after index ICH as follows: 
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𝑅𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 = 1.45 + 0.64 ∗ (𝑎𝑔𝑒) − 0.20 ∗ (𝐺𝐶𝑆) + 0.10
∗ (𝑖𝑛𝑓𝑟𝑎𝑡𝑒𝑛𝑡𝑜𝑟𝑖𝑎𝑙 𝐼𝐶𝐻 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛) + 0.02 ∗ (𝐼𝐶𝐻 𝑣𝑜𝑙𝑢𝑚𝑒) + 0.76
∗ (𝑖𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 ℎ𝑎𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒𝑥𝑝−𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 
 
The value of the predictor age is 1 when the age is ≥80 years and 0 when 
age is <80 years. The other categorical predictor values are 1 when present 
and 0 when absent. ICH volume is the volume of the largest ICH in ml and 







Table 11.4 Full pre-specified multivariable logistic regression prediction models for death at one year after the index ICH in 
first-ever SVD-associated ICH 
 Original model Shrunken model 
  Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
 Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
Intercept -3.05 (1.20)    -2.41 (1.08)    
Age (per year increase) 0.05 (0.01) 1.05 (1.02-1.08) <0.001 0.04 (0.01) 1.04 (1.02-1.07) <0.001 
Male sex 0.72 (0.27) 2.05 (1.20-3.51) 0.008 0.59 (0.25) 1.81 (1.12-2.92) 0.016 
Pre-ICH dementia  -0.14 (0.41) 0.87 (0.39-1.96) 0.736 -0.06 (0.35) 0.95 (0.48-1.87) 0.874 
Pre-ICH diabetes 0.44 (0.52) 1.55 (0.69-3.51) 0.288 0.31 (0.35) 1.36 (0.69-2.69) 0.381 
Antiplatelet use at ICH -0.46 (0.30) 0.63 (0.35-1.14) 0.127 -0.32 (0.26) 0.83 (0.44-1.21) 0.223 
Anticoagulant use at ICH -0.07 (0.42) 0.93 (0.41-2.12) 0.863 -0.01 (0.36) 0.99 (0.50-1.94) 0.969 
Glasgow coma scale (per point 
increase) 
-0.21 (0.05) 0.81 (0.73-0.89) <0.001 -0.20 (0.04) 0.82 (0.75-0.89) <0.001 
Non lobar ICH location 0.65 (0.30) 1.91 (1.07-3.41) 0.028 0.50 (0.26) 1.65 (0.99-2.74) 0.052 
ICH volume (per ml increase) 0.03 (0.01) 1.03 (1.02-1.04) <0.001 0.02 (0.00) 1.02 (1.01-1.03) <0.001 
Intraventricular haemorrhage 0.63 (0.29) 1.87 (1.06-3.29) 0.030 0.63 (0.26) 1.88 (1.14-3.10) 0.014 
CT SVD score ≥1 0.91 (0.29) 2.48 (1.39-4.41) 0.002 0.76 (0.26) 2.15 (1.29-3.58) 0.003 







Table 11.5 ICH score multivariable logistic regression prediction models for death at one year after the index ICH in first-ever 
SVD-associated ICH 
 Original model Shrunken model 
  Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
 Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
Intercept 1.56 (0.70)    1.45 (0.65)    
Age ≥80 0.67 (0.25) 1.96 (1.21-3.20) 0.007 0.64 (0.24) 1.89 (1.18-3.03) 0.008 
Glasgow coma scale (per point 
increase) 
-0.21 (0.05) 0.81 (0.74-0.89) <0.001 
-0.20 (0.04) 0.82 (0.75-0.89) 
<0.001 
Infratentorial ICH location 0.45 (0.38) 1.57 (0.75-3.27) 0.233 0.10 (0.36) 1.51 (0.74-3.08) 0.254 
ICH volume (per ml increase) 0.02 (0.00) 1.02 (1.01-1.03) <0.001 0.02 (0.00) 1.02 (1.01-1.02) <0.001 
Intraventricular haemorrhage 0.76 (0.26) 2.13 (1.28-3.54) 0.004 0.76 (0.25) 2.14 (1.31-3.49) 0.002 
ICH = intracerebral haemorrhage. SVD = small vessel disease. 
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ICH-SVD score model 
I combined the CT SVD score predictor with the other variables from the ICH 
score logistic regression model to create a modified ICH (ICH-SVD) score 
logistic regression prediction model (Table 11.6). The variance inflation factor 
values ranged from 1.04 to 1.19, indicating no evidence of multicollinearity 
between the predictors. 
The shrunken model calculates the predicted probability of death at one year 
after index ICH as follows: 
𝑅𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 = 0.80 + 0.46 ∗ (𝑎𝑔𝑒) − 0.20 ∗ (𝐺𝐶𝑆) + 0.41
∗ (𝑖𝑛𝑓𝑟𝑎𝑡𝑒𝑛𝑡𝑜𝑟𝑖𝑎𝑙 𝐼𝐶𝐻 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛) + 0.02 ∗ (𝐼𝐶𝐻 𝑣𝑜𝑙𝑢𝑚𝑒) + 0.72
∗ (𝑖𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 ℎ𝑎𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒) + 0.98 ∗ (𝐶𝑇 𝑆𝑉𝐷 𝑠𝑐𝑜𝑟𝑒 ≥ 1) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒𝑥𝑝−𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 
 
The value of the predictor age is 1 when the age is ≥80 years and 0 when 
age is <80 years. The other categorical predictor values are 1 when present 
and 0 when absent. ICH volume is the volume of the largest ICH in ml and 
GCS is GCS score on hospital admission. 
11.4.3.3 Performance of the shrunken prediction models  
The performance measures of the three models are summarised in Table 
11.7. The full pre-specified model showed good discrimination (c statistic 
0.86, 95%CI 0.82-0.89) and good calibration (Figure 11.3). The ICH score 
model showed good discrimination (c statistic 0.82, 95%CI 0.78-0.86) and no 
evidence of miscalibration (Figure 11.4). The ICH-SVD score model also 
showed good discrimination (c statistic 0.84, 95%CI 0.80-0.88) and 
calibration (Figure 11.5). The AIC was best for the full pre-specified model 
(407.8), followed by the ICH-SVD model (413.5) then the ICH score model 
(427.6). 
Internal validation resulted in small optimism-adjusted differences in the 
overall performance measures and discrimination for all three models (Table 
11.7), with no evidence of poor calibration (Figure 11.3 to Figure 11.5). 
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11.4.4 ICH score versus the ICH-SVD score 
The ICH score had a c statistic of 0.79 (95%CI 0.74-0.83). The addition of the 
predictor CT SVD ≥1 (ICH-SVD score) slightly increased the c statistic to 
0.80 (95%CI 0.76-0.84) (Figure 11.6). 
The percentage of patients who were dead at one year after the index ICH 
increased with both the ICH score and ICH-SVD score (Figure 11.7). Twenty-
three percent (95%CI 15-33%) of patients with an ICH score of 0 were dead 
at one year. Ninety-three percent of patients (95%CI 82-98%) with an ICH 
score of 4 died within the first year, whereas 100% (95%CI 82-100%) with an 
ICH score of 5 or 6 had died. 
Eleven percent (95%CI 4-25%) of patients with an ICH-SVD score of 0 were 
dead at one year. Ninety-five percent of patients (95%CI 82-99%) with an 
ICH-SVD score of 5 died within the first year, and 100% (95%CI 78-100%) 







Table 11.6 ICH-SVD score multivariable logistic regression prediction models for death at one year after the index ICH in first-
ever SVD-associated ICH 
 Original model Shrunken model 
  Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
 Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
Intercept 0.81 (0.73)    0.80 (0.70)    
Age ≥80 0.47 (0.26) 1.59 (0.96-2.64) 0.071 0.46 (0.25) 1.58 (0.97-2.59) 0.067 
Glasgow coma scale (per point 
increase) 
-0.20 (0.05) 0.82 (0.74-0.90) <0.001 
-0.20 (0.05) 0.82 (0.75-0.90) 
<0.001 
Infratentorial  ICH location 0.44 (0.39) 1.55 (0.73-3.33) 0.256 0.41 (0.38) 1.51 (0.72-3.17) 0.272 
ICH volume (per ml increase) 0.02 (0.00) 1.02 (1.01-1.03) <0.001 0.02 (0.00) 1.02 (1.01-1.03) <0.001 
Intraventricular haemorrhage 0.71 (0.27) 2.03 (1.20-3.42) 0.008 0.72 (0.26) 2.05 (1.23-3.40) 0.006 
CT SVD score ≥1 1.07 (0.28) 2.92 (1.70-5.02) <0.001 0.98 (0.26) 2.67 (1.60-4.45) <0.001 







Table 11.7 Performance measures of the shrunken multivariable logistic regression prediction models for death at one year 
after the index ICH in the development dataset (n=401) and following internal validation using the same dataset (n=401; 2,000 
bootstrap samples) 












Overall       
 Brier score 0.15 0.17 0.16 0.16 0.18 0.17 
 R2 (Nagelkerke) 0.45 0.38 0.42 0.44 0.38 0.41 
Discrimination       
 c statistic 0.86 0.82 0.84 0.84 0.81 0.83 
ICH = intracerebral haemorrhage. SVD = small vessel disease.
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Figure 11.3 Discrimination and calibration measures of the full pre-specified 
prediction model for death at one year after the index ICH in first-ever SVD-
associated ICH following shrinkage. 
A. Receiver operating characteristic plot. The AUC is equivalent to the c statistic. 
The shaded area represents the 95% CI of the AUC based on 2000 bootstrap 
replicates. The grey line indicates a non-informative AUC of 0.50 for comparison. 
B. Calibration plot of model predicted probability versus observed frequency. The 
dashed grey line indicates ideal calibration, the model's apparent calibration is 
shown by the dotted grey line. The bias-corrected calibration after internal validation 
with 2000 bootstrap replicates is shown by the black line. The vertical lines at the 
top of the plot represent the distribution of model predicted probabilities.  
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.   
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Figure 11.4 Discrimination and calibration measures of the ICH score 
prediction model for death at one year after the index ICH in first-ever SVD-
associated ICH following shrinkage. 
A. Receiver operating characteristic plot. The AUC is equivalent to the c statistic. 
The shaded area represents the 95% CI of the AUC based on 2000 bootstrap 
replicates. The grey line indicates a non-informative AUC of 0.50 for comparison. 
B. Calibration plot of model predicted probability versus observed frequency. The 
dashed grey line indicates ideal calibration, the model's apparent calibration is 
shown by the dotted grey line. The bias-corrected calibration after internal validation 
with 2000 bootstrap replicates is shown by the black line. The vertical lines at the 
top of the plot represent the distribution of model predicted probabilities.  
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.  
  Chapter 11 
565 
Figure 11.5 Discrimination and calibration measures of the ICH-SVD score 
prediction model for death at one year after the index ICH in first-ever SVD-
associated ICH following shrinkage. 
A. Receiver operating characteristic plot. The AUC is equivalent to the c statistic. 
The shaded area represents the 95% CI of the AUC based on 2000 bootstrap 
replicates. The grey line indicates a non-informative AUC of 0.50 for comparison. 
B. Calibration plot of model predicted probability versus observed frequency. The 
dashed grey line indicates ideal calibration, the model's apparent calibration is 
shown by the dotted grey line. The bias-corrected calibration after internal validation 
with 2000 bootstrap replicates is shown by the black line. The vertical lines at the 
top of the plot represent the distribution of model predicted probabilities.  
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.  
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Figure 11.6 Receiver operating characteristic plots for death at one year after 
the index ICH in first-ever SVD-associated ICH. 
A. The ICH score. B. The ICH-SVD score. 
The AUC is equivalent to the c statistic. The shaded area represents the 95% 
CI of the AUC based on 2000 bootstrap replicates. The grey line indicates a 
non-informative AUC of 0.50 for comparison. 
 
AUC = area under the curve. ICH = intracerebral haemorrhage SVD = small vessel 
disease.  
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Figure 11.7 Bar plots showing the number of patients with first-ever SVD-
associated ICH who were dead at one year after their index ICH. 
A. The ICH score, B. The ICH-SVD score. 
 
ICH = intracerebral haemorrhage. SVD = small vessel disease.  
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11.4.5 Prognostic models for death or disability (modified Rankin 
scale 4-6) at one year after first-ever SVD-associated ICH 
I excluded one patient because of missing data for pre-ICH diabetes, two for 
missing admission GCS score and ten patients with missing one year 
modified Rankin scales. Therefore, I included 391 patients who had complete 
data for all predictors and the outcome. 
11.4.5.1 Baseline clinical and diagnostic CT brain characteristics  
Two hundred and eighty-three patients (72%) were dead or disabled 
(modified Rankin scale 4-6) at one year after their index ICH while 111 
patients were not (modified Rankin scale 0-3). Those who were dead or 
disabled were older, with a more frequent history of pre-ICH ischaemic 
stroke, dementia or diabetes, worse pre-ICH modified Rankin scale scores, 
and lower GCS on admission (Table 11.8). Larger ICH volume and more 
frequent intraventricular haemorrhage, subarachnoid haemorrhage, and 
finger-like projections were also associated with death or disability at one 
year, as was more severe CT SVD score (Table 11.9). There was no 
association between sex, antiplatelet or anticoagulant drug use at the time of 
ICH and ICH location and death or disability at one year. 
11.4.5.2 Multivariable logistic regression prediction models 
Full pre-specified model 
The full prediction model for death included 11 pre-specified predictors and is 
shown in Table 11.10. The variance inflation factor values ranged from 1.05 
to 1.76, confirming no evidence of multicollinearity between the predictors. 
 
The shrunken model calculates the predicted probability of death or disability 
(modified Rankin scale 4-6) at one year after index ICH as follows: 
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𝑅𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 = −2.43 + 0.06 ∗ (𝑎𝑔𝑒) + 0.34 ∗ (𝑚𝑎𝑙𝑒 𝑠𝑒𝑥) − 0.05
∗ (𝑝𝑟𝑒 − 𝐼𝐶𝐻 𝑑𝑒𝑚𝑒𝑛𝑡𝑖𝑎) + 1.14 ∗ (𝑝𝑟𝑒 − 𝐼𝐶𝐻 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠) − 0.50
∗ (𝑎𝑛𝑡𝑖𝑝𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝑢𝑠𝑒) − 0.17 ∗ (𝑎𝑛𝑡𝑖𝑐𝑜𝑎𝑔𝑢𝑙𝑎𝑛𝑡 𝑢𝑠𝑒) − 0.24
∗ (𝐺𝐶𝑆) + 0.50 ∗ (𝑛𝑜𝑛 𝑙𝑜𝑏𝑎𝑟 𝐼𝐶𝐻 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛) + 0.04
∗ (𝐼𝐶𝐻 𝑣𝑜𝑙𝑢𝑚𝑒 ) + 1.17 ∗ (𝑖𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 ℎ𝑎𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒)
+ 0.95 ∗ (𝐶𝑇 𝑆𝑉𝐷 𝑠𝑐𝑜𝑟𝑒 ≥ 1) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒𝑥𝑝−𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 
 
 
The categorical predictor values are 1 when present and 0 when absent, age 
is the age at the time of the index ICH in years, GCS is the GCS score on 
hospital admission and ICH volume is the volume of the largest ICH in ml. 
ICH score model 
The logistic regression prediction model for the variables used in the ICH 
score is shown in Table 11.11. The variance inflation factor values ranged 
from 1.01 to 1.09, confirming no evidence of multicollinearity between the 
predictors. 
The shrunken model calculates the predicted probability of death or disability 
(modified Rankin scale 4-6) at one year after index ICH as follows: 
𝑅𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 = 2.88 + 0.78 ∗ (𝑎𝑔𝑒) − 0.26 ∗ (𝐺𝐶𝑆) − 0.02
∗ (𝑖𝑛𝑓𝑟𝑎𝑡𝑒𝑛𝑡𝑜𝑟𝑖𝑎𝑙 𝐼𝐶𝐻 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛) + 0.03 ∗ (𝐼𝐶𝐻 𝑣𝑜𝑙𝑢𝑚𝑒) + 1.14
∗ (𝑖𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 ℎ𝑎𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒𝑥𝑝−𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 
 
The value of the predictor age is 1 when the age is ≥80 years and 0 when 
age is <80 years. The other categorical predictor values are 1 when present 
and 0 when absent. ICH volume is the volume of the largest ICH in ml and 
GCS is GCS score on hospital admission. 
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Table 11.8 Baseline clinical features in first-ever SVD-associated ICH 
patients who were dead or dependent (modified Rankin scale 4-6) at one 
year after the index ICH versus those who were not (modified Rankin scale 
0-3) 
 Modified Rankin 
scale 0-3 (n=111) 
Modified Rankin 
scale 4-6 (n=283) 
p value 


















Co-morbidities      
Hypertension 68 (61) 193 (68) 0.175 
Ischaemic stroke† 10 (9) 57 (20) 0.008 
Transient ischaemic attack† 11 (10) 34 (12) 0.547 
Dementia 7 (6) 43 (15) 0.017 
Diabetes† 6 (5) 39 (14) 0.018 
Atrial fibrillation† 23 (21) 64 (23) 0.671 
Myocardial infarction 7 (6) 30 (11) 0.186 



























































Pre-ICH modified Rankin 
scale; median (IQR) 
1 (1-2) 3 (2-4) <0.001 
Medications on admission      
Antiplatelet drug(s) 41 (37) 129 (46) 0.119 
Anticoagulant drug(s) 14 (13) 38 (13) 0.830 
Antihypertensive drug(s) 54 (49) 143 (51) 0.737 
Admission GCS score; median 
(IQR)* 
15 (14-15) 12 (8-14) <0.001 
Data are n (%), median (IQR) or mean (SD). † data missing in 1 patient . * 
data missing in 2 patients. ‡ data missing in 34. GCS = Glasgow coma scale. 
ICH = intracerebral haemorrhage. SVD = small vessel disease.  
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Table 11.9 Non-contrast brain CT features in first-ever SVD-associated ICH 
patients who were dead or dependent (modified Rankin scale 4-6) at one 
year after the index ICH versus those who were not (modified Rankin scale 
0-3) 
 Modified Rankin 
scale 0-3 (n=111) 
Modified Rankin 
























ICH volume (ml); median (IQR) 7 (3-16) 33 (12-76) <0.001 
Intraventricular haemorrhage 19 (17) 169 (60) <0.001 
Subarachnoid haemorrhage 38 (34) 134 (47) 0.018 
Subdural haemorrhage 8 (7) 34 (12) 0.164 
Finger-like projections 5 (5) 39 (14) 0.009 
Number of lacunes; median 
(IQR) 
0 (0-1) 0 (0-1) 0.896 




















































































































Data are n (%), median (IQR) or mean (SD). CT = computed tomography. 
ICH = intracerebral haemorrhage. SVD = small vessel disease. 





Table 11.10 Full pre-specified multivariable logistic regression prediction models for death or disability (modified Rankin scale 
4-6) at one year after the index ICH in first-ever SVD-associated ICH 
 Original model Shrunken model 
  Coefficient 
(standard error) 






Intercept -2.85 (1.67)    -2.43 (1.54)    
Age (per year increase) 0.06 (0.02) 1.06 (1.03-1.10) <0.001 0.06 (0.01) 1.06 (1.03-1.09) <0.001 
Male sex 0.38 (0.33) 1.46 (0.77-2.76) 0.250 0.34 (0.31) 1.40 (0.77-2.56) 0.274 
Pre-ICH dementia  -0.12 (0.54) 0.89 (0.31-2.57) 0.830 -0.05 (0.50) 0.95 (0.36-2.51) 0.920 
Pre-ICH diabetes 1.36 (0.55) 3.89 (1.33-11.36) 0.013 1.14 (0.49) 3.14 (1.20-8.21) 0.020 
Antiplatelet use at ICH -0.60 (0.35) 0.55 (0.29-1.09) 0.085 -0.50 (0.33) 0.61 (0.32-1.15) 0.124 
Anticoagulant use at ICH -0.23 (0.50) 0.80 (0.30-2.11) 0.649 -0.17 (0.45) 0.84 (0.35-2.05) 0.708 
Glasgow coma scale (per point 
increase) 
-0.25 (0.08) 0.78 (0.67-0.90) 0.001 
-0.24 
(0.07) 0.79 (0.69-0.91) 0.001 
Non lobar ICH location 0.59 (0.33) 1.80 (0.94-3.45) 0.076 0.50 (0.31) 1.65 (0.89-3.04) 0.109 
ICH volume (per ml increase) 0.04 (0.01) 1.04 (1.03-1.06) <0.001 0.04 (0.01) 1.04 (1.02-1.05) <0.001 
Intraventricular haemorrhage 1.20 (0.37) 3.33 (1.61-6.89) 0.001 1.17 (0.35) 3.22 (1.63-6.36) 0.001 
CT SVD score ≥1 1.03 (0.33) 2.81 (1.48-5.34) 0.001 0.95 (0.31) 2.60 (1.42-4.76) 0.002 
CT = computed tomography. ICH = intracerebral haemorrhage. SVD = small vessel disease. 
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ICH-SVD score model 
I combined the CT SVD score predictor with the other variables from the ICH 
score to create the ICH-SVD score logistic regression prediction model 
(Table 11.12). The variance inflation factor values ranged from 1.04 to 1.13, 
confirming no evidence of multicollinearity between the predictors. 
The shrunken model calculates the predicted probability of death or disability 
(modified Rankin scale 4-6) at one year after index ICH as follows: 
𝑅𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 = 1.97 + 0.56 ∗ (𝑎𝑔𝑒) − 0.24 ∗ (𝐺𝐶𝑆) − 0.04
∗ (𝑖𝑛𝑓𝑟𝑎𝑡𝑒𝑛𝑡𝑜𝑟𝑖𝑎𝑙 𝐼𝐶𝐻 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛) + 0.03 ∗ (𝐼𝐶𝐻 𝑣𝑜𝑙𝑢𝑚𝑒) + 1.14
∗ (𝑖𝑛𝑡𝑟𝑎𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 ℎ𝑎𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒) + 1.17 ∗ (𝐶𝑇 𝑆𝑉𝐷 𝑠𝑐𝑜𝑟𝑒 ≥ 1) 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒𝑥𝑝−𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 
 
The value of the predictor age is 1 when the age is ≥80 years and 0 when 
age is <80 years. The other categorical predictor values are 1 when present 
and 0 when absent. ICH volume is the volume of the largest ICH in ml and 
GCS is GCS score on hospital admission. 
11.4.5.3 Performance of the prediction models  
The performance measures of the models are summarised in Table 11.13. 
The full pre-specified model showed good discrimination (c statistic 0.89, 
95%CI 0.86-0.92) and good calibration (Figure 11.8). The ICH score model 
showed good discrimination (c statistic 0.85, 95%CI 0.82-0.89) and no 
evidence of miscalibration (Figure 11.9). The ICH-SVD score model also 
showed good discrimination (c statistic 0.87, 95%CI 0.84-0.90) and 
calibration (Figure 11.10). The AIC was best for the full pre-specified model 
(311.9), followed by the ICH-SVD model (323.6) then the ICH score model 
(338.5). 
Internal validation resulted in small optimism-adjusted differences in the 
overall performance measures and discrimination for all three models (Table 
11.13), with no evidence of poor calibration (Figure 11.8 to Figure 11.10). 






Table 11.11 ICH score multivariable logistic regression prediction models for death or disability (modified Rankin scale 4-6) at 
one year after the index ICH in first-ever SVD-associated ICH 
 Original model Shrunken model 
  Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
 Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
Intercept 3.04 (1.11)    2.88 (1.03)    
Age ≥80 0.80 (0.29) 2.24 (1.27-3.95) 0.006 0.78 (0.28) 2.19 (1.25-3.82) 0.006 
Glasgow coma scale (per point 
increase) 
-0.27 (0.08) 0.76 (0.66-0.89) <0.001 
-0.26 
(0.07) 0.77 (0.67-0.89) <0.001 
Infratentorial ICH location -0.01 (0.42) 0.99 (0.44-2.23) 0.975 -0.02 (0.41) 0.98 (0.44-2.17) 0.952 
ICH volume (per ml increase) 0.03 (0.01) 1.03 (1.02-1.04) <0.001 0.03 (0.01) 1.03 (1.01-1.04) <0.001 
Intraventricular haemorrhage 1.14 (0.32) 3.12 (1.67-5.84) <0.001 1.14 (0.31) 3.14 (1.70-5.78) <0.001 
ICH = intracerebral haemorrhage. SVD = small vessel disease. 
  






Table 11.12 ICH-SVD score multivariable logistic regression prediction models for death or disability (modified Rankin scale 4-
6) at one year after the index ICH in first-ever SVD-associated ICH 
 Original model Shrunken model 
  Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
 Coefficient 
(standard error) 
Odds ratio (95%CI) p value 
Intercept 2.02 (1.11)    1.97 (1.03)    
Age ≥80 0.56 (0.30) 1.76 (0.97-3.18) 0.063 0.56 (0.30) 1.74 (0.98-3.11) 0.060 
Glasgow coma scale (per point 
increase) 
-0.25 (0.07) 0.78 (0.67-0.90) 0.001 
-0.24 (0.07) 0.79 (0.69-0.90) 
0.001 
Infratentorial ICH location -0.02 (0.44) 0.98 (0.42-2.30) 0.959 -0.04 (0.42) 0.96 (0.42-2.21) 0.924 
ICH volume (per ml increase) 0.03 (0.01) 1.03 (1.02-1.05) <0.001 0.03 (0.01) 1.03 (1.02-1.04) <0.001 
Intraventricular haemorrhage 1.14 (0.33) 3.14 (1.64-6.03) 0.001 1.14 (0.32) 3.14 (1.67-5.90) <0.001 
CT SVD score ≥1 1.25 (0.30) 3.50 (1.93-6.35) <0.001 1.17 (0.29) 3.23 (1.82-5.71) <0.001 
CT = computed tomography. ICH = intracerebral haemorrhage. SVD = small vessel disease. 
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11.4.6 ICH score versus the ICH-SVD score 
The ICH score had a c statistic of 0.81 (95%CI 0.77-0.85). The addition of the 
predictor CT SVD ≥1 (ICH-SVD score) led to a small increase in the c 
statistic to 0.83 (95%CI 0.79-0.87) (Figure 11.11). 
The percentage of patients who were dead or disabled at one year after the 
index ICH increased with both the ICH score and ICH-SVD (Figure 11.12). 
Thirty-eight percent (95%CI 28-49%) of patients with an ICH score of 0 were 
dead or disabled at one year, whereas 94% (85-98%) with an ICH score of 3 
and 100% (95%CI 94-100%) with an ICH score of 4, 5 or 6 were dead or 
disabled. 
Twenty-four percent (95%CI 12-40%) of patients with an ICH-SVD score of 0 
were dead or disabled at one year after their index ICH, whereas 96% 
(95%CI 88-99%) with an ICH-SVD score 4 and 100% (95%CI 93-100%) with 
an ICH-SVD score of 5, 6 or 7 were dead or disabled. 
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Figure 11.8 Discrimination and calibration measures of the full pre-specified 
prediction model for death or disability (modified Rankin scale 4-6) at one 
year after the index ICH in first-ever SVD-associated ICH following 
shrinkage. 
A. Receiver operating characteristic plot. The AUC is equivalent to the c statistic. 
The shaded area represents the 95% CI of the AUC based on 2000 bootstrap 
replicates. The grey line indicates a non-informative AUC of 0.50 for comparison. 
B. Calibration plot of model predicted probability versus observed frequency. The 
dashed grey line indicates ideal calibration, the model's apparent calibration is 
shown by the dotted grey line. The bias-corrected calibration after internal validation 
with 2000 bootstrap replicates is shown by the black line. The vertical lines at the 
top of the plot represent the distribution of model predicted probabilities.  
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.  
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Figure 11.9 Discrimination and calibration measures of the ICH score 
prediction model for death or disability (modified Rankin scale 4-6) at one 
year after the index ICH in first-ever SVD-associated ICH following 
shrinkage. 
A. Receiver operating characteristic plot. The AUC is equivalent to the c statistic. 
The shaded area represents the 95% CI of the AUC based on 2000 bootstrap 
replicates. The grey line indicates a non-informative AUC of 0.50 for comparison. 
B. Calibration plot of model predicted probability versus observed frequency. The 
dashed grey line indicates ideal calibration, the model's apparent calibration is 
shown by the dotted grey line. The bias-corrected calibration after internal validation 
with 2000 bootstrap replicates is shown by the black line. The vertical lines at the 
top of the plot represent the distribution of model predicted probabilities.  
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.  
  Chapter 11 
579 
Figure 11.10 Discrimination and calibration measures of the ICH-SVD score 
prediction model for death or disability (modified Rankin scale 4-6) at one 
year after the index ICH in first-ever SVD-associated ICH following 
shrinkage. 
A. Receiver operating characteristic plot. The AUC is equivalent to the c statistic. 
The shaded area represents the 95% CI of the AUC based on 2000 bootstrap 
replicates. The grey line indicates a non-informative AUC of 0.50 for comparison. 
B. Calibration plot of model predicted probability versus observed frequency. The 
dashed grey line indicates ideal calibration, the model's apparent calibration is 
shown by the dotted grey line. The bias-corrected calibration after internal validation 
with 2000 bootstrap replicates is shown by the black line. The vertical lines at the 
top of the plot represent the distribution of model predicted probabilities.  
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.





Table 11.13 Performance measures of the multivariable logistic regression prediction models for death or disability (modified 
Rankin scale 4-6) at one year after the index ICH in the development dataset (n=391) and following internal validation using 
the same dataset (n=391; 2,000 bootstrap samples) 
 Development Internal validation 










Overall       
 Brier score 0.12 0.14 0.13 0.13 0.14 0.14 
 R2 (Nagelkerke) 0.52 0.43 0.47 0.50 0.42 0.46 
Discrimination       
 c statistic 0.89 0.85 0.87 0.88 0.85 0.86 
ICH = intracerebral haemorrhage. SVD = small vessel disease 
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Figure 11.11 Receiver operating characteristic curves for death or disability 
(modified Rankin scale 4-6) at one year after the index ICH in first-ever SVD-
associated ICH.  
A. The ICH score and B. The ICH-SVD score. 
The AUC is equivalent to the c statistic. The shaded area represents the 95% CI of 
the AUC based on 2000 bootstrap replicates. The grey line indicates a non-
informative AUC of 0.50 for comparison. 
 
AUC = area under the curve. ICH = intracerebral haemorrhage. SVD = small vessel 
disease.  
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Figure 11.12 Bar plots showing the number of patients with first-ever SVD-
associated ICH who were dead or disabled (modified Rankin scale 4-6) at 
one year after their index ICH. 
A. The ICH score and B. The ICH-SVD score. 
 
ICH = intracerebral haemorrhage. SVD = small vessel disease.  
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11.5 Discussion 
11.5.1 Main findings 
 42% of patients with first-ever SVD-associated ICH died within 30 
days of their index ICH whilst 56% were dead by one year. 
 Death at one year after the index ICH: 
o Increasing age, male sex, decreasing admission GCS, 
increasing ICH volume, intraventricular haemorrhage and a CT 
SVD≥1 were independently associated with death at one year. 
o The full pre-specified logistic regression prediction model had 
the best fit (AIC 407.8) and discrimination (c statistic 0.86) for 
death at one year. 
o The discrimination of the ICH score was slightly improved by 
including the CT SVD score (ICH score c statistic 0.79; ICH-
SVD score c statistic versus 0.80). This occurred through better 
stratification of patients at low risk of death (23% with ICH score 
0 died within a year compared with 11% with ICH-SVD score 
0). 
 Death or disability at one year after the index ICH: 
o Increasing age, pre-ICH history of diabetes, decreasing 
admission GCS, increasing ICH volume, intraventricular 
haemorrhage and a CT SVD≥1 were independently associated 
with death or disability at one year. 
o The full pre-specified logistic regression prediction model had 
the best fit (AIC 311.9) and discrimination (c statistic 0.89) for 
death or disability at one year. 
o The inclusion of the CT SVD score into the ICH score slightly 
improved discrimination (ICH score c statistic 0.81; ICH-SVD 
score c statistic versus 0.83). The ICH-SVD score resulted in 
better stratification of patients at low risk of death or disability 
(38% with ICH score 0 were dead or disabled (modified Rankin 
scale 4-6) at a year compared to 24% with ICH-SVD score 0). 
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11.5.2 Strengths of the studies 
I performed and reported the study according to the TRIPOD guidelines for 
multivariable prediction models.[332] Important strengths are: 
 I reduced selection bias by using data from LATCH, a prospective 
community-based cohort, which used multiple overlapping sources of 
case ascertainment. The data is, therefore, representative of a 
relatively large, contemporary UK population of SVD-associated ICH. 
 I only included patients with first-ever ICH to provide a standard 
inception point. 
 I minimised information bias for CT predictor assessment by 
standardising imaging format and rating the diagnostic non-contrast 
brain CT using a standardised pro forma. I performed the ratings 
masked to clinical and outcome data. 
 Patients were followed up using multiple sources of data for the 
outcomes of interest. The completeness of follow-up was very high 
(>98%). 
 The amount of missing predictor and outcome data was low. 
 I used clinically relevant, pre-specified outcomes of death and death or 
disability at one year after the index ICH. 
 To minimise overfitting, I pre-specified the predictors for the logistic 
regression models based on evidence from the literature[151, 244] 
and restricted the number of predictors to ensure there were at least 
ten outcomes per predictor in all models. I used penalised maximum 
likelihood estimation to shrink my prediction models to reduce 
optimism.[334, 396, 398] I performed internal validation with 
bootstrapping to account for optimism in the performance of the 
models[334, 340] and reported the relevant apparent and optimism-
adjusted measures of model performance. 
 I compared the prediction models against a logistic regression model 
based on the ICH score,[244] the most widely used prognostic tool for 
ICH.[375] 
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 I performed a pragmatic update to the original ICH score by including 
the CT SVD score (ICH-SVD score) and compared this against the 
original ICH score.  
11.5.3 Limitations of the studies 
GCS was assessed by the clinical team caring for the patient, which may 
introduce variability in its assessment. However, the clinicians in the 
emergency departments are experienced in assessing GCS, and GCS is 
known to be reliably used by experienced practitioners.[400] Also, this 
approach reflects real life clinical practice, making the prediction models 
more clinically applicable. 
The modified Rankin scale at one year after the index ICH was obtained from 
a postal questionnaire sent to the patients’ GPs. The GP may not have 
specifically assessed the patient for this purpose, which can influence the 
accuracy of the modified Rankin scale.[401] The modified Rankin scale has 
only moderate inter-rater agreement, even by experienced researchers.[402] 
The inter-observer agreement may be lower amongst GPs. These factors will 
affect the accuracy of the modified Rankin outcome data. Also, GPs were not 
masked to the presence or absence of the predictors I included in the 
models. However, they were not aware of this study at the time of their 
assessment. 
The clinical treatment decisions for patients may have been influenced by 
some of the predictors I included in the models. Both do not attempt 
resuscitation orders and withdrawal of active care are known predictors of 
death in those with ICH considered to have a poor prognosis ICH,[403-405] 
whereas physical therapy and rehabilitation improves functional outcome in 
ICH.[406] While there were no local guidelines for the use of these 
interventions during the study period, their use may have been influenced by 
some of the predictors included in the models, such as age, admission GCS 
and ICH volume.[403-405] Therefore, the measured outcomes are likely to 
result from a combination of the direct effects of the predictors and the 
indirect effect of do not attempt resuscitation orders, withdrawal of active 
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care[407, 408] - the so-called self-fulfilling prophecy in ICH,[403] and the 
provision of rehabilitation. Previous studies have shown that prediction 
models underestimate adverse outcomes in those with early do not attempt 
resuscitation or withdrawal of active care orders and overestimate them in 
those without such orders.[408-410] It is difficult to account for this 
intervention effect bias in predictive modelling. One option is to include the 
intervention in the prediction model,[407] but this can only be done if the 
intervention occurs before the follow-up period.[333] An alternative solution is 
to develop a model in a cohort who received a maximum level of care.[376, 
389] However, in my models I wanted to predict the outcome at the time of 
ICH diagnosis, before do not attempt resuscitation orders and withdrawal of 
active care are made. This is because the likely prognosis of a patient is 
important in the decision making for these interventions.[371, 392] 
I excluded patients with an ICH secondary to an underlying cause other than 
SVDs from my studies. However, this information is not known for all patients 
at the time of initial presentation when the prognostic models might be used. 
Therefore, to determine their clinical utility, it would be useful to assess the 
prognostic value of these models in all ICH patients who did not have an 
underlying cause, such as arteriovenous malformation, aneurysm, venous 
sinus thrombosis or tumour, identified at the time of initial presentation, 
regardless of whether one was later identified. 
11.5.4 Study findings 
11.5.4.1 Survival after ICH 
Most of the deaths in ICH occur early after the index event. The 30-day case 
fatality for patients with first-ever SVD-associated ICH in LATCH was 42% 
(95%CI 37-46%, Figure 11.1), which is similar to the early ICH case fatality of 
approximately 40% in a systematic review of population-based studies in 
high-income countries.[133] The early case fatality in ICH has not improved 
for several decades.[133]  
ICH case fatality continues to increase beyond 30 days. In LATCH, the one-
year case fatality rate in first-ever SVD-associated ICH was 56% (95%CI 51-
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60%, Figure 11.1), while five-year fatality was 75% (95%CI 71-80%). These 
figures are similar to the pooled estimates for one-year fatality (54%, 95%CI 
51-57%) from nine population-based studies and five-year fatality (71%, 
95%CI 67-74%) based on three population-based studies.[151] 
In line with previous studies, I found that increasing age, decreasing 
admission GCS, increasing ICH volume and the presence of intraventricular 
haemorrhage were independently associated with death at one year.[151] 
The association between other variables, such as sex and pre-ICH 
anticoagulant drug use and long term death after ICH is inconsistent.[151] I 
found male sex was independently associated with death at one year. There 
was no association between pre-ICH anticoagulant use and death. Some 
studies have shown pre-ICH anticoagulant drug use is associated with three 
month mortality, which may relate to its association with haematoma 
growth.[411] Few studies have assessed the associations of death beyond 
three months,[151] with one study showing no independent association 
between anticoagulant use and death three years after ICH.[412] 
11.5.4.2 External validation of the ICH score for predicting death and 
functional outcome at one year after the index ICH 
The ICH score[244] is the most widely used outcome prediction tool in 
ICH.[375] It was developed in 2001 to predict 30-day fatality in ICH and is a 
simple, pragmatic tool which uses five categorical variables (age, admission 
GCS, ICH location, ICH volume and intraventricular extension). The ICH 
score has been widely validated for short term fatality, showing good 
diagnostic accuracy across a variety of settings.[245, 375, 377-384]  
Validation of the ICH score for predicting longer-term fatality is less 
comprehensive. Two hospital-based studies showed that the ICH score had 
moderate to good discrimination for 90-day fatality (c statistic 0.74-0.86).[380, 
385] I found that in our prospective community-based LATCH cohort, the ICH 
score had moderate discrimination for one-year fatality after ICH (c statistic 
0.79, 95%CI 0.74-0.83). The ICH score was good at identifying those at very 
high risk of dying (93% with ICH score 4 died, 100% with ICH score 5 or 6 
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died). In contrast, it was less effective at identifying those with the lowest 
chance of dying (23% of patients with an ICH score 0 died). 
The ICH score has been validated for functional outcome in a several 
settings.[380, 385-390] In the studies that assessed the modified Rankin 
scale at one year after the index ICH, the ICH score showed moderate to 
good discrimination for death or disability (modified Rankin scale 4-6) (c 
statistic ranged from 0.77 to 0.81).[386-388] I found that the ICH score had 
good discrimination for one year death or disability (modified Rankin scale 4-
6) (c statistic 0.81, 95%CI 0.77-0.85). Again the ICH score appears good at 
identifying patients with a very high risk of death or disability (94% with ICH 
score 3 were dead or disabled, while 100% with ICH score of 4 to 6 were). It 
was less effective at identifying those with a low chance of death or disability 
(38% with ICH score 0 were dead or disabled at one-year). 
11.5.4.3 Improving predictions of death and functional outcome in ICH 
The ICH score shows moderate and good discrimination for death and death 
or disability at one year respectively. However, the ICH score has several 
limitations. For example, the methodological approaches used to develop the 
ICH were suboptimal. The ICH score was derived from a logistic regression 
model. The sample size was modest, with only 68 events. The authors 
included 11 variables in their model and used stepwise selection to generate 
the final model. This approach is known to have many disadvantages, such 
as unstable predictor selection and overestimated model performance, 
especially when the number of events is low.[334, 336, 339, 413] There was 
no shrinkage of the regression coefficients, which would have helped reduce 
overfitting.[336, 413] The model was not internally validated. Internal 
validation is particularly useful to establish the stability of predictor selection 
when a stepwise approach has been used.[334, 340]  To derive the ICH 
score, the authors simplified the final logistic regression model by converting 
the continuous predictors into categorical predicts. This helps make the score 
easy to implement, but at the cost of a considerable loss of power. The cut-
points derived in their relatively small cohort are also likely to introduce 
bias.[334, 339, 414] Furthermore, the ICH score was developed nearly 20 
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years ago. The strength of predictor associations may have changed over 
that time. Also, new potentially important predictors associated with outcome 
after ICH have been identified,[151] such as white matter lucencies and other 
CT features of SVD.[195, 391] Therefore, there is potential to update the ICH 
score in order to improve its prognostic accuracy. 
The most effective method to update a prediction model is to assess and 
update the logistic regression model it is derived from.[334] Unfortunately, 
the logistic regression equation used to develop the ICH score was not 
published in the paper,[244] nor was it available after contacting the 
corresponding author. Therefore, I decided to generate new prediction 
models using the optimum approaches for predictor selection and modelling 
(11.3.6.2), and compare them against logistic regression models based on 
the variables used in the ICH score logistic regression model. 
The full pre-specified logistic regression prediction model for death at one 
year after the index ICH had a better AIC (407.8), a higher c statistic (0.86) 
and wider range of model predicted probabilities (0.05 to 1, Figure 11.3) 
compared with the ICH score logistic regression model (AIC 427.6, c statistic 
0.82, predicted probability range 0.18 to 0.99, Figure 11.4). A similar pattern 
was seen for the outcome of death or disability at one year; the full pre-
specified logistic regression prediction model had an AIC of 311.9, c statistic 
of 0.89 with predictions ranging from 0.05 to 1 (Figure 11.8) compared with 
the model using the ICH score variable (AIC 338.5, c statistic of 0.85, 
predicted probability range 0.28 to 1, Figure 11.9). 
Many modifications to the ICH score have been described.[245, 382, 393, 
415] All of these modifications involved adding or adjusting categorical 
predictors to the original ICH score. I wanted to perform a similar pragmatic 
update of the ICH model. I added CT SVD score to the other ICH score 
variables based on the strength of its independent association with the 
outcomes. The addition of CT SVD score ≥1 into the ICH score led to a small 
improvement in the c statistic for death at one year (Figure 11.6) and for 
death or disability at one year (Figure 11.11). The addition of the CT SVD 
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score improved predictions in those with the lower predicted risk of poor 
outcomes. 
11.5.5 Clinical implications 
Prediction modelling is designed to improve the accuracy and reliability of 
prognostication beyond clinical judgement. Such information is useful to help 
guide treatment decisions and inform discussions with the patient and their 
relatives.[371-373] Well designed prediction models can provide accurate 
estimates for the overall outcome of a population or cohort. One of the 
benefits of simple scores, such as the ICH score, is that they are quick and 
easy to calculate. The main disadvantage is the loss of predictive power. 
The best prediction models for death and death or disability in my study were 
the full pre-specified models, which showed high discrimination and good 
calibration. These models would require external validation before being 
considered for use in clinical practice. Also, the practicality of full regression-
based models need to be assessed. The ICH score is simple to implement, 
whereas my models would require the use of an online calculator or an app. 
This is likely to limit the widespread uptake of such a prediction model. 
The addition of the CT SVD score to the ICH score did improve the 
discrimination for death and death or disability at one year, but the magnitude 
of the improvement is unlikely to be large enough to warrant the use of the 
ICH-SVD score over the ICH score in clinical practice. 
11.5.6 Future directions 
As with many areas in medicine, there are multiple prognostic models in ICH, 
all aiming to predict similar outcomes.[376] Many have significant 
methodological limitations, such as small sample size, selection bias, 
detrimental modelling approaches (dichotomising continuous predictors, 
stepwise selection, overfitting of models without shrinkage or internal 
validation) and poor reporting of relevant performance measures. 
Future research should aim to improve prognostic modelling in ICH through 
the use of collaborative, multicentre studies. These should ideally be 
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prospective, with minimal selection bias and low levels of missing data. The 
outcomes should be clinically relevant, such as death or disability at one 
year, and assessed in a standardised fashion, with the assessors being 
masked to the predictors. The predictors assessed in the models should 
ideally be pre-specified, and the models shrunk and internally validated using 
bootstrapping to reduce over-fitting. Relevant performance measures should 
be reported, such as discrimination and calibration. Robust external 
validation studies need to be performed to establish the true prognostic 
accuracy. These should also assess models using different patient groups to 
determine the generalisability, given the racial/ethnic differences in ICH 
aetiology and outcome.[416] The regression equation should be published to 
allow external validation and updating of the model in the future.[334, 336, 
376] 
There is, however, a concern that use of prognostic tools to inform decisions 
about do not attempt resuscitation orders and withdrawal of active care can 
result in a self-fulfilling prophecy.[403-405, 407-409] Therefore, further work 
is needed to assess the clinical impact of prediction models in ICH. Given the 
trend to avoid early do not attempt resuscitation and withdrawal of active care 
orders,[417] and the potential for early deterioration,[418, 419] the value of 
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Chapter 12 Conclusions 
 
12.1 Main findings of thesis 
12.1.1 Cross-sectional studies of SVD-associated ICH 
12.1.1.1 Baseline clinical characteristics, radiological features and APOE 
genotype 
 Between 1st June 2010 and 31st May 2013 the crude incidence of first-
ever SVD-associated ICH in LATCH was 20.2 per 100,000 per year (95% 
CI 18.3 to 22.2). 
 The crude incidence of lobar and non-lobar first-ever SVD-associated 
ICH was similar and increased with age. 
 Hypertension was a common co-morbidity regardless of ICH location. 
 There were no independent associations between pre-existing co-
morbidities and ICH location.  
 Larger ICH volumes, multiple simultaneous acute ICHs, subarachnoid 
haemorrhage and subdural haemorrhage were independently associated 
with lobar ICHs. 
 Intraventricular haemorrhage was independently associated with non-
lobar ICHs. 
 Only 28% of SVD-associated ICH patients underwent brain MRI as part 
of routine clinical practice or the LINCHPIN study, and they tended to be 
younger, have fewer co-morbidities and small ICHs than those who did 
not have MRI. 
 Overall, 16% of patients were classified as probable CAA on the modified 
Boston criteria, 37% as possible CAA and 47% as no CAA. 
 In first-ever SVD-associated ICH patients who had a research MRI, 
cortical superficial siderosis was more frequent in lobar ICH and deep 
CMBs were more frequent in non-lobar ICH. 
 The frequency of lobar CMBs, the total number of CMBs, and the 
severity of WMH, atrophy and PVS were similar between lobar and non-
lobar ICH. 
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 In first-ever SVD-associated ICH patients, APOE 2 possession was 
independently associated with lobar ICH location while APOE  allele 
possession showed a borderline independent association 
12.1.1.2 Histopathological features 
 First-ever SVD-associated ICH patients who had a research brain 
autopsy were older with more frequent pre-ICH dementia and more 
severe pre-ICH disability, had larger ICHs and more frequent 
subarachnoid haemorrhage than the rest of the LATCH cohort. 
 Histopathological assessment of parenchymal CAA, meningeal CAA and 
vasculopathy in the left cerebral hemisphere had excellent sensitivity and 
specificity (≥97%) compared with the global cerebral assessment. 
 The Love et al. parenchymal and meningeal CAA scale in the cerebral 
lobe affected by ICH had good sensitivity and excellent specificity 
compared with the global cerebral assessment, regardless of age. 
 Vonsattel grade≥2 was 95% sensitive and 79% specific compared with 
global cerebral CAA assessment, but the specificity decreased with age. 
 98% of non-lobar ICHs had moderate or severe non-CAA SVD. 
 45% of lobar ICHs had mixed moderate or severe CAA and non-CAA 
SVD, 37% had moderate or severe non-CAA alone, while only 15% had 
moderate or severe CAA alone. 
 Moderate or severe parenchymal CAA was significantly associated with 
APOE 4 allele possession. 
 There was no occipital predominance for parenchymal CAA, meningeal 
CAA or vasculopathy, whereas capillary CAA showed an occipital 
predominance irrespective of age, APOE genotype or Thal phase. 
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12.1.2 Diagnostic value of SVD imaging biomarkers in SVD-
associated ICH 
12.1.2.1 Diagnostic test accuracy studies of the original and modified 
Boston criteria for CAA-associated ICH against a 
histopathological reference standard 
 The probable CAA category in the original Boston criteria showed 55% 
sensitivity and 60% specificity for histopathologically defined CAA-
associated ICH. 
 The probable CAA category in the modified Boston criteria was 64% 
sensitive and 40% specific for histopathologically defined CAA-
associated ICH. 
 However, the study had a small sample size and selection bias. 
12.1.2.2 Diagnostic value of -amyloid PET in SVD-associated ICH 
 6-CN-flutemetamol labels both perivascular (CAA) and non-vascular -
amyloid in ex vivo brain tissue from first-ever SVD-associated ICH 
participants. 
 18F-flutemetamol MRI-PET scans are difficult to perform in ICH patients. 
 Overall visual assessment of flutemetamol PET scans showed almost 
perfect inter-observer agreement ( 0.90) and correlated with maximum 
cortical SUVr with no overlap between positive and negative visual 
classifications. 
 Visual assessment of flutemetamol PET had 86% sensitivity and 77% 
specificity against the modified Boston criteria. 
 Maximum cortical SUVr was significantly higher in CAA-associated ICH 
versus non-CAA-associated ICH, although there was overlap between 
the groups. 
12.1.2.3 The Edinburgh CT and genetic criteria for lobar ICH associated 
with CAA: model development and diagnostic test accuracy study 
 The CT and APOE diagnostic model of subarachnoid haemorrhage, 
finger-like projections and APOE 4 allele possession showed excellent 
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discrimination and good calibration for histopathologically defined CAA-
associated lobar ICH. 
 The Edinburgh CT-APOE rule out criteria of neither subarachnoid 
haemorrhage nor APOE 4 possession had 100% sensitivity, while the 
rule in criteria of subarachnoid haemorrhage and either APOE 4 
possession or finger-like projections had 96% specificity. 
 The CT-only diagnostic model of subarachnoid haemorrhage and finger-
like projections showed good discrimination and excellent calibration for 
histopathologically assessed CAA-associated lobar ICH. 
 The Edinburgh CT-only rule out criteria of no subarachnoid haemorrhage 
or finger-like projections had 89% sensitivity, while the rule in criteria of 
subarachnoid haemorrhage and finger-like projections had 100% 
specificity. 
12.1.2.4 External validation studies of the Edinburgh CT-only and CT-
APOE diagnostic models and criteria for CAA-associated lobar 
ICH 
 In 146 first-ever lobar ICH participants, the Edinburgh CT-only rule out 
criteria had 88% sensitivity for histopathologically defined CAA-
associated lobar ICH, while the rule in criteria were 84% specific. 
 In 65 first-ever lobar ICH participants, the Edinburgh CT-APOE rule out 
criteria were 94% sensitive for histopathologically defined CAA-
associated lobar ICH, but the rule in criteria were only 63% specific. 
12.1.2.5 Diagnostic test accuracy studies of the Edinburgh diagnostic 
criteria for CAA-associated lobar ICH against the modified Boston 
criteria 
 Among 70 LINCHPIN first-ever lobar ICH participants with diagnostic CT 
and research MRI, the Edinburgh CT-only rule out criteria were 81% 
sensitive for probable CAA on the modified Boston criteria, while the 
Edinburgh CT-only rule in criteria were 96% specific. 
 Among 58 LINCHPIN first-ever lobar ICH participants with diagnostic CT, 
research MRI and APOE genotyping, the Edinburgh CT-APOE rule out 
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criteria were 89% sensitive for probable CAA on the modified Boston 
criteria, and the Edinburgh CT-APOE rule in criteria were 78% specific. 
12.1.3 Prognostic value of CT SVD biomarkers in SVD-associated 
ICH 
12.1.3.1 The association between the Edinburgh diagnostic criteria for 
CAA-associated lobar ICH and the risk of recurrent ICH 
 The relative risk and rate of recurrent ICH were significantly higher in 
participants with first-ever lobar ICH compared with non-lobar ICH. 
 In a meta-analysis of the subdistribution hazard models of 462 LATCH 
and CROMIS-2 participants with first-ever SVD-associated lobar ICH, 
high risk participants on the Edinburgh CT-only criteria had a significantly 
higher risk of recurrent ICH compared with the low-risk group. 
 Secondary multivariable analyses assessing the individual components 
of the Edinburgh CT-only criteria showed that subarachnoid 
haemorrhage was associated with an increased relative risk and rate of 
recurrent ICH, while finger-like projections were associated with a non-
significant increased risk of recurrent ICH. 
 In a meta-analysis pooling 384 LINCHPIN and CROMIS-2-DNA 
participants with first-ever SVD-associated lobar ICH, participants 
classified as high risk on the Edinburgh CT-APOE criteria had 
significantly higher risk and rate of recurrent ICH compared with the low-
risk group. CT SVD score of 1, 2 or 3 was also associated with an 
increased hazard of recurrent ICH and death. 
 Secondary multivariable analyses assessing the individual components 
of the Edinburgh CT-APOE criteria and APOE 2 genotype showed that 
APOE 2 allele possession was independently associated with an 
increased risk and rate of recurrent ICH. Subarachnoid haemorrhage, 
finger-like projections and APOE 4 allele possession were not 
significantly associated with an increased risk of recurrent ICH. 
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12.1.3.2 Prediction models for death and disability at one year after first-
ever SVD-associated ICH 
 42% of first-ever SVD-associated ICH LATCH patients died within 30 
days of their index ICH whilst 56% were dead by one year. 
 Increasing age, male sex, decreasing admission GCS, increasing ICH 
volume, intraventricular haemorrhage and a CT SVD≥1 were 
independently associated with death at one year. 
 The discrimination of the ICH score was significantly improved by 
including the CT SVD score (ICH score c statistic 0.79; ICH-SVD score c 
statistic versus 0.80, p=0.048). 
 72% of first-ever SVD-associated ICH LATCH patients were dead or 
disabled (modified Rankin scale 4-6) at one year after their index ICH. 
 Increasing age, pre-ICH history of diabetes, decreasing admission GCS, 
increasing ICH volume, intraventricular haemorrhage and a CT SVD≥1 
were independently associated with death or disability at one year. 
 The inclusion of the CT SVD score into the ICH score did not significantly 
improve discrimination (ICH score c statistic 0.81; ICH-SVD score c 
statistic versus 0.83, p=0.052). 
 
12.2 Implications for routine clinical practice 
The incidence of SVD-associated ICH increases dramatically with age, 
meaning its overall incidence and economic impact is likely to increase as the 
population ages. Currently there is a lack of effective acute or specific 
treatments for SVD-associated ICH highlighted by the high levels of death or 
disability after ICH. Therefore, better prevention of first-ever and recurrent 
ICH is likely to be the most promising strategy to decrease its burden. 
Hypertension is a common co-morbidity in all SVD-associated ICH, 
regardless of ICH location. In addition, non-CAA SVD, which is associated 
with hypertension, is the most common type of SVD on histopathological 
assessment in SVD-associated ICH, even in lobar ICH. The prevention, early 
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detection and effective management of hypertension is therefore likely to be 
key to reduce the impact of SVD-associated ICH. 
Non-lobar ICH is almost universally associated with moderate or severe non-
CAA SVD. Lobar ICH has more heterogeneous histopathology. Whilst 60% 
of lobar ICH participants had moderate or severe CAA, 82% had moderate or 
severe non-CAA-SVD. Therefore, lobar ICH should not be assumes to be 
CAA-associated, even in the elderly. 
Diagnosing CAA-associated ICH is clinically important given the associated 
increased risk of recurrent ICH and post-stroke dementia. When available, 
histopathological assessment is the reference standard for diagnosing CAA. 
The absence of amyloid- in a cortical biopsy (Vonsattel grade 0) can be 
used to rule out CAA-associated lobar ICH. The presence of complete 
replacement of a vessel wall with amyloid- (Vonsattel grade ≥2) in a cortical 
biopsy can be used to rule in CAA-associated ICH in those aged under 85 
years. Its specificity for CAA-associated ICH decreases in those older than 
85 years due to the higher frequency of incidental CAA. 
However, cortical biopsy is rarely performed, so neuroimaging is usually used 
to identify CAA-associated ICH. The MRI-based modified Boston criteria are 
the most commonly used approach. There are two main drawbacks of these 
criteria in clinical practice. Firstly, their diagnostic accuracy is unclear in ICH, 
let alone in non-ICH presentations, as the criteria have never undergone 
rigorous external validation. I showed the modified Boston criteria had limited 
sensitivity and specificity for CAA-associated ICH in my small external 
validation study. And secondly, MRI is difficult to perform in ICH. In my 
community-based cross-sectional study only 28% of ICH patients were able 
to have an MRI, and these tended to be younger with less severe ICHs. 
Amyloid PET may be more sensitive for CAA than structural neuroimaging, 
however its diagnostic accuracy for CAA-associated ICH is currently 
unknown. In addition, it is often difficult to perform in ICH patients due to 
frailty or co-morbidities. 
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CT is readily available and the most frequent test to diagnose SVD-
associated ICH. The Edinburgh CT-only criteria for CAA-associated lobar 
ICH showed good sensitivity and specificity CAA-associated lobar ICH in 
both my development and external validation studies. Therefore, the criteria 
can be used to help rule out and rule in CAA-associated ICH. This potentially 
obviates the need for further invasive investigations, such as cortical biopsy, 
which carries potential complications. 
The risk of recurrent ICH is higher in patients with a lobar ICH, and appears 
highest in lobar ICH with CT features of a CAA-associated ICH and severe 
SVD. Therefore effective secondary prevention in these groups is particularly 
important. 
Finally, I showed that the ICH score is good pragmatic tool for predicting 
death and death or disability at one year after ICH, particularly for those with 
a very low or very high score. 
 
12.3 Implications for future research 
12.3.1 Epidemiology 
Future epidemiological studies should assess the changing incidence of ICH 
in high-, middle- and low-income countries and investigate the associations 
with age, co-morbidities and medication use, such as antithrombotic drugs. 
12.3.2 Pathology 
Further representative histopathological studies of ICH are needed to 
investigate the clinical, genetic and histopathological associations of CAA 
and non-CAA SVDs in ICH. The associations and clinical relevance of "pure” 
CAA-associated lobar ICH, “pure” non-CAA-associated lobar ICH and mixed 
SVD-associated lobar ICH would be interesting to investigate. 
12.3.3 Diagnostic value of SVD imaging biomarkers 
The Edinburgh CT-APOE criteria should be externally validated in a large, 
unselected group to determine its diagnostic accuracy. It will be important to 
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assess the diagnostic accuracy of the Edinburgh criteria in non-European or 
North American ICH patients, in whom the incidence of CAA-associated lobar 
ICH may differ to those included in the development and external validation 
studies. The inter-rater agreement of the Edinburgh criteria CT markers 
should be measured in raters of differing experience. Future studies could 
aim to improve the Edinburgh diagnostic models and criteria through the 
assessment of CT, genetic and clinical features for differentiating "pure” 
CAA-associated lobar ICH, “pure” non-CAA-associated lobar ICH and mixed 
SVD-associated lobar ICH. 
Large, rigorous external validation studies of the diagnostic accuracy of MRI-
based SVD biomarkers for CAA-associated ICH are required to establish 
their diagnostic accuracy. Use of prediction models, based on logistic 
regression or machine learning approaches, will help develop more reliable 
diagnostic criteria, particularly as most patients with lobar ICH have mixed 
CAA and non-CAA SVDs underlying their haemorrhage. 
It will be vital to compare the diagnostic accuracy of CT and MRI biomarkers 
for CAA-associated ICH, to determine whether the diagnostic CT scan can 
be used to identify which patients will benefit from MRI scanning, access to 
which is often more limited. 
Molecular imaging has the theoretical advantages of better sensitivity and 
specificity than structural imaging for neurodegenerative diseases, such as 
SVDs. However, the diagnostic value of amyloid PET imaging in SVD-
associated ICH is unclear. Well-designed diagnostic accuracy studies 
assessing clinically relevant amyloid PET tracers (e.g. 18F-labelled tracers) 
against a histopathological reference standard are needed. The value of 
amyloid PET for detecting CAA early in the disease process, before ICH 
occurs, is difficult to assess as tissue samples are not usually available and 
the diagnostic accuracy of MRI-based SVD biomarkers in this group is not 
known. One approach would be to perform longitudinal studies comparing 
amyloid PET and MRI biomarkers in pre-symptomatic hereditary CAA 
carriers against non-affected family members. 
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The current amyloid PET tracers are non-specific amyloid ligands, binding to 
both perivascular and non-vascular -amyloid. Non-vascular -amyloid is a 
frequent finding in the elderly, even those without dementia. Hence, the 
development of a specific PET tracer for CAA would be an important step to 
improve the specificity of PET imaging for CAA. 
12.3.4 Prognostic value of SVD imaging biomarkers 
The prognostic value of the Edinburgh criteria for predicting risk of recurrent 
ICH should be studied in further detail, accounting for relevant confounders, 
such as blood pressure control and antithrombotic drug use. 
ICH survivors are at risk of both ischaemic and haemorrhagic future events. 
Studies assessing the risk of vaso-occlusive and haemorrhagic outcomes in 
ICH survivors randomised to taking or avoid antithrombotics according to 
neuroimaging biomarkers of SVDs will be important to help guide treatment 
decisions. 
The association of the Edinburgh criteria and CT SVD score with the 
development of post-stroke dementia will be interesting to investigate given 
that CAA-associated ICH is thought to be associated with a higher risk of 
developing this outcome. 
Prognostic tools, such as the ICH score, are useful for predicting short and 
longer term fatality. These tools are usually based on baseline clinical and 
radiological features. Early reassessment of some of these features may help 
improve the predictions and should be investigated. 
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